TW202200013A - Fungicidal halomethyl ketones and hydrates and their mixtures - Google Patents

Abstract

Disclosed is a fungicidal composition comprising (a) at least one compound selected from the compounds of Formula1 , including all geometric and stereoisomers, tautomers,N ‑oxides, and salts thereof,

wherein E, L, J, A and T are as defined in the disclosure; and (b) at least one additional fungicidal compound. Also disclosed is a method for controlling plant diseases caused by fungal plant pathogens comprising applying to the plant or portion thereof, or to the plant seed, a fungicidally effective amount of a compound of Formula1 , ann -oxide, or salt thereof (e.g., as a component in the aforesaid composition). Also disclosed is a composition comprising:(a) at least one compound selected from the compounds of Formula1 described above,n -oxides, and salts thereof; and at least one invertebrate pest control compound or agent.

Description

Fungicides halomethyl ketones and hydrates and mixtures thereof

The present invention relates to certain halomethyl ketones and hydrate derivatives, N -oxides and salts thereof, to mixtures and compositions comprising such halomethyl ketones and hydrate derivatives, and to the use of such derivatives and methods for their mixtures and compositions as fungicides.

Controlling plant diseases caused by fungal phytopathogens is extremely important to achieve high crop efficiency. Plant diseases of ornamental plants, vegetables, fields, grains, and fruit crops can lead to significant reductions in productivity and, in turn, increased costs to consumers. In addition to being often highly destructive, plant diseases can be difficult to control and may develop resistance to commercial fungicides. Many commercially available products are available for these applications, but there is still a need for new compounds that are more effective, less expensive, less toxic, safer and more environmentally friendly, or have different sites of action. In addition to introducing new fungicides, combinations of fungicides are often used to improve disease control, expand control and delay the development of drug resistance. In addition, certain rare fungicide combinations exhibit greater-than-summary (ie, synergistic) effects to provide a commercially important degree of plant disease control. The advantages of a particular combination of fungicides are recognized in the art and depend on factors such as the specific plant species and the plant disease to be treated, and whether the plants are treated before or after infection by the fungal phytopathogen. Therefore, new advantageous combinations are needed to provide various options to best meet specific plant disease control needs. Such combinations have now been discovered.

其中 T係選自由下列所組成之群組：

，

， T-1    T-2    T-3    其中延伸至左側的化學鍵連接A； R¹ 為CF₃ 、CHF₂ 、CCl₃ 、CHCl₂ 、CF₂ Cl、CFCl₂ 或CHFCl； W為O、S或NR³ ； R³ 為H、氰基、硝基、C(=O)OH、芐基、C₁ -C₄ 烷基、C₂ -C₄ 烷基羰基、C₂ -C₄ 鹵代烷基羰基、OR^3a 或NR^3b R^3c ； R^3a 為H、芐基、C₁ -C₄ 烷基、C₂ -C₄ 烷基羰基或C₂ -C₄ 鹵代烷基羰基； R^3b 為H、C₁ -C₄ 烷基、C₂ -C₄ 烷基羰基或C₂ -C₄ 鹵代烷基羰基； R^3c 為H或C₁ -C₄ 烷基；或 R^3b 與R^3c 一起形成一4至6元完全飽和的雜環，每個環除了連接的氮原子外，還包含環成員，其係選自碳原子以及最多2個雜原子，該雜原子獨立地選自最多2個O、最多2個S以及最多2個N原子，每個環可選擇地被最多2個甲基取代； X為O、S或NR^5a ； Y為O、S或NR^5b ； 每個R^5a 與R^5b 獨立地為H、羥基或C₁ -C₄ 烷基； 每個R^2a 與R^2b 獨立地為H、C₁ -C₄ 烷基、C₂ -C₄ 烯基、C₃ -C₁₅ 三烷基甲矽烷基、C₃ -C₁₅ 鹵代三烷基甲矽烷基、(CR^4a R^4b )_p -OH、(CR^4a R^4b )_p -SH、(CR^4a R^4b )_p -Cl或(CR^4a R^4b )_p -Br；或 R^2a 與R^2b 與其所連接的X及Y原子一起形成一5至7元含環成員的飽和的環，除X及Y原子外，還選自碳原子，其中最多2個碳原子環成員獨立地選自C(=O)以及C(=S)，該環在碳原子環成員上可選擇地被最多2個獨立地選自鹵素、氰基、C₁ -C₂ 烷基、C₁ -C₂ 鹵代烷基、C₁ -C₂ 烷氧基以及C₁ -C₂ 鹵代烷氧基的取代基所取代； R^2c 為C₁ -C₄ 烷基、C₁ -C₄ 鹵代烷基、C₂ -C₄ 烯基、C₂ -C₄ 鹵代烯基、C₂ -C₄ 炔基、C₂ -C₄ 鹵代炔基或三氟甲基磺醯基，每個可選擇地被最多2個獨立地選自氰基、羥基、SC≡N以及C₁ -C₂ 烷氧基的取代基所取代； R^2d 為H、氰基、鹵素或C₁ -C₄ 烷基； 每個R^4a 與R^4b 獨立地為H或C₁ -C₄ 烷基； p為2或3； 當T為T-1或T-2，則A為A¹ -A² -CR^6a R^6b ，其中A¹ 連接J，且CR^6a R^6b 連接T； 當T為T-3，則A為A¹ -A² ，其中A¹ 連接J，且A² 連接T； A¹ 為CR^6c R^6d 、N(R^7a )、O或S； A² 為一直接鍵、CR^6e R^6f 、N(R^7b )、O或S； 每個R^6a 、R^6b 、R^6c 、R^6d 、R^6e 與R^6f 獨立地為H、氰基、羥基、鹵素、C(=O)OCH₃ 或C₁ ‑C₄ 烷基； 每個R^7a 與R^7b 獨立地為H、C(=O)H、氰基、C₁ -C₄ 烷基或C₂ -C₄ 烷基羰基； J 係選自由下列所組成之群組：

，

，

，

， J-1    J-2    J-3    J-4   

，

，

，

， J-5    J-6    J-7    J-8   

，

，

，

， J-9    J-10    J-11    J-12   

，             J-13    J-14                其中延伸至左側的化學鍵連接L，且延伸至右側的化學鍵連接A； 每個R⁸ 獨立地為F、Cl、I、Br、氰基、甲基、三氟甲基或甲氧基； q為0、1、2、3或4； L為(CR^9a R^9b )_n ； 每個R^9a 與R^9b 獨立地為H、鹵素、氰基、羥基、硝基、C₁ -C₃ 烷基、C₁ -C₃ 鹵代烷基、C₁ -C₃ 烷氧基或C₁ -C₃ 鹵代烷氧基； n為0、1、2或3； E為C₁ -C₆ 烷基或C₁ -C₆ 鹵代烷基；或 E為E¹ 或E² ； E¹ 為胺基、氰基、羥基、硝基、CH(=O)、C(=O)OH、C(=O)NH₂ 、C(=S)NH₂ 、OC(=O)NH₂ 、OC(=S)NH₂ 、NHC(=O)NH₂ 、NHC(=S)NH₂ 、SC≡N、‑CH=NNHC(=O)OC₁ -C₆ 烷基或‑N(OCH₃ )C(=O)C₁ -C₆ 烷基；或 E¹ 為C₁ -C₆ 烷氧基、C₂ -C₆ 烯氧基、C₂ -C₆ 炔氧基、C₁ -C₆ 烷硫基、C₂ -C₆ 烯硫基、C₂ -C₆ 炔硫基、C₁ -C₆ 烷基亞磺醯基、C₂ -C₆ 烯基亞磺醯基、C₂ -C₆ 炔基亞磺醯基、C₁ -C₆ 烷基磺醯基、C₂ -C₆ 烯基磺醯基、C₂ -C₆ 炔基磺醯基、C₁ -C₆ 烷基磺醯基胺基、C₂ -C₆ 烯基磺醯基胺基、C₂ -C₆ 炔基磺醯胺基、C₁ ‑C₆ 烷基胺基磺醯基、C₂ ‑C₆ 二烷基胺基磺醯基、C₂ ‑C₆ 烯基胺基磺醯基、C₂ -C₆ 炔基胺基磺醯基、C₁ -C₆ 烷基胺基磺醯基胺基、C₂ -C₆ 烯基胺基磺醯基胺基、C₂ -C₆ 炔基胺基磺醯基胺基、C₂ -C₆ 烷基羰基、C₃ -C₆ 烯基羰基、C₃ -C₆ 炔基羰基、C₂ -C₆ 烷基胺基羰基、C₃ -C₆ 烯基胺基羰基、C₃ ‑C₆ 炔基胺基羰基、C₂ -C₆ 烷基羰基胺基、C₃ -C₆ 烯基羰基胺基、C₃ -C₆ 炔基羰基胺基、C₂ -C₆ 烷基胺基羰基胺基、C₃ -C₆ 烯基胺基羰基胺基、C₃ -C₆ 炔基胺基羰基胺基、C₂ -C₆ 烷基羰基氧基、C₃ -C₆ 烯基羰氧基、C₃ -C₆ 炔基羰氧基、C₂ ‑C₆ 烷氧羰基、C₃ -C₆ 烯基氧羰基、C₃ -C₆ 炔基氧羰基、C₂ -C₆ 烷基胺基羰基氧基、C₃ -C₆ 烯基胺基羰基氧基、C₃ -C₆ 炔基胺基羰基氧基、C₂ -C₆ 烷氧羰基胺基、C₃ -C₆ 烯基氧羰基胺基、C₃ -C₆ 炔基氧羰基胺基、C₂ -C₆ 烷基胺基（硫代羰基）氧基、C₃ -C₆ 烯基胺基（硫代羰基）氧基、C₃ -C₆ 炔基胺基（硫代羰基）氧基、C₂ -C₆ 烷氧基（硫代羰基）胺基、C₃ -C₆ 烯氧基（硫代羰基）胺基、C₃ -C₆ 炔氧基（硫代羰基）胺基、C₂ -C₆ 烷基（硫代羰基）、C₂ -C₆ （烷硫基）羰基、C₃ -C₆ 烯基（硫代羰基）、C₃ -C₆ （烯硫基）羰基、C₃ -C₆ 炔基（硫代羰基）、C₃ -C₆ （炔硫基）羰基、C₂ ‑C₆ 烷基胺基（硫代羰基）、C₃ -C₆ 烯基胺基（硫代羰基）、C₃ -C₆ 炔基胺基（硫代羰基）、C₂ -C₆ 烷基（硫代羰基）胺基、C₂ -C₆ （烷硫基）羰基胺基、C₃ -C₆ 烯基（硫代羰基）胺基、C₃ -C₆ （烯硫基）羰基胺基、C₃ -C₆ 炔基（硫代羰基）胺基、C₃ -C₆ （炔硫基）羰基胺基、C₂ ‑C₆ 烷基胺基（硫代羰基）胺基、C₃ -C₆ 烯基胺基（硫代羰基）胺基或C₃ -C₆ 炔基胺基（硫代羰基）胺基，其中每個碳原子可選擇地被最多1個選自R^10a 以及最多3個獨立地選自R^10b 的取代基所取代； R^10a 為苯基，其可選擇地被最多3個獨立地選自R^11a 的取代基所取代；或一5至6元雜環，其包含環成員，其係選自碳原子以及1至4個雜原子，該雜原子獨立地選自最多2個O、最多2個S以及最多4個N原子，其中最多3個碳原子環成員獨立地選自C(=O)以及C(=S)，且硫原子環成員獨立地為S(=O)_u (=NR¹² )_v ，每個環在碳原子環成員上可選擇地被最多3個獨立地選自R^11a 的取代基所取代，以及在氮原子環成員上可選擇地被最多3個獨立地選自R^11b 的取代基所取代； 每個R^10b 獨立地為胺基、氰基、鹵素、羥基、硝基、SC≡N、-SH、C₁ -C₄ 烷基、C₁ -C₄ 鹵代烷基、C₃ -C₆ 環烷基、C₃ -C₆ 鹵代環烷基、C₁ -C₄ 烷氧基、C₁ ‑C₄ 鹵代烷氧基、C₁ -C₄ 烷硫基、C₁ -C₄ 烷基亞磺醯基、C₁ -C₄ 烷基磺醯基、C₁ -C₄ 鹵代烷基磺醯基、C₁ -C₄ 烷基胺基、C₂ -C₄ 二烷基胺基、C₂ -C₄ 烷基羰基、C₂ ‑C₄ 鹵代烷基羰基、C₂ -C₅ 烷氧羰基、C₂ -C₅ 鹵代烷氧羰基、C₂ -C₅ 烷基胺基羰基或C₃ -C₅ 二烷基胺基羰基； 每個R^11a 獨立地為鹵素、羥基、氰基、胺基、硝基、C₁ -C₄ 烷基、C₁ -C₄ 鹵代烷基、C₂ -C₄ 烯基、C₂ -C₄ 炔基、C₁ -C₄ 羥烷基、C₃ -C₆ 環烷基、C₄ ‑C₇ 環烷基烷基、C₁ -C₄ 烷氧基、C₁ -C₄ 鹵代烷氧基、C₂ -C₄ 烯氧基、C₂ -C₄ 炔氧基、C₂ -C₄ 烷氧基烷基、C₂ -C₆ 烷基羰基氧基、C₁ ‑C₄ 烷硫基、C₁ -C₄ 鹵代烷硫基、C₂ -C₆ 烷基羰基硫基、C₁ -C₄ 烷基亞磺醯基、C₁ -C₄ 鹵代烷基亞磺醯基、C₁ -C₄ 烷基磺醯基、C₁ -C₄ 鹵代烷基磺醯基、C₁ -C₄ 烷基磺醯基氧基、C₁ -C₄ 烷基胺基、C₂ -C₈ 二烷基胺基、C₃ -C₆ 環烷基胺基、C₂ -C₄ 烷基羰基、C₃ ‑C₅ 烯基羰基、C₃ -C₅ 炔基羰基、C₄ -C₇ 環烷基羰基、C₅ -C₈ 環烷基烷基羰基、C₂ -C₆ 烷氧羰基、C₃ -C₇ 烯基氧羰基、C₃ -C₇ 炔基氧羰基、C₄ -C₇ 環烷氧羰基、C₅ -C₈ 環烷基烷氧羰基、C₂ -C₆ 烷基胺基羰基、C₃ -C₆ 烯基胺基羰基、C₃ -C₆ 炔基胺基羰基、C₄ -C₇ 環烷基胺基羰基、C₅ -C₈ 環烷基烷基胺基羰基、C₃ -C₈ 二烷基胺基羰基或C₃ ‑C₆ 三烷基甲矽烷基； 每個R^11b 獨立地為C(=O)H、C₁ -C₃ 烷基、C₁ -C₃ 烷氧基、C₂ -C₃ 烷基羰基或C₂ -C₃ 烷氧羰基； 每個R¹² 獨立地為H、氰基、C₁ -C₃ 烷基或C₁ -C₃ 鹵代烷基； 每個u及v獨立地為0、1或2，前提是u及v的總和為0、1或2； E² 為G-Z，其中Z連接L； G為苯基，其可選擇地被最多3個獨立地選自R¹³ 的取代基所取代；或 G為一5至6元雜芳環，每個環包含環成員，其選自碳原子以及1至4個獨立地選自最多2個O、最多2個S以及最多4個N原子的雜原子，每個環可選擇地被最多3個獨立地選自R¹³ 的取代基所取代；或 G為一3至7元非芳香環或一8至11元雙環的環系統，每個環或環系統包含環成員，其選自碳原子以及可選擇地最多4個雜原子，該雜原子獨立地選自最多2個O、最多2個S以及最多4個N原子，其中最多2個環成員獨立地選自C(=O)、C(=S)、S(=O)以及S(=O)₂ ，每個環或環系統可選擇地被最多3個獨立地選自R¹³ 的取代基所取代； 每個R¹³ 獨立地為氰基、鹵素、羥基、硝基、‑SH、SF₅ 、CH(=O)、C(=O)OH、NR^14a R^14b 、C(=O)NR^14a R^14b 、C(=O)C(=O)NR^14a R^14b 、C(=S)NR^14a R^14b 、C(R¹⁵ )=NR¹⁶ 、N=CR¹⁷ NR^18a R^18b 或‑U-V-Q；或C₁ -C₆ 烷基、C₂ ‑C₆ 烯基、C₂ -C₆ 炔基、C₃ -C₇ 環烷基、C₃ -C₇ 環烯基、C₁ -C₆ 烷氧基、C₂ -C₆ 烯氧基、C₂ -C₆ 炔氧基、C₃ -C₇ 環烷氧基、C₁ -C₆ 烷硫基、C₁ ‑C₆ 烷基亞磺醯基、C₁ -C₆ 烷基磺醯基、C₁ -C₆ 烷基胺基亞磺醯基、C₂ -C₆ 二烷基胺基亞磺醯基、C₁ -C₆ 烷基磺醯基氧基、C₁ -C₆ 烷基磺醯基胺基、C₂ -C₆ 烷基羰基、C₄ -C₇ 環烷基羰基、C₂ -C₆ 烷氧羰基、C₃ -C₆ 烯基氧羰基、C₃ -C₆ 炔基氧羰基、C₄ -C₇ 環烷氧羰基、C₃ -C₆ 烷氧羰基羰基、C₂ -C₆ 烷基羰基氧基、C₄ -C₇ 環烷基羰基氧基、C₂ -C₆ 烷氧羰基氧基、C₄ ‑C₇ 環烷氧羰基氧基、C₂ -C₆ 烷基胺基羰基氧基、C₄ ‑C₇ 環烷基胺基羰基氧基、C₂ -C₆ 烷基羰基胺基、C₄ -C₇ 環烷基羰基胺基、C₂ -C₆ 烷氧羰基胺基、C₄ -C₇ 環烷氧羰基胺基、C₂ -C₆ 烷基胺基羰基胺基、C₄ -C₇ 環烷基胺基羰基胺基或C₂ -C₆ 二烷氧基次膦基，每個可選擇地被最多3個獨立地選自R¹⁹ 的取代基所取代； 每個R^14a 獨立地為H、氰基、羥基、C₁ -C₄ 烷基、C₁ -C₄ 鹵代烷基、C₂ -C₄ 烯基、C₂ -C₄ 鹵代烯基、C₂ -C₄ 炔基、C₂ -C₄ 鹵代炔基、C₁ -C₅ 烷氧基、C₂ -C₄ 烷氧基烷基、C₁ -C₄ 烷基磺醯基、C₁ -C₄ 鹵代烷基磺醯基、C₂ -C₄ 烷硫基烷基、C₂ ‑C₄ 烷基磺醯基烷基、C₂ -C₄ 烷基磺醯基烷基、C₂ -C₄ 烷基羰基、C₂ -C₄ 鹵代烷基羰基、C₄ -C₇ 環烷基羰基、C₂ -C₅ 烷氧羰基、C₃ -C₅ 烷氧羰基烷基、C₂ -C₅ 烷基胺基羰基或C₃ ‑C₅ 二烷基胺基羰基； 每個R^14b 獨立地為H、C₁ -C₆ 烷基、C₁ -C₆ 鹵代烷基、C₂ -C₆ 烯基、C₂ -C₆ 鹵代烯基、C₂ -C₆ 炔基、C₂ -C₆ 鹵代炔基、C₁ -C₆ 羥烷基、C₂ -C₆ 氰基烷基、C₃ -C₈ 環烷基、C₃ -C₈ 鹵代環烷基、C₃ -C₈ 環烯基、C₃ -C₈ 鹵代環烯基、C₄ -C₁₀ 烷基環烷基、C₄ -C₁₀ 環烷基烷基、C₄ -C₁₀ 鹵代環烷基烷基、C₆ -C₁₄ 環烷基環烷基、C₅ -C₁₀ 烷基環烷基烷基、C₂ ‑C₆ 烷氧基烷基、C₂ -C₆ 鹵代烷氧基烷基、C₄ -C₁₀ 環烷氧基烷基、C₃ -C₈ 烷氧基烷氧基烷基、C₂ -C₆ 烷硫基烷基、C₂ -C₆ 烷基磺醯基烷基、C₂ -C₆ 烷基磺醯基烷基、C₂ -C₆ 烷基胺基烷基、C₂ -C₆ 鹵代烷基胺基烷基、C₃ -C₈ 二烷基胺基烷基或C₄ -C₁₀ 環烷基胺基烷基，每個可選擇地被最多1個選自氰基、羥基、硝基、C₂ ‑C₄ 烷基羰基、C₂ ‑C₄ 烷氧羰基、C₃ -C₁₅ 三烷基甲矽烷基、C₃ -C₁₅ 鹵代三烷基甲矽烷基以及嘧啶基的取代基所取代；或 R^14a 與R^14b 一起形成一4至6元完全飽和的雜環，每個環除了連接的氮原子外，還包含環成員，其係選自碳原子以及最多2個雜原子，該雜原子獨立地選自最多2個O、最多2個S以及最多2個N原子，每個環可選擇地被最多3個獨立地選自鹵素以及C₁ -C₃ 烷基的取代基所取代； 每個R¹⁵ 獨立地為H、氰基、鹵素、甲基、甲氧基、甲硫基或甲氧羰基； 每個R¹⁶ 獨立地為羥基或NR^20a R^20b ；或C₁ -C₄ 烷氧基、C₂ -C₄ 烯氧基、C₂ -C₄ 炔氧基、C₂ -C₄ 烷基羰基氧基、C₂ -C₅ 烷氧羰基氧基、C₂ -C₅ 烷基胺基羰基氧基或C₃ -C₅ 二烷基胺基羰基氧基，每個可選擇地被最多1個選自氰基、鹵素、羥基以及C(=O)OH的取代基所取代； 每個R¹⁷ 獨立地為H、甲基、甲氧基或甲硫基； 每個R^18a 與R^18b 獨立地為H或C₁ -C₄ 烷基；或 R^18a 與R^18b 一起形成一5至6元完全飽和的雜環，每個環除了連接的氮原子外，還包含環成員，其係選自碳原子以及最多2個雜原子，該雜原子獨立地選自最多2個O、最多2個S以及最多2個N原子，每個環可選擇地被最多2個甲基取代； 每個R¹⁹ 獨立地為胺基、氰基、鹵素、羥基、硝基、‑SH、C₁ -C₄ 烷基、C₁ -C₄ 鹵代烷基、C₃ -C₆ 環烷基、C₃ -C₆ 鹵代環烷基、C₁ -C₄ 烷氧基、C₁ -C₄ 鹵代烷氧基、C₂ -C₄ 烷氧基烷氧基、C₁ -C₄ 烷硫基、C₁ -C₄ 烷基亞磺醯基、C₁ -C₄ 烷基磺醯基、C₁ ‑C₄ 鹵代烷基磺醯基、C₂ -C₄ 烷基羰基、C₂ -C₄ 鹵代烷基羰基、C₂ -C₅ 烷氧羰基、C₁ -C₆ 烷基胺基、C₂ -C₆ 二烷基胺基、C₂ -C₅ 烷基胺基羰基、C₃ -C₅ 二烷基胺基羰基、C₃ -C₅ 烷硫基烷基羰基、C₃ ‑C₁₅ 三矽烷基、C₃ ‑C₁₅ 鹵代三烷基甲矽烷基、C(R²¹ )=NOR²² 或C(R²³ )=NR²⁴ ； 每個U獨立地為一直接鍵、C(=O)O、C(=O)N(R²⁵ )或C(=S)N(R²⁶ )，其中該左側的原子連接G，且該右側的原子連接V； 每個V獨立地為一直接鍵；或C₁ -C₆ 亞烷基、C₂ -C₆ 亞烯基、C₃ -C₆ 亞炔基、C₃ -C₆ 亞環烷基或C₃ -C₆ 亞環烯基，其中最多1個碳原子為C(=O)，每個可選擇地被最多3個獨立地選自鹵素、氰基、硝基、羥基、C₁ -C₂ 烷基、C₁ -C₂ 鹵代烷基、C₁ -C₂ 烷氧基以及C₁ -C₂ 鹵代烷氧基的取代基所取代； 每個Q獨立地為苯基或苯氧基，每個可選擇地被最多2個獨立地選自R²⁷ 的取代基所取代；或 每個Q獨立地為一5至6元雜芳環，每個環包含環成員，其選自碳原子以及1至4個雜原子，該雜原子獨立地選自最多2個O、最多2個S以及最多4個N原子，每個環可選擇地被最多2個獨立地選自R²⁷ 的取代基所取代；或 每個Q獨立地為一3至7元非芳族雜環，每個環包含環成員，其選自碳原子以及1至4個雜原子，該雜原子獨立地選自最多2個O、最多2個S以及最多4個N原子，其中最多2個環成員獨立地選自C(=O)、C(=S)、S(=O)以及S(=O)₂ ，每個環可選擇地被最多2個獨立地選自R²⁷ 的取代基所取代； 每個R^20a 獨立地為H、C₁ -C₄ 烷基或C₂ -C₄ 烷基羰基； 每個R^20b 獨立地為H、氰基、C₁ -C₅ 烷基、C₂ -C₅ 烷基羰基、C₂ -C₅ 鹵代烷基羰基、C₄ -C₇ 環烷基羰基、C₂ -C₅ 烷氧羰基、C₃ -C₅ 烷氧羰基烷基、C₂ -C₅ 烷基胺基羰基或C₃ -C₅ 二烷基胺基羰基；或 R^20a 與R^20b 一起形成一5至6元完全飽和的雜環，每個環除了連接的氮原子外，還包含環成員，其係選自碳原子以及最多2個雜原子，該雜原子獨立地選自最多2個O、最多2個S以及最多2個N原子，每個環可選擇地被最多2個甲基取代； 每個R²¹ 與R²³ 獨立地為H、氰基、鹵素、C₁ -C₃ 烷基、C₁ -C₃ 鹵代烷基、C₃ ‑C₆ 環烷基或C₁ -C₃ 烷氧基；或苯基可選擇地被最多2個獨立地選自鹵素以及C₁ -C₃ 烷基的取代基所取代； 每個R²² 獨立地為H、C₁ -C₅ 烷基、C₁ -C₅ 鹵代烷基、C₂ -C₅ 烯基、C₂ -C₅ 鹵代烯基、C₂ -C₅ 炔基、C₃ -C₆ 環烷基、C₃ -C₆ 鹵代環烷基、C₂ -C₅ 烷基羰基或C₂ -C₅ 烷氧羰基；或 每個R²² 為苯基，其可選擇地被最多2個獨立地選自鹵素以及C₁ -C₃ 烷基的取代基所取代；或一5至6元完全飽和的雜環，每個環包含環成員，其選自碳原子以及最多2個雜原子，該雜原子獨立地選自最多2個O、最多2個S以及最多2個N原子，每個環可選擇地被最多2個獨立地選自鹵素以及C₁ -C₃ 烷基的取代基所取代； 每個R²⁴ 獨立地為H、氰基、C₁ -C₃ 烷基、C₁ -C₃ 鹵代烷基、C₁ -C₄ 烷氧基、C₂ ‑C₄ 烷基羰基或C₂ -C₄ 烷氧羰基； 每個R²⁵ 與R²⁶ 獨立地為H、氰基、羥基、C₁ -C₄ 烷基、C₁ -C₄ 鹵代烷基、C₂ ‑C₄ 烷基羰基、C₂ -C₄ 鹵代烷基羰基、C₂ -C₄ 烷氧羰基或C₂ -C₄ 鹵代烷氧羰基； 每個R²⁷ 獨立地為鹵素、氰基、羥基、硝基、C₁ -C₄ 烷基、C₁ -C₄ 鹵代烷基、C₂ -C₄ 烯基、C₁ -C₄ 烷氧基、C₂ -C₄ 烷基羰基或C₂ -C₄ 烷氧羰基； Z為一直接鍵、O、S(=O)_m 、N(R²⁸ )、C(=O)、C(=O)O、C(=O)N(R²⁸ )、NR²⁸ C(=O)、N(R²⁸ )C(=O)N(R²⁸ )、N(R²⁸ )C(=S)N(R²⁸ )、OC(=O)N(R²⁸ )、N(R²⁸ )C(=O)O、S(O)₂ N(R²⁸ )、N(R²⁸ )S(=O)₂ 或N(R²⁸ )S(O)₂ N(R²⁸ )，其中該右側的原子連接L； 每個R²⁸ 獨立地為H、C₁ -C₃ 烷基、C₁ -C₃ 烷氧基、C₂ -C₃ 烷基羰基或C₂ -C₃ 烷氧羰基；以及 m為0、1或2；以及 （b）至少一種其他殺真菌化合物； 前提為： （a）當A¹ 為N(R^7a )、O或S，則A² 為一直接鍵或CR^6e R^6f ；以及 （b）當A² 為N(R^7b )、O或S，則A¹ 為CR^6c R^6d 。The present invention relates to a fungicidal composition (ie, combination, mixture) comprising (a) at least one compound selected from the group consisting of compounds of formula 1 (including all stereoisomers), tautomers, N -oxidation substances, and their salts,

where T is selected from the group consisting of:

,

, T-1 T-2 T-3 The chemical bond extending to the left connects A; R ¹ is CF ₃ , CHF ₂ , CCl ₃ , CHCl ₂ , CF ₂ Cl, CFCl ₂ or CHFCl; W is O, S or NR ³ ; R ³ is H, cyano, Nitro, C(=O)OH, benzyl, C ₁ -C ₄ alkyl, C ₂ -C ₄ alkylcarbonyl, C ₂ -C ₄ haloalkylcarbonyl, OR ^3a or NR ^3b R ^3c ; R ^3a is H, benzyl, C ₁ -C ₄ alkyl, C ₂ -C ₄ alkylcarbonyl or C ₂ -C ₄ haloalkylcarbonyl; R ^3b is H, C ₁ -C ₄ alkyl, C ₂ -C ₄ alkane or C ₂ -C ₄ haloalkylcarbonyl; R ^3c is H or C ₁ -C ₄ alkyl; or R ^3b and R ^3c together form a 4- to 6-membered fully saturated heterocycle, each ring except the attached In addition to nitrogen atoms, ring members are selected from carbon atoms and up to 2 heteroatoms independently selected from up to 2 O, up to 2 S, and up to 2 N atoms, optionally selected for each ring is substituted with up to 2 methyl groups; X is O, S or NR ^5a ; Y is O, S or NR ^5b ; each R ^5a and R ^5b are independently H, hydroxy or C ₁ -C ₄ alkyl; each R ^2a and R ^2b are independently H, C ₁ -C ₄ alkyl, C ₂ -C ₄ alkenyl, C ₃ -C ₁₅ trialkylsilyl, C ₃ -C ₁₅ halotrialkylmethyl Silyl, (CR ^4a R ^4b ) _p -OH, (CR ^4a R ^4b ) _p -SH, (CR ^4a R ^4b ) _p -Cl or (CR ^4a R ^4b ) _p -Br; or R ^2a and R ^2b and their The attached X and Y atoms together form a 5- to 7-membered saturated ring containing ring members, in addition to the X and Y atoms, are also selected from carbon atoms, wherein up to 2 carbon atomic ring members are independently selected from C(= O) and C(=S), the ring optionally having up to 2 on the carbon atom ring members independently selected from the group consisting of halogen, cyano, _C1 - _C2 alkyl, _{C1 -} C2 haloalkyl, C ₁ -C ₂ alkoxy and C ₁ -C ₂ haloalkoxy substituents; R ^2c is C ₁ -C ₄ alkyl, C ₁ -C ₄ haloalkyl, C ₂ -C ₄ alkenyl, C ₂ - _C4 haloalkenyl, C2 _{- C4} alkynyl, C2 _{- C4} haloalkynyl or trifluoromethylsulfonyl, each optionally by up to 2 independently selected from cyano , hydroxy, SC≡N and C ₁ -C ₂ alkoxy substituents; R ^2d is H, cyano, halogen or C ₁ -C ₄ alkyl; each R ^4a and R ^4b are independently H or C ₁ -C ₄ alkyl; p is 2 or 3; when T is T-1 or T-2, then A is A ¹ -A ² -CR ^6a R ^6b , wherein A ¹ is connected to J, and CR ^6a R ^6b is connected to T; When T is T-3, then A is A ¹ -A ² , wherein A ¹ is connected to J, and A ² is connected to T; A ¹ is CR ^6c R ^6d , N(R ^7a ), O or S; A ² is a direct bond, CR ^6e R ^6f , N(R ^7b ), O or S; each of R ^6a , R ^6b , R ^6c , R ^6d , R ^6e and R ^6f are independently H, cyano, hydroxyl, halogen, C(=O)OCH ₃ or C ₁ -C ₄ alkyl; each R ^7a and R ^7b are independently H, C(=O) H, cyano, C ₁ -C ₄ alkyl or C ₂ -C ₄ alkylcarbonyl; J is selected from the group consisting of:

,

,

,

, J-1 J-2 J-3 J-4

,

,

,

, J-5 J-6 J-7 J-8

,

,

,

, J-9 J-10 J-11 J-12

, J-13 J-14 wherein the bond extending to the left connects L, and the bond extending to the right connects A; each R ^is independently F, Cl, I, Br, cyano, methyl, trifluoromethyl, or methoxy; q is 0, 1, 2, 3 or 4; L is (CR ^9a R ^9b ) _n ; each R ^9a and R ^9b is independently H, halogen, cyano, hydroxy, nitro, C ₁ -C ₃ alkyl, C ₁ -C ₃ haloalkyl, C ₁ -C ₃ alkoxy or C ₁ -C ₃ haloalkoxy; n is 0, 1, 2 or 3; E is C ₁ -C ₆ alkyl or C ₁ -C ₆ haloalkyl; or E is E ¹ or E ² ; E ¹ is amino, cyano, hydroxyl, nitro, CH(=O), C(=O)OH, C(=O)NH ₂ , C( =S)NH ₂ , OC(=O)NH ₂ , OC(=S)NH ₂ , NHC(=O)NH ₂ , NHC(=S)NH ₂ , SC≡N, ‑CH=NNHC(=O) OC ₁ -C ₆ alkyl or -N(OCH ₃ )C(=O)C ₁ -C ₆ alkyl; or E ¹ is C ₁ -C ₆ alkoxy, C ₂ -C ₆ alkenyloxy, C ₂ -C ₆ alkynyloxy, C ₁ -C ₆ alkylthio, C ₂ -C ₆ alkenylthio, C ₂ -C ₆ alkynylthio, C ₁ -C ₆ alkylsulfinyl, C ₂ - C ₆ alkenylsulfinyl, C ₂ -C ₆ alkynylsulfinyl, C ₁ -C ₆ alkylsulfonyl, C ₂ -C ₆ alkenyl sulfonyl, C ₂ -C ₆ alkynyl Sulfonyl, C ₁ -C ₆ alkylsulfonamido, C ₂ -C ₆ alkenylsulfonamido, C ₂ -C ₆ alkynylsulfonamido, C ₁ -C ₆ alkylamine Sulfonyl, C ₂ -C ₆ dialkylaminosulfonyl, C ₂ -C ₆ alkenylaminosulfonyl, C ₂ -C ₆ alkynylaminosulfonyl, C ₁ -C ₆ Alkylaminosulfonamido, C ₂ -C ₆ alkenylaminosulfonamido, C ₂ -C ₆ alkynylaminosulfonamido, C ₂ -C ₆ alkylcarbonyl, C ₃ - _{C6alkenylcarbonyl} , C3 _{- C6alkynylcarbonyl} , C2 _{- C6alkylaminocarbonyl} , C3 _{- C6alkenylaminocarbonyl} , C3 _{- C6alkynylaminocarbonyl} , C2 _{- C6} alkylcarbonylamino, C3 _{- C6} alkenylcarbonylamino, C3 _{- C6} alkynylcarbonylamino, C2 _{- C6} alkylaminocarbonylamino, C3 _- C ₆ alkenylaminocarbonylamino, C3 _{- C6alkynylaminocarbonylamino} , C2 _{- C6alkylcarbonyloxy} , C3 _{- C6alkenylcarbonyloxy} , C3 _{- C6alkyne} Alkylcarbonyloxy, C ₂ -C ₆ alkoxycarbonyl, C ₃ -C ₆ alkenyloxycarbonyl, C ₃ -C ₆ alkynyloxycarbonyl, C ₂ -C ₆ alkylaminocarbonyloxy, C ₃ -C ₆ alkenylaminocarbonyloxy, C ₃ -C ₆ alkynylaminocarbonyloxy, C ₂ -C ₆ alkoxycarbonylamino, C ₃ -C ₆ alkenyloxycarbonylamino, C ₃ - C ₆ alkynyloxycarbonylamino, C ₂ -C ₆ alkylamino (thiocarbonyl) oxy, C ₃ -C ₆ alkenylamino (thiocarbonyl) oxy, C ₃ -C ₆ alkynyl Amino (thiocarbonyl)oxy, C ₂ -C ₆ alkoxy (thiocarbonyl) amine, C ₃ -C ₆ alkenyloxy (thiocarbonyl) amine, C ₃ -C ₆ alkynyloxy (thiocarbonyl) amine, C ₂ -C ₆ alkyl (thiocarbonyl), C ₂ -C ₆ (alkylthio) carbonyl, C ₃ -C ₆ alkenyl (thiocarbonyl), C ₃ -C ₆ (Alkenylthio) carbonyl, C ₃ -C ₆ alkynyl (thiocarbonyl), C ₃ -C ₆ (alkynylthio) carbonyl, C ₂ -C ₆ alkylamino (thiocarbonyl), C ₃ -C ₆ alkenylamino (thiocarbonyl), C ₃ -C ₆ alkynylamino (thiocarbonyl), C ₂ -C ₆ alkyl (thiocarbonyl) amino, C ₂ -C ₆ (alkane) thio) carbonylamino, C ₃ -C ₆ alkenyl (thiocarbonyl) amine, C ₃ -C ₆ (alkenylthio) carbonyl amine, C ₃ -C ₆ alkynyl (thiocarbonyl) amine , C ₃ -C ₆ (alkynylthio) carbonylamino, C ₂ -C ₆ alkylamino (thiocarbonyl) amino, C ₃ -C ₆ alkenylamino (thiocarbonyl) amino or C ₃ - _{C6alkynylamino} (thiocarbonyl)amino, wherein each carbon atom is optionally substituted with up to 1 substituent selected from R ^10a and up to 3 independently selected from R ^10b ; R ^10a is phenyl, optionally substituted with up to 3 substituents independently selected from R ^11a ; or a 5- to 6-membered heterocycle comprising ring members selected from carbon atoms and 1 to 4 heterocycles atoms, the heteroatoms are independently selected from up to 2 O, up to 2 S, and up to 4 N atoms, wherein up to 3 carbon atom ring members are independently selected from C(=O) and C(=S), and Sulfur atom ring members are independently S(=O) _u (=NR ¹² ) _v , each ring is optionally substituted on carbon atom ring members with up to 3 substituents independently selected from R ^11a , and in The nitrogen atom ring member is optionally substituted with up to 3 substituents independently selected from R ^11b ; each R ^10b is independently amine, cyano, halogen, hydroxyl, nitro, SC≡N, -SH , C ₁ -C ₄ alkyl, C ₁ -C ₄ haloalkyl, C ₃ -C ₆ cycloalkyl, C ₃ -C ₆ halocycloalkyl, C ₁ -C ₄ alkoxy, C ₁ -C ₄ haloalkoxy, C ₁ -C ₄ alkylthio, C ₁ -C ₄ alkyl sulfinyl, C ₁ -C ₄ alkyl sulfonyl, C ₁ -C ₄ haloalkyl sulfonyl, C ₁ -C ₄ alkane amino, C ₂ -C ₄ dialkylamine, C ₂ -C ₄ alkylcarbonyl, C ₂ -C ₄ haloalkylcarbonyl, C ₂ -C ₅ alkoxycarbonyl, C ₂ -C ₅ haloalkoxycarbonyl , C ₂ -C ₅ alkylaminocarbonyl or C ₃ -C ₅ dialkylaminocarbonyl; each R ^11a is independently halogen, hydroxy, cyano, amino, nitro, C ₁ -C ₄ alkane base, C ₁ -C ₄ haloalkyl, C ₂ -C ₄ alkenyl, C ₂ -C ₄ alkynyl, C ₁ -C ₄ hydroxyalkyl, C ₃ -C ₆ cycloalkyl, C ₄ -C ₇ ring Alkyl alkyl, C ₁ -C ₄ alkoxy, C ₁ -C ₄ haloalkoxy, C ₂ -C ₄ alkenyloxy, C ₂ -C ₄ alkynyloxy, C ₂ -C ₄ alkoxy alkoxy base, C ₂ -C ₆ alkylcarbonyloxy, C ₁ -C ₄ alkylthio, C ₁ -C ₄ haloalkylthio, C ₂ -C ₆ alkylcarbonylthio, C ₁ -C ₄ alkylidene Sulfonyl, C ₁ -C ₄ haloalkylsulfinyl, C ₁ -C ₄ alkylsulfonyl, C ₁ -C ₄ haloalkylsulfonyl, C ₁ -C ₄ alkylsulfonyloxy , C ₁ -C ₄ alkylamine group, C ₂ -C ₈ dialkylamine group, C ₃ -C ₆ cycloalkylamine group, C ₂ -C ₄ alkyl carbonyl group, C ₃ -C ₅ alkenyl carbonyl group , C ₃ -C ₅ alkynylcarbonyl, C ₄ -C ₇ cycloalkylcarbonyl, C ₅ -C ₈ cycloalkylalkylcarbonyl, C ₂ -C ₆ alkoxycarbonyl, C ₃ -C ₇ alkenyloxycarbonyl , C ₃ -C ₇ alkynyloxycarbonyl, C ₄ -C ₇ cycloalkoxycarbonyl, C ₅ -C ₈ cycloalkyl alkoxycarbonyl, C ₂ -C ₆ alkylaminocarbonyl, C ₃ -C ₆ alkene alkynylaminocarbonyl, C3 _{- C6alkynylaminocarbonyl} , _C4 - _{C7cycloalkylaminocarbonyl} , _{C5 - C8cycloalkylalkylaminocarbonyl} , C3- _C8dialkyl Aminocarbonyl or C ₃ -C ₆ trialkylsilyl; each R ^11b is independently C(=O)H, C ₁ -C ₃ alkyl, C ₁ -C ₃ alkoxy, C ₂ - C ₃ alkylcarbonyl or C ₂ -C ₃ alkoxycarbonyl; each R ¹² is independently H, cyano, C ₁ -C ₃ alkyl or C ₁ -C ₃ haloalkyl; each u and v is independently is 0, 1, or 2, provided that the sum of u and v is 0, 1, or 2; E ² is GZ, where Z is attached to L; G is phenyl, optionally up to 3 independently selected from R ¹³ or G is a 5- to 6-membered heteroaromatic ring, each ring comprising ring members selected from carbon atoms and 1 to 4 independently selected from up to 2 O, up to 2 S, and up to A heteroatom of 4 N atoms, each ring optionally substituted with up to ³ substituents independently selected from R; or G is a 3- to 7-membered non-aromatic ring or a 8 to 11 membered bicyclic ring systems, each ring or ring system comprising ring members selected from carbon atoms and optionally up to 4 heteroatoms independently selected from up to 2 O, up to 2 S and up to 4 N atoms, of which up to 2 ring members are independently selected from C(=O), C(=S), S(=O), and S(=O) ₂ , selectable for each ring or ring system is substituted with up to 3 substituents independently selected from R ¹³ ; each R ¹³ is independently cyano, halogen, hydroxyl, nitro, -SH, SF ₅ , CH(=O), C(=O )OH, NR ^14a R ^14b , C(=O)NR ^14a R ^14b , C(=O)C(=O)NR ^14a R ^14b , C(=S)NR ^14a R ^14b , C(R ¹⁵ )=NR ¹⁶ , N=CR ¹⁷ NR ^18a R ^18b or -UVQ; or C ₁ -C ₆ alkyl, C ₂ -C ₆ alkenyl, C ₂ -C ₆ alkynyl, C ₃ -C ₇ cycloalkyl, C ₃ -C ₇ cycloalkenyl, C ₁ -C ₆ alkoxy, C ₂ -C ₆ alkenyloxy, C ₂ -C ₆ alkynyloxy, C ₃ -C ₇ cycloalkoxy, C ₁ -C ₆ alkane Thio, C ₁ -C ₆ alkylsulfinyl, C ₁ -C ₆ alkylsulfinyl, C ₁ -C ₆ alkylaminosulfinyl, C ₂ -C ₆ dialkylamino Sulfinyl, C ₁ -C ₆ alkylsulfonyloxy, C ₁ -C ₆ alkylsulfonylamino, C ₂ -C ₆ alkylcarbonyl, C ₄ -C ₇ cycloalkylcarbonyl, C ₂ -C ₆ alkoxycarbonyl, C ₃ -C ₆ alkenyloxycarbonyl, C ₃ -C ₆ alkynyloxycarbonyl, C ₄ -C ₇ cycloalkoxycarbonyl, C ₃ -C ₆ alkoxycarbonyl carbonyl, C ₂ -C ₆ alkylcarbonyloxy, C ₄ -C ₇ cycloalkylcarbonyloxy, C ₂ -C ₆ alkoxycarbonyloxy, C ₄ -C ₇ cycloalkoxycarbonyloxy, C ₂ -C ₆ Alkylaminocarbonyloxy, _C4 -C7cycloalkylaminocarbonyloxy, C2 _{- C6alkylcarbonylamino} , _{C4 - C7cycloalkylcarbonylamino} , C2 _{- C6} Alkoxycarbonylamino, _{C4 -} C7cycloalkoxycarbonylamino, C2 _- C6alkylaminocarbonylamino, _{C4 - C7cycloalkylaminocarbonylamino} or C2 _{- C6} A dialkoxyphosphino group, each optionally substituted with up to 3 substituents independently selected from R ¹⁹ ; each R ^14a is independently H, cyano, hydroxy, C ₁ -C ₄ alkyl , C ₁ -C ₄ haloalkyl, C ₂ -C ₄ alkenyl, C ₂ -C ₄ haloalkenyl, C ₂ -C ₄ alkynyl, C ₂ -C ₄ haloalkynyl, C ₁ -C ₅ Alkoxy, C ₂ -C ₄ alkoxyalkyl, C ₁ -C ₄ alkylsulfonyl, C ₁ -C ₄ haloalkylsulfonyl, C ₂ -C ₄ alkylthioalkyl, C ₂ -C ₄ alkylsulfonyl alkyl, C ₂ -C ₄ alkylsulfonyl alkyl, C ₂ - C ₄ alkylcarbonyl, C ₂ -C ₄ haloalkylcarbonyl, C ₄ -C ₇ cycloalkylcarbonyl, C ₂ -C ₅ alkoxycarbonyl, C ₃ -C ₅ alkoxycarbonyl alkyl, C ₂ -C ₅ Alkylaminocarbonyl or C ₃ -C ₅ dialkylamino carbonyl; each R ^14b is independently H, C ₁ -C ₆ alkyl, C ₁ -C ₆ haloalkyl, C ₂ -C ₆ alkenyl , C ₂ -C ₆ haloalkenyl, C ₂ -C ₆ alkynyl, C ₂ -C ₆ haloalkynyl, C ₁ -C ₆ hydroxyalkyl, C ₂ -C ₆ cyanoalkyl, C ₃ -C ₈ cycloalkyl, C ₃ -C ₈ halocycloalkyl, C ₃ -C ₈ cycloalkenyl, C ₃ -C ₈ halocycloalkenyl, C ₄ -C ₁₀ alkylcycloalkyl, C ₄ - _C10 cycloalkylalkyl, _C4 - _C10 halogenated cycloalkylalkyl, _C6 - _C14 cycloalkylcycloalkyl, _C5 - _C10 alkylcycloalkylalkyl, _C2 -C ₆ alkoxyalkyl, C ₂ -C ₆ haloalkoxyalkyl, C ₄ -C ₁₀ cycloalkoxyalkyl, C ₃ -C ₈ alkoxyalkoxyalkyl, C ₂ -C ₆ alkylthioalkyl, C ₂ -C ₆ alkylsulfonyl alkyl, C ₂ -C ₆ alkylsulfonyl alkyl, C ₂ -C ₆ alkylaminoalkyl, C ₂ -C ₆ alkyl haloalkylaminoalkyl, C3 _- C8 dialkylaminoalkyl or _C4 - _C10 cycloalkylaminoalkyl, each optionally with up to ₁ selected from cyano, hydroxy, nitro Substitution of C ₂ -C ₄ alkylcarbonyl, C ₂ -C ₄ alkoxycarbonyl, C ₃ -C ₁₅ trialkylsilyl, C ₃ -C ₁₅ halotrialkylsilyl and pyrimidinyl or R ^14a and R ^14b together form a 4- to 6-membered fully saturated heterocyclic ring, each ring containing, in addition to the nitrogen atom to which it is attached, ring members selected from carbon atoms and up to 2 heteroatoms , the heteroatoms are independently selected from up to 2 O, up to 2 S, and up to 2 N atoms, each ring is optionally substituted with up to 3 substituents independently selected from halogen and _{C1 -} C3 alkyl substituted; each R ¹⁵ is independently H, cyano, halogen, methyl, methoxy, methylthio or methoxycarbonyl; each R ¹⁶ is independently hydroxy or NR ^20a R ^20b ; or C ₁ - C ₄ alkoxy, C ₂ -C ₄ alkenyloxy, C ₂ -C ₄ alkynyloxy, C ₂ -C ₄ alkylcarbonyloxy, C ₂ -C ₅ alkoxycarbonyloxy, C ₂ -C _{5Alkylaminocarbonyloxy} or C3 _{- C5dialkylaminocarbonyloxy} , each optionally by up to 1 selected from cyano, halogen, hydroxyl and C(= O) substituted by a substituent of OH; each R ¹⁷ is independently H, methyl, methoxy or methylthio; each R ^18a and R ^18b are independently H or C ₁ -C ₄ alkyl; or R ^18a and R ^18b together form a 5- to 6-membered fully saturated heterocyclic ring, each ring containing, in addition to the nitrogen atom to which it is attached, ring members selected from carbon atoms and up to 2 heteroatoms, the heteroatoms being independent is selected from up to 2 O, up to 2 S, and up to 2 N atoms, each ring is optionally substituted with up to ² methyl groups; each R is independently amine, cyano, halogen, hydroxy, Nitro, -SH, C ₁ -C ₄ alkyl, C ₁ -C ₄ haloalkyl, C ₃ -C ₆ cycloalkyl, C ₃ -C ₆ halocycloalkyl, C ₁ -C ₄ alkoxy , C ₁ -C ₄ haloalkoxy, C ₂ -C ₄ alkoxy alkoxy, C ₁ -C ₄ alkylthio, C ₁ -C ₄ alkylsulfinyl, C ₁ -C ₄ alkyl Sulfonyl, C ₁ -C ₄ haloalkylsulfonyl, C ₂ -C ₄ alkylcarbonyl, C ₂ -C ₄ haloalkylcarbonyl, C ₂ -C ₅ alkoxycarbonyl, C ₁ -C ₆ alkylamine base, C ₂ -C ₆ dialkylamino, C ₂ -C ₅ alkylaminocarbonyl, C ₃ -C ₅ dialkylamino carbonyl, C ₃ -C ₅ alkylthioalkylcarbonyl, C ₃ -C ₁₅ trisilyl group, C ₃ -C ₁₅ halogenated trialkylsilyl group, C(R ²¹ )=NOR ²² or C(R ²³ )=NR ²⁴ ; each U is independently a direct bond, C (=O)O, C(=O)N(R ²⁵ ), or C(=S)N(R ²⁶ ), where the atom on the left connects G and the atom on the right connects V; each V is independently A direct bond; or C ₁ -C ₆ alkylene, C ₂ -C ₆ alkenylene, C ₃ -C ₆ alkynylene, C ₃ -C ₆ cycloalkylene, or C ₃ -C ₆ cycloalkene radicals, wherein up to 1 carbon atom is C(=O), each optionally being up to 3 independently selected from halogen, cyano, nitro, hydroxy, _{C1 -} C2 alkyl, _C1 -C ₂ haloalkyl, C ₁ -C ₂ alkoxy, and C ₁ -C ₂ haloalkoxy substituents; each Q is independently phenyl or phenoxy, each optionally being replaced by up to 2 independently or each Q is independently a 5- to ⁶ -membered heteroaromatic ring, each ring comprising ring members selected from carbon atoms and 1 to 4 heteroatoms, the heteroatoms independently selected from up to 2 O, up to 2 S, and up to 4 N atoms, each ring is optionally substituted with up to ² substituents independently selected from R; or each Q is independently a 3 to 7 membered non-aromatic heterocycles, each ring comprising ring members selected from carbon atoms and 1 to 4 heteroatoms independently selected from up to 2 O, up to 2 S, and up to 4 N atoms, of which up to 2 ring members are independently selected from C(=O), C(=S), S(=O), and S(=O) ₂ , each ring optionally separated by up to 2 independently is substituted with a substituent selected from R ²⁷ ; each R ^20a is independently H, C ₁ -C ₄ alkyl or C ₂ -C ₄ alkylcarbonyl; each R ^20b is independently H, cyano, C ₁ -C ₅ alkyl, C ₂ -C ₅ alkylcarbonyl, C ₂ -C ₅ haloalkylcarbonyl, C ₄ -C ₇ cycloalkylcarbonyl, C ₂ -C ₅ alkoxycarbonyl, C ₃ -C ₅ alkane Oxycarbonylalkyl, C2 _{- C5} alkylaminocarbonyl or C3 _{- C5} dialkylaminocarbonyl; or R ^20a and R ^20b together form a 5- to 6-membered fully saturated heterocycle, each ring In addition to the attached nitrogen atom, also contains ring members selected from carbon atoms and up to 2 heteroatoms independently selected from up to 2 O, up to 2 S, and up to 2 N atoms, each The ring is optionally substituted with up to 2 methyl groups; each R ²¹ and R ²³ are independently H, cyano, halogen, C ₁ -C ₃ alkyl, C ₁ -C ₃ haloalkyl, C ₃ -C ₆ cycloalkyl or C ₁ -C ₃ alkoxy; or phenyl optionally substituted with up to 2 substituents independently selected from halogen and C ₁ -C ₃ alkyl; each R ²² is independently H , C ₁ -C ₅ alkyl, C ₁ -C ₅ haloalkyl, C ₂ -C ₅ alkenyl, C ₂ -C ₅ haloalkenyl, C ₂ -C ₅ alkynyl, C ₃ -C ₆ cycloalkane group, C ₃ -C ₆ halocycloalkyl, C ₂ -C ₅ alkylcarbonyl, or C ₂ -C ₅ alkoxycarbonyl; or each R ²² is phenyl, which is optionally separated by up to 2 independently substituted with substituents selected from halogen and _{C1 -} C3 alkyl; or a 5- to 6-membered fully saturated heterocyclic ring, each ring containing ring members selected from carbon atoms and up to 2 heteroatoms, the heterocyclic ring atoms independently selected from up to 2 O, up to 2 S, and up to 2 N atoms, each ring optionally substituted with up to 2 substituents independently selected from halogen and _{C1 -} C3 alkyl; Each R ²⁴ is independently H, cyano, C ₁ -C ₃ alkyl, C ₁ -C ₃ haloalkyl, C ₁ -C ₄ alkoxy, C ₂ -C ₄ alkylcarbonyl, or C ₂ -C ₄ alkoxycarbonyl; each R ²⁵ and R ²⁶ are independently H, cyano, hydroxyl, C ₁ -C ₄ alkyl, C ₁ -C ₄ haloalkyl, C ₂ -C ₄ alkylcarbonyl, C ₂ - C ₄ haloalkylcarbonyl, C ₂ -C ₄ alkoxycarbonyl, or C ₂ -C ₄ haloalkoxycarbonyl; each R ²⁷ is independently halogen, cyano, hydroxy, nitro, C ₁ -C ₄ alkyl, C ₁ -C ₄ haloalkyl, C ₂ -C ₄ alkenyl, C ₁ -C ₄ alkoxy, C ₂ -C ₄ alkylcarbonyl or C ₂ -C ₄ alkoxycarbonyl; Z is a direct bond, O, S(=O) _m , N(R ²⁸ ), C(=O), C(=O)O , C(=O)N(R ²⁸ ), NR ²⁸ C(=O), N(R ²⁸ )C(=O)N(R ²⁸ ), N(R ²⁸ )C(=S)N(R ²⁸ ), OC(=O)N(R ²⁸ ), N(R ²⁸ )C(=O)O, S(O) ₂ N(R ²⁸ ), N(R ²⁸ )S(=O) ₂ or N( R ²⁸ )S(O) ₂ N(R ²⁸ ), wherein the right atom is attached to L; each R ²⁸ is independently H, C ₁ -C ₃ alkyl, C ₁ -C ₃ alkoxy, C ₂ -C ₃ alkylcarbonyl or C ₂ -C ₃ alkoxycarbonyl; and m is 0, 1 or 2; and (b) at least one other fungicidal compound; provided that: (a) when A ¹ is N(R ^7a ), O or S, then A ² is a direct bond or CR ^6e R ^6f ; and (b) when A ² is N(R ^7b ), O or S, then A ¹ is CR ^6c R ^6d .

The present invention also relates to a composition comprising (a) at least one compound selected from the group consisting of compounds of formula 1 as described above, N -oxides thereof, and salts thereof; and at least one invertebrate pest control compound or agent.

The present invention also relates to a composition comprising a composition as described above, comprising component (a) and at least one other component selected from the group consisting of surfactants, solid diluents and Liquid thinner.

The present invention also relates to a method of controlling plant diseases caused by fungal phytopathogens, comprising applying to the plant or a part thereof or the seed of the plant a fungicidally effective amount of a composition as described above.

The above method can also be described as a method of protecting a plant or plant seed from disease caused by a fungal pathogen comprising applying to the plant (or part thereof) or plant seed (directly a fungicidally effective amount of a composition as described above) Applied to or through the environment of the plant or plant seed (eg, growth medium)).

The present invention also relates to a compound of the above formula 1, its tautomer, its N -oxide or its salts.

As used herein, the terms "comprises", "comprising", "includes", "including", "has", "having", "containing" contains," "containing," "characterized by," or any other variation intended to cover the non-exclusive specification of inclusion, subject to any limitations expressly stated. For example, a composition, mixture, process, method, article, or device comprising a series of elements is not necessarily limited to those elements, but may include such compositions, mixtures, processes, methods, articles not expressly listed or inherent, or other elements of the installation.

The conjunction "consisting of" excludes any unspecified element, step, or ingredient. If within the scope of the patent application, those substances other than those listed are excluded, with the exception of impurities generally associated therewith. If the conjunction "consisting of" appears in a clause of the main body of the patentable scope, but not immediately after the preamble, it only limits what is stated in that clause; other factors do not preclude the patentability of the entire application outside the scope.

The conjunction "consisting essentially of" is used to define a composition, method, or device that includes a material, step, feature, component, or element, except where it is literally disclosed, as long as such additional material, step, The features, components, or elements do not materially affect the basic and novel characteristics of the claimed invention. The term "consisting essentially of" is a middle ground between "comprising" and "consisting of."

Where the applicant has defined the invention or a portion thereof using an open link such as "comprising", it should be readily understood (unless otherwise stated) that the description should be construed as also using the term "consisting essentially of... ...consists of" or "consisting of".

Furthermore, unless expressly stated to the contrary, "or" is meant to be inclusive and not exclusive. For example, any one of the following conditions A or B is satisfied: A is true (or present) and B is false (or absent), A is false (or absent) and B is true (or present), and both A and B are is real (or exists).

Furthermore, the indefinite articles "a" and "an" preceding an element or component of the invention are intended to be non-limiting with respect to the number of instances (ie, occurrences) of that element or component. Thus, it should be understood that "a" or "an" shall include one or at least one and that the singular form of the element or component also includes the plural unless the number clearly means the singular.

The term "agricultural" refers to the production of field crops for food and fiber, including maize or corn, soybeans and other legumes, rice, grains (eg, wheat, oats, barley, rye, and rice), leafy vegetables ( For example, lettuce, kale, and other canola crops), fruiting vegetables (eg, tomatoes, peppers, eggplants, crucifers, and cucurbits), potatoes, sweet potatoes, grapes, cotton, tree fruits (eg, pears, stone fruits, and citrus), small fruits (eg, berries and cherries), and other specialty crops (eg, canola, sunflower, and olives).

The term "non-agricultural" refers to non-field crops, such as horticultural crops (eg, greenhouses, nurseries, or ornamentals not grown in the field), residential, agricultural, commercial, and industrial structures, turf (eg, turf farms, pastures, golf golf courses, lawns, sports fields, etc.), wood products, storage products, agroforestry, and vegetation management, public health (i.e., humans), and animal health (e.g., domestic animals such as pets, livestock and poultry, and undomesticated animals such as wild animals) )application.

The term "crop vigor" refers to the growth rate or biomass accumulation of a crop plant. "Increased vigor" refers to increased growth or biomass accumulation in crop plants relative to untreated control crop plants. The term "crop yield" refers to the quantitative and qualitative return of crop material obtained after harvesting the crop plants. "Increase in crop yield" refers to an increase in crop yield relative to untreated control crop plants.

The term "a biologically effective amount" refers to when applied to (i.e., contacting) the fungus to be controlled or its environment, or to a plant, the seeds from which the plant grows, or the locus of the plant (e.g., growing culture medium), an amount of a biologically active compound (eg, a compound of formula 1) sufficient to produce the desired biological effect to protect the plant from the fungal disease or other desired effect (eg, increase plant vigor).

As mentioned in this case and in the scope of the patent application, "plants" include all life stages of members of the plant kingdom, especially seed plants (Spermatopsida), including young plants (eg, germinated seeds that develop into seedlings) and mature, reproductive stages ( For example, plants that produce flowers as well as seeds). Parts of plants include terrestrial members, such as roots, tubers, bulbs, and bulbs, that typically grow below the surface of the growing medium (eg, soil), and members that grow on the growing medium, such as leaves (including stems and leaves), flowers , fruits and seeds.

As referred to herein, the term "seedling", used alone or in combination of words, refers to a young plant that develops from the embryo of a seed.

As referred to herein, the term "broadleaf" used alone or in words such as "broadleaf" refers to a dicot or dicotyledon, the term being used to describe a plant characterized by A group of embryonic angiosperms with two cotyledons.

As referred to in this case, the terms "fungal pathogen" and "fungal phytopathogen" include pathogens in the phyla Ascomycota, Basidiomycota and Zygomycota, as well as the eggs of fungi responsible for plant disease pathogens of great economic importance Fungi, affecting ornamental plants, turf, vegetables, fields, cereals and fruit crops. In the context of this case, "protecting plants from disease" or "controlling plant diseases" includes preventive effects (interruption of the fungal cycle of infection, colonization, symptom development, and spore production) and/or therapeutic effects (inhibition of colonization of plant host tissues) ).

As used herein, the term "mode of action" (MOA) is as defined by the Fungicide Resistance Action Committee (FRAC) and is based on its mode of biochemical action in the biosynthetic pathway of plant pathogens and their resistance risk to differentiate fungicides. The modes of action defined by FRAC include (A) nucleic acid metabolism, (B) cytoskeleton and motor proteins, (C) respiration, (D) amino acid and protein synthesis, (E) signaling, (F) lipid synthesis or transport, and Membrane integrity or function, (G) sterol biosynthesis in membrane, (H) cell wall biosynthesis, (I) melanin synthesis in cell wall, (P) host plant defense induction, (U) unknown mode of action, (M) has Multiple-site active chemicals, and (BM) organisms with multiple modes of action. Each mode of action (i.e., letters A through BM) contains one or more subgroups (eg, A includes subgroups A1, A2, A3, and A4) based on individually validated target sites of action, or In cases where the precise target site is unknown, based on cross-resistance distribution within a cohort or in relation to other cohorts. Each of these subgroups (eg, Al, A2, A3, and A4) is assigned a numeric and/or alpha FRAC code. For example, the FRAC code of subgroup A1 is 4. Additional information regarding target sites and FRAC codes can be obtained, for example, from public databases maintained by FRAC.

As used herein, the term "cross-resistance" refers to the phenomenon that occurs when pathogens become resistant to one fungicide and simultaneously become resistant to one or more other fungicides. These other fungicides are usually, but not all, in the same chemical class or have the same target site of action, or detoxify by the same mechanism.

In the above description, the term "alkyl" used alone or in compound words such as "alkylthio" or "haloalkyl" includes straight and branched chain alkyl groups, eg, methyl, ethyl, n-propyl , isopropyl, and the different butyl, pentyl, and hexyl isomers. "Alkenyl" includes straight and branched chain olefins such as vinyl, 1-propenyl, 2-propenyl, and the various butenyl, pentenyl, and hexenyl isomers. "Alkenyl" also includes polyenes such as 1,2-propadienyl and 2,4-pentadienyl. "Alkynyl" includes straight and branched chain alkynes such as ethynyl, 1-propynyl, 2-propynyl, and the various butynyl, pentynyl, and hexenyl isomers. "Alkynyl" may also include moieties consisting of multiple triple bonds, such as 2,5-hexadiynyl. "Alkylene" means a straight or branched chain alkanediyl group. Examples of "alkylene" include _CH2 , CH2CH2, _{CH ( CH3 )} , _CH2CH2CH2 , CH2CH _{( CH3 )} , and the different butene isomers. "Alkenylene" means a straight or branched chain alkenediyl group containing an olefinic bond. Examples of "alkenylene" include CH=CH, CH2CH= _CH , CH=C( _CH3 ), and the different butene isomers. "Alkynylene" means a straight or branched chain alkynediyl group containing one triple bond. Examples of "alkynylene" include _CH2C≡C , _C≡CCH2 , and the different butene, pentyne or hexyne isomers. The term "cycloalkylene" refers to a cycloalkanediyl ring. Examples of "cycloalkylene" include cyclobutanediyl, cyclopentanediol, and cyclohexanediyl. The term "cycloalkenylene" refers to a cycloalkenediyl ring containing one olefinic bond. Examples of "cycloalkenylene" include cyclopropenediyl and cyclopentenediyl.

"Alkoxy" includes, for example, methoxy, ethoxy, n-propoxy, isopropoxy, and the various butoxy, pentyloxy, and hexoxy isomers. "Alkenyloxy" includes straight and branched chain alkenyl groups attached to and through an oxygen atom. Examples of "alkenyloxy" include _H2C = _CHCH2O and CH3CH _{= CHCH2O} . "Alkynyloxy" includes both straight and branched chain linkages and alkynyl groups linked through an oxygen atom. Examples of " _alkynyloxy " include _HC≡CCH2O and _CH3C≡CCH2O .

The term "alkylthio" includes straight and branched chain alkylthio moieties such as methylthio, ethylthio, and the various propylthio and butylthio isomers. "Alkylsulfinyl" includes both enantiomers of alkylsulfinyl. Examples of "alkylsulfinyl" include _CH3S (=O), _CH3CH2S (=O), _{CH3CH2CH2S ( =} O), ( _{CH3 ) 2CHS} (=O ), and the different butylsulfinyl isomers. Examples of "alkylsulfonyl" include _CH3S (=O) ₂ , _CH3CH2S (=O) ₂ , _CH3CH2CH2S ( ₌ O _{)2 ,} ( _{CH3 ) 2CHS} ( =O) ₂ , and the different butylsulfonyl isomers. "Alkenylthio" includes straight and branched chain alkenyl groups attached and linked through a sulfur atom. Examples of "alkenylthio" include _H2C = _CHCH2S and CH3CH _{= CHCH2S} . "Alkenylsulfinyl" includes both enantiomers of alkenylsulfinyl. Examples of "alkenylsulfinyl" include _H2C = _CHCH2S (=O), CH3CH= _CHCH2S (=O), ( _{CH3 ) 2C} = _CHCH2S (=O). Examples of "alkenylsulfonyl" include CH3CH=CHS( ₌ O) ₂ , ( _CH3 ) _2C =CHCH2S(=O _{)2 .} "Alkynylthio" includes straight and branched chain alkynyl groups attached and linked through a sulfur atom. Examples of " _alkynylthio " include _HC≡CCH2S and _CH3C≡CCH2S . "Alkynylsulfinyl" includes both enantiomers of alkynylsulfinyl. Examples of "alkynylsulfinyl" include _HC≡CCH2S (=O), _{CH3C≡CCH2S (} =O). Examples of "alkynylsulfonyl" include _CH3C≡CS (=O) ₂ , _CH3C≡CCH2S (=O _{)2 .}

"Alkylthioalkyl" means alkylthio substitution on an alkyl group. _{Examples of} " _{alkylthioalkyl " include CH3SCH2 , CH3SCH2CH2 , CH3CH2SCH2 , CH3CH2CH2SCH2 , and CH3CH2SCH2CH2 ;} "Sulfinylalkyl" and "alkylsulfonylalkyl" include the corresponding sulfene and sulfoxide, respectively.

"(Alkylthio)carbonyl" means a straight or branched chain alkylthio group bound to a C(=O) moiety. Examples of "(alkylthio)carbonyl" include _CH3SC (=O), _CH3CH2CH2SC ( ₌ O), and ( _{CH3 ) 2CHSC} (=O). The terms "(alkenylthio)carbonyl" and "(alkynylthio)carbonyl" are defined similarly. Examples of "(alkenylthio)carbonyl" include _H2C = _CHCH2SC (=O) and _{CH3CH2CH =} CHSC(=O). Examples of "( _alkynylthio )carbonyl" include _HC≡CCH2SC (=O) and _{CH3C≡CCH2SC} (=O).

"Alkyl(thiocarbonyl)" means a straight or branched chain alkyl group bound to a C(=S) moiety. Examples of "alkyl(thiocarbonyl)" include _CH3CH2C (=S), _{CH3CH2CH2C ( =} S), and ( _{CH3 ) 2CHCH2C (} =S). The terms "alkenyl (thiocarbonyl)" and "alkynyl (thiocarbonyl)" are defined similarly. Examples of "alkenyl (thiocarbonyl)" include _H2C = _CHCH2CH2C (=S ₎ and _{CH3CH2CH =} CHC(=S). Examples of "alkynyl (thiocarbonyl)" include _{HC≡CCH2CH2C} (=S) and _{CH3C≡CCH2C ( =} S).

"Alkylamino (thiocarbonyl)" means a straight or branched chain alkylamino group bound to a C(=S) moiety. "Examples of an alkylamino group (thiocarbonyl)" include _CH3NHC (=S), _CH3CH2CH2NHC (=S ₎ , and ( _{CH3 ) 2CHNHC} (=S). The terms "alkenylamino (thiocarbonyl)" and "alkynylamino (thiocarbonyl)" are defined similarly. Examples of "alkenylamino (thiocarbonyl)" include _H2C = _CHCH2CH2NHC (=S) and _{CH3CH2CH = CHNHC} (=S). Examples of "alkynylamino (thiocarbonyl)" include _{HC≡CCH2CH2NHC} (=S) and _{CH3C≡CCH2NHC ( =} S).

"(Alkylthio)carbonylamino" means a straight or branched chain alkylthio group bound to a C(=O)NH moiety. Examples of "(alkylthio)carbonylamino" include _CH3CH2SC (=O)NH, _CH3CH2CH2SC ( ₌ O)NH, and ( _{CH3 ) 2CHSC (} =O)NH. The terms "(alkenylthio)carbonylamino" and "(alkynylthio)carbonylamino" are defined similarly. Examples of "(alkenylthio)carbonylamino" include _H2C = _CHCH2SC (=O)NH and CH3CH ₌ CHSC(=O)NH. Examples of "( _alkynylthio )carbonylamino" include _{HC≡CCH2CH2SC} (=O)NH and _{CH3C≡CCH2CH2SC (} =O ₎ NH.

"Alkylamino" includes NH groups substituted with straight or branched chain alkyl groups. Examples of " _alkylamine groups" include _CH3CH2NH , _CH3CH2CH2NH , and _{( CH3 ) 2CHCH2NH .} Examples of "dialkylamine groups" include ( _{CH3 )} 2N, _{( CH3CH2CH2 )} 2N, and _{CH3CH2 ( CH3 )} N. "Alkylaminoalkyl" means alkylamino substitution on an alkyl group. _{Examples of " alkylaminoalkyl " include CH3NHCH2 , CH3NHCH2CH2 , CH3CH2NHCH2 , CH3CH2CH2CH2NHCH2 , and CH3CH2NHCH2CH2 .}

"Alkylcarbonyl" means a straight or branched chain alkyl group bound to a C(=O) moiety. Examples of "alkylcarbonyl" include _CH3C (=O), _{CH3CH2CH2C (} =O), and ( _{CH3 ) 2CHC} (=O). The terms "alkenylcarbonyl" and "alkynylcarbonyl" are defined similarly. Examples of "alkenylcarbonyl" include _H2C = _CHCH2C (=O) and _{CH3CH2CH =} CHC(=O). Examples of "alkynylcarbonyl" include _HC≡CCH2C (=O) and _{CH3C≡CCH2C (} =O). "Alkoxycarbonyl" includes C(=O) moieties substituted with straight or branched chain alkoxy groups. Examples of "alkoxycarbonyl" include _CH3OC (=O ₎ , _CH3CH2OC ( ₌ O), _CH3CH2CH2OC (=O), ( _{CH3 ) 2CHOC} (=O). The terms "alkenyloxycarbonyl" and "alkynyloxycarbonyl" are defined similarly. Examples of "alkenyloxycarbonyl" include _H2C = _CHCH2OC (=O) and _{CH3CH2CH =} CHOC(=O). Examples of " _{alkynyloxycarbonyl} " include _HC≡CCH2OC (=O) and _{CH3C≡CCH2OC} (=O).

"Alkylaminocarbonyl" means a straight or branched chain alkyl group bound to an NHC(=O) moiety. Examples of "alkylaminocarbonyl" include _CH3NHC (=O), _CH3CH2NHC (=O ₎ , _{CH3CH2CH2NHC (} =O), ( _{CH3 ) 2CHNHC} (=O) . The terms "alkenylaminocarbonyl" and "alkynylaminocarbonyl" are similarly defined. Examples of "alkenylaminocarbonyl" include _H2C =CHCH2NHC(=O) and ( _{CH3 ) 2C} = _CHCH2NHC (=O). Examples of "alkynylaminocarbonyl" include _CH3C≡CNHC (=O) and _{CH3C≡CCH2NHC (} =O). Examples of "dialkylaminocarbonyl" include (CH ₃ ) ₂ N(=O), (CH ₃ CH ₂ ) ₂ NC(=O), CH ₃ CH ₂ (CH ₃ )NC(=O), ( CH ₃ ) ₂ CH(CH ₃ )NC(=O) and CH ₃ CH ₂ CH ₂ (CH ₃ )NC(=O).

The term "alkylcarbonylamino" refers to a straight or branched chain alkyl group bound to a C(=O)NH moiety. Examples of "alkylcarbonylamino" groups include _CH3CH2C ( ₌ O)NH and _{CH3CH2CH2C ( =} O)NH. The terms "alkenylcarbonylamino" and "alkynylcarbonylamino" are defined similarly. Examples of "alkenylcarbonylamino" include _H2C =CHCH2C(=O)NH and ( _{CH3 ) 2C} = _CHCH2C (=O)NH. Examples of "alkynylcarbonylamino" include _CH3C≡CCH ( _{CH3 )} C(=O)NH and HC≡CCH2CH2C ₍ =O)NH. The term "alkoxycarbonylamino" refers to an alkoxy group bound to a C(=O)NH moiety. Examples of "alkoxycarbonylamine groups" include _CH3OC (=O)NH and _CH3CH2OC ( ₌ O)NH.

The term "alkylaminocarbonylamino" refers to a straight or branched chain alkyl group bound to an NHC(=O)NH moiety. Examples of "alkylaminocarbonylamino" include _CH3CH2NHC ( ₌ O)NH and _{( CH3CH2 ) 2CH2NHC} (=O)NH. The terms "alkenylaminocarbonylamino" and "alkynylaminocarbonylamino" are defined similarly. Examples of "alkenylaminocarbonylamino" include _H2C = _CHCH2NHC (=O)NH and ( _CH3 ) _2C = _CHCH2NHC (=O)NH. Examples of "alkynylaminocarbonylamino" include _CH3C≡CCH ( _{CH3 )} NHC(=O)NH and HC≡CCH2CH2NHC ₍ =O)NH.

"Alkylsulfonylamino" means an NH group substituted with an alkylsulfonyl group. Examples of "alkylsulfonamido" include _CH3CH2S (=O)2NH and ( _{CH3 ) 2CHS} (=O _{) 2NH} . The terms "alkenylsulfonamido" and "alkynylsulfonamido" are similarly defined. Examples of "alkenylsulfonylamino" include _H2C = _CHCH2CH2S (=O)2NH and ( _{CH3 ) 2C} = _{CHCH2S (} =O ₎ 2NH. Examples of "alkynylsulfonamido" include _CH3C≡CCH ( _{CH3 )} S(=O)2NH and _{HC≡CCH2CH2S (} =O ₎ 2NH. The term "alkylsulfonyloxy" refers to an alkylsulfonyl group bound to an oxygen atom. Examples of "alkylsulfonyloxy" include _CH3S (=O)2O, _CH3CH2S ( ₌ O) _2O , _{CH3CH2CH2S ( =} O) _2O , ( _{CH 3} ) ₂ CHS(=O) ₂ O, and the different butylsulfonyloxy, pentylsulfonyloxy and hexylsulfonyloxy isomers.

"Alkylaminosulfonyl" means a straight or branched chain alkyl group bound to an NHS(=0) ₂ moiety. Examples of "alkylaminosulfonyl" include _CH3CH2NHS (=O) ₂ and ( _CH3 ) _2CHNHS (=O _{)2 .} The terms "alkenylaminosulfonyl" and "alkynylaminosulfonyl" are similarly defined. Examples of "alkenylaminosulfonyl" include _H2C =CHCH2CH2NHS( ₌ O) ₂ and ( _CH3 ) _2C = _CHCH2NHS (=O _{)2 .} Examples of "alkynylaminosulfonyl" include _CH3C≡CCH ( _{CH3 )} NHS(=O) ₂ and HC≡CCH2CH2NHS(=O _{)2 .}

"Alkylaminosulfonamido" means a straight or branched chain alkyl group bound to an NHS(= ₀ )2NH moiety. Examples of "alkylaminosulfonamido" include _CH3CH2NHS (=O)2NH and ( _{CH3 ) 2CHNHS} (=O _{) 2NH} . The terms "alkenylaminosulfonamido" and "alkynylaminosulfonamido" are defined similarly. Examples of "alkenylaminosulfonamido" include _H2C = _CHCH2CH2NHS (=O)2NH and ( _{CH3 ) 2C} = _{CHCH2NHS (} =O ₎ 2NH. Examples of "alkynylaminosulfonylamino" include _CH3C≡CCH ( _{CH3 )} NHS(=O)2NH and _{HC≡CCH2CH2NHS (} =O ₎ 2NH.

"Alkoxyalkyl" means alkoxy substitution on an alkyl group. _{Examples of " alkoxyalkyl " include CH3OCH2 , CH3OCH2CH2 , CH3CH2OCH2 , CH3CH2CH2OCH2 , and CH3CH2OCH2CH2 .} "Alkoxyalkoxy" means alkoxy substitution on another alkoxy moiety. "Alkylalkoxyalkyl" means alkoxyalkoxy substitution on an alkyl group. _{Examples of} " _{alkoxyalkoxyalkyl} " _{include CH3OCH2OCH2 , CH3OCH2OCH2CH2 , and CH3CH2OCH2OCH2 .}

The term "alkylcarbonyloxy" refers to a straight or branched chain alkyl group bonded to a C(=O)O moiety. Examples of "alkylcarbonyloxy" include _CH3CH2C (=O)O and ( _{CH3 ) 2CHC} (=O)O. The terms "alkenylcarbonyloxy" and "alkynylcarbonyloxy" are defined similarly. Examples of "alkenylcarbonyloxy" include _H2C = _CHCH2CH2C (=O)O and ( _{CH3 ) 2C} = _CHCH2C (=O)O. Examples of "alkynylcarbonyloxy" include _CH3C≡CCH ( _{CH3 )} C(=O)O and HC≡CCH2CH2C ₍ =O)O. The term "alkoxycarbonyloxy" refers to a straight or branched chain alkoxy group bound to a C(=O)O moiety. Examples of "alkoxycarbonyloxy" include _CH3CH2CH2OC (=O)O and ( _{CH3 ) 2CHOC (} =O)O. The term "alkoxycarbonylalkyl" refers to alkoxycarbonyl substitution on an alkyl group. Examples of "alkoxycarbonylalkyl" include _CH3CH2OC (=O) _CH2 , ( _CH3 ) _2CHOC (=O) _CH2 , and _CH3OC ( ₌ O _{) CH2CH2} . The term "alkylaminocarbonyloxy" refers to a straight or branched chain alkylaminocarbonyl group attached and linked through an oxygen atom. Examples of "alkylaminocarbonyloxy" include ( _{CH3 ) 2CHCH2NHC} (=O)O and _{CH3CH2NHC (} =O)O. The terms "alkenylaminocarbonyloxy" and "alkynylaminocarbonyloxy" are similarly defined.

The term "alkylcarbonylthio" refers to a straight or branched chain alkyl group bound to a C(=O)S moiety. Examples of "alkylcarbonylthio" include _CH3CH2C (=O) _S and _{CH3CH2CH2C ( =} O)S.

"Cycloalkyl" includes, for example, cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl. The term "cycloalkylalkyl" refers to cycloalkyl substitution on the alkyl moiety. Examples of "cycloalkylalkyl" include cyclopropylmethyl, cyclopentylethyl, and other cycloalkyl moieties bonded to straight or branched chain alkyl groups. The term "alkylcycloalkyl" denotes alkyl substitution on the cycloalkyl moiety, and includes, for example, ethylcyclopropyl, isopropylcyclobutyl, methylcyclopentyl, and methylcyclohexyl. "Alkylcycloalkylalkyl" means an alkylcycloalkyl substituent on an alkyl group. Examples of "alkylcycloalkylalkyl" include methylcyclohexylmethyl and ethylcyclopropylmethyl. "Cycloalkenyl" includes groups such as cyclopentenyl and cyclohexenyl as well as groups having more than one double bond such as 1,3- or 1,4-cyclohexadienyl. The term "cycloalkylcycloalkyl" refers to cycloalkyl substitution on another cycloalkyl ring, wherein each cycloalkyl ring independently has from 3 to 7 carbon atom ring members. Examples of cycloalkylcycloalkyl include cyclopropylcyclopropyl (eg 1,1'-bicyclopropyl-1-yl, 1,1'-bicyclopropyl-2-yl), cyclohexylcyclopentyl ( such as 4-cyclopentylcyclohexyl) and cyclohexylcyclohexyl (such as 1,1'-bicyclohexyl-1-yl), and the different cis- and trans-cycloalkylcycloalkyl isomers, ( For example ( 1R , 2S )-1,1'-bicyclopropyl-2-yl) and ( 1R , 2R )-1,1'-bicyclopropyl-2-yl).

The term "cycloalkoxy" refers to a cycloalkyl group attached to an oxygen atom and through an oxygen atom including, for example, cyclopentyloxy and cyclohexyloxy. The term "cycloalkoxyalkyl" refers to cycloalkoxy substitution on the alkyl moiety. Examples of "cycloalkoxyalkyl" include cyclopropoxymethyl, cyclopentoxyethyl, and other cycloalkoxy groups bonded to straight or branched chain alkyl moieties.

The term "cycloalkylaminoalkyl" refers to a cycloalkylamino substitution on an alkyl group. Examples of "cycloalkylaminoalkyl" include cyclopropylaminomethyl, cyclopentylaminoethyl, and other cycloalkylamino moieties bonded to straight or branched chain alkyl groups.

"Cycloalkylcarbonyl" means a cycloalkyl group bonded to a C(=O) group, including, for example, cyclopropylcarbonyl and cyclopentylcarbonyl. "Cycloalkylcarbonyloxy" means a cycloalkylcarbonyl group linked to and through an oxygen atom. Examples of "cycloalkylcarbonyloxy" include cyclohexylcarbonyloxy and cyclopentylcarbonyloxy. The term "cycloalkoxycarbonyl" refers to a cycloalkoxy group bonded to a C(=O) group, such as cyclopropyloxycarbonyl and cyclopentyloxycarbonyl. "Cycloalkylaminocarbonylamino" means a cycloalkylamino group bonded to a C(=O)NH group, for example, cyclopentylaminocarbonylamino and cyclohexylaminocarbonylamino.

The term "halogen" includes fluorine, chlorine, bromine, or iodine, whether alone or in compound words such as "haloalkyl," or when used in a description such as "halogen-substituted alkyl." Furthermore, when used in compound words such as "haloalkyl", or when used in descriptions such as "halogen-substituted alkyl", the alkyl group may be partially or fully substituted with halogen atoms which may be the same or different . Examples of "haloalkyl" or "halogen _- substituted _alkyl " include _CF3 , _ClCH2 , _CF3CH2 , and _CF3CCl2 . The terms "haloalkenyl,""haloalkynyl,""haloalkoxy,""haloalkylsulfonyl,""halocycloalkyl," and the like are defined similarly to the term "haloalkyl." Examples of "haloalkenyl" include _Cl2C = _CHCH2 and _{CF3CH2CH = CHCH2} . Examples of "haloalkynyl" include _HC≡CCHCl , _CF3C≡C , _CCl3C≡C , and _FCH2C≡CCH2 . Examples _of " _haloalkoxy " _{include CF3O} , _CCl3CH2O , _F2CHCH2CH2O , _{and CF3CH2O} . Examples of "haloalkylsulfonyl" include _CF3S (=O) ₂ , _CCl3S (=O) ₂ , _CF3CH2S ( ₌ O) ₂ , and _CF3CF2S (=O _{) 2} . Examples of "halocycloalkyl" include 2-chlorocyclopropyl, 2-fluorocyclobutyl, 3-bromocyclopentyl, and 4-chlorocyclohexyl.

"Cyanoalkyl" means an alkyl group substituted with one cyano group. Examples of "cyanoalkyl" include NCCH ₂ , NCCH ₂ CH ₂ , and CH ₃ CH(CN)CH ₂ . "Hydroxyalkyl" means an alkyl group substituted with one hydroxy group. Examples of " _hydroxyalkyl " include _HOCH2CH2 , _{CH3CH2 ( OH ) CH} , and _{HOCH2CH2CH2CH2} .

"Trialkylsilyl" includes tri-branched and/or straight-chain alkyl groups attached and linked through a silicon atom, such as trimethylsilyl, triethylsilyl, and tert -butyldimethylsilyl silyl group. The term "halotrialkylsilyl" is similarly defined. Examples of "halotrialkylsilyl" include trifluoromethylsilyl and trichloromethylsilyl.

The total number of carbon atoms in a substituent is indicated by the "C _i -C _j " prefix, where i and j are numbers from 1 to 15. For example, _{C1 - C4} alkylsulfonyl represents methylsulfonyl to butylsulfonyl _; C2 alkoxyalkyl represents _{CH3OCH2 ;} C3 alkoxyalkyl represents, for example, _CH3 CH(OCH ₃ ), CH ₃ OCH ₂ CH ₂ or CH ₃ CH ₂ OCH ₂ ; C ₄ alkoxyalkyl represents various isomers of alkyl substituted with alkoxy groups containing a total of 4 carbon atoms, examples Including CH ₃ CH ₂ CH ₂ OCH ₂ and CH ₃ CH ₂ OCH ₂ CH ₂ .

Typically when a molecular fragment (ie, a group) is represented by a series of atomic symbols (eg, C, H, N, O, and S), one or more points of attachment will be readily recognized by those skilled in the art. In some cases herein, particularly when alternative attachment points are possible, the attachment point may be explicitly indicated by a hyphen ("-").

The term "unsubstituted" in connection with a group such as a ring or ring system means that the group does not have any substituents other than its attachment to the remainder of Formula 1 (s). The term "optionally substituted" means that the substituent may be zero. Unless otherwise specified, optionally substituted groups can be substituted with any number of optionally substituted groups that can be accommodated by substituting a non-hydrogen substituent for a hydrogen atom on any available carbon or nitrogen atom. Typically, the number of optionally substituted groups (when present) is from 1 to 3. As used herein, the term "optionally substituted" is used interchangeably with the phrase "substituted or unsubstituted" or with the term "(un)substituted."

The number of optional substituents may be limited by the limitations of expression. For example, the phrase "optionally substituted with up to 3 substituents independently selected from ^R13 " means that 0, 1, 2 or 3 substituents may be present (if the number of potential points of attachment allows). When the specified range of the number of substituents (eg, x is an integer from 0 to 3 in Schedule A) exceeds the number of positions available for substituents on a ring (eg, (R ¹³ ) on G-7 in Schedule A _x has only 1 position available), the actual limit of the range is identified as the number of positions available.

When a compound is substituted with a substituent with a subscript, the substituent indicates that the number of the substituent may vary (eg, (R ¹³ ) _x in Schedule A, where x is 1 to 3), unless otherwise stated, the substituents are independently selected from the defined substituents. When a variable group is shown to be optionally attached, for example at the position of (R ¹³ ) _x in Schedule A, where x may be 0, then hydrogen may be used even if not listed in the definition of variable group at this location.

Dashed lines within rings described in this specification (eg, G-44, G-45, G-48, and G-49 rings in Schedule A) represent that the indicated chemical bond may be a single bond or a double bond.

The nomenclature of substituents in the context of this application uses generally accepted terms that provide brevity to accurately convey chemical structure to those skilled in the art. For brevity of reference, the index description may be omitted.

Unless otherwise stated, a "ring" or "ring system" that is a constituent of Formula 1 (eg, G) is a carbocyclic or heterocyclic ring. The term "ring system" refers to two or more linked rings. The term "spiroring system" refers to a ring system consisting of two rings joined at a single atom (thus the rings have a single atom in common). The term "bicyclic ring system" refers to a ring system consisting of two rings that share two or more atoms in common. In a "fused bicyclic ring system," the common atoms are adjacent, so the rings share two adjacent atoms and the chemical bonds that connect them.

The term "ring member" refers to an atom (eg, C, O, N, or S) or other moiety (eg, C(=O), C(=S), S(=O), and S(=O) ₂ ) form the backbone of a ring or ring system. The term "aromatic" means that each ring atom is substantially in the same plane and has a p- orbital perpendicular to the plane of the ring, and (4n + 2)π electrons, where n is a positive integer, associated with the ring to obey Hückel's rule.

The term "carbocycle" refers to a ring in which the atoms forming the ring backbone are selected from carbon only. Unless otherwise specified, carbocycles can be saturated, partially unsaturated or fully unsaturated rings. When a fully unsaturated carbocyclic ring satisfies Hückel's rule, the ring is also referred to as an "aromatic ring". "Saturated carbocycle" refers to a ring having a skeleton consisting of carbon atoms connected to each other by single bonds; unless otherwise stated, the remaining carbon valences are occupied by hydrogen atoms.

As used herein, the term "partially unsaturated ring" or "partially unsaturated heterocycle" refers to a ring that contains unsaturated ring atoms and one or more double bonds but is not aromatic.

The term "heterocyclic ring" or "heterocycle" refers to a ring in which at least one of the atoms forming the ring skeleton is not carbon. Unless otherwise specified, heterocycles can be saturated, partially unsaturated or fully unsaturated rings. When a fully unsaturated heterocyclic ring satisfies Hückel's rule, the ring is also referred to as a "heteroaromatic ring" or "aromatic heterocyclic ring". "Saturated heterocycle" refers to a heterocycle containing only single bonds between ring members.

Unless otherwise specified, heterocycles and ring systems are attached to the remainder of Formula 1 through any available carbon or nitrogen atom by replacing a hydrogen on the carbon or nitrogen atom.

The compounds of the present invention may exist as one or more stereoisomers. Stereoisomers are isomers that have the same structure but differ in the arrangement of their atoms in space, including mirror isomers, non-spiroisomers, cis and trans isomers (also known as geometric isomers), and Atropisomers. Atropisomers are rotationally restricted around a single bond because the rotational barrier is high enough to allow separation of isomeric species. Those skilled in the art will appreciate that one stereoisomer may be more active and/or may exhibit beneficial effects when enriched relative to other stereoisomers or when separated from other stereoisomers. Additionally, those skilled in the art know how to separate, enrich and/or selectively prepare such stereoisomers. For a comprehensive discussion of all aspects of stereoisomerism, see Ernest L. Eliel and Samuel H. Wilen, Stereochemistry of ORganic Compounds , John Wiley & Sons, 1994.

The compounds of the present invention may exist as mixtures of stereoisomers, individual stereoisomers, or in optically active forms. For example, when T is T-3, then the compound of formula 1 contains at least one double bond and the configuration of the substituents around the double bond can be ( Z ) or ( E ) (cis or trans), or a mixture thereof. In the context of this invention and the scope of the claims, a wavy chemical bond (eg, as shown in the T-3 moiety in the Summary) represents a single bond attached to an adjacent double bond, wherein the geometry surrounding the adjacent double bond The shape is ( Z )-configuration ( syn -isomer or cis -isomer) or ( E )-configuration (trans-isomer ( anti -isomer) isomer) or trans -isomer), or a mixture thereof. That is, a wavy chemical bond represents an unspecified ( Z )- or ( E )-(cis or trans) isomer or a mixture thereof. Additionally, the compounds of the present invention may contain one or more chiral centers and thus exist as enantiomers as well as diastereomers. Unless the structure or language of the present invention explicitly specifies a particular cis or trans isomer or configuration of a chiral center, the scope of the present invention is intended to encompass all such isomers per se, as well as cis and trans isoforms Constructs, mixtures of diastereomers, and racemic mixtures of enantiomers (optical isomers).

The present invention also includes compounds of formula 1 wherein one stereoisomer is enriched relative to the other. Of note are compounds of formula 1 wherein T is T-3 and the substituent attached to the double bond in the T-3 moiety is predominantly ( Z )-configuration, or predominantly ( E )-configuration. The ratio of ( Z )- to ( E )-isomers in any compound of formula 1, whether resulting stereoselective or non-stereoselective, can have a wide range of values. For example, the compound of Formula 1 may contain from about 10 to 90% by weight of the ( Z )-isomer to about 90 to 10% by weight of the ( E )-isomer. In other embodiments, the compound of formula 1 may comprise about 15 to 85% by weight of the ( Z )-isomer and about 85 to 15% by weight of the ( E )-isomer; in another embodiment, The mixture comprises about 25 to 75% by weight of the ( Z )-isomer and about 75 to 25% by weight of the ( E )-isomer; in another specific embodiment, the mixture comprises about 35-65% by weight of the ( Z )-isomer and about 65-35 wt% of the ( E )-isomer; in another specific embodiment, the mixture comprises about 45-55 wt% of the ( Z )-isomer and About 55-45 wt% ( E )-isomer. These weight percentages are based on the total weight of the composition and it is understood that the sum of the weight percentages of the ( Z )-isomer and the ( E )-isomer is 100% by weight. In other words, the compound of formula 1 may contain 65% by weight of the ( Z )-isomer and 35% by weight of the ( E )-isomer, and vice versa.

In addition, the present invention also includes compounds that are more enriched than the racemic mixture in the enantiomer of Formula 1. Substantially pure enantiomers of the compounds of formula 1 are also included. When enantiomers are enriched, one enantiomer is present in more than the other, and the degree of enrichment can be defined in terms of enantiomeric excess (“ee”), which Defined as (2x-1) 100%, where x is the molar fraction of the predominant enantiomer in the mixture (eg, ee is 20%, corresponding to a 60:40 enantiomer ratio).

Preferably, the more active isomer in the composition of the present invention has at least a 50% enantiomer excess; preferably, at least a 75% enantiomer excess; more preferably, at least 90% and preferably at least a 94% enantiomer excess. Of particular note are specific examples of pure enantiomers with higher activity isomers.

Due to the limited rotation around the amide bond (eg, C(=O)-N) in Formula 1, the compounds of the present invention may exist as one or more conformational isomers. The present invention encompasses mixtures of conformational isomers. In addition, the present invention includes compounds that are enriched in one conformer relative to other configurations.

The present invention includes all ratios of stereoisomers, conformational isomers and mixtures thereof as well as isotopic forms such as deuterated compounds.

Those skilled in the art will appreciate that not all nitrogen-containing heterocycles can form N -oxides because nitrogen requires available lone electron pairs to oxidize to oxides; those skilled in the art will recognize that those that can form N -oxides nitrogen-containing heterocycles. Those skilled in the art will also recognize that tertiary amines can form N -oxides. Synthetic methods for the preparation of N -oxides of heterocycles and tertiary amines are well known to those skilled in the art and include the use of peroxyacids such as peracetic acid and m -chloroperbenzoic acid (MCPBA), hydrogen peroxide , alkyl hydroperoxides such as tert-butyl hydroperoxide, sodium perborate, and dioxiranes such as dimethyldioxirane to oxidize heterocycles and tertiary amines. These methods for preparing N -oxides have been extensively described and reviewed in the literature, see e.g.: TL Gilchrist in Comprehensive ORganic Synthesis , vol. 7, pp 748-750, edited by SV Ley, PeRgamon Press; M. Tisler and B. Stanovnik in C omprehensive Heterocyclic Chemistry , vol. 3, pp 18-20, edited by AJ Boulton and A. McKillop, PeRgamon Press; MR Grimmett and BRT Keene in Advances in Heterocyclic Chemistry , vol. 43, pp 149-161, edited by AR Katritzky , Academic Press; M. Tisler and B. Stanovnik in Advances in Heterocyclic Chemistry , vol. 9, pp 285-291, edited by AR Katritzky and AJ Boulton, Academic Press; and GWH Cheeseman and ESG Werstiuk in Advances in Heterocyclic Chemistry , vol. 22 , pp 390-392, edited by AR Katritzky and AJ Boulton, Academic Press.

Those skilled in the art recognize that salts have the biological utility of non-salt forms of chemical compounds because they are in equilibrium with their corresponding non-salt forms under environmental and physiological conditions. Accordingly, various salts of the compounds of formula 1 are useful (ie, agriculturally suitable) for controlling plant diseases caused by fungal phytopathogens. Salts of compounds of formula 1 include compounds with inorganic or organic acids such as hydrobromic acid, hydrochloric acid, nitric acid, phosphoric acid, sulfuric acid, acetic acid, butyric acid, fumaric acid, lactic acid, maleic acid, malonic acid, oxalic acid, propionic acid, water Sylic acid, tartaric acid, 4-toluenesulfonic acid or valeric acid. When the compound of formula 1 contains an acidic moiety such as a carboxylic acid, the salts also include amides, hydrides, hydroxides with organic or inorganic bases such as pyridine, triethylamine or ammonia or sodium, potassium, lithium, calcium, magnesium or barium salts formed from compounds or carbonates. Accordingly, the present invention encompasses compounds selected from the group consisting of compounds of formula 1, their N -oxides, and agriculturally suitable salts, and solvates.

Compounds selected from Formula 1, whose stereoisomers, tautomers, N -oxides and salts usually exist in more than one form, therefore Formula 1 includes all crystalline forms and non-crystalline forms of the compounds represented by Formula 1 . crystalline form. Amorphous forms include embodiments of solids such as waxes and gums and embodiments of liquids such as solutions and melts. Crystalline forms include specific embodiments that represent substantially single crystal types as well as specific embodiments that represent mixtures of polymorphs (ie, different crystal types). The term "polymorph" refers to a specific crystalline form of a chemical compound that can crystallize in different crystalline forms having different arrangements and/or conformations of the molecules in the crystal lattice. While polymorphs may have the same chemical composition, they may also differ in composition due to the presence or absence of co-crystallized water or other molecules, which may be weakly or strongly bound in the crystal lattice. Polymorphs can vary in chemical, physical, and biological properties such as crystal shape, density, hardness, color, chemical stability, melting point, hygroscopicity, suspension, dissolution rate, and bioavailability. Those skilled in the art will appreciate that a polymorph of a compound represented by Formula 1 may exhibit beneficial effects relative to another polymorph or mixture of polymorphs of the same compound represented by Formula 1 (eg, suitability for the preparation of useful formulations, improved biological properties). The preparation and isolation of particular polymorphs of the compound represented by Formula 1 can be accomplished by methods known to those skilled in the art, including, for example, crystallization using selected solvents and temperatures. For a comprehensive discussion of polymorphism, see R. Hilfiker, ed., Polymorphism in the Pharmaceutical Industry , Wiley-VCH Publishing, Weinheim, 2006.

One skilled in the art recognizes that the compounds of Formula 1 can exist as a mixture of ketone and solvated forms (eg, hemiketals, ketals, and hydrates), and each independently is interconvertible and agriculturally active. For example, a ketone of formula 1 ¹ (ie, a compound of formula 1 wherein T is T-1) may exist in equilibrium with its corresponding hydrate of formula 1 ² (ie, wherein T is T-2, and R ^2a X and compounds of formula 1 in which both R ^2b Y are OH). In cases where the keto group is very close to an electron ^- withdrawing group, such as when R1 is trifluoromethyl, the equilibrium generally favors the hydrate form.

The present invention includes all ketone and solvated forms of the compounds of formula 1, and mixtures thereof. Unless otherwise stated, reference to a compound by one tautomer description shall be considered to include all tautomers.

In addition, some of the unsaturated rings and ring systems shown in Schedule A may have different arrangements of single and double bonds between the ring members than shown. This different arrangement of chemical bonds corresponds to different tautomers for a particular arrangement of ring atoms. For these unsaturated rings and ring systems, the particular tautomers described should be considered to represent all possible tautomers for the arrangement of ring atoms shown.

As described in the Summary of the Invention, one aspect of the present invention pertains to a composition comprising (a) at least one compound selected from Formula 1, its N -oxides, and salts thereof, and (b) at least one other fungicidal compound. More particularly, component (b) is selected from the group consisting of: (b1) methyl benzimidazole Carbamate (MBC) fungicides; (b2) dimethyl imide fungicides; (b3) demethylation inhibitor (DMI) fungicides; (b4) phenylamide (PA) fungicides; (b5) amine/morpholine fungicides; (b6) phospholipid biosynthesis inhibitor fungicides; (b7) succinate dehydrogenase inhibitor (SDHI) fungicides; (b8) hydroxy(2-amino-)pyrimidine fungicides; (b9) Anilinopyrimidine (AP) fungicides; (b10) N -phenylcarbamate fungicides; (b11) Quinone outside inhibitor (QoI) fungicides; ( b12) Phenylpyrrole (PP) fungicides; (b13) Azanaphthalene fungicides; (b14) Cell peroxidation inhibitor fungicides; (b15) Melanin biosynthesis inhibitor-reductase (melanin biosynthesis) inhibitor-reductase, MBI-R) fungicides; (b16a) melanin biosynthesis inhibitor-dehydratase (MBI-D) fungicides; (b16b) melanin biosynthesis inhibitor-polyketide Enzyme (melanin biosynthesis inhibitor-polyketideSynthase, MBI-P) fungicides; (b17) keto reductase inhibitor (KRI) fungicides; (b18) squalene-epoxidase inhibitor fungicides ; (b19) polytoxin fungicides; (b20) phenylurea fungicides; (b21) quinone inside inhibitor (QiI) fungicides; (b22) benzamide and thiazole carboxylate Amide fungicides; (b23) Dipyranosyl antibiotic fungicides; (b24) Hexopyranosyl antibiotic fungicides; (b25) Glucosylpyranosyl antibiotics: protein synthesis fungicides; (b26) glucopyranosyl antibiotic fungicides; (b27) cyanoacetamide oxime fungicides; (b28) carbamate fungicides; (b29) oxidative phosphorylation uncoupling fungicides; (b30) )organic Tin fungicides; (b31) Carboxylic acid fungicides; (b32) Heteroaromatic fungicides; (b33) Phosphonate fungicides; (b34) Phthalic acid fungicides; (b35) Benzene Natriazine fungicides; (b36) Benzyl sulfonamides fungicides; (b37) pyridoxine fungicides; (b38) Thiophene-carboxyamide fungicides; (b39) Complex I NADH oxidation Reductase inhibitor fungicides; (b40) Carboxylic acid amide (CAA) fungicides; (b41) Tetracycline antibiotic fungicides; (b42) Thiocarbamate fungicides; ( b43) Benzylamide fungicides; (b44) Microbial fungicides; (b45) Q _x I fungicides; quinone outside inhibitor, QoSI (quinone outside inhibitor, QoSI) fungicides; ( b46) Plant extract fungicides; (b47) Cyanoacrylate fungicides; (b48) Polyene fungicides; (b49) Oxysterol binding protein inhibitor (OSBPI) fungicides ; (b50) Aryl-phenyl-ketone fungicides (b51) Host plant defense-inducing fungicides; (b52) Multisite active fungicides; (b53) Organisms with multiple modes of action; (b54) Bactericides other than fungicides of component (a) and components (b1) to (b53); and salts of compounds (b1) to (b54).

Notably, specific embodiments of fungicidal compounds wherein component (b) comprises at least one of two different groups selected from (b1) to (b54).

"Methylbenzimidazolcarbamate (MBC) fungicide (b1)" (FRAC code 1) inhibits mitosis by binding to β-tubulin during microtubule assembly. Inhibition of microtubule assembly disrupts cell division, intracellular trafficking, and cellular architecture. Methyl benzimidazole carbamate fungicides include benzimidazole and phenylthiourea fungicides. Benzimidazoles include benomyl, carbendazim, fuberidazole, and thiabendazole. Thiouraformic acids include thiophanate and thiophanate-methyl.

"Dimethylimide fungicides (b2)" (FRAC code 2) inhibit mitogen-activated protein (MAP)/histidine kinase in osmotic signaling. Examples include chlozolinate, dimethachlone, iprodione, procymidone, and vinclozolin.

"Demethylation inhibitor (DMI) fungicide (b3)" (FRAC code 3) (sterologenic synthesis inhibitor (SBI): class I) inhibits _C14 demethylase, which in sterol function in production. Sterols, such as ergosterol, are essential for membrane structure as well as function, making them essential for the development of functional cell walls. Thus, exposure to these fungicides results in abnormal growth and eventual death of sensitive fungi. DMI fungicides are divided into several chemical classes: piperazines, pyridines, pyrimidines, imidazoles, triazoles, and triazolinethiones. Piperazines include triforine. Pyridines include butiobate, pyrifenox, pyrisoxazole, and (α S )-[3-(4-chloro-2-fluorophenyl)-5-(2, 4-Difluorophenyl)-4-isoxazolyl]-3-pyridinemethanol. Pyrimidines include fenarimol, nuarimol, and triarimol. Imidazoles include econazole, imazalil, oxpoconazole, pefurazoate, prochloraz and triflumizole. Triazoles include azaconazole, bitertanol, bromuconazole, cyproconazole, difenoconazole, diniconazole (including denizole) -M (diniconazole M), epoxiconazole, etaconazole, fenbuconazole, fluquinconazole, flusilazole, flutriafol, Hexaconazole, imibenconazole, ipconazole, ipfentrifluconazole, mefentrifluconazole, metconazole, meconazole myclobutanil, penconazole, propiconazole, quinconazole, simeconazole, tebuconazole, tetraconazole, Triadimefon , triadimenol, triticonazole, uniconazole, uniconazole P (uniconazole-P), α-(1-chlorocyclopropyl)-α-[2-(2,2 -Dichlorocyclopropyl ]ethyl]-1H-1,2,4-triazole-1-ethanol, rel -1-[[( 2R , 3S )-3-(2-chlorophenyl) -2-(2,4-Difluorophenyl)-2- oxiranyl ]methyl]-1H-1,2,4-triazole, rel -2-[[( 2R , 3S )-3-(2-chlorophenyl)-2-(2,4-difluorophenyl)-2-epoxyethylmethyl]-1,2-dihydro- 3H -1,2,4 -Triazole -3-thione, and rel -1-[[( 2R ,3S)-3-(2-chlorophenyl)-2-(2,4-difluorophenyl)-2-ring Oxyethyl]methyl]-5-(2-propen-1- ylthio )-1H-1,2,4-triazole. Triazolinones include prothioconazole. Biochemistry Studies have shown that all of the above fungicides are DMI fungicides as described by KH Kuck et al in ModernSelective Funicides-Properties , Applicatio ns , and Mechanisms of Action , in H. LyR (ed.), Gustav FischeRVerlag: New York, 1995, 205–258.

"Phenylamide (PA) fungicides (b4)" (FRAC code 4) are specific inhibitors of RNA polymerase in Oomycetes. Sensitive fungi exposed to these fungicides showed a reduced ability to incorporate uridine into rRNA. Exposure to these fungicides prevents the growth and development of sensitive fungi. Phenylamide fungicides include acylalanine, oxazolidinone, and butyrolactone fungicides. Acylalanine includes benalaxyl, benalaxyl-M (also known as kiralaxyl), furalaxyl, metalaxyl, and metalaxyl-M -M) (also known as mefenoxam). Oxazolidinones include oxadixyl. Butyrolactones include ofurace.

"Amine/morpholine fungicides (b5)" (FRAC code 5) (SBI: class II) inhibit two target sites in the ^sterologenic synthesis pathway, ^Δ8 → ^Δ7 isomerase and Δ14 reductase. Sterols, such as ergosterol, are essential for membrane structure as well as function, making them essential for the development of functional cell walls. Thus, exposure to these fungicides results in abnormal growth and eventual death of sensitive fungi. Amine/morpholine fungicides (also known as non-DMI steroidogenesis inhibitors) include morpholine, piperidine, and spiroketal amine fungicides. Morpholines include aldimorph, dodemorph, fenpropimorph, tridemorph, and trimorphamide. fenpropidin and piperalin. Spiroketal amines include spiroxamine.

"Phospholipid biosynthesis inhibitor fungicide (b6)" (FRAC code 6) inhibits the growth of fungi by affecting phospholipid biosynthesis. Phospholipid biosynthetic fungicides include phosphorus thiolates and dithiolane fungicides. Phosphothiolates include edifenphos, iprobenfos, and pyrazophos. Dithiolanes include isoprothiolanes.

"Succinate dehydrogenase inhibitor (SDHI) fungicides (b7)" (FRAC code 7) work by disrupting a key enzyme in the Krebs Cycle (TCA cycle) called succinate dehydrogenase Inhibits complex II fungal respiration. Inhibition of respiration prevents fungi from producing ATP, which in turn inhibits growth and reproduction. SDHI fungicides include phenylbenzamide, phenoxyethylthiophenamide, pyridylethylbenzamide, furancarboxamide, thiazole carboxamide, thiazolecarboxamide, pyridine azole-4-carboxamide, N -cyclopropyl- N -benzyl-pyrazolecarboxamide, N -methoxy-(phenylethyl)-pyrazolecarboxamide, pyridinecarboxamide, and Pyrazine carboxamide fungicides. Phenylbenzamides include benodanil, flutolanil, and mepronil. Phenyloxoethylthiophenamide includes isofetamid. Pyridylethylbenzamide includes fluopyram. Furancarboxamides include fenfuram. The thiane carboxamides include carboxin and oxycarboxin. Thiazole carboxamides include thifluzamide. Pyrazole-4-carboxamides include benzovindiflupyr, bixafen, flubeneteram (provisional generic name, registration number 1676101-39-5), fluorine Fluindapyr, Fluxapyroxad, Furametpyr, Inpyrfluxam, Isopyrazam, Penflufen, Penthiopyrad, Perry Pyrapropoyne (provisional generic name, registration number 1803108-03-3), sedaxane and N- [2-(2,4-dichlorophenyl)-2-methoxy -1-Methylethyl]-3-(difluoromethyl)-1-methyl- 1H -pyrazol-4-carboxamide. N -Cyclopropyl- N -benzyl-pyrazolecarboxamides include isoflucypram. N -methoxy-(phenyl-ethyl 4)-pyrazolecarboxamides include pydiflumetofen. Picolinamides include boscalid. Pyrazine carboxamides include pyraziflumid.

"Hydroxy-(2-amino-)pyrimidine fungicides (b8)" (FRAC code 8) inhibit nucleic acid synthesis by interfering with adenosine deaminase. Examples include bupirimate, dimethirimol, and ethirimol.

"Anilinopyrimidine (AP) fungicides (b9)" (FRAC code 9) are proposed to inhibit the biosynthesis of the amino acid methionine and disrupt the secretion of hydrolases that lyse plant cells during infection. Examples include cyprodinil, mepanipyrim, and pyrimethanil.

" N -phenylcarbamate fungicides (b10)" (FRAC code 10) inhibit mitosis by binding to β-tubulin and disrupting microtubule assembly. Inhibition of microtubule assembly disrupts cell division, intracellular trafficking, and cellular structure. Examples include diethofencarb.

Quinone external inhibitor (QoI) fungicides (b11) (FRAC code 11) inhibit complex III mitochondrial respiration in fungi by affecting ubiquinol oxidase. Oxidation of ubiquinol is blocked at the "exoquinone" (Qo) site of the cytochrome bc1 complex located on the inner mitochondrial membrane of fungi. Inhibition of mitochondrial respiration prevents normal fungal growth and development. Quinone external inhibitor fungicides include methoxyacrylates, methoxyacetamides, methoxycarbamates, oximoacetates, oximoacetamides, and dihydrodioxazine fungicides ( collectively referred to as strobilurin fungicides), and oxazolidinediones, imidazolidinones, and benzyl carbamate fungicides. Methoxyacrylates include azoxystrobin, coumoxystrobin, enoxastrobin (also known as enestroburin), flufenoxystrobin, Picoxystrobin and pyraoxystrobin. Methoxyacetamides include mandestrobin. Methoxycarbamates include pyraclostrobin, pyrametostrobin, and triclopyricarb. Oxime acetates include kresoxim-methyl and trifloxystrobin. Oximinoacetamides include dimoxystrobin, fenaminstrobin, metminostrobin, and orysastrobin. Dihydrodioxazines include fluoxastrobin. Oxazolidinediones include famoxadone. Imidazolidinones include fenamidone. Benzyl carbamates include pyribencarb.

"Phenylpyrrole (PP) fungicide (b12)" (FRAC code 12) inhibits MAP/histidine kinase involved in osmotic signaling in fungi. Examples of such fungicides are fenpiclonil and fludioxonil.

"Azaphthalene bactericide (b13)" (FRAC code 13) is proposed to inhibit signaling through an as yet unknown mechanism. They have been shown to interfere with germination and/or appressorium formation in powdery mildew-causing fungi. Azanaphthalene fungicides include aryloxyquinolines and quinazolinones. Aryloxyquinolines include quinoxyfen. Quinazolinones include proquinazid.

"Cytoperoxidation inhibitor fungicides (b14)" (FRAC code 14) are proposed to inhibit lipid peroxidation that affects membrane synthesis in fungi. Members of this class, such as etridiazole, may also affect other biological processes, such as respiration and melanogenesis. Cell peroxidative fungicides include aromatic hydrocarbons and 1,2,4-thiadiazole fungicides. Aromatic hydrocarbon carbon fungicides include biphenyl, chloroneb, dicloran, quintozene, tecnazene, and dexamethasone ( tolclofos-methyl). 1,2,4-thiadiazoles include etridiazole.

"Melanin biosynthesis inhibitor-reductase (MBI-R) fungicides (b15)" (FRAC code 16.1) inhibit the naphthalene reduction step in melanin biosynthesis. Melanin is required for infection of host plants by some fungi. Melanogenesis inhibitor-reductase fungicides include isobenzofuranones, pyrroloquinolinones, and triazolobenzothiazole fungicides. Isobenzofuranones include fthalide. Pyrroloquinolinones include pyroquilon. Triazolobenzothiazoles include tricyclazoles.

"Melanogenesis inhibitor-dehydratase (MBI-D) fungicide (b16a)" (FRAC code 16.2) inhibits Cylindrosporidium dehydratase in melanogenesis. Melanin is required for infection of host plants by some fungi. Melanogenesis inhibitor-dehydratase fungicides include cyclopropane carboxamides, carboxamides, and propionamide fungicides. Cyclopropanecarboxamides include carpropamid. Carboxamides include diclocymet. Propionamides include blastamide (fenoxanil).

"Melanin biosynthesis inhibitor-polyketideSynthase (MBI-P) fungicide (b16b)" (FRAC code 16.3) inhibits polyketide synthase in melanin biosynthesis. Melanin is required for certain fungi to infect host plants. Melanin biosynthesis inhibitor-polyketide synthase fungicides include trifluoroethylcarbamate fungicides. Trifluoroethyl carbamates include tolprocarbs.

"Ketoreductase Inhibitor (KRI) Bactericide (b17)" (FRAC Code 17) inhibits 3-ketoreductase during C4-demethylation in sterol production. Ketoreductase inhibitor fungicides (also known as Sterol Biosynthesis Inhibitors (SBI): Class III) include hydroxyanilines and aminopyrazolones. Hydroxycyanides include fenhexamid. Aminopyrazolones include fenpyrazamine. Quinofumelin (provisional generic name, registration number 861647-84-9) and ipflufenoquin (provisional generic name, registration number 1314008-27-9) are also considered ketones Reductase inhibitor fungicide.

"Squalene-epoxidase inhibitor fungicide (b18)" (FRAC code 18) (SBI: Class IV) inhibits squalene epoxidase in the sterologenic synthesis pathway. Sterols such as ergosterol are essential for membrane structure as well as function, which are essential for the development of functional cell walls. Exposure to these fungicides thus results in abnormal growth and ultimately the death of sensitive fungi. Squalene-epoxidase inhibitor fungicides include thiocarbamates and allylamine fungicides. Thiocarbamates include pyributicarb. Allylamines include naftifine and terbinafine.

"Polytoxin fungicides (b19)" (FRAC code 19) inhibit chitin synthase. Examples include polyoxin.

"Phenylurea fungicides (b20)" (FRAC code 20) are proposed to affect cell division. Examples include pencycuron.

"Quinone inhibitor (QiI) fungicides (b21)" (FRAC code 21) inhibit complex III mitochondrial respiration in fungi by affecting ubiquinone reductase. The reduction of ubiquinone is blocked at the "quinone-internal" (Qi) site of the cytochrome bc ₁ complex located on the endometriotic membrane of fungi. Inhibition of mitochondrial respiration prevents normal fungal growth and development. Quinone inhibitor fungicides include cyanoimidazoles, sulfamonotriazoles, and picolinamide fungicides. Cyanoimidazoles include cyazofamid. Sulfamonotriazoles include indazosulfamide (amisulbrom). Picolinamides include fenpicoxamid (registration number 517875-34-2).

"Benzalamide and thiazole carboxamide fungicides (b22)" (FRAC code 22) inhibit mitosis by binding to β-tubulin and disrupting microtubule assembly. Inhibition of microtubule assembly disrupts cell division, intracellular trafficking, and cellular architecture. Benzylamides include toluidines such as zoxamide. Thiazole carboxamides include ethylaminothiazole carboxamides such as ethaboxam.

"Enpyranuronic acid antibiotic fungicides (b23)" (FRAC code 23) inhibit the growth of fungi by affecting protein biosynthesis. Examples include blasticidin-S.

"Hexopyranosyl antibiotic fungicides (b24)" (FRAC code 24) inhibit the growth of fungi by affecting protein biosynthesis. Examples include kasugamycin.

"Glucopyranosyl Antibiotic: Protein Synthesis Bactericide (b25)" (FRAC Code 25) inhibits fungal growth by affecting protein biosynthesis. Examples include streptomycin.

"Glucopyranosyl antibiotic fungicide (b26)" (FRAC code U18, former FRAC code 26, reclassified as U18) is used to inhibit trehalase and inositol biosynthesis. Examples include validamycin.

"Cyanoacetamide oxime fungicide (b27)" (FRAC code 27) includes cymoxanil.

"Carbamate fungicides (b28)" (FRAC code 28) are considered to be multi-site inhibitors of fungal growth. It is proposed to interfere with the synthesis of fatty acids in the cell membrane and then disrupt the permeability of the cell membrane. Examples of such fungicides are iodocarb, propamacarb and prothiocarb.

"Oxidative phosphorylation uncoupling fungicide (b29)" (FRAC code 29) inhibits fungal respiration by uncoupling oxidative phosphorylation. Inhibition of respiration prevents normal fungal growth and development. This category includes dinitrophenyl crotonates, such as binapacryl, meptyldinocap, and dinocap, and 2,6-dinitroanilines, such as fluazinam .

"Organotin fungicides (b30)" (FRAC code 30) inhibit adenosine triphosphate (ATP) synthase in the oxidative phosphorylation pathway. Examples include fentin acetate, fentin chloride and fentin hydroxide.

"Carboxylic acid fungicides (b31)" (FRAC code 31) inhibit the growth of fungi by affecting deoxyribonucleic acid (DNA) type II topoisomerase (gyrase). Examples include oxolinic acid.

"Heteroaromatic fungicides (b32)" (FRAC code 32) are used to affect DNA/ribonucleic acid (RNA) synthesis. Heteroaromatic fungicides include isoxazoles and isothiazolones. Isoxazoles include hymexazole and isothiazolones include octhilinone.

"Phosphonate fungicides (b33)" (FRAC code P07, formerly FRAC code 33, reclassified as P07) include phosphorous acid and its various salts, including fosetyl-aluminum.

"Phthalic acid fungicide (b34)" (FRAC code 34) includes teclofthalam.

"Benzotriazine fungicides (b35)" (FRAC code 35) include triazoxide.

"Sulfonamide fungicides (b36)" (FRAC code 36) include flusulfamide.

"Ta𠯤 ketone fungicides (b37)" (FRAC code 37) include diclomezine.

"Thiophene-carboxyamide fungicides (b38)" (FRAC code 38) are proposed to affect ATP production. Examples include silthiofam.

"Complex I NADH oxidoreductase inhibitor fungicides (b39)" (FRAC code 39) inhibit electron transport in the mitochondria, including pyrimidinamines such as diflumetorim, pyrazole-5-carboxamide Such as tofenrui (tolfenpyrad), and quinazolines such as fen kill mites (fenazaquin).

"Carboxyamide (CAA) Fungicide (b40)" (FRAC code 40) inhibits cellulose synthase, which prevents growth and leads to the death of target fungi. Carboxylic amide fungicides include cinnamate amide fungicides, valine amide amine methylate, and mandelic acid amide fungicides. Cinnamates include dimethomorph, flumorph, and pyrimorph. Valinamide carbamates include benthiavalicarb, benthiavalicarb-isopropyl, iprovalicarb, carbamate fungicides tolprocarb, and Valifenalate (also known as valiphenal). Mandelates include mandipropamid, N- [2-[4-[[3-(4-chlorophenyl)-2-propyn-1-yl]oxy]-3- Methoxyphenyl]ethyl]-3-methyl-2-[(methylsulfonyl)amino]butanamide and N- [2-[4-[[3-(4-chlorophenyl )-2-propyn-1-yl]oxy]-3-methoxyphenyl]ethyl]methyl-2-[(ethylsulfonyl)amino]butanamide.

"Tetracycline antibiotic fungicides (b41)" (FRAC code 41) inhibit the growth of fungi by affecting protein synthesis. Examples include oxytetracycline.

"Thiocarbamate fungicides (b42)" (FRAC code M12, formerly FRAC code 42, reclassified as M12) includes methasulfocarb.

"Benzalamide fungicides (b43)" (FRAC code 43) inhibit fungal growth through spectrin-like delocalization. Examples include pyridylmethylbenzamides such as fluopicolide and fluopimomide.

"Microbial fungicides (b44)" (FRAC code BM02, formerly FRAC code 44, reclassified as BM02) disrupts fungal pathogen cell membranes. Microbial fungicides include Bacillus species such as Bacillus amyloliquefaciens strains AP-136, AP-188, AP-218, AP-219, AP-295, QST713, FZB24, F727, MB1600, D747, TJ100 (also known as strain 1 BE; published from EP2962568), and the fungicidal lipopeptides they produce.

"Quinone Outside Inhibitor, Paxillomycin Binding (QoSI) Fungicide (b45)" (FRAC Code 45) works by affecting the "quinone outside" (Qo) site of the cytochrome bc ₁ complex, labeling Paxillin-binding subsite of ubiquinone reductase inhibits complex III mitochondrial respiration in fungi. Inhibition of mitochondrial respiration prevents normal fungal growth and development. QoSI fungicides include triazolopyrimidine amines such as ametoctradin.

"Plant Extract Fungicide (b46)" (FRAC No. 46) causes cell membrane damage. Plant extract fungicides include terpene olefins, terpene alcohols, and terpene phenols, such as extracts from Melaleuca alternifolia (tea tree), and vegetable oils (mixtures) such as eugenol , geraniol, and thymol.

"Cyanoacrylate fungicide (b47)" (FRAC code 47) binds to the myosin motor domain and affects motor activity as well as actin assembly. Cyanoacrylates include fungicides such as phenacril.

"Polyethylene fungicide (b48)" (FRAC code 48) causes the destruction of fungal cell membranes by binding to ergosterol, the major sterol in the membrane. Examples include natamycin (pimaricin).

"Oxysterol-binding protein inhibitor (OSBPI) bactericide (b49)" (FRAC code 49) binds to oxysterol-binding protein in oomycetes, resulting in inhibition of zoospore release, zoospore motility, and sporangia germination . Oxysterol-binding fungicides include piperidinylthiazole isoxazolines such as oxathiapiprolin and fluoxapiprolin.

"Aryl-phenyl-ketone fungicides (b50)" (FRAC code 50, formerly FRAC code U8, reclassified to 50) inhibit mycelial growth in fungi. Aryl-phenone fungicides include benzophenones, such as metrafenone, and benzalkonium pyridines, such as pyriofenone.

"Host Plant Defense Inducing Fungicide (b51)" induces host plant defense mechanisms. Host plant defense-inducing fungicides include benzothiadiazoles (FRAC code P01), benzisothiazoles (FRAC code P02), thiadiazole carboxamides (FRAC code P03), polysaccharides (FRAC code P04), plant extracts biocides (FRAC code P05), microorganisms (FRAC code P06) and phosphonate fungicides (FRAC code P07, see above (b33)). Benzothiadiazoles include acibenzolar-S-methyl. Benzisothiazoles include probenazole. Thiadiazole carboxamides include tiadinil and isotianil. Polysaccharides include laminarin. Botanical extracts include extracts from Reynoutria Sachalinensis (Knotweed). Microorganisms included Bacillus mycoides isolate J and cell walls of Saccharomyces Cerevisiae strain LAS117.

"Multi-site active fungicide (b52)" inhibits fungal growth through multiple sites of action and has contact/preventive activity. Multisite active fungicides include copper fungicides (FRAC code M01), sulfur fungicides (FRAC code M02), dithiocarbamate fungicides (FRAC code M03), phthalimide fungicides ( FRAC code M04), chlornitrile fungicides (FRAC code M05), sulfonamides fungicides (FRAC code M06), multi-site contact guanidine fungicides (FRAC code M07), triazine fungicides (FRAC code M08) , quinone fungicides (FRAC code M09), quinoxaline fungicides (FRAC code M10), maleimide fungicides (FRAC code M11) and thiocarbamates (FRAC code M12, please See above (b42)) biocides. Copper fungicides are inorganic compounds containing copper, usually in the copper(II) oxidation state; examples include copper oxychloride, copper sulfate, and copper hydroxide, for example, compositions including, for example, Bordeaux mixture (copper tribasic sulfate) . Sulfur-containing biocides are inorganic chemicals that contain rings or chains of sulfur atoms; examples include elemental sulfur. Dithiocarbamate fungicides contain dithiocarbamate moieties; examples include ferbam, mancozeb, maneb, metiram, Methyl zinc is propineb, thiram, zinc thiazole, zineb and ziram. Phthalimide fungicides contain phthalimide molecular moieties; examples include folpet, captan, and captafol. Chloronitrile fungicides contain aromatic rings substituted with chlorine and cyano groups; examples include chlorothalonil. Sulfonamide fungicides include dichlofluanid and tolyfluanid. Multiple-site exposure guanidine fungicides include guazatine, iminoctadine albesilate, and imnoctadine triacetate. Triazine fungicides include anilazine. Quinone fungicides include dithianon. Quinoxaline fungicides include quinomethionates (also known as thiosulfates). Maleimide fungicides include fluoroimide.

"Biologics with multiple modes of action (b53)" include agents of biological origin that exhibit multiple mechanisms of action without evidence of a primary mode of action. Such fungicides include polypeptides (lectins), phenols, sesquiterpenes, triterpenes, and coumarin fungicides (FRAC code BM01), such as extracts from lupin leaflets. This class also includes microbial fungicides (FRAC code BM02, see above (b44)).

"Fungicides other than fungicides of component (a) and components (b1) to (b53); (b54)"; includes certain fungicides, the mode of action of which may be unknown. These include: (b54.1) "Phenylacetamide fungicides" (FRAC code U06), (b54.2) "Guidine fungicides" (FRAC code U12), (b54.3) "Thiazolidine fungicides" Fungicides” (FRAC code U13), (b54.4) “Pyrimidone hydrazone fungicides” (FRAC code U14), (b54.5) “4-quinolinyl acetate fungicides” (FRAC code U16) , (54.6) "tetrazolium hydroxime fungicides" (FRAC code U17) and "glucopyranosyl antibiotics" fungicides" (FRAC code U18, see (b26) above). Phenylacetamides include cyflufenamid. Guanidines include dodine. Thiazolidines include flutianil. Pyrimidone hydrazones include ferimzone. 4-Quinolinyl acetate includes tebufloquin. Tetrazolyl oximes include picarbutrazox.

Class (b54) also includes bethoxazin, benzothiazole fungicide dichlobentiazox (provisional generic name, registration number 957144-77-3), dipymetitrone (provisional generic name, registration number 957144-77-3) No. 16114-35-5), flometoquin, neo-asozin, pyrrolnitrin, tolnifanide (Registration No. 304911-98-6) , N '-[4-[4-Chloro-3-(trifluoro-methyl)phenoxy]-2,5-dimethyl-phenyl] -N -ethyl- N -methyl-methyl Imidamide, 5-fluoro-2-[(4-fluorophenyl)methoxy]-4-pyrimidinamine, and 4-fluorophenyl N- [1-[[[1-(4-cyano Phenyl)ethyl]sulfonyl]methyl]-propyl]carbamate.

Fungicides other than fungicides of action classes (1) to (54) "The mode of action may be unknown, or may not yet be classified. Fungicides include those selected from the group consisting of components (b54.7) to ( b54.13) fungicidal compounds, as described below.

Composition (54.7) involves ( 1S )-2,2-bis(4-fluorophenyl)-1-methylethyl N -[[3-(acetoxy)-4-methoxy-2 -Pyridyl]carbonyl]-L-alanine salt (provisional generic name florylpicoxamid, registration number 1961312-55-9), considered to be a quinone inhibitor that inhibits mitochondrial respiration of endocomplex III in fungi (Quinone inside inhibitor, QiI) fungicide (FRAC code 21).

Composition (54.8) involves 1-[2-[[[1-(4-chlorophenyl) -1H -pyrazol-3-yl]oxy]methyl]-3-methylphenyl]-1 ,4-Dihydro-4-methyl- 5H -tetrazol-5-one (provisional common name metyltetraprole, registration number 1472649-01-6), considered to be an inhibitory compound in fungi III Exoquinone inhibitor (QoI) fungicide (FRAC code 45) of mitochondrial respiration and effective against QoI-resistant strains.

Composition (54.9) involves 3-chloro-4-(2,6-difluorophenyl)-6-methyl-5-phenylpyridazine (provisionally generic name pyridachlometyl), Registration No. 1358061-55-8), is thought to promote the polymerization of tubulin, which in turn produces antifungal activity against fungal species belonging to the phyla Ascomycota and Basidiomycota.

Composition (54.10) relates to (4-phenoxyphenyl)methyl 2-amino-6-methyl-pyridine-3-carboxylate (provisional generic name aminopyrifen, registration number 1531626-08-0), which is thought to inhibit the GWT-1 protein in the biosynthesis of glycosylphosphatidylinositol in the pink bread mold ( Neurospora Crassa).

其中 每個R^b1 與R^b3 獨立地為鹵素；以及 R^b2 為H、鹵素、C₁ -C₃ 烷基、C₁ -C₃ 鹵代烷基或C₃ -C₆ 環烷基。Composition (b54.11) involves a compound of formula b54.11

wherein each of R ^b1 and R ^b3 is independently halogen; and R ^b2 is H, halogen, C ₁ -C ₃ alkyl, C ₁ -C ₃ haloalkyl, or C ₃ -C ₆ cycloalkyl.

Examples of compounds of formula b54.11 include ( b54.11a )methyl N -[[5-[1-(2,6-difluoro-4-carboxyphenyl)-1H-pyrazole-3- yl]-2-methylphenyl]methyl]carbamate, (b54.11b)methyl N -[[5-[1-(4-cyclopropyl-2,6-dichlorophenyl )-1H-pyrazol-3-yl]-2-methylphenyl]methyl]carbamate, ( b54.11c)methyl N - [[5-[1-(4-chloro- 2,6-Difluorophenyl)-1H-pyrazol-3-yl]-2-methylphenyl]methyl]carbamate, ( b54.11d)methyl N - [[5- [1-(4-Cyclopropyl-2,6-difluorophenyl) -1H -pyrazol-3-yl]-2-methylphenyl]methyl]carbamate, (b54. 11e) Methyl N -[[5-[1-[2,6-difluoro-4-(1-methylethyl)phenyl] -1H -pyrazol-3-yl]-2-methyl Phenyl]methyl]carbamate and ( b54.11f )methyl N -[[5-[1-[2,6-difluoro-4-(trifluoromethyl)phenyl]-1H - Pyrazol-3-yl]-2-methylphenyl]methyl]carbamate. Compounds of formula b54.11, their use as fungicides and methods of preparation are known; see, eg, PCT Patent Application Publication Nos. WO 2008/124092, WO 2014/066120 and WO 2020/097012.

其中 R^b4 為

  

； R^b6 為C₂ -C₄ 烷氧羰基或C₂ -C₄ 鹵代烷基胺基羰基； L為CH₂ 或CH₂ O，其中右側的原子連接式b54.12 中的苯基環；以及 R^b5 為

。 Composition (b54.12) involves a compound of formula b54.12

where R ^b4 is

; R ^b6 is C ₂ -C ₄ alkoxycarbonyl or C ₂ -C ₄ haloalkylaminocarbonyl; L is CH ₂ or CH ₂ O, wherein the atom on the right is connected to the phenyl ring in formula b54.12 ; and R ^b5 for

.

Examples of compounds of formula b54.12 include (b54.12a) N- (2,2,2-trifluoroethyl)-2-[[4-[5-(trifluoromethyl)-1,2,4 -Oxadiazol-3-yl]phenyl]methyl]-4-oxazolecarboxamide and (b54.12b)ethyl 1-[[4-[5-(trifluoromethyl)-1,2 ,4-oxadiazol-3-yl]phenoxy]methyl] -1H -pyrazole-4-carboxylate. Compounds of formula b54.11, their use as fungicides, and methods of preparation are known; see, eg, PCT Patent Publication No. WO 2020/056090.

其中 每個R^b7 、R^b8 與R^b9 獨立地為H、鹵素或氰基；以及 每個R^b10 與R^b11 獨立地為H、鹵素、C₁ -C₃ 烷基或C₁ -C₃ 甲氧基。Composition (b54.13) involves a compound of formula b54.13

wherein each R ^b7 , R ^b8 and R ^b9 is independently H, halogen or cyano; and each R ^b10 and R ^b11 is independently H, halogen, C ₁ -C ₃ alkyl or C ₁ -C ₃ methyl Oxygen.

Examples of compounds of formula b54.13 include (b54.13a)4-(2-chloro-4-fluorophenyl)-N-(2-fluoro - 4-methyl-6-nitrobenzene)-1,3 -Dimethyl- 1H -pyrazol-5-amine, (b54.13b)4-(2-chloro-4-fluorophenyl)-N-(2-fluoro - 6-nitrobenzene)-1, 3-Dimethyl-1 H -pyrazol-5-amine, (b54.13c) 3,5-difluoro-4-[5-[(4-methoxy-2-nitrophenyl)amino] -1,3-Dimethyl- 1H -pyrazol-4-yl]-benzonitrile and (b54.13d) N- (2-chloro-4-fluoro-6-nitrobenzene)-4-(2 -chloro-4-fluorophenyl)-1,3-dimethyl- 1H -pyrazol-5-amine. Compounds of formula b54.11 , their use as fungicides and methods of preparation are known; see, eg, PCT Patent Publication No. WO 2020051402.

Specific embodiments of the invention as described in the Summary of the Invention include those described below. In the following specific examples, formula 1 includes its stereoisomers, N -oxides, and salts, and unless further defined in the specific examples, references to "a compound of formula 1" are included in the Summary of the Invention Definitions of the mentioned substituents.

Specific Example 1. A composition comprising components (a) and (b) described in the Summary of the Invention, wherein in Formula 1, T is T-1.

Embodiment 2. A composition comprising components (a) and (b) described in the Summary of the Invention, wherein in Formula 1, T is T-2.

Embodiment 3. A composition comprising components (a) and (b) described in the Summary of the Invention, wherein in Formula 1, T is T-3.

Embodiment 3a. A composition comprising components (a) and (b) described in the Summary of the Invention, wherein in Formula 1, T is T-2 or T-3.

Example 4. A composition comprising components (a) and (b) described in the Summary, wherein in Formula 1, R ¹ is CF ₃ .

Embodiment 5. A composition comprising components (a) and (b) described in the Summary of the Invention or any one of Embodiments 1 to 4, wherein in Formula 1, W is O or S.

Example 6. The composition of Example 5, wherein W is O.

Embodiment 7. A composition comprising components (a) and (b) described in the Summary of the Invention or any one of Embodiments 1 to 4, wherein in Formula 1, W is NR ³ .

Embodiment 8. A composition comprising components (a) and (b) described in the Summary of the Invention or any one of Embodiments 1 to 7, wherein in Formula 1, ^R is H, cyano, C(=O)OH, C ₁ -C ₂ alkyl, C ₂ -C ₃ alkylcarbonyl, C ₂ -C ₃ haloalkylcarbonyl, OR ^3a or NR ^3b R ^3c .

Embodiment 9. The composition of Embodiment 8, wherein R ³ is H, cyano, C ₁ -C ₂ alkyl, or OR ^3a .

Embodiment 10. The composition of Embodiment 9, wherein R ³ is H, cyano, or OR ^3a .

Embodiment 11. A composition comprising components (a) and (b) described in the Summary of the Invention or any one of Embodiments 1 to 10, wherein in Formula 1, R ^3a is H, C ₁ - C ₂ alkyl, C ₂ -C ₃ alkylcarbonyl or C ₂ -C ₃ haloalkylcarbonyl.

Embodiment 12. The composition of Embodiment 11, wherein ^R3a is H.

Embodiment 13. A composition comprising components (a) and (b) described in the Summary of the Invention or any one of Embodiments 1 to 12, wherein in Formula 1, when R ^3b is isolated (also That is, not forming a ring together with R ^3c ), then R ^3b is H, C ₁ -C ₃ alkyl, C ₂ -C ₃ alkylcarbonyl or C ₂ -C ₃ haloalkylcarbonyl.

Embodiment 14. The composition of Embodiment 13, wherein ^R3b is H or methyl.

Embodiment 15. A composition comprising components (a) and (b) described in the Summary of the Invention or any one of Embodiments 1 to 14, wherein in Formula 1, when R ^3c is isolated (also That is, not together with R ^3b to form a ring), then R ^3c is H or C ₁ -C ₂ alkyl.

Embodiment 16. The composition of Embodiment 15, wherein ^R3c is H or methyl.

Embodiment 17. A composition comprising components (a) and (b) described in the Summary of the Invention or any one of Embodiments 1 to 16, wherein in Formula 1, X is O or ^NR5a .

Embodiment 18. A composition comprising components (a) and (b) described in the Summary of the Invention or any one of Embodiments 1 to 16, wherein in Formula 1, X is O, S, NH or NOH.

Embodiment 19. The composition of Embodiment 18, wherein X is O or NOH.

Embodiment 20. The composition of Embodiment 20, wherein X is O.

Embodiment 21. A composition comprising components (a) and (b) as described in the Summary of the Invention or any one of Embodiments 1 to 20, wherein in Formula 1, Y is O or NR ^5b .

Embodiment 22. A composition comprising components (a) and (b) described in the Summary of the Invention or any one of Embodiments 1 to 20, wherein in Formula 1, Y is O, S, NH or NOH.

Embodiment 23. The composition of Embodiment 22, wherein Y is O or NOH.

Embodiment 24. The composition of Embodiment 23, wherein Y is O.

Embodiment 25. A composition comprising components (a) and (b) described in the Summary of the Invention or any one of Embodiments 1 to 24, wherein in Formula 1, each R ^5a and R ^5b are independently is H, hydroxy or C ₁ -C ₂ alkyl.

Embodiment 26. The composition of Embodiment 25, wherein each R ^5a and R ^5b is independently H, hydroxy, or methyl.

Embodiment 27. A composition comprising components (a) and (b) described in the Summary of the Invention or any one of Embodiments 1 to 26, wherein in Formula 1, when R ^2a is separated from R ^2b ( That is, do not together form a ring), then each R ^2a and R ^2b are independently H, C ₁ -C ₃ alkyl, C ₂ -C ₃ alkenyl, (CR ^4a R ^4b ) _p -OH, (CR ^4a R ^4b ) _p -Cl or (CR ^4a R ^4b ) _p -Br.

Embodiment 27a. A composition comprising components (a) and (b) described in the Summary of the Invention or any one of Embodiments 1 to 26, wherein in Formula 1, when R ^2a and R ^2b are separated ( that is, not together forming a ring), then each R ^2a and R ^2b is independently H, C ₁ -C ₃ alkyl, C ₃ -C ₁₅ trialkylsilyl, or C ₃ -C ₁₅ halo Substituted trialkylsilyl.

Embodiment 27b. The composition of Embodiment 27a, wherein each R ^2a and R ^2b is independently H, methyl, trimethylsilyl, or halotrimethylsilyl.

Embodiment 27c. The composition of Embodiment 27b, wherein each R ^2a and R ^2b is independently H, methyl, trimethylsilyl, or trifluoromethylsilyl.

Embodiment 27d. The composition of Embodiment 27c, wherein each R ^2a and R ^2b is independently H, methyl, or trimethylsilyl.

Embodiment 27e. The composition of Embodiment 27d, wherein R ^2a is H and R ^2b is trimethylsilyl.

Embodiment 27f. The composition of Embodiment 27d, wherein R ^2a is methyl and R ^2b is trimethylsilyl.

Embodiment 28. The composition of Embodiment 27, wherein each R ^2a and R ^2b are independently H, C ₁ -C ₃ alkyl, (CR ^4a R ^4b ) _p -Cl or (CR ^4a R ^4b ) _p -Br.

Embodiment 29. The composition of Embodiment 28, wherein each R ^2a and R ^2b is independently H, methyl, (CR ^4a R ^4b ) _p -Cl or (CR ^4a R ^4b ) _p -Br.

Embodiment 30. The composition of Embodiment 28, wherein each R ^2a and R ^2b is independently H or C ₁ -C ₃ alkyl.

Embodiment 31. The composition of Embodiment 30, wherein each R ^2a and R ^2b is independently H or C ₁ -C ₂ alkyl.

Embodiment 32. The composition of Embodiment 31 wherein each R ^2a and R ^2b is independently H or methyl.

Embodiment 33. The composition of Embodiment 32, wherein each of R ^2a and R ^2b is H.

Embodiment 34. A composition comprising components (a) and (b) described in the Summary of the Invention or any one of Embodiments 1 to 33, wherein in Formula 1, when R ^2a and R ^2b are separated ( That is, do not form a ring together), then one of R ^2a and R ^2b is (CR ^4a R ^4b ) _p -OH, (CR ^4a R ^4b ) _p -SH, (CR ^4a R ^4b ) _p -Cl or (CR ^4a R ^4b ) _p -Br, and the other is H.

Embodiment 35. The composition of Embodiment 34, wherein one of R ^2a and R ^2b is (CR ^4a R ^4b ) _p -Cl or (CR ^4a R ^4b ) _p -Br, and the other is H.

Embodiment 36. A composition comprising components (a) and (b) described in the Summary of the Invention or any one of Embodiments 1 to 35, wherein in Formula 1, each R ^2a and R ^2b are independently is H, methyl, (CR ^4a R ^4b ) _p -OH, (CR ^4a R ^4b ) _p -Cl or (CR ^4a R ^4b ) _p -Br; or X and Y to which R ^2a and R ^2b are attached The atoms together form a 5- to 6-membered saturated ring comprising ring members, selected from carbon atoms in addition to the X and Y atoms, wherein up to 2 carbon atomic ring members are independently selected from C(=O) and C(= S), the ring can optionally be up to 2 of the carbon atom ring members independently selected from the group consisting of halogen, cyano, _{C1 -} C2 alkyl, _{C1 -} C2 haloalkyl, _C1 - _C2 alkoxy and C ₁ -C ₂ haloalkoxy substituents.

Embodiment 37. The composition of Embodiment 36, wherein each R ^2a and R ^2b are independently H or methyl; or R ^2a and R ^2b together with the X and Y atoms to which they are attached form a 5- to 6-membered A saturated ring comprising ring members, in addition to the X and Y atoms, is also selected from carbon atoms, wherein at most 1 carbon atom ring member is selected from C(=O), the ring is optionally composed of at most carbon atom ring members Substituted with 2 substituents independently selected from halogen, cyano, methyl, halomethyl, methoxy and halomethoxy.

Embodiment 38. The composition of Embodiment 37, wherein each R ^2a and R ^2b are independently H or methyl; or R ^2a and R ^2b together with the X and Y atoms to which they are attached form a 5-membered saturated A ring comprising ring members, in addition to the X and Y atoms, is also selected from carbon atoms, and the ring is optionally substituted on the carbon atom ring members with up to one substituent selected from halogen, cyano and methyl.

Embodiment 39. The composition of Embodiment 38, wherein each R ^2a and R ^2b is H; or R ^2a and R ^2b together with the X and Y atoms to which they are attached form a 5-membered saturated ring comprising ring members , in addition to the X and Y atoms, is also selected from carbon atoms, and the ring is optionally substituted on a carbon atom ring member with up to one substituent selected from methyl.

Embodiment 40. The composition of Embodiment 39, wherein each R ^2a and R ^2b is H; or R ^2a and R ^2b together with the X and Y atoms to which they are attached form a 5-membered saturated ring comprising ring members , in addition to X and Y atoms, is selected from carbon atoms.

Embodiment 41. A composition comprising components (a) and (b) as described in the Summary of the Invention or any one of Embodiments 1 to 40, wherein in Formula 1, when R ^2a and R ^2b together form a ring (i.e., not separate), then R ^2a and R ^2b together with the X and Y atoms to which they are attached form a 5- to 6-membered saturated ring containing ring members, selected from carbon in addition to the X and Y atoms atom, wherein up to 1 carbon atom ring member is selected from C(=O), the ring is optionally selected from up to 2 independently selected from halogen, cyano, methyl, halomethyl, methoxy and halomethoxy substituted by the substituents of the base.

Embodiment 42. The composition of Embodiment 41, wherein R ^2a and R ^2b together with the X and Y atoms to which they are attached form a 5-membered saturated ring comprising ring members, in addition to the X and Y atoms, also selected from Carbon atoms optionally substituted on carbon atom ring members with up to 2 substituents independently selected from halogen, cyano, methyl, halomethyl, and methoxy.

Embodiment 43. The composition of Embodiment 42, wherein R ^2a and R ^2b together with the X and Y atoms to which they are attached form a 5-membered saturated ring comprising ring members, in addition to the X and Y atoms, also selected from A carbon atom optionally substituted on a carbon atom ring member with up to one substituent selected from halogen, methyl and halomethyl.

Embodiment 44. The composition of Embodiment 43, wherein R ^2a and R ^2b together with the X and Y atoms to which they are attached form a 5-membered saturated ring comprising ring members, other than the X and Y atoms, selected from carbon atom.

Embodiment 45. A composition comprising components (a) and (b) described in the Summary of the Invention or any one of Embodiments 1 to 44, wherein in Formula 1, R ^2c is C ₁ -C ₃ alkyl, C ₁ -C ₃ haloalkyl, C ₂ -C ₃ alkenyl, C ₂ -C ₃ haloalkenyl, C ₂ -C ₃ alkynyl or C ₂ -C ₃ haloalkynyl, each of which may be Optionally substituted with up to 1 substituent selected from cyano, hydroxy, SC≡N and _C1 - _C2alkoxy .

Embodiment 46. The composition of Embodiment 45, wherein R ^2c is C ₁ -C ₂ alkyl, C ₁ -C ₂ haloalkyl, C ₂ -C ₃ alkenyl, C ₂ -C ₃ haloalkenyl , C2 _{- C3alkynyl} or C2 _{- C3haloalkynyl} , each optionally substituted with up to 1 substituent selected from cyano and methoxy.

Embodiment 46a. The composition of Embodiment 46, wherein R ^2c is C ₁ -C ₂ alkyl, C ₁ -C ₂ haloalkyl, C ₂ -C ₃ alkenyl, C ₂ -C ₃ haloalkenyl or C ₂ -C ₃ alkynyl.

Embodiment 47. The composition of Embodiment 46a, wherein R ^2c is C ₁ -C ₂ alkyl, C ₂ -C ₃ alkenyl, or C ₂ -C ₃ alkynyl.

Embodiment 48. The composition of Embodiment 47, wherein R ^2c is methyl or ethyl.

Embodiment 48a. The composition of Embodiment 48, wherein R ^2c is ethyl.

Embodiment 49. A composition comprising components (a) and (b) described in the Summary of the Invention or any one of Embodiments 1 to 48a, wherein in Formula 1, R ^2d is H, cyano, halogen or C ₁ -C ₂ alkyl.

Specific Example 49a. The composition of Specific Example 49, wherein R ^2d is H, cyano, Cl, F, or methyl.

Embodiment 50. The composition of Embodiment 49a, wherein R ^2d is H or methyl.

Embodiment 51. The composition of Embodiment 50, wherein R ^2d is H.

Embodiment 52. A composition comprising components (a) and (b) as described in the Summary of the Invention or any one of Embodiments 1 to 51, wherein in Formula 1, each R ^4a and R ^4b are independently is H or C ₁ -C ₂ alkyl.

Embodiment 53. The composition of Embodiment 52, wherein each R ^4a and R ^4b is independently H or methyl.

Embodiment 54. The composition of Embodiment 53, wherein each of R ^4a and R ^4b is H.

Embodiment 55. A composition comprising components (a) and (b) as described in the Summary of the Invention or any one of Embodiments 1 to 54, wherein in Formula 1, p is 2.

Embodiment 56. A composition comprising components (a) and (b) as described in the Summary of the Invention or any one of Embodiments 1 to 54, wherein in Formula 1, p is 3.

Embodiment 57. A composition comprising components (a) and (b) described in the Summary of the Invention or any one of Embodiments 1 to 56, wherein in Formula 1, wherein A ¹ is CR ^6c R ^6d , O, or S.

Embodiment 58. The composition of Embodiment 57, wherein A ¹ is CR ^6c R ^6d or O.

Embodiment 59. The composition of Embodiment 58, wherein A ¹ is CR ^6c R ^6d .

Embodiment 60. The composition ^of Embodiment 58, wherein A1 is O.

Embodiment 61. A composition comprising components (a) and (b) described in the Summary of the Invention or any one of Embodiments 1 to 60, wherein in Formula 1, A ¹ is CH ₂ , NH, O or S.

Embodiment 62. A composition comprising components (a) and (b) described in the Summary of the Invention or any one of Embodiments 1 to 61, wherein in Formula 1, A ¹ is N(R ^7a ) .

Embodiment 63. A composition comprising components (a) and (b) described in the Summary of the Invention or any one of Embodiments 1 to 63, wherein in Formula 1, A ² is a direct bond, CR ^6e R ^6f , O or S.

Embodiment 64. The composition of Embodiment 63, wherein A ² is a direct bond, CR ^6e R ^6f or O.

Embodiment 65. The composition of Embodiment 64, wherein A ² is a direct bond or O.

Embodiment 66. The composition of Embodiment 65, wherein A ² is a direct bond.

Embodiment 67. A composition comprising components (a) and (b) described in the Summary of the Invention or any one of Embodiments 1 to 62, wherein in Formula 1, A ² is a direct bond, CH ₂ , NH, O or S.

Embodiment 67a. The composition of Embodiment 67, wherein A ² is a direct bond, CH ₂ or O.

Embodiment 68. The composition of Embodiment 67a, wherein A ² is a direct bond or O.

Embodiment 69. A composition comprising components (a) and (b) described in the Summary of the Invention or any one of Embodiments 1 to 62, wherein in Formula 1, A ² is N(R ^7b ) .

Embodiment 70. A composition comprising components (a) and (b) described in the Summary of the Invention or any one of Embodiments 1 to 69, wherein in Formula 1, when A is A ¹ -A ² -CR ^6a R ^6b , then A ¹ -A ² -CR ^6a R ^6b is selected from OCH ₂ , OCH(Me), CH(OH)CH ₂ , CH ₂ CH ₂ , SCH ₂ , OCF ₂ and CH ₂ OCH ₂ .

Specific Example 71. The composition of Specific Example 70, wherein A1 _- ^{A2 - CR6aR6b} is selected from the group consisting of ^OCH2 , OCH(Me ₎ and _CH2CH2 .

Embodiment 72. _The composition of Embodiment 71, wherein A1 _{- A2} ^{- CR6aR6b} is selected from ^OCH2 and ^CH2CH2 .

Embodiment 73. The composition of Embodiment 72, wherein A1 _- ^{A2 - CR6aR6b} is ^OCH2 .

Embodiment 74. A composition comprising components (a) and (b) described in the Summary of the Invention or any one of Embodiments 1 to 74, wherein in Formula 1, when A is A ¹ -A ² , then A ¹ -A ² is selected from O, CH ₂ , OCH ₂ and CH ₂ O.

Embodiment 75. _The composition of Embodiment 74, wherein A1 ^- A2 is selected from O, ^CH2 , and _CH2O .

Embodiment 76. The composition of Embodiment 75, wherein A ¹ -A ² are selected from O and CH ₂ .

Embodiment 77. The composition of Embodiment 76, wherein A ¹ -A ² are O.

Embodiment 78. A composition comprising components (a) and (b) described in the Summary of the Invention or any one of Embodiments 1 to 77, wherein in Formula 1, each of R ^6a , R ^6b , R ^6c , R ^6d , R ^6e and R ^6f are independently H, cyano, hydroxyl, Br, Cl, F or methyl.

Embodiment 79. The composition of Embodiment 78, wherein each R ^6a , R ^6b , R ^6c , R ^6d , R ^6e and R ^6f is independently H, cyanohydroxy, or methyl.

Embodiment 80. The composition of Embodiment 79, wherein each of R ^6a , R ^6b , R ^6c , R ^6d , R ^6e and R ^6f is independently H or methyl.

Specific Example 81. The composition of Specific Example 80, wherein each of R ^6a , R ^6b , R ^6c , R ^6d , R ^6e , and R ^6f is H.

Embodiment 82. A composition comprising components (a) and (b) described in the Summary of the Invention or any one of Embodiments 1 to 81, wherein in Formula 1, each R ^7a and R ^7b are independently is H, C ₁ -C ₂ alkyl or C ₂ -C ₃ alkylcarbonyl.

Embodiment 83. The composition of Embodiment 82, wherein each R ^7a and R ^7b is independently H or C ₁ -C ₂ alkyl.

Embodiment 84. The composition of Embodiment 83 wherein each of R ^7a and R ^7b is H.

Embodiment 85. A composition comprising components (a) and (b) described in the Summary of the Invention or any one of Embodiments 1 to 84, wherein in Formula 1, when T is T-1 or T -2, then A is A ¹ -A ² -CH ₂ .

Embodiment 86. A composition comprising components (a) and (b) described in the Summary of the Invention or any one of Embodiments 1 to 85, wherein in Formula 1, when T is T-1 or T _-2 , then _A is _OCH2 , _{SCH2 , NHCH2} , _CH2CH2 , _OCH2CH2 , _{SCH2CH2 , NHCH2CH2} , _CH2OCH2 , _{CH2SCH2 , or CH2NHCH2 .}

Example 87. The composition of Example 86, wherein when T is T-1 or T-2, then A is OCH ₂ , SCH ₂ , CH ₂ CH ₂ , OCH ₂ CH ₂ , SCH ₂ CH ₂ , CH ₂ OCH ₂ or CH ₂ SCH ₂ .

Embodiment 88. The composition of Embodiment 87, wherein when T is T- ₁ or T- ₂ , then _A is OCH2 or CH2CH2.

Embodiment 89. The composition of Embodiment 88, wherein when T is T-1 or T- ₂ , then A is OCH2.

Embodiment 90. A composition comprising components (a) and (b) described in the Summary of the Invention or any one of Embodiments 1 to 89, wherein in Formula 1, when T is T-3, then _A is O, _OCH2 , _SCH2 , _NHCH2 , _CH2 , _CH2CH2 , _CH2O , _CH2S or _CH2NH .

Embodiment 91. The composition of Embodiment 82, wherein when T is T- ₃ , then A is O, _CH2 , or OCH2.

Embodiment 92. The composition of Embodiment 91, wherein when T is T-3, then A is O or _CH2 .

Embodiment 93. The composition of Embodiment 92, wherein when T is T-3, then A is O.

Embodiment 94. A composition comprising components (a) and (b) described in the Summary of the Invention or any one of Embodiments 1 to 93, wherein in Formula 1, J is J-1 to J- 3. J-6 to J-10 or J-14.

Embodiment 95. The composition of Embodiment 94, wherein J is J-1, J-2, J-3, J-6, or J-14.

Embodiment 96. The composition of Embodiment 95, wherein J is J-1, J-6, or J-14.

Embodiment 97. The composition of Embodiment 96, wherein J is J-1 or J-6.

Embodiment 97a. The composition of Embodiment 96, wherein J is J-14.

Embodiment 98. The composition of Embodiment 97, wherein J is J-1.

Specific Example 99. The composition of Specific Example 97, wherein J is J-6.

Embodiment 100. A composition comprising components (a) and (b) described in the Summary of the Invention or any one of Embodiments 1 to 99, wherein in Formula ¹ , each R is independently F , Cl or methyl.

Embodiment 100a. The composition of Embodiment 100, wherein each ^R8 is independently F or Cl.

Embodiment 101. The composition of Embodiment 100, wherein each ^R8 is independently F or methyl.

Embodiment 101a. The composition of Embodiment 101 wherein each ^R8 is F.

Embodiment 102. A composition comprising components (a) and (b) described in the Summary of the Invention or any one of Embodiments 1 to 101a, wherein in Formula 1, q is 0 or 1.

Embodiment 102a. A composition comprising components (a) and (b) described in the Summary of the Invention or any of Embodiments 1 to 101a, wherein in Formula 1, q is 3 or 4.

Embodiment 102b. The composition of Embodiment 102a, wherein in Formula 1, q is 4.

Embodiment 103. The composition of Embodiment 102, wherein q is 0.

Embodiment 103a. The composition of Embodiment 102, wherein q is 1.

Embodiment 104. A composition comprising components (a) and (b) described in the Summary of the Invention or any one of Embodiments 1 to 103a, wherein in Formula 1, each R ^9a and R ^9b are independently is H, halogen, C ₁ -C ₃ alkyl, C ₁ -C ₃ haloalkyl, C ₁ -C ₃ alkoxy or C ₁ -C ₃ haloalkoxy.

Embodiment 105. The composition of Embodiment 104, wherein each R ^9a and R ^9b is independently H, halogen, C ₁ -C ₂ alkyl, or C ₁ -C ₂ haloalkyl.

Embodiment 106. The composition of Embodiment 105, wherein each R ^9a and R ^9b is independently H, halo, or methyl.

Embodiment 107. The composition of Embodiment 106, wherein each R ^9a and R ^9b is independently H or methyl.

Embodiment 108. The composition of Embodiment 107, wherein each of R ^9a and R ^9b is H.

Embodiment 109. A composition comprising components (a) and (b) described in the Summary of the Invention or any one of Embodiments 1 to 108, wherein in Formula 1, n is 0, 1, or 2.

Embodiment 109a. The composition of Embodiment 109, wherein n is 1 or 2.

Embodiment 110. A composition comprising components (a) and (b) described in the Summary of the Invention or any one of Embodiments 1 to 109a, wherein in Formula 1, n is 0 or 1.

Embodiment 111. The composition of Embodiment 109, 109a, or 110, wherein n is 1.

Embodiment 112. The composition of Embodiment 109 or 110, wherein n is 0.

Embodiment 113. A composition comprising components (a) and (b) described in the Summary of the Invention or any one of Embodiments 1 to 112, wherein in Formula 1, L is a direct bond, CH ₂ , _CH (Me) or _CH2CH2 .

Embodiment 113a. _The composition of Embodiment 113, wherein L is a direct bond, _CH2 , or _CH2CH2 .

Embodiment 114. The composition of Embodiment 113a, wherein L is a direct bond or _CH2 .

Specific Example 115. The composition of Specific Example 114, wherein L is _CH2 .

Embodiment 115a. The composition of Embodiment 114, wherein L is a direct bond.

Embodiment 116. A composition comprising components (a) and (b) as described in the Summary of the Invention or any one of Embodiments 1 to 115a, wherein in Formula ¹ , E is E1.

Embodiment 116a. A composition comprising components (a) and (b) described in the Summary of the Invention or any one of Embodiments 1 to 116, wherein in Formula 1, when L is a direct bond, then E is E ¹ .

Embodiment 117. A composition comprising components (a) and (b) described in the Summary of the Invention or any one of Embodiments 1 to 116a, wherein in Formula 1, E ¹ is cyano, nitro , C(=O)H, C(=O)OH or SC≡N; or C ₁ -C ₆ alkoxy, C ₂ -C ₆ alkenyloxy, C ₁ -C ₆ alkylsulfonyl, C ₂ -C ₆ alkenylsulfonyl, C ₂ -C ₆ alkynylsulfonyl, C ₁ -C ₆ alkylsulfonylamino, C ₂ -C ₆ alkenylsulfonylamino, C ₂ - C ₆ alkynyl sulfonamido, C ₁ -C ₆ alkylaminosulfonamido, C ₂ -C ₆ dialkylamino sulfonamido, C ₂ -C ₆ alkenylamine sulfonamido, C ₂ - _C6 alkylcarbonyl, C2 _{- C6} alkylaminocarbonyl, C3 _{- C6} alkenylaminocarbonyl, C3 _{- C6} alkynylaminocarbonyl, C2 _{- C6} alkoxycarbonyl, C ₃ -C ₆ alkenyloxycarbonyl, C ₃ -C ₆ alkynyloxycarbonyl or C ₂ -C ₆ alkoxycarbonylamino, wherein each carbon atom is optionally selected by at most 1 from R ^10a and at most 3 substituted with substituents independently selected from R ^10b .

Specific Example 118. The composition of Specific Example 117, wherein E ¹ is cyano, nitro, C(=O)H, C(=O)OH, or SC≡N; or C ₁ -C ₆ alkoxy , C ₂ -C ₆ alkenyloxy, C ₁ -C ₆ alkyl sulfonamido, C ₁ -C ₆ alkyl sulfonamido, C ₂ -C ₆ alkenyl sulfonamido, C ₂ - C ₆ alkylcarbonyl, C ₂ -C ₆ alkoxycarbonyl, C ₃ -C ₆ alkenyloxycarbonyl or C ₃ -C ₆ alkynyloxycarbonyl, wherein each carbon atom is optionally selected by at most 1 from R ^10a and up to 3 substituents independently selected from R ^10b .

Embodiment 119. The composition of Embodiment 118, wherein E ¹ is C ₁ -C ₆ alkoxy, C ₁ -C ₆ alkylsulfonyl, C ₂ -C ₆ alkylcarbonyl, or C ₂ -C ₆ alkoxycarbonyl wherein each carbon atom is optionally substituted with up to 1 substituent selected from R ^10a and up to 3 independently selected from R ^10b .

Embodiment 120. The composition of Embodiment 119, wherein E ¹ is C ₁ -C ₃ alkoxy, C ₂ -C ₃ alkylcarbonyl, or C ₂ -C ₃ alkoxycarbonyl, wherein each carbon atom can optionally substituted with up to 1 substituent selected from R ^10a and up to 3 independently selected from R ^10b .

Embodiment 120a. The composition of Embodiment 120, wherein E ¹ is C ₁ -C ₃ alkoxy or C ₂ -C ₃ alkoxycarbonyl, wherein each carbon atom is optionally selected by up to 1 R Substituents of ^10a are substituted.

Specific Example 121. The composition of Specific Example 120, wherein E ¹ is C ₁ -C ₂ alkoxy, wherein each carbon atom is optionally up to 1 selected from R ^10a and up to 3 independently selected from R 10a substituted with the substituent of R ^10b .

Embodiment 121a. The composition of Embodiment 120, wherein E ¹ is C ₁ -C ₂ alkoxy, wherein each carbon atom is optionally substituted with up to 1 substituent selected from R ^10a .

Embodiment 121b. The composition of Embodiment 121a, wherein E1 is methoxy optionally substituted with up to ¹ substituent selected from ^R10a .

Embodiment 121c. The composition of Embodiment 121a, wherein E1 is methoxy, substituted with ¹ substituent selected from ^R10a .

Embodiment 122. A composition comprising components (a) and (b) described in the Summary of the Invention or any one of Embodiments 1 to 121c, wherein in Formula 1, R ^10a is phenyl, which can be optionally substituted with up to 3 substituents independently selected from R ^11a ; or a 5- to 6-membered heterocycle comprising ring members selected from carbon atoms and 1 to 4 heteroatoms independently Selected from up to 2 O, up to 2 S, and up to 4 N atoms, each ring optionally substituted on carbon atom ring members with up to 3 substituents independently selected from R ^11a , and on nitrogen atoms Ring members are optionally substituted with up to 3 substituents independently selected from R ^11b .

Embodiment 123. The composition of Embodiment 122, wherein R ^10a is phenyl optionally substituted with up to 2 substituents independently selected from R ^11a ; or a 5- to 6-membered heterocycle, which comprising ring members selected from carbon atoms and 1 to 4 heteroatoms independently selected from up to 2 O, up to 2 S, and up to 4 N atoms, each ring optionally being replaced by a carbon atom ring member Substituted with up to 2 substituents independently selected from R ^11a , and optionally substituted on the nitrogen atom ring member with up to 2 substituents independently selected from R ^11b .

Specific Embodiment 123a. The composition of Specific Embodiment 123, wherein R ^10a is a 5-membered heterocycle comprising ring members selected from carbon atoms and 1 to 4 independently selected from up to 2 O and up to 3 The heteroatoms of the N atoms, each ring is optionally substituted on carbon atom ring members with up to 2 substituents independently selected from R ^11a .

Embodiment 123b. The composition of Embodiment 123a, wherein R ^10a is pyrazolyl, imidazolyl or triazolyl, each optionally on a carbon atom ring member with up to 2 independently selected from R ^11a Substituents are substituted.

Embodiment 123c. The composition of Embodiment 123b wherein R ^10a is pyrazolyl or imidazolyl, each optionally substituted on a carbon atom ring member with up to 2 substituents independently selected from R ^11a .

Specific Example 123d. The composition of Specific Example 123c, wherein R ^10a is pyrazolyl optionally substituted on the carbon atom ring member with up to 1 substituent selected from R ^11a .

Embodiment 124. A composition comprising components (a) and (b) described in the Summary of the Invention or any one of Embodiments 1 to 123c, wherein in Formula 1, each R ^10b is independently cyanide base, halogen, hydroxyl, C ₁ -C ₄ alkyl, C ₁ -C ₄ haloalkyl, C ₃ -C ₆ cycloalkyl, C ₁ -C ₄ alkoxy, C ₁ -C ₄ haloalkoxy, C ₁ -C ₄ alkylsulfonyl, C ₁ -C ₄ haloalkylsulfonyl, C ₁ -C ₄ alkylamino, C ₂ -C ₄ dialkylamino, C ₂ -C ₄ alkylcarbonyl or C ₂ -C ₅ alkoxycarbonyl.

Embodiment 125. The composition of Embodiment 124, wherein each R ^10b is independently halogen, hydroxy, C ₁ -C ₄ alkyl, C ₁ -C ₄ haloalkyl, C ₁ -C ₄ alkoxy, C ₁ -C ₄ haloalkoxy, C ₁ -C ₄ alkylsulfonyl, C ₂ -C ₄ alkylcarbonyl or C ₂ -C ₅ alkoxycarbonyl.

Embodiment 125a. The composition of Embodiment 125 wherein each R ^10b is independently halogen, C ₁ -C ₂ alkyl, C ₁ -C ₂ haloalkyl, C ₁ -C ₂ alkoxy, or C ₂ -C _{4alkoxycarbonyl} .

Embodiment 126. A composition comprising components (a) and (b) described in the Summary of the Invention or any one of Embodiments 1 to 125a, wherein in Formula 1, each R ^11a is independently halogen , C ₁ -C ₄ alkyl, C ₁ -C ₄ haloalkyl, C ₂ -C ₄ alkenyl, C ₂ -C ₄ alkynyl, C ₁ -C ₄ alkoxy, C ₁ -C ₄ haloalkoxy , C ₂ -C ₄ alkenyloxy, C ₂ -C ₄ alkynyloxy, C ₂ -C ₄ alkoxyalkyl, C ₂ -C ₆ alkylcarbonyloxy, C ₁ -C ₄ alkyl sulfonic acid base, C ₁ -C ₄ haloalkylsulfonyl, C ₁ -C ₄ alkylsulfonyloxy, C ₂ -C ₄ alkylcarbonyl, C ₃ -C ₅ alkenylcarbonyl, C ₃ -C ₅ alkyne carbonyl, C ₂ -C ₆ alkoxycarbonyl, C ₃ -C ₇ alkenyloxycarbonyl, C ₃ -C ₇ alkynyloxycarbonyl, C ₂ -C ₆ alkylaminocarbonyl, C ₃ -C ₆ alkenyl Aminocarbonyl, C3 _{- C6alkynylaminocarbonyl} or C3 _{- C8dialkylaminocarbonyl} .

Embodiment 127. The composition of Embodiment 126 wherein each R ^11a is independently halogen, C ₁ -C ₄ alkyl, C ₁ -C ₄ haloalkyl, C ₂ -C ₄ alkenyl, C ₁ - C ₄ alkoxy, C ₁ -C ₄ haloalkoxy, C ₂ -C ₄ alkenyloxy, C ₂ -C ₄ alkoxyalkyl, C ₂ -C ₄ alkylcarbonyl, C ₂ -C ₆ alkane Oxycarbonyl, C ₃ -C ₇ alkenyloxycarbonyl or C ₂ -C ₆ alkylaminocarbonyl.

Specific Example 128. The composition of Specific Example 127, wherein each R ^11a is independently halogen, C ₁ -C ₄ alkyl, C ₁ -C ₄ haloalkyl, C ₁ -C ₄ alkoxy, C ₁ -C ₄ haloalkoxy, C ₂ -C ₄ alkenyloxy, C ₂ -C ₄ alkylcarbonyl, C ₂ -C ₄ alkoxycarbonyl or C ₃ -C ₅ alkenyloxycarbonyl.

Embodiment 128a. The composition of Embodiment 128 wherein each R ^11a is independently halogen, C ₁ -C ₂ alkyl, C ₁ -C ₂ haloalkyl, C ₁ -C ₂ alkoxy, or C ₂ -C ₃ alkoxycarbonyl.

Embodiment 128b. The composition of Embodiment 128a, wherein each R ^11a is independently methoxycarbonyl or ethoxycarbonyl.

Specific Example 128c. The composition of Specific Example 128b, wherein each R ^11a is ethoxycarbonyl.

Embodiment 129. A composition comprising components (a) and (b) described in the Summary of the Invention or any one of Embodiments 1 to 128c, wherein in Formula 1, each R ^11b is independently C _{1 - C2alkyl} , _{C1 - C2alkoxy} , C2 _- C3alkylcarbonyl or C2 _- C3alkoxycarbonyl.

Embodiment 130. The composition of Embodiment 129, wherein each R ^11b is independently methyl, methoxy, methylcarbonyl, or methoxycarbonyl.

Embodiment 131. The composition of Embodiment 130, wherein each R ^11b is independently methyl or methoxy.

Embodiment 132. A composition comprising components (a) and (b) as described in the Summary of the Invention or any one of Embodiments 1 to 131, wherein in Formula 1, E is ^E2 .

Embodiment 133. A composition comprising components (a) and (b) described in the Summary of the Invention or any one of Embodiments 1 to 132, wherein in Formula 1, G is phenyl, which may be selected is substituted with up to ³ substituents independently selected from R; or a 5- to 6-membered heteroaromatic ring, each ring containing ring members selected from carbon atoms and 1 to 4 heteroatoms, the heteroatom independently selected from up to 2 O, up to 2 S, and up to 4 N atoms, each ring optionally substituted with up to ³ substituents independently selected from R; or a 3- to 7-membered non-aromatic Ring or an 8 to 11 membered bicyclic ring system, each ring or ring system comprising ring members selected from carbon atoms and optionally up to 4 heteroatoms independently selected from up to 2 O, up to 2 S and up to 4 N atoms, wherein up to 2 ring members are independently selected from C(=O), S(=O) and S(=O) ₂ , each ring or ring system optionally being up to substituted with 3 substituents independently selected from R ¹³ .

，

，

，

， G-1    G-2    G-3    G-4   

，

，

，

， G-5    G-6    G-7    G-8   

，

，

，

， G-9    G-10    G-11    G-12   

，

，

，

， G-13    G-14    G-15    G-16   

，

，

，

， G-17    G-18    G-19    G-20   

，

，

，

， G-21    G-22    G-23    G-24   

，

，

，

， G-25    G-26    G-27    G-28   

，

，

，

， G-29    G-30    G-31    G-32   

，

，

，

， G-33    G-34    G-35    G-36   

，

，

，

， G-37    G-38    G-39    G-40   

，

，

，

， G-41    G-42    G-43    G-44   

，

，

，

， G-45    G-46    G-47    G-48   

，

，

，

， G-49    G-50    G-51    G-52   

，

，

，

， G-53    G-54    G-55    G-56   

，

，

，

， G-57    G-58    G-59    G-60   

，

，

，

， G-61    G-62    G-63    G-64   

，

，

，

， G-65    G-66    G-67    G-68   

，

，

，

， G-69    G-70    G-71    G-72   

，

，

，

， G-73    G-74    G-75    G-76   

，

，

，

， G-77    G-78    G-79    G-80   

，

，

，

， G-81    G-82    G-83    G-84   

，

，

，

， G-85    G-86    G-87    G-88   

，

，

，

， G-89    G-90    G-91    G-92   

，

，

，

， G-93    G-94    G-95    G-96   

，

，

，

， G-97    G-98    G-99    G-100   

，

，

，

， G-101    G-102    G-103    G-104   

，

，

，

， G-105    G-106    G-107    G-108   

，

，

，

， G-109    G-110    G-111    G-112   

，

，

＇

， G-113    G-114    G-115    G-116   

，             G-117    G-118                其中該浮動鍵連接式1中的Z透過所示之環或環系統中任何可用之碳或氮原子；以及 x為0、1、2或3。Embodiment 134. The composition of Embodiment 133, wherein G is selected from G-1 to G-118 as shown in Schedule A. Schedule A

,

,

,

, G-1 G-2 G-3 G-4

,

,

,

, G-5 G-6 G-7 G-8

,

,

,

, G-9 G-10 G-11 G-12

,

,

,

, G-13 G-14 G-15 G-16

,

,

,

, G-17 G-18 G-19 G-20

,

,

,

, G-21 G-22 G-23 G-24

,

,

,

, G-25 G-26 G-27 G-28

,

,

,

, G-29 G-30 G-31 G-32

,

,

,

, G-33 G-34 G-35 G-36

,

,

,

, G-37 G-38 G-39 G-40

,

,

,

, G-41 G-42 G-43 G-44

,

,

,

, G-45 G-46 G-47 G-48

,

,

,

, G-49 G-50 G-51 G-52

,

,

,

, G-53 G-54 G-55 G-56

,

,

,

, G-57 G-58 G-59 G-60

,

,

,

, G-61 G-62 G-63 G-64

,

,

,

, G-65 G-66 G-67 G-68

,

,

,

, G-69 G-70 G-71 G-72

,

,

,

, G-73 G-74 G-75 G-76

,

,

,

, G-77 G-78 G-79 G-80

,

,

,

, G-81 G-82 G-83 G-84

,

,

,

, G-85 G-86 G-87 G-88

,

,

,

, G-89 G-90 G-91 G-92

,

,

,

, G-93 G-94 G-95 G-96

,

,

,

, G-97 G-98 G-99 G-100

,

,

,

, G-101 G-102 G-103 G-104

,

,

,

, G-105 G-106 G-107 G-108

,

,

,

, G-109 G-110 G-111 G-112

,

,

'

, G-113 G-114 G-115 G-116

, G-117 G-118 wherein the floating bond connects Z in Formula 1 through any available carbon or nitrogen atom in the ring or ring system shown; and x is 0, 1, 2, or 3.

Specific Example 135. The composition of Specific Example 134, wherein G is G-1 to G-16, G-20, G-22 to G-30, G-36 to G-42, G-54 to G- 60, G-85, G-86, G-108, G‑110 or G-111.

Specific Example 136. The composition of Specific Example 135, wherein G is G-1 to G-16, G-22, G-24, G-25, G-26, G-28, G-29, G- 30, G-36, G-37, G-38, G-41, G-42, G-54, G-57, G-58, G-59, G-60, G-85, G-86, G-108, G-110 or G-111.

Specific Example 137. The composition of Specific Example 136, wherein G is G-1 to G-13, G-22, G-24, G-25, G-26, G-28, G-29, G- 41, G-42, G-54, G-57, G-58, G-59 or G-60.

Specific Example 138. The composition of Specific Example 137, wherein G is G-1, G-2, G-3, G-7, G-8, G-9, G-10, G-12, G- 13. G-22, G-29, G-42, G-54 or G-58.

Specific Embodiment 139. The composition of Specific Embodiment 138, wherein G is G-1, G-3, G-12, G-13, G-22, or G-42.

Specific Embodiment 140. The composition of Specific Embodiment 139, wherein G is G-1, G-3, G-12, G-13, or G-22.

Embodiment 141. The composition of Embodiment 140, wherein G is G-1, G-3, G-12, or G-22.

Embodiment 142. The composition of Embodiment 141, wherein G is G-1 or G-12.

Embodiment 143. The composition of Embodiment 142, wherein G is G-1.

Embodiment 144. The composition of Embodiment 142, wherein G is G-12.

Embodiment 145. The composition of Embodiment 140, wherein G is G-3.

Embodiment 146. The composition of Embodiment 140, wherein G is G-22.

Embodiment 147. The composition of Embodiment 143, wherein the 2nd position of G-1 is attached to Z and its 4th position is attached to ^R13 .

Embodiment 148. The composition of Embodiment 143, wherein the 2nd position of G-1 is attached to Z and its 5th position is attached to ^R13 .

Embodiment 149. The composition of Embodiment 144, wherein the 1st position of G-12 is attached to Z and its 4th position is attached to ^R13 .

Embodiment 150. The composition of Embodiment 144, wherein the first position of G-12 is attached to Z and its third position is attached to ^R13 .

Embodiment 151. The composition of Embodiment 144, wherein the 1st position of G-12 is attached to Z and its 3rd and 5th positions are attached to ^R13 .

Embodiment 152. The composition of Embodiment 144, wherein the 1st position of G-12 is attached to Z and its 5th position is attached to ^R13 .

Embodiment 153. The composition of Embodiment 145, wherein the 1st position of G-3 is attached to Z and its 4th position is attached to ^R13 .

Embodiment 154. The composition of Embodiment 146, wherein the 4th position of G-22 is attached to Z and the 1st position is attached to ^R13 .

Embodiment 155. The composition of any one of Embodiments 147 to 154, wherein Z is a direct bond.

Embodiment 156. The composition of any one of Embodiments 147 to 155, wherein x is 1 and R ¹³ is methoxycarbonyl or ethoxycarbonyl.

Embodiment 157. The composition of any one of Embodiments 134 to 155, wherein x is 1 or 2.

Specific Example 158. The composition of Specific Example 157, wherein x is 1.

Specific Example 159. The composition of Specific Example 157, wherein x is 2.

Embodiment 160. A composition comprising components (a) and (b) described in the Summary of the Invention or any one of Embodiments 134 to 155, wherein in Formula 1, x is 0.

Embodiment 161. A composition comprising components (a) and (b) described in the Summary of the Invention or any one of Embodiments 1 to 159, wherein in Formula ¹ , each R is independently cyanide radical, halogen, NR ^14a R ^14b , C(=O)NR ^14a R ^14b , C(R ¹⁵ )=NR ¹⁶ , N=CR ¹⁷ NR ^18a R ^18b or -UVQ; or C ₁ -C ₆ alkyl, C ₂ -C6alkenyl, C2 _{- C6alkynyl} , _{C1 - C6alkoxy} , C2 _- C6alkenyloxy, C2 _{- C6alkynyloxy} , _{C1 - C6alkylsulfonic} Acyl, C ₁ -C ₆ alkylsulfonyloxy, C ₁ -C ₆ alkylsulfonylamino, C ₂ -C ₆ alkylcarbonyl, C ₂ -C ₆ alkoxycarbonyl, C ₃ - C ₆ alkenyloxycarbonyl, C ₃ -C ₆ alkynyloxycarbonyl, C ₄ -C ₇ cycloalkoxycarbonyl, C ₂ -C ₆ alkylcarbonyloxy, C ₂ -C ₆ alkoxycarbonyloxy, C ₄ -C ₇ cycloalkoxycarbonyloxy, C ₂ -C ₆ alkylaminocarbonyloxy, C ₂ -C ₆ alkylcarbonylamino, C ₂ -C ₆ alkoxycarbonylamino or C ₂ -C ₆ alkylaminocarbonylamino groups, each optionally substituted with up to 3 substituents independently selected from R ¹⁹ .

Embodiment 162. The composition of Embodiment 161 wherein each R is independently cyano, halogen, C(=O)NR ^14a R ^14b or ^-UVQ ; or C ₁ -C ₆ alkyl, C ₂ -C ₆ alkenyl, C ₂ -C ₆ alkynyl, C ₁ -C ₆ alkoxy, C ₂ -C ₆ alkenyloxy, C ₂ -C ₆ alkynyloxy, C ₁ -C ₆ alkylsulfonyl base, C ₁ -C ₆ alkylsulfonyloxy, C ₁ -C ₆ alkylsulfonylamino, C ₂ -C ₆ alkylcarbonyl, C ₂ -C ₆ alkoxycarbonyl, C ₃ -C _{6Alkenyloxycarbonyl} , C3 _{- C6alkynyloxycarbonyl} or C2 _{- C6alkoxycarbonyloxy} , each optionally substituted with up to 3 substituents independently selected from ^R19 .

Embodiment 163. The composition of Embodiment 162, wherein each R is independently C(=O)NR ^14a R ^14b or ^-UVQ ; or C ₁ -C ₆ alkyl, C ₂ -C ₆ alkenyl , C ₂ -C ₆ alkynyl, C ₁ -C ₆ alkoxy, C ₂ -C ₆ alkenyloxy, C ₂ -C ₆ alkynyloxy, C ₁ -C ₆ alkylsulfonyl, C ₁ - C ₆ alkylsulfonyloxy, C ₁ -C ₆ alkylsulfonylamino, C ₂ -C ₆ alkylcarbonyl, C ₂ -C ₆ alkoxycarbonyl, C ₃ -C ₆ alkenyloxycarbonyl , C ₃ -C ₆ alkynyloxycarbonyl, C ₄ -C ₆ cycloalkoxycarbonyl or C ₂ -C ₆ alkoxycarbonyloxy, each optionally by up to 3 substituents independently selected from R ¹⁹ replaced.

Embodiment 163a. The composition of Embodiment 162, wherein each R is independently C(=O)NR ^14a R ^14b or ^-UVQ ; or C ₂ -C ₅ alkoxycarbonyl, C ₃ -C ₅ alkene oxycarbonyl, C3 _{- C5alkynyloxycarbonyl} or _{C4 -} C6cycloalkoxycarbonyl, each optionally substituted with up to 3 substituents independently selected from ^R19 .

Specific Example 163b. The composition of Specific Example 163a, wherein each R ¹³ is independently C(=O)NR ^14a R ^14b or -UVQ; or C ₂ -C ₅ alkoxycarbonyl, C ₃ -C ₅ alkyne oxycarbonyl or C ₄ -C ₆ cycloalkoxycarbonyl, each optionally substituted with up to 1 substituent selected from R ¹⁹ .

Embodiment 164. The composition of Embodiment 163a, wherein each R is independently C(=O)NR ^14a R ^14b or ^-UVQ ; or C ₂ -C ₆ alkoxycarbonyl, C ₃ -C ₆ alkene oxycarbonyl, C3 _{- C6alkynyloxycarbonyl} or C2 _{- C6alkoxycarbonyloxy} , each optionally substituted with up to 3 substituents independently selected from ^R19 .

Embodiment 164a. The composition of Embodiment 164, wherein each R is independently C(=O)NR ^14a R ^14b or ^-UVQ ; or C ₂ -C ₆ alkoxycarbonyl, C ₃ -C ₆ alkene oxycarbonyl, or C3 _{- C6} alkynyloxycarbonyl, each optionally substituted with up to 3 substituents independently selected from ^R19 .

Embodiment 165. The composition of Embodiment 164a, wherein each R is independently C(=O)NR ^14a R ^14b or ^-UVQ ; or C ₂ -C ₅ alkoxycarbonyl, C ₃ -C ₅ alkene alkynyloxycarbonyl, or C3 _{- C5alkynyloxycarbonyl} , each optionally substituted with up to 3 substituents independently selected from ^R19 .

Embodiment 165a. The composition of Embodiment 165, wherein each R is independently C(=O)NR ^14a R ^14b or ^-UVQ ; or C ₂ -C ₅ alkoxycarbonyl or C ₃ -C ₅ alkene oxycarbonyl, each optionally substituted with up to 3 substituents independently selected from R ¹⁹ .

Specific Example 166. The composition of Specific Example 165, wherein each R ¹³ is independently a C ₂ -C ₅ alkoxycarbonyl group or a C ₃ -C ₅ alkenyloxycarbonyl group, each optionally by up to 3 independently is substituted with a substituent selected from R ¹⁹ .

Specific Embodiment 167. The composition of Specific Embodiment 166, wherein each R ¹³ is independently a C ₂ -C ₅ alkoxycarbonyl group, each optionally substituted with up to 3 substituents independently selected from R ¹⁹ .

Embodiment 168. The composition of Embodiment 167 wherein each ^R13 is independently methoxycarbonyl or ethoxycarbonyl, each optionally substituted with up to 3 substituents independently selected from ^R19 .

Embodiment 169. The composition of Embodiment 168 wherein each R ¹³ is independently methoxycarbonyl or ethoxycarbonyl, each optionally substituted with up to 1 substituent selected from R ¹⁹ .

Embodiment 170. The composition of Embodiment 169 wherein each R ¹³ is independently ethoxycarbonyl optionally substituted with up to 1 substituent selected from R ¹⁹ .

Specific Example 171. The composition of Specific Example 169, wherein each ^R13 is independently methoxycarbonyl or ethoxycarbonyl.

Specific Example 172. The composition of Specific Example 171 wherein each R ¹³ is ethoxycarbonyl.

Embodiment 173. A composition comprising components (a) and (b) described in the Summary of the Invention or any one of Embodiments 1 to 172, wherein in Formula 1, when each R ^14a is isolated (that is, not forming a ring together with R ^14b ), then each R ^14a is independently H, cyano, hydroxy, C ₁ -C ₄ alkyl, C ₁ -C ₄ haloalkyl, C ₂ -C ₄ alkenyl, C ₂ -C ₄ haloalkenyl, C ₂ -C ₄ alkynyl, C ₂ -C ₄ haloalkynyl, C ₂ -C ₄ alkylcarbonyl, C ₂ -C ₅ alkoxycarbonyl or C ₃ -C ₅ dialkylaminocarbonyl.

Specific Example 174. The composition of Specific Example 173, wherein each R ^14a is independently H, cyano, C ₁ -C ₄ alkyl, C ₁ -C ₄ haloalkyl, C ₂ -C ₄ alkenyl, C2 _{- C4alkynyl} , C2 _{- C4alkylcarbonyl} , C2 _{- C5alkoxycarbonyl} or C3 _{- C5dialkylaminocarbonyl} .

Specific Example 175. The composition of Specific Example 174 wherein each R ^14a is independently H, C ₁ -C ₂ alkyl, C ₂ -C ₄ alkenyl, C ₂ -C ₄ alkynyl, C ₂ - C ₄ alkylcarbonyl or C ₂ -C ₄ alkoxycarbonyl.

Specific Example 176. The composition of Specific Example 175, wherein each R ^14a is independently H or C ₁ -C ₂ alkyl.

Specific Example 177. The composition of Specific Example 176, wherein each R ^14a is independently H or methyl.

Specific Example 177a. The composition of Specific Example 177, wherein each R ^14a is H.

Embodiment 178. A composition comprising components (a) and (b) described in the Summary of the Invention or any one of Embodiments 1 to 177a, wherein in Formula 1, when each R ^14b is isolated (that is, not forming a ring together with R ^14a ), then each R ^14b is independently H, C ₁ -C ₆ alkyl, C ₁ -C ₆ haloalkyl, C ₂ -C ₆ alkenyl, C ₂ -C ₆ haloalkenyl, C ₂ -C ₆ alkynyl, C ₂ -C ₆ haloalkynyl, C ₂ -C ₆ cyanoalkyl, C ₃ -C ₈ cycloalkyl, C ₃ -C ₈ halocycloalkyl, C ₃ -C ₈ cycloalkenyl, C ₃ -C ₈ halocycloalkenyl, C ₄ -C ₁₀ alkylcycloalkyl, C ₄ -C ₁₀ cycloalkylalkyl, C ₄ -C ₁₀ halocycloalkylalkyl, C ₂ -C ₆ alkoxyalkyl, C ₂ -C ₆ haloalkoxyalkyl, C ₂ -C ₆ alkylthioalkyl, C ₂ -C ₆ Alkylsulfonylalkyl, C2 _{- C6} alkylaminoalkyl or C3 _- C8 dialkylaminoalkyl, each optionally with up to ₁ selected from cyano, hydroxy, nitro substituted by substituents of radicals, C ₂ -C ₄ alkylcarbonyl or C ₂ -C ₄ alkoxycarbonyl.

Specific Example 179. The composition of Specific Example 178 wherein each R ^14b is independently H, C ₁ -C ₄ alkyl, C ₁ -C ₄ haloalkyl, C ₂ -C ₄ alkenyl, C ₂ - C ₄ haloalkenyl, C ₂ -C ₄ alkynyl, C ₃ -C ₅ cycloalkyl, C ₄ -C ₆ cycloalkyl alkyl, C ₂ -C ₄ alkoxyalkyl, C ₂ -C ₄ haloalkoxyalkyl, C ₂ -C ₄ alkylaminoalkyl or C ₃ -C ₅ dialkylaminoalkyl.

Specific Example 180. The composition of Specific Example 179 wherein each R ^14b is independently H, C ₁ -C ₃ alkyl, C ₁ -C ₃ haloalkyl, C ₂ -C ₄ alkenyl, C ₂ - C ₄ haloalkenyl, C ₃ -C ₅ cycloalkyl, C ₄ -C ₆ cycloalkylalkyl or C ₂ -C ₄ alkoxyalkyl.

Specific Example 181. The composition of Specific Example 180, wherein each R ^14b is independently H, C ₁ -C ₃ alkyl, C ₁ -C ₃ haloalkyl, cyclopropylmethyl, or C ₂ -C ₄ Alkoxyalkyl.

Embodiment 181a. The composition of Embodiment 181 wherein each R ^14b is independently H, C ₁ -C ₂ alkyl, C ₁ -C ₂ haloalkyl, or cyclopropylmethyl.

Embodiment 181b. The composition of Embodiment 181a, wherein each R ^14b is independently H, methyl, or cyclopropylmethyl.

Embodiment 182. A composition comprising components (a) and (b) described in the Summary of the Invention or any one of Embodiments 1 to 181b, wherein in Formula 1, when R ^14a and R ^14b together form A 4- to 6-membered fully saturated heterocycle, then the ring contains ring members other than the attached nitrogen atom, selected from carbon atoms and up to 1 heteroatom selected from up to 1 O, up to 1 S and up to 1 N atom In addition, each ring is optionally substituted with up to 2 substituents independently selected from halo or methyl.

Specific Example 183. The composition of Specific Example 182, wherein R ^14a and R ^14b together form an azetidinyl, morpholinyl, pyrrolidinyl, piperidinyl, piperazinyl, or thiomorpholinyl ring, Each ring is optionally substituted with up to 2 substituents independently selected from halo or methyl.

Specific Example 184. The composition of Specific Example 183, wherein R ^14a and R ^14b together form an azetidinyl or pyrrolidinyl ring, each ring optionally being up to 2 independently selected from halogen or methyl substituted by the substituents of the base.

Embodiment 185. A composition comprising components (a) and (b) described in the Summary of the Invention or any one of Embodiments 1 to 184, wherein in Formula 1, each R ¹⁵ is independently H , cyano, halogen, methyl or methoxy.

Specific Example 186. The composition of Specific Example 185, wherein each R ¹⁵ is independently H or methyl.

Embodiment 187. A composition comprising components (a) and (b) as described in the Summary of the Invention or any one of Embodiments 1 to 186, wherein in Formula 1, each R ¹⁶ is independently hydroxyl , NR ^20a R ^20b , C ₁ -C ₂ alkoxy, C ₂ -C ₄ alkenyloxy, C ₂ -C ₄ alkylcarbonyloxy or C ₂ -C ₄ alkoxycarbonyloxy.

Specific Example 188. The composition of Specific Example 187 wherein each R ¹⁶ is independently hydroxy, NR ^20a R ^20b , or C ₁ -C ₄ alkoxy.

Specific Example 189. The composition of Specific Example 188, wherein each R ¹⁶ is independently hydroxy, NR ^20a R ^20b , or methoxy.

Specific Example 190. The composition of Specific Example 189, wherein each R ¹⁶ is hydroxy.

Embodiment 191. A composition comprising components (a) and (b) described in the Summary of the Invention or any one of Embodiments 1 to 190, wherein in Formula 1, each R ¹⁷ is independently H or methyl.

Specific Example 192. The composition of Specific Example 191 wherein each ^R17 is H.

Embodiment 193. A composition comprising components (a) and (b) described in the Summary of the Invention or any one of Embodiments 1 to 192, wherein in Formula 1, when each of R ^18a and R ^18b To be separated (ie, not together forming a ring), each R ^18a and R ^18b is independently H, methyl or ethyl.

Specific Example 194. The composition of Specific Example 193, wherein each R ^18a and R ^18b are independently H or methyl.

Embodiment 195. A composition comprising components (a) and (b) described in the Summary of the Invention or any one of Embodiments 1 to 194, wherein in Formula 1, when R ^18a and R ^18b together form A 5- to 6-membered fully saturated heterocyclic ring, then the ring contains ring members except for a nitrogen atom attached, selected from carbon atoms and up to 1 heterocyclic selected from up to 1 O, up to 1 S, and up to 1 N atom Atoms, each ring is optionally substituted with up to 2 methyl groups.

Specific Example 196. The composition of Specific Example 195, wherein R ^18a and R ^18b together form an azetidinyl, morpholinyl, pyrrolidinyl, piperidinyl, piperazinyl, or thiomorpholinyl ring , each ring is optionally substituted with up to 2 methyl groups.

Embodiment 197. A composition comprising components (a) and (b) described in the Summary of the Invention or any one of Embodiments 1 to 196, wherein in Formula 1, each R ¹⁹ is independently cyanide base, halogen, hydroxyl, C ₁ -C ₃ alkyl, C ₁ -C ₃ haloalkyl, C ₃ -C ₆ cycloalkyl, C ₁ -C ₃ alkoxy, C ₁ -C ₃ haloalkoxy, C ₂ -C ₃ alkoxyalkoxy, C ₁ -C ₃ alkylthio, C ₁ -C ₃ alkylsulfinyl, C ₁ -C ₃ alkylsulfonyl, C ₁ -C ₃ haloalkyl Sulfonyl, C ₂ -C ₃ alkylcarbonyl, C ₂ -C ₃ haloalkylcarbonyl, C ₂ -C ₃ alkoxycarbonyl, C ₂ -C ₃ alkylaminocarbonyl or C ₃ -C ₅ dialkyl Aminocarbonyl.

Specific Example 198. The composition of Specific Example 197 wherein each R ¹⁹ is independently cyano, halogen, hydroxy, C ₁ -C ₂ alkyl, C ₁ -C ₂ haloalkyl, C ₃ -C ₆ ring Alkyl, C ₁ -C ₂ alkoxy, C ₁ -C ₂ haloalkoxy, C ₁ -C ₂ alkylthio, C ₁ -C ₂ alkylsulfonyl, C ₁ -C ₂ haloalkylsulfonyl group, C ₂ -C ₃ alkylcarbonyl, C ₂ -C ₃ haloalkylcarbonyl, C ₂ -C ₃ alkoxycarbonyl or C ₂ -C ₃ alkylaminocarbonyl.

Specific Example 199. The composition of Specific Example 197 wherein each R ¹⁹ is independently cyano, halogen, C ₁ -C ₂ alkyl, C ₁ -C ₂ haloalkyl, C ₃ -C ₆ cycloalkyl , C ₁ -C ₂ alkoxy, C ₁ -C ₂ haloalkoxy, C ₂ -C ₃ alkylcarbonyl, C ₂ -C ₃ haloalkylcarbonyl or C ₂ -C ₃ alkoxycarbonyl.

Specific Example 200. The composition of Specific Example 199, wherein each R ¹⁹ is independently cyano, halogen, cyclopropyl, cyclobutyl, methoxy, halomethoxy, or methoxycarbonyl.

Embodiment 200a. The composition of Embodiment 200, wherein each R ¹⁹ is independently cyano, halo, cyclopropyl, or methoxy.

Embodiment 200b. The composition of Embodiment 200a, wherein each R ¹⁹ is independently cyano, Cl, F, cyclopropyl, or methoxy.

Embodiment 201. A composition comprising components (a) and (b) described in the Summary of the Invention or any one of Embodiments 1 to 200b, wherein in Formula 1, each U is independently a direct bond, C(=O)O or C(=O)N(R ²⁵ ).

Embodiment 202. The composition of Embodiment 201, wherein each U is independently a direct bond or C(=O)O.

Embodiment 203. The composition of Embodiment 202, wherein each U is C(=O)O.

Embodiment 204. A composition comprising components (a) and (b) described in the Summary of the Invention or any one of Embodiments 1 to 203, wherein in Formula 1, each V is independently a direct bond; or C ₁ -C ₆ alkylene, C ₂ -C ₆ alkenylene or C ₃ -C ₆ alkynylene, each optionally up to 2 independently selected from halogen, cyano, nitro , hydroxy, C ₁ -C ₂ alkyl, C ₁ -C ₂ haloalkyl, C ₁ -C ₂ alkoxy and C ₁ -C ₂ haloalkoxy substituents.

Specific Embodiment 205. The composition of Specific Embodiment 204, wherein each V is independently a direct bond; or a _{C1 -} C3 alkylene group, each optionally by up to 2 independently selected from halogen, hydroxy , C ₁ -C ₂ alkyl, C ₁ -C ₂ alkoxy and C ₁ -C ₂ haloalkoxy substituents.

Embodiment 206. The composition of Embodiment 205, wherein each V is independently a direct bond or a _{C1 -} C3 alkylene.

Embodiment 207. The composition of Embodiment 206, wherein each V is independently a direct bond or _CH2 .

Embodiment 208. The composition of Embodiment 207, wherein each V is a direct bond.

Embodiment 209. The composition of Embodiment 207, wherein each V is independently a _{C1 -} C2 alkylene.

Specific Example 210. The composition of Specific Example 209, wherein each V is _CH2 .

Embodiment 211. A composition comprising components (a) and (b) described in the Summary of the Invention or any one of Embodiments 1 to 210, wherein in Formula 1, each Q is independently phenyl , which is optionally substituted with up to 2 substituents independently selected from R; or a 5- to ⁶ -membered heteroaromatic ring, each ring containing ring members selected from carbon atoms and 1 to 4 independently Heteroatoms selected from up to 2 O, up to 2 S, and up to 4 N atoms, each ring optionally substituted with up to 2 substituents independently selected from R; or a 3- to ⁶ -membered non- Aromatic heterocycles, each ring comprising ring members selected from carbon atoms and 1 to 4 heteroatoms independently selected from up to 2 O, up to 2 S, and up to 4 N atoms, of which up to The 2 ring members are independently selected from C(=O), C(=S), S(=O) and S(=O) ₂ , each ring optionally being up to 2 independently selected from R ²⁷ Substituents are substituted.

Embodiment 212. The composition of Embodiment 210 wherein each Q is independently phenyl optionally substituted with up to ² substituents independently selected from R; or pyridyl, pyrazolyl , imidazolyl, triazolyl, thiazolyl, oxazolyl, isoxazolyl, thienyl, isoxazolinyl, piperidinyl, morpholinyl or piperazinyl, each optionally by up to 2 substituted with substituents independently selected from R ²⁷ .

Embodiment 213. The composition of Embodiment 212, Embodiment wherein each Q is independently phenyl optionally substituted with up to ² substituents independently selected from R; or pyridyl, Pyrazolyl, imidazolyl, triazolyl, thiazolyl or oxazolyl, each optionally substituted with up to 2 substituents independently selected from ^R27 .

Embodiment 214. The composition of Embodiment 213, Embodiment wherein each Q is independently phenyl optionally substituted with up to ² substituents independently selected from R; or pyridyl or Pyrazolyl, each optionally substituted with up to 2 substituents independently selected from ^R27 .

Embodiment 214a. The composition of Embodiment 214, Embodiment wherein each Q is independently phenyl or pyridyl, each optionally substituted with up to 2 substituents independently selected from R ²⁷ .

Specific embodiment 214b. The composition of specific embodiment 214a, specific embodiment wherein each Q is independently phenyl optionally substituted with up to 2 substituents independently selected from ^R27 .

Embodiment 215. A composition comprising components (a) and (b) described in the Summary of the Invention or any one of Embodiments 1 to 214b, wherein in Formula 1, when each R ^20a is separate (ie, not forming a ring together with R ^20b ), then each R ^20a is independently H, methyl or methylcarbonyl.

Embodiment 216. A composition comprising components (a) and (b) described in the Summary of the Invention or any one of Embodiments 1 to 215, wherein in Formula 1, when each R ^20b is isolated (that is, not forming a ring together with ^R20a ), then each ^R20b is independently H, cyano, methyl, methylcarbonyl, methoxycarbonyl, methoxycarbonylmethyl, methylaminocarbonyl or dimethylaminocarbonyl.

Embodiment 217. A composition comprising components (a) and (b) described in the Summary of the Invention or any one of Embodiments 1 to 216, wherein in Formula 1, when R ^20a and R ^20b are formed together A 5- to 6-membered fully saturated heterocyclic ring, then the ring contains ring members except for a nitrogen atom attached, selected from carbon atoms and up to 1 heterocyclic selected from up to 1 O, up to 1 S, and up to 1 N atom Atoms, each ring is optionally substituted with up to 2 methyl groups.

Specific Example 218. The composition of Specific Example 217, wherein R ^20a and R ^20b together form an azetidinyl, morpholinyl, pyrrolidinyl, piperidinyl, piperazinyl, or thiomorpholinyl ring , each ring is optionally substituted with up to 2 methyl groups.

Embodiment 219. A composition comprising components (a) and (b) described in the Summary of the Invention or any one of Embodiments 1 to 218, wherein in Formula 1, each R ²¹ and R ²³ are independently is H, cyano, halogen, methyl or methoxy.

Embodiment 220. A composition comprising components (a) and (b) described in the Summary of the Invention or any one of Embodiments 1 to 219, wherein in Formula 1, each R ^is independently H , C ₁ -C ₃ alkyl, C ₁ -C ₃ haloalkyl, C ₂ -C ₃ alkylcarbonyl, or C ₂ -C ₃ alkoxycarbonyl; or phenyl optionally by up to 2 independently selected from halogen and methyl substituents; or a 5- to 6-membered fully saturated heterocyclic ring, each ring containing ring members selected from carbon atoms and up to 2 heteroatoms independently selected from up to 2 O, up to 2 S and up to 2 N atoms, each ring is optionally substituted with up to 2 substituents independently selected from halogen and methyl.

Embodiment 221. The composition of Embodiment 220 wherein each R ²² is independently H or C ₁ -C ₂ alkyl.

Embodiment 222. A composition comprising components (a) and (b) described in the Summary of the Invention or any one of Embodiments 1 to 221, wherein in Formula ¹ , each R is independently H , cyano or C ₁ -C ₂ alkyl.

Embodiment 223. A composition comprising components (a) and (b) described in the Summary of the Invention or any one of Embodiments 1 to 222, wherein in Formula 1, each R ²⁵ and R ²⁶ are independently is H, cyano, hydroxy, C ₁ -C ₄ alkyl or C ₁ -C ₄ haloalkyl.

Specific Example 224. The composition of Specific Example 223, wherein each of R ²⁵ and R ²⁶ is independently H, cyano, hydroxy, or C ₁ -C ₂ alkyl.

Embodiment 225. A composition comprising components (a) and (b) described in the Summary of the Invention or any one of Embodiments 1 to 224, wherein in Formula 1, each R ^is independently halogen , cyano, C ₁ -C ₄ alkyl, C ₁ -C ₄ haloalkyl or C ₁ -C ₄ alkoxy.

Specific Example 226. The composition of Specific Example 225 wherein each R ²⁷ is independently halogen, cyano, C ₁ -C ₂ alkyl, C ₁ -C ₂ haloalkyl, or C ₁ -C ₂ alkoxy .

Specific Example 227. The composition of Specific Example 226, wherein each R ²⁷ is independently halo, methyl, or methoxy.

Specific Example 228. The composition of Specific Example 227, wherein each R ²⁷ is independently halogen.

Embodiment 229. A composition comprising components (a) and (b) described in the Summary of the Invention or any one of Embodiments 1 to 228, wherein in Formula 1, Z is a direct bond, O, NH, C(=O), C(=O)NH, NHC(=O), NHC(=O)NH, OC(=O)NH, NHC(=O)O, S(=O) ₂ NH, NHS(=O) ₂ or NHS(=O) ₂ NH.

Specific Example 230. The composition of Specific Example 229, wherein Z is a direct bond, O, NH, C(=O), C(=O)NH, or NHC(=O).

Embodiment 231. The composition of Embodiment 230, wherein Z is a direct bond, O, NH, or C(=O).

Embodiment 232. The composition of Embodiment 231, wherein Z is a direct bond.

Embodiment 233. The composition of Formula 1 or any one of Embodiments 1 to 232, wherein each R ²⁸ is independently H or C ₁ -C ₃ alkyl.

Specific Example 234. The composition of Specific Example 233, wherein each R ²⁸ is independently H or methyl.

Embodiment 235. A composition comprising components (a) and (b) described in the Summary of the Invention or any one of Embodiments 1 to 234, wherein in Formula 1, m is 0 or 2.

Specific Example 236. The composition of Specific Example 235, wherein m is 2.

Embodiment 237. A composition comprising components (a) and (b) as described in the Summary of the Invention or any one of Embodiments 1 to 236, wherein component (a) does not comprise the N of a compound of formula 1 -Oxides.

Embodiment 238. A composition comprising components (a) and (b) as described in the Summary of the Invention or any one of Embodiments 1 to 236, wherein component (a) comprises a compound selected from The following groups are formed: Ethyl 1-[[4-(3,3,3-trifluoro-2,2-dihydroxypropoxy)phenyl]methyl] -1H -pyrazole-4-carboxylate (Compound 1) ; Ethyl 1-[[4-[[2-(trifluoromethyl)-1,3-dioxolan-2-yl]methoxy]phenyl]methyl] -1H -pyrazole-4 -carboxylate (compound 32); Ethyl 1-[[4-[[(1 Z )-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]phenyl]methyl] -1H - Pyrazole-4-carboxylate (compound 64); Ethyl 1-[[4-[[(1 Z )-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]phenyl]methyl] -1H - Pyrazole-3-carboxylate (Compound 231); Ethyl 1-[[4-[[(1 Z )-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]-3-fluorophenyl]methyl ] -1H -pyrazole-4-carboxylate (Compound 262); Ethyl 1-[[3-[[(1 Z )-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]phenyl]methyl] -1H - Pyrazole-4-carboxylate (Compound 265); Ethyl 1-[[4-[[(1 Z )-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]phenoxy]methyl]-1 H -pyrazole-4-carboxylate (compound 364); N- (Cyclopropylmethyl)-2-[[4-[[2-(trifluoromethyl)-1,3-dioxolan-2-yl]methoxy]phenyl]methyl] Thiazole-4-carboxamide (Compound 71); 2-Methylpropyl 1-[[4-[[2-(trifluoromethyl)-1,3-dioxolan-2-yl]methoxy]phenyl]methyl]-1 H - Pyrazole-4-carboxylate (Compound 126); Cyclopropylmethyl 1-[[4-[[2-(trifluoromethyl)-1,3-dioxolan-2-yl]methoxy]phenyl]methyl] -1H -pyridine oxazole-4-carboxylate (compound 127); Ethyl 1-[2-[4-[[(1 Z )-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]phenyl]ethyl]- 1 H -Pyrazole-4-carboxylate (Compound 132); 2-Methoxyethyl 1-[[4-[[2-(trifluoromethyl)-1,3-dioxolan-2-yl]methoxy]phenyl]methyl]-1 H - Pyrazole-4-carboxylate (Compound 162); 2-Butyn-1-yl 1-[[4-[[2-(trifluoromethyl)-1,3-dioxolan-2-yl]methoxy]phenyl]methyl]-1 H -pyrazole-4-carboxylate (compound 163); 3-cyanopropyl 1-[[4-[[2-(trifluoromethyl)-1,3-dioxolan-2-yl]methoxy]phenyl]methyl]-1 H -pyridine oxazole-4-carboxylate (Compound 171); Benzyl 1-[[4-[[(1 Z )-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]phenyl]methyl]-1 H -pyrazole-4-carboxylate (compound 186); Butyl 1-[[4-[[(1 Z )-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]phenyl]methyl] -1H - Pyrazole-4-carboxylate (Compound 218); 3-Chloropropyl 1-[[4-[[( 1Z )-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]phenyl]methyl] -1H -pyrazole-4-carboxylate (compound 221); Phenyl methyl 4-(3,3,3-trifluoro-2,2-dihydroxypropoxy)carboxylate (Compound 229); Ethyl 1-[[3-Fluoro-4-[[2-(trifluoromethyl)-1,3-dioxolan-2-yl]methoxy]phenyl]methyl]-1 H - Pyrazole-4-carboxylate (Compound 263); Ethyl 1-[[4-[[(1 Z )-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]benzyloxy]methyl]- 1 H -Pyrazole-4-carboxylate (Compound 297); Methyl 1-[[3-[[(1 Z )-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]phenyl]methyl] -1H - Pyrazole-4-carboxylate (Compound 330); and Propyl 1-[[3-[[(1 Z )-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]phenyl]methyl] -1H - Pyrazole-4-carboxylate (compound 331).

Embodiment 239. The composition of Embodiment 238, wherein component (a) comprises a compound selected from the group consisting of: compounds 32, 64, 71, 126, 127, 132, 162, 163, 171, 186, 218, 229, 263, 297, 330 and 331.

Embodiment 240. The composition of Embodiment 239, wherein component (a) comprises a compound selected from the group consisting of: compounds 32, 64, 71, 126, 127, 132, 162, 163, 171, 218, 229 and 263.

Embodiment 241. The composition of Embodiment 240, wherein component (a) comprises a compound selected from the group consisting of compounds 32, 64, 126, 127, 132, 162, 163, 171 and 263.

Embodiment 242. The composition of Embodiment 241, wherein component (a) comprises a compound selected from the group consisting of compounds 32, 64, 126, 132, 163, and 263.

Embodiment 243. The composition of Embodiment 242, wherein component (a) comprises a compound selected from the group consisting of compounds 32 and 64.

Specific Example 243a. The composition of Specific Example 243, wherein component (a) is Compound 32.

Specific Example 243b. The composition of Specific Example 243, wherein component (a) is Compound 64.

Embodiment 244. A composition comprising components (a) and (b) as described in the Summary of the Invention or any one of Embodiments 1 to 243, wherein component (a) is ethyl 1-[[4 -[[2-(trifluoromethyl)-1,3-dioxolan-2-yl]methoxy]phenyl]methyl] -1H -pyrazole-4-carboxylate, its ( E )-isomer or a mixture thereof.

Embodiment 245. A composition comprising components (a) and (b) as described in the Summary of the Invention or any one of Embodiments 1 to 243, wherein component (a) is ethyl 1-[[4 -[[(1 Z )-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]phenyl]methyl] -1H -pyrazole-4-carboxylate acid salt, its ( E )-isomer or a mixture thereof.

Embodiment 246. A composition comprising components (a) and (b) as described in the Summary of the Invention or any one of Embodiments 1 to 243, wherein component (a) is ethyl 1-[[4 -[[(1 Z )-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]-3-fluorophenyl]methyl] -1H -pyrazole -4-carboxylate, its ( E )-isomer or a mixture thereof.

Embodiment 247. A composition comprising components (a) and (b) as described in the Summary of the Invention or any one of Embodiments 1 to 243, wherein component (a) is ethyl 1-[[3 -[[(1 Z )-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]phenyl]methyl] -1H -pyrazole-4-carboxylate acid salt, its ( E )-isomer or a mixture thereof.

Embodiment 248. A composition comprising components (a) and (b) as described in the Summary of the Invention or any one of Embodiments 1 to 243, wherein component (a) is ethyl 1-[[4 -[[(1 Z )-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]phenoxy]methyl] -1H -pyrazole-4- Carboxylate, its ( E )-isomer or a mixture thereof.

Embodiment 249. A composition comprising components (a) and (b) as described in the Summary of the Invention or any one of Embodiments 1 to 243, wherein component (a) is ethyl 1-[2- [4-[[(1 Z )-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]phenyl]ethyl] -1H -pyrazole-4 - Carboxylate, its ( E )-isomer or a mixture thereof.

Embodiment 250. A composition comprising components (a) and (b) as described in the Summary of the Invention or any one of Embodiments 1 to 243, wherein component (a) is a benzyl 1-[[ 4-[[(1 Z )-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]phenyl]methyl] -1H -pyrazole-4- Carboxylate, its ( E )-isomer or a mixture thereof.

Embodiment 251. A composition comprising components (a) and (b) as described in the Summary of the Invention or any one of Embodiments 1 to 243, wherein component (a) is butyl 1-[[4 -[[(1 Z )-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]phenyl]methyl] -1H -pyrazole-4-carboxylate acid salt, its ( E )-isomer or a mixture thereof.

Embodiment 252. A composition comprising components (a) and (b) as described in the Summary of the Invention or any one of Embodiments 1 to 243, wherein component (a) is 3-chloropropyl 1- [[4-[[(1 Z )-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]phenyl]methyl] -1H -pyrazole- 4-carboxylate, its ( E )-isomer or a mixture thereof.

Embodiment 253. A composition comprising components (a) and (b) as described in the Summary of the Invention or any one of Embodiments 1 to 243, wherein component (a) is ethyl 1-[[4 -[[(1 Z )-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]benzyloxy]methyl] -1H -pyrazole-4 - Carboxylate, its ( E )-isomer or a mixture thereof.

Embodiment 254. A composition comprising components (a) and (b) as described in the Summary of the Invention or any one of Embodiments 1 to 243, wherein component (a) is methyl 1-[[3 -[[(1 Z )-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]phenyl]methyl] -1H -pyrazole-4-carboxylate acid salt, its ( E )-isomer or a mixture thereof.

Embodiment 255. A composition comprising components (a) and (b) as described in the Summary of the Invention or any one of Embodiments 1 to 243, wherein component (a) is propyl 1-[[3 -[[(1 Z )-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]phenyl]methyl] -1H -pyrazole-4-carboxylate acid salt, its ( E )-isomer or a mixture thereof.

Specific Example 256. The composition of Specific Examples 238 to 255, wherein when component (b) comprises at least two fungicidal compounds, and when component (b) consists of a binary combination of the two fungicidal compounds, One of the fungicidal compounds is cyproconazole, Difenoconazole, epoxiconazole, flutriafol, metconazole, prothioconazole or tebuconazole, another fungicidal compound other than azoxystrobin, benzovindiflupyr, bixafen, boscalid, fluopyram Fluopyram, fluindapyr, fluxapyroxad, isopyrazam, kresoxim-methyl, penthiopyrad, picoxystrobin (picoxystrobin), proquinazid, pyraclostrobin, quinoxyfen, sedaxane, or trifloxystrobin.

Specific Example 257. The composition of Specific Examples 238 to 256, when component (b) comprises at least two fungicidal compounds, and when component (b) consists of a binary combination of the two fungicidal compounds, wherein One of the fungicidal compounds is cyproconazole, Difenoconazole, epoxiconazole, flutriafol, prothioconazole or tebuconazole ), the other fungicidal compound is not azoxystrobin, benzovindiflupyr, bixafen, fluindapyr, fluxapyroxad, Isopyrazam, picoxystrobin, pyraclostrobin, or trifloxystrobin.

Specific Example 258. The composition of Specific Example 257, wherein when component (b) comprises at least two fungicidal compounds, and when component (b) consists of a binary combination of two fungicidal compounds, wherein the One of the fungicidal compounds is cyproconazole, Difenoconazole, epoxiconazole, flutriafol, prothioconazole or tebuconazole , the other fungicidal compound is not azoxystrobin, benzovindiflupyr, bixafen, fluindapyr, fluxapyroxad, pyridoxine Isopyrazam, picoxystrobin, pyraclostrobin, or trifloxystrobin.

Embodiments of the invention, including Embodiments 1 through 258 above and any other embodiments described herein, may be combined in any manner, and the description of variables in the embodiments is not only directed to compounds comprising formula 1 with at least A composition of other fungicidal compounds, but also directed to compositions comprising a compound of formula 1 and at least one invertebrate pest control compound or agent, and to compounds of formula 1 and compositions thereof, also directed to use in the preparation of formula 1 The starting compounds and intermediate compounds of the compounds. In addition, specific embodiments of the present invention, including Examples 1-258 described above, as well as any other specific embodiments described herein, and combinations thereof, belong to the methods of the present invention. Therefore, as another specific embodiment, it is worth noting that the compositions disclosed above comprise (a) at least one compound selected from the group consisting of compounds of formula 1 above, N -oxides and salts thereof; and at least one invertebrate Pest control compounds or agents.

The combination of specific embodiments 1 to 258 is described in the following manner:

，

，

，

， G-1    G-2    G-3    G-4   

，

，

，

， G-5    G-6    G-7    G-8   

，

，

，

， G-9    G-10    G-11    G-12   

，

，

，

， G-13    G-14    G-15    G-16   

，

，

，

， G-17    G-18    G-19    G-20   

，

，

，

， G-21    G-22    G-23    G-24   

，

，

，

， G-25    G-26    G-27    G-28   

，

，

，

， G-29    G-30    G-31    G-32   

，

，

，

， G-33    G-34    G-35    G-36   

，

，

，

， G-37    G-38    G-39    G-40   

，

，

，

， G-41    G-42    G-43    G-44   

，

，

，

， G-45    G-46    G-47    G-48   

，

，

，

， G-49    G-50    G-51    G-52   

，

，

，

， G-53    G-54    G-55    G-56   

，

，

，

， G-57    G-58    G-59    G-60   

，

，

，

， G-61    G-62    G-63    G-64   

，

，

，

， G-65    G-66    G-67    G-68   

，

，

，

， G-69    G-70    G-71    G-72   

，

，

，

， G-73    G-74    G-75    G-76   

，

，

，

， G-77    G-78    G-79    G-80   

，

，

，

， G-81    G-82    G-83    G-84   

，

，

，

， G-85    G-86    G-87    G-88   

，

，

，

， G-89    G-90    G-91    G-92   

，

，

，

， G-93    G-94    G-95    G-96   

，

，

，

， G-97    G-98    G-99    G-100   

，

，

，

， G-101    G-102    G-103    G-104   

，

，

，

， G-105    G-106    G-107    G-108   

，

，

，

， G-109    G-110    G-111    G-112   

，

，

＇

， G-113    G-114    G-115    G-116   

，             G-117    G-118                其中該浮動鍵透過所示之環或環系統的任何可用之碳或氮原子與式1中的Z連接；以及x為0、1、2或3； 每個R¹³ 獨立地為C(=O)NR^14a R^14b 或‑U-V-Q；或C₁ -C₆ 烷基、C₂ ‑C₆ 烯基、C₂ ‑C₆ 炔基、C₁ ‑C₆ 烷氧基、C₂ -C₆ 烯氧基、C₂ -C₆ 炔氧基、C₁ -C₆ 烷基磺醯基、C₁ -C₆ 烷基磺醯基氧基、C₁ -C₆ 烷基磺醯基胺基、C₂ -C₆ 烷基羰基、C₂ -C₆ 烷氧羰基、C₃ -C₆ 烯基氧羰基、C₃ -C₆ 炔基氧羰基、C₄ -C₆ 環烷氧羰基或C₂ -C₆ 烷氧羰基氧基，每個可選擇地被最多3個獨立地選自R¹⁹ 的取代基所取代； 每個R^14a 獨立地為H、C₁ -C₂ 烷基、C₂ -C₄ 烯基、C₂ -C₄ 炔基、C₂ -C₄ 烷基羰基或C₂ -C₄ 烷氧羰基； 每個R^14b 獨立地為H、C₁ -C₄ 烷基、C₁ -C₄ 鹵代烷基、C₂ -C₄ 烯基、C₂ -C₄ 鹵代烯基、C₂ -C₄ 炔基、C₃ ‑C₅ 環烷基、C₄ -C₆ 環烷基烷基、C₂ -C₄ 烷氧基烷基、C₂ -C₄ 鹵代烷氧基烷基、C₂ ‑C₄ 烷基胺基烷基或C₃ -C₅ 二烷基胺基烷基；或 R^14a 與R^14b 一起形成一氮雜環丁烷基、嗎啉基、吡咯烷基、哌啶基、哌嗪基或硫嗎啉基環，每個環可選擇地被最多2個獨立地選自鹵素或甲基的取代基所取代； 每個R¹⁹ 獨立地為氰基、鹵素、C₁ -C₂ 烷基、C₁ -C₂ 鹵代烷基、C₃ -C₆ 環烷基、C₁ -C₂ 烷氧基、C₁ ‑C₂ 鹵代烷氧基、C₂ -C₃ 烷基羰基、C₂ -C₃ 鹵代烷基羰基或C₂ -C₃ 烷氧羰基； 每個U獨立地為一直接鍵、C(=O)O或C(=O)N(R²⁵ )； 每個V獨立地為一直接鍵；或C₁ -C₃ 亞烷基，每個可選擇地被最多2個獨立地選自鹵素、羥基、C₁ -C₂ 烷基、C₁ ‑C₂ 烷氧基以及C₁ -C₂ 鹵代烷氧基的取代基所取代； 每個Q獨立地為苯基，其可選擇地被最多2個獨立地選自R²⁷ 的取代基所取代；或吡啶基、吡唑基、咪唑基、三唑基、噻唑基或噁唑基，每個可選擇地被最多2個獨立地選自R²⁷ 的取代基所取代； 每個R²⁵ 獨立地為H、氰基、羥基或C₁ -C₂ 烷基； 每個R²⁷ 獨立地為鹵素、氰基、C₁ -C₂ 烷基、C₁ -C₂ 鹵代烷基或C₁ -C₂ 烷氧基；以及 Z為一直接鍵、O、NH、C(=O)、C(=O)NH、NHC(=O)、NHC(=O)NH、OC(=O)NH、NHC(=O)O、S(=O)₂ NH、NHS(=O)₂ 或NHS(=O)₂ NH。EXAMPLES A. A composition comprising components (a) and (b) described in the Summary of the Invention, wherein component (a) comprises a compound of formula 1 or a salt thereof, wherein in formula 1, R ¹ is _CF3 , CCl3, or _{CF2Cl ;} W is O; each ^R5a and ^R5b is independently H, hydroxy or methyl; each ^R2a and ^R2b is independently H or methyl; or ^R2a Together with R ^2b and the X and Y atoms to which it is attached, form a 5- to 6-membered saturated ring comprising ring members, in addition to the X and Y atoms, also selected from carbon atoms, wherein at most 1 carbon atom ring member is selected from C(=O) optionally substituted on carbon atom ring members with up to 2 substituents independently selected from halogen, cyano, methyl, halomethyl, methoxy and halomethoxy ; R ^2c is C ₁ -C ₂ alkyl, C ₂ -C ₃ alkenyl or C ₂ -C ₃ alkynyl; R ^2d is H or methyl; A ¹ is CR ^6c R ^6d or O; A ² is a Direct bond, CR ^6e R ^6f or O; each R ^6a , R ^6b , R ^6c , R ^6d , R ^6e and R ^6f is independently H, cyano, hydroxyl, Br, Cl, F or methyl; J is J-1, J-6 or J-14; each ^R8 is independently F, Cl or methyl; each ^R9a and ^R9b is independently H, halogen or methyl; n is 0, 1 or 2 ; E ¹ is C ₁ -C ₆ alkoxy, C ₁ -C ₆ alkylsulfonyl, C ₂ -C ₆ alkylcarbonyl or C ₂ -C ₆ alkoxycarbonyl, wherein each carbon atom is optionally substituted with up to 1 substituent selected from R ^10a and up to 3 independently selected from R ^10b ; R ^10a is phenyl optionally substituted with up to 2 substituents independently selected from R ^11a ; or a 5- to 6-membered heterocycle comprising ring members selected from carbon atoms and 1 to 4 heteroatoms independently selected from up to 2 O, up to 2 S, and up to 4 N atoms, Each ring is optionally substituted on carbon atom ring members with up to 2 substituents independently selected from R ^11a , and optionally substituted on nitrogen atom ring members with up to 2 substituents independently selected from R ^11b each R ^10b is independently halogen, hydroxy, C ₁ -C ₄ alkyl, C ₁ -C ₄ haloalkyl, C ₁ -C ₄ alkoxy, C ₁ -C ₄ haloalkoxy, C ₁ -C ₄ alkylsulfonyl, C ₂ -C ₄ alkylcarbonyl or C ₂ -C ₅ alkoxycarbonyl; each R ^11a is independently halogen, C ₁ -C ₂ alkyl, C ₁ -C ₂ haloalkyl, C ₁ -C ₂ alkoxy or C ₂ -C ₃ alkoxycarbonyl; each R ^11b is independently methyl, methoxy, methylcarbonyl or methoxycarbonyl; G is selected from the group consisting of group of:

,

,

,

, G-1 G-2 G-3 G-4

,

,

,

, G-5 G-6 G-7 G-8

,

,

,

, G-9 G-10 G-11 G-12

,

,

,

, G-13 G-14 G-15 G-16

,

,

,

, G-17 G-18 G-19 G-20

,

,

,

, G-21 G-22 G-23 G-24

,

,

,

, G-25 G-26 G-27 G-28

,

,

,

, G-29 G-30 G-31 G-32

,

,

,

, G-33 G-34 G-35 G-36

,

,

,

, G-37 G-38 G-39 G-40

,

,

,

, G-41 G-42 G-43 G-44

,

,

,

, G-45 G-46 G-47 G-48

,

,

,

, G-49 G-50 G-51 G-52

,

,

,

, G-53 G-54 G-55 G-56

,

,

,

, G-57 G-58 G-59 G-60

,

,

,

, G-61 G-62 G-63 G-64

,

,

,

, G-65 G-66 G-67 G-68

,

,

,

, G-69 G-70 G-71 G-72

,

,

,

, G-73 G-74 G-75 G-76

,

,

,

, G-77 G-78 G-79 G-80

,

,

,

, G-81 G-82 G-83 G-84

,

,

,

, G-85 G-86 G-87 G-88

,

,

,

, G-89 G-90 G-91 G-92

,

,

,

, G-93 G-94 G-95 G-96

,

,

,

, G-97 G-98 G-99 G-100

,

,

,

, G-101 G-102 G-103 G-104

,

,

,

, G-105 G-106 G-107 G-108

,

,

,

, G-109 G-110 G-111 G-112

,

,

'

, G-113 G-114 G-115 G-116

, G-117 G-118 wherein the floating bond is attached to Z in formula 1 through any available carbon or nitrogen atom of the ring or ring system shown; and x is 0, 1, 2, or ³ ; each R is independently C(=O ) NR ^14a R ^14b or -UVQ; or C ₁ -C ₆ alkyl, C ₂ -C ₆ alkenyl, C ₂ -C ₆ alkynyl, C ₁ -C ₆ alkoxy, C ₂ -C ₆ alkenyl base, C ₂ -C ₆ alkynyloxy, C ₁ -C ₆ alkylsulfonyl, C ₁ -C ₆ alkylsulfonyloxy, C ₁ -C ₆ alkylsulfonylamino, C ₂ -C ₆ alkylcarbonyl, C ₂ -C ₆ alkoxycarbonyl, C ₃ -C ₆ alkenyloxycarbonyl, C ₃ -C ₆ alkynyloxycarbonyl, C ₄ -C ₆ cycloalkoxycarbonyl or C ₂ -C ₆ alkoxycarbonyloxy, each optionally substituted with up to 3 substituents independently selected from R ¹⁹ ; each R ^14a is independently H, C ₁ -C ₂ alkyl, C ₂ -C ₄ alkenyl, C ₂ -C ₄ alkynyl, C ₂ -C ₄ alkylcarbonyl, or C ₂ -C ₄ alkoxycarbonyl; each R ^14b is independently H, C ₁ -C ₄ alkyl, C ₁ -C ₄ haloalkyl, C ₂ -C ₄ alkenyl, C ₂ -C ₄ haloalkenyl, C ₂ -C ₄ alkynyl, C ₃ -C ₅ cycloalkyl, C ₄ -C ₆ cycloalkyl alkyl, C ₂ -C ₄ alkoxyalkyl, C ₂ -C ₄ haloalkoxyalkyl, C ₂ -C ₄ alkylaminoalkyl or C ₃ -C ₅ dialkylaminoalkyl; or R ^14a together with R ^14b form an azetidinyl, morpholinyl, pyrrolidinyl, piperidinyl, piperazinyl or thiomorpholinyl ring, each ring optionally being up to 2 independently selected from halogen or methyl substituent; each R ¹⁹ is independently cyano, halogen, C ₁ -C ₂ alkyl, C ₁ -C ₂ haloalkyl, C ₃ -C ₆ cycloalkyl, C ₁ -C ₂ alkoxy, C ₁ -C ₂ haloalkoxy, C ₂ -C ₃ alkylcarbonyl, C ₂ -C ₃ haloalkylcarbonyl or C ₂ -C ₃ alkoxycarbonyl; each U is independently a direct bond , C(=O)O, or C(=O)N(R ²⁵ ); each V is independently a direct bond; or a C ₁ -C ₃ alkylene group, each optionally by up to 2 independently substituted with a substituent selected from halogen, hydroxy, C ₁ -C ₂ alkyl, C ₁ -C ₂ alkoxy, and C ₁ -C ₂ haloalkoxy; each Q is independently phenyl, which is optionally substituted with up to ² substituents independently selected from R; or pyridyl, pyrazolyl, imidazolyl, triazolyl, thiazolyl or oxazolyl, each optionally selected by up to 2 independently Substituted from a substituent of R ²⁷ ; each R ²⁵ is independently H, cyano, hydroxy or C ₁ -C ₂ alkyl; each R ²⁷ is independently halogen , cyano, C ₁ -C ₂ alkyl, C ₁ -C ₂ haloalkyl or C ₁ -C ₂ alkoxy; and Z is a direct bond, O, NH, C(=O), C(=O )NH, NHC(=O), NHC(=O)NH, OC(=O)NH, NHC(=O)O, S(=O) ₂ NH, NHS(=O) ₂ or NHS(=O) _2NH .

Specific Example AA. The composition of Specific Example A, wherein in Formula 1, R ¹ is CF ₃ ; X is O; Y is O; L is a direct bond or CH ₂ ; and Z is a direct bond.

Specific embodiment AAA. The composition of specific embodiment A, wherein in formula 1, R ¹ is CF ₃ ; Z is a direct bond.

Specific Example B. The composition of Specific Example A, wherein in Formula 1, T is T-2 or T-3; R ¹ is CF ₃ ; X is O; Y is O; each R ^2a and R ^2b independently H or methyl; or R ^2a and R ^2b together with the X and Y atoms to which they are attached form a 5-membered saturated ring comprising ring members, in addition to the X and Y atoms, selected from carbon atoms, the ring The carbon atom ring members are optionally substituted with at most 1 substituent selected from halogen, methyl and halomethyl; R ^2c is methyl or ethyl; R ^2d is H; A ¹ is O; A ² is a direct bond or CH ₂ ; each R ^6a and R ^6b is independently H, cyanohydroxy or methyl; J is J-1 or J-6; q is 0 or 1; each R ^9a and R ^9b independently H or methyl; E ¹ is C ₁ -C ₃ alkoxy, C ₂ -C ₃ alkylcarbonyl or C ₂ -C ₃ alkoxycarbonyl, wherein each carbon atom is optionally replaced by up to 1 substituted with up to 3 substituents independently selected from R ^10a and R ^10b ; R ^10a is pyrazolyl, imidazolyl or triazolyl, each optionally on a carbon atom ring member by up to 2 independently is substituted with a substituent selected from R ^11a ; each R ^10b is independently halogen, C ₁ -C ₂ alkyl, C ₁ -C ₂ haloalkyl, C ₁ -C ₂ alkoxy, or C ₂ -C ₄ alkoxycarbonyl; G is G-1, G-3, G-12 or G-22; x is 1 or 2; each R ¹³ is independently C(=O)NR ^14a R ^14b or -UVQ; or C _{2 -} C5alkoxycarbonyl, C3 _{- C5alkenyloxycarbonyl} , C3 _{- C5alkynyloxycarbonyl} , or _{C4 -} C6cycloalkoxycarbonyl, each optionally selected by up to 3 independently Substituted from the substituents of R ¹⁹ ; each R ^14a is independently H or C ₁ -C ₂ alkyl; each R ^14b is independently H, C ₁ -C ₃ alkyl, C ₁ -C ₃ haloalkyl , cyclopropylmethyl or C ₂ -C ₄ alkoxyalkyl; each R ¹⁹ is independently cyano, halogen, cyclopropyl, cyclobutyl, methoxy, halomethoxy or methoxycarbonyl each U is independently a direct bond or C(=O)O; each V is independently a direct bond or CH ₂ ; each Q is independently phenyl or pyridyl, each optionally being up to 2 substituents independently selected from R ²⁷ are substituted; each R ²⁷ is independently halogen, methyl or methoxy; and Z is a direct bond, O, NH, C(=O), C(= O)NH or NHC(=O).

Embodiment BB. The composition of Embodiment B, wherein in Formula 1, L is a direct bond or CH ₂ ; G is G-1 or G-12; and Z is a direct bond.

Specific embodiment BBB. The composition of specific embodiment B, wherein in formula 1, Z is a direct key.

Embodiment C. The composition of Embodiment B, wherein in Formula 1, each of R ^2a and R ^2b is H; or R ^2a and R ^2b together with the X and Y atoms to which they are attached form a 5-membered saturated A ring comprising ring members, except X and Y atoms, selected from carbon atoms; A ² is a direct bond; Each R ^6a and R ^6b is H; R ⁸ is F or Cl; L is a direct bond, CH ₂ or CH ₂ CH ₂ ; E ¹ is C ₁ -C ₂ alkoxy or C ₂ -C ₃ alkoxycarbonyl, wherein each carbon atom is optionally substituted by at most 1 substituent selected from R ^10a ; R ^10a is pyrazolyl or imidazolyl, each optionally substituted on a carbon atom ring member with up to 2 substituents independently selected from R ^11a ; each R ^11a is independently methoxycarbonyl or ethoxy Carbonyl; G is G-1 and the 2nd position of G-1 is connected to Z and its 4th position is connected to R ¹³ ; or G is G-12 and the 1st position of G-12 is connected to Z and its 4th position is connected to R ¹³ Or G is G-12 and the 1st position of G-12 is connected to Z and its 3rd position is connected to R ¹³ ; x is 1; R ¹³ is C(=O)NR ^14a R ^14b or -UVQ; or C ₂ - C ₅ alkoxycarbonyl, C ₃ -C ₅ alkynyloxycarbonyl or C ₄ -C ₆ cycloalkoxycarbonyl, each optionally substituted with up to 1 substituent selected from R ¹⁹ ; R ^14a is H; R ^14b is H, methyl or cyclopropylmethyl; R ¹⁹ is cyano, halogen, cyclopropyl or methoxy; U is C(=O)O; V is CH ₂ ; Q is phenyl, which optionally substituted with up to 2 substituents independently selected from ^R27 ; and Z is a direct bond, O, NH, or C(=O).

Specific Example CC. The composition of Specific Example C, wherein in Formula 1, L is a direct bond or _CH2 ; and Z is a direct bond.

Specific Example D. The composition of Specific Example C, wherein in Formula 1, R ⁸ is F; L is a direct bond or CH ₂ ; E ¹ is a methoxy group, which is substituted by a substituent selected from R ^10a Substituted; R ^10a is pyrazolyl optionally substituted on a carbon atom ring member with up to 1 substituent selected from R ^11a ; G is G-12 and the first position of G-12 connects Z and its or G is G-12 and the 1st position of G-12 is attached to Z and its 3rd position is attached to R ¹³ _{; and R 13 is C 2 -C 5} ^{alkoxycarbonyl} _, ^which is optionally Substituted with at most 1 substituent selected from R ¹⁹ ; R ¹⁹ is cyano, Cl, F, cyclopropyl or methoxy; and Z is a direct bond.

Specific embodiment DD. The composition of specific embodiment D, wherein in formula 1, L is a direct bond or CH ₂ , provided that when L is a direct bond, then E is E ¹ , and when L is CH ₂ , Then E is E ² .

Specific Example E. The composition of Specific Example D, wherein in Formula 1, J is J-1; q is 0; L is CH ₂ ; E is E ² ; G is G-12, and G-12’s Z is attached at the 1st position and ^R13 is attached at the 4th position; and ^R13 is methoxycarbonyl or ethoxycarbonyl.

Embodiment EE. The composition of Embodiment E, wherein in Formula 1, R ^2a and R ^2b together with the X and Y atoms to which they are attached form a 5-membered saturated ring comprising ring members except X and Y Atoms, selected from carbon atoms.

Specific Embodiment F. The composition of any of Specific Embodiments A to EE, wherein in Formula 1, T is T-2; and R ¹³ is ethoxycarbonyl.

Embodiment G. The composition of any one of Embodiments A to E, wherein in Formula 1, T is T-3; and R ¹³ is ethoxycarbonyl.

Embodiment H. The composition of any one of Embodiments A to G, wherein component (a) comprises a compound selected from the group consisting of: Compound 1, Compound 32, Compound 64, Compound 71 , compound 126, compound 127, compound 132, compound 162, compound 163, compound 171, compound 186, compound 218, compound 221, compound 229, compound 231, compound 262, compound 263, compound 265, compound 297, compound 330, compound 331 and compound 364.

Embodiment I. The composition of Embodiment H, wherein component (a) comprises a compound selected from the group consisting of: compound 32, compound 64, compound 71, compound 126, compound 127, compound 132, compound 162, compound 163, compound 171, compound 186, compound 218, compound 229, compound 263, compound 297, compound 330 and compound 331.

Specific Example J. The composition of Specific Example I, wherein component (a) comprises Compound 32.

Specific Example K. The composition of Specific Example I, wherein component (a) comprises Compound 64.

Embodiment B1. The composition described in the Summary of the Invention (including but not limited to the compositions of any one of Embodiments 1 to 258 and A to K), wherein component (b) comprises at least one compound that is Selected from (b1) methyl benzimidazole carbamate fungicides, such as benomyl, carbendazim, fuberidazole, thiabendazole, polyphenol ( thiophanate) and thiophanate-methyl.

Embodiment B2. The composition described in the Summary of the Invention (including but not limited to the compositions of any one of Embodiments 1 to 258 and A to K), wherein component (b) comprises at least one compound that is (b2) Dimethylimide fungicides such as chlozolinate, dimethachlone, iprodione, procymidone and vinclozolin ).

Embodiment B3. The composition described in the Summary of the Invention (including but not limited to the compositions of any one of Embodiments 1 to 258 and A to K), wherein component (b) comprises at least one compound that is (b3) Demethylation inhibitor fungicides such as triforine, butthiobate, pyrifenox, pyrisoxazole, fenarimol , nuarimol, triarimol, econazole, imazalil, oxpoconazole, pefurazoate, prochloraz, Saifu Triflumizole, azaconazole, bitertanol, bromuconazole, cyproconazole, difenoconazole, diniconazole, (including Niazole-M (diniconazole M), epoxiconazole, etaconazole, fenbuconazole, fluquinconazole, flusilazole, flutriafol ), hexaconazole, imibenconazole, ipconazole, mefentrifluconazole, metconazole, myclobutanil, penconazole, Propiconazole, ipfentrifluconazole, quinconazole, simeconazole, tebuconazole, tetraconazole three Triadimefon, triadimenol, triticonazole, uniconazole, and uniconazole-P.

Embodiment B4. The composition described in the Summary of the Invention (including but not limited to the compositions of any one of Embodiments 1 to 258 and A to K), wherein component (b) comprises at least one compound that is (b4) benzamide fungicides such as metalaxyl, metalaxyl-M, benalaxyl, benalaxyl-M (benalaxyl-M), Furalaxyl, ofurace, and oxadixyl.

Embodiment B5. The composition described in the Summary of the Invention (including but not limited to the compositions of any one of Embodiments 1 to 258 and A to K), wherein component (b) comprises at least one compound that is (b5) Amine/morpholine fungicides such as aldimorph, dodemorph, fenpropimorph, tridemorph, trimorphamide ( trimorphamide), fenpropidin, piperalin, and spiroxamine.

Embodiment B6. The composition described in the Summary of the Invention (including but not limited to the compositions of any one of Embodiments 1 to 258 and A to K), wherein component (b) comprises at least one compound that is (b6) Phospholipid biosynthesis inhibitor fungicides such as edifenphos, iprobenfos, pyrazophos and isoprothiolane.

Embodiment B7. The composition described in the Summary of the Invention (including but not limited to the compositions of any one of Embodiments 1 to 258 and A to K), wherein component (b) comprises at least one selected from (b7 ) succinate dehydrogenase inhibitor fungicides such as benodanil, flutolanil, mepronil, isofetamid, fluopyram ( fluopyram, fenfuram, carboxin, oxycarboxin, thifluzamide, benzovindiflupyr, bixafen, fluindene Fluindapyr, fluxapyroxad, furametpyr, inpyrfluxam, isopyrazam, penflufen, penthiopyrad, paripole Pyrapropoyne, sedaxane, flubeneteram, isoflucypram, pydiflumetofen, boscalid, and bifena pyraziflumid.

Embodiment B8. The composition described in the Summary of the Invention (including but not limited to the compositions of any one of Embodiments 1 to 258 and A to K), wherein component (b) comprises at least one selected from (b8 ) hydroxy(2-amino-)pyrimidine fungicides such as bupirimate, dimethirimol and ethirimol.

Embodiment B9. The composition described in the Summary of the Invention (including but not limited to the composition of any one of Embodiments 1 to 258 and A to K), wherein component (b) comprises at least one selected from (b9 ) Compounds of anilinopyrimidine fungicides such as cyprodinil, mepanipyrim and pyrimethanil.

Embodiment B10. The composition described in the Summary of the Invention (including but not limited to the composition of any one of Embodiments 1 to 258 and A to K), wherein component (b) comprises at least one selected from (b10 ) Compounds of N -phenylcarbamate fungicides, such as diethofencarb.

Embodiment B11. The composition described in the Summary of the Invention (including but not limited to the composition of any one of Embodiments 1 to 258 and A to K), wherein component (b) comprises at least one selected from (b11 ) quinone external inhibitor fungicides such as azoxystrobin, coumoxystrobin, enoxastrobin, flufenoxystrobin, picoxystrobin ), pyraoxystrobin, mandestrobin, pyraclostrobin, pyrametostrobin, triclopyricarb, kresoxim-methyl, triflu Trifloxystrobin, dimoxystrobin, fenaminstrobin, metminostrobin, orysastrobin, fluoxastrobin, famoxadone ), fenamidone and pyribencarb.

Embodiment B12. The composition described in the Summary of the Invention (including but not limited to the composition of any one of Embodiments 1 to 258 and A to K), wherein component (b) comprises at least one selected from (b12 ) Compounds of phenylpyrrole (PP) fungicides, such as fenpiclonil and fludioxonil.

Embodiment B13. The composition described in the Summary of the Invention (including but not limited to the composition of any one of Embodiments 1 to 258 and A to K), wherein component (b) comprises at least one selected from (b13 ) compounds of azanaphthalene fungicides, such as quinoxyfen and proquinazid.

Embodiment B14. The composition described in the Summary of the Invention (including but not limited to the compositions of any one of Embodiments 1 to 258 and A to K), wherein component (b) comprises at least one compound that is Selected from (b14) cytoperoxidation inhibitor fungicidal, such as biphenyl, chloroneb, dicloran, pentachloronitrobenzene (quintozene), tetrachloronitrobenzene (tecnazene) ), tolclofos-methyl and etridiazole.

Embodiment B15. The composition described in the Summary of the Invention (including but not limited to the compositions of any one of Embodiments 1 to 258 and A to K), wherein component (b) comprises at least one compound that is (b15) Melanogenesis inhibitor-reductase fungicides such as fthalide, pyroquilon and tricyclazole.

Embodiment B16a. The composition described in the Summary of the Invention (including but not limited to the compositions of any one of Embodiments 1 to 258 and A to K), wherein component (b) comprises at least one compound that is (b16a) Melanogenesis inhibitor-dehydratase fungicides such as carpropamid, diclocymet, and fenoxanil.

Embodiment B16b. The composition described in the Summary of the Invention (including but not limited to the compositions of any of Embodiments 1 to 258 and A to K), wherein component (b) comprises at least one compound that is Selected from (b16b) melanin biosynthesis inhibitor-polyketide synthase fungicides, such as urethane fungicides tolprocarb.

Embodiment B17. The composition described in the Summary of the Invention (including but not limited to the compositions of any one of Embodiments 1 to 258 and A to K), wherein component (b) comprises at least one compound that is (b17) Ketoreductase inhibitor fungicides such as fenhexamid, fenpyrazamine, quinofumelin and ipflufenoquin ).

Embodiment B18. The composition described in the Summary of the Invention (including but not limited to the compositions of any one of Embodiments 1 to 258 and A to K), wherein component (b) comprises at least one compound that is Selected from (b18) squalene-epoxidase inhibitor fungicides such as pyributicarb, naftifine and terbinafine.

Embodiment B19. The composition described in the Summary of the Invention (including but not limited to the compositions of any one of Embodiments 1 to 258 and A to K), wherein component (b) comprises at least one compound that is Selected from (b19) polytoxin fungicides such as polyoxin.

Embodiment B20. The composition described in the Summary of the Invention (including but not limited to the compositions of any one of Embodiments 1 to 243 and A to K), wherein component (b) comprises at least one compound that is Selected from (b20) phenylurea fungicides such as pencycuron.

Embodiment B21. The composition described in the Summary of the Invention (including but not limited to the compositions of any one of Embodiments 1 to 258 and A to K), wherein component (b) comprises at least one compound that is Selected from (b21) quinone inhibitor fungicides such as cyazofamid, amisulbrom and fenpicoxamid (registration number 517875-34-2).

Embodiment B22. The composition described in the Summary of the Invention (including but not limited to the compositions of any one of Embodiments 1 to 258 and A to K), wherein component (b) comprises at least one compound that is Selected from (b22) benzylamide and thiazole carboxamide fungicides such as zoxamide and ethaboxam.

Embodiment B23. The composition described in the Summary of the Invention (including but not limited to the compositions of any one of Embodiments 1 to 258 and A to K), wherein component (b) comprises at least one compound that is Selected from (b23) dipyranuronic acid antibiotic fungicides, such as blasticidin-S.

Embodiment B24. The composition described in the Summary of the Invention (including but not limited to the compositions of any one of Embodiments 1 to 258 and A to K), wherein component (b) comprises at least one compound that is (b24) Hexopyranosyl antibiotic fungicides such as kasugamycin.

Embodiment B25. The composition described in the Summary of the Invention (including but not limited to the compositions of any one of Embodiments 1 to 258 and A to K), wherein component (b) comprises at least one compound that is Selected from (b25) glucopyranosyl antibiotics: protein synthesis bactericides such as streptomycin.

Embodiment B26. The composition described in the Summary of the Invention (including but not limited to the compositions of any one of Embodiments 1 to 258 and A to K), wherein component (b) comprises at least one compound that is Selected from (b26) glucopyranosyl antibiotics: trehalase and inositol biosynthetic fungicides such as validamycin.

Embodiment B27. The composition described in the Summary of the Invention (including but not limited to the compositions of any one of Embodiments 1 to 258 and A to K), wherein component (b) comprises at least one compound that is Selected from (b27) cyanoacetamidoxime bactericides such as cymoxanil.

Embodiment B28. The composition described in the Summary of the Invention (including but not limited to the compositions of any one of Embodiments 1 to 258 and A to K), wherein component (b) comprises at least one compound that is Selected from (b28) carbamate fungicides such as propamacarb, prothiocarb and iodocarb.

Embodiment B29. The composition described in the Summary of the Invention (including but not limited to the compositions of any one of Embodiments 1 to 258 and A to K), wherein component (b) comprises at least one compound that is (b29) Oxidative phosphorylation uncoupling fungicides such as fluazinam, binapacryl, meptyldinocap and dinocap.

Embodiment B30. The composition described in the Summary of the Invention (including but not limited to the compositions of any one of Embodiments 1 to 258 and A to K), wherein component (b) comprises at least one compound that is Selected from (b30) organotin fungicides such as fentin acetate, fentin chloride and fentin hydroxide.

Embodiment B31. The composition described in the Summary of the Invention (including but not limited to the compositions of any one of Embodiments 1 to 258 and A to K), wherein component (b) comprises at least one compound that is Selected from (b31) carboxylic acid fungicides, such as oxolinic acid.

Embodiment B32. The composition described in the Summary of the Invention (including but not limited to the compositions of any one of Embodiments 1 to 258 and A to K), wherein component (b) comprises at least one compound that is Selected from (b32) heteroaromatic fungicides such as hymexazole and octhilinone.

Embodiment B33. The composition described in the Summary of the Invention (including but not limited to the compositions of any one of Embodiments 1 to 258 and A to K), wherein component (b) comprises at least one compound that is Selected from (b33) phosphonate fungicides, such as phosphorous acid and its various salts, including fosetyl-aluminum.

Embodiment B34. The composition described in the Summary of the Invention (including but not limited to the compositions of any one of Embodiments 1 to 258 and A to K), wherein component (b) comprises at least one compound that is Selected from (b34) phthalic acid fungicides such as teclofthalam.

Embodiment B35. The composition described in the Summary of the Invention (including but not limited to the compositions of any of Embodiments 1 to 258 and A to K), wherein component (b) comprises at least one compound that is Selected from (b35) benzotriazine fungicides such as triazoxide.

Embodiment B36. The composition described in the Summary of the Invention (including but not limited to the compositions of any one of Embodiments 1 to 258 and A to K), wherein component (b) comprises at least one compound that is Selected from (b36) besylate fungicides such as flusulfamide.

Embodiment B37. The composition described in the Summary of the Invention (including but not limited to the compositions of any one of Embodiments 1 to 258 and A to K), wherein component (b) comprises at least one compound that is Selected from (b37) ta𠯤 ketone fungicides such as diclomezine.

Embodiment B38. The composition described in the Summary of the Invention (including but not limited to the compositions of any of Embodiments 1 to 258 and A to K), wherein component (b) comprises at least one compound that is Selected from (b38) thiophene-carboxamide fungicides such as silthiofam.

Embodiment B39. The composition described in the Summary of the Invention (including but not limited to the compositions of any one of Embodiments 1 to 258 and A to K), wherein component (b) comprises at least one compound that is Selected from (b39) complex I NADH oxidoreductase inhibitor fungicides such as diflumetorim, tolfenpyrad and fenazaquin.

Embodiment B40. The composition described in the Summary of the Invention (including but not limited to the compositions of any one of Embodiments 1 to 258 and A to K), wherein component (b) comprises at least one compound that is (b40) Carboxylic amide fungicides such as dimethomorph, benthiavalicarb, benthiavalicarb-isopropyl, iprovalicarb ), valifenalate, mandipropamid, flumorph, dimethomorph, flumorph, pyrimorph, benzothiazine Benthiavalicarb, benthiavalicarb-isopropyl, iprovalicarb, carbamate fungicides tolprocarb, valifenalate, and pyraclostrobin (mandipropamid).

Embodiment B41. The composition described in the Summary of the Invention (including but not limited to the compositions of any one of Embodiments 1 to 258 and A to K), wherein component (b) comprises at least one compound that is Selected from (b41) tetracycline antibiotic fungicides such as oxytetracycline.

Embodiment B42. The composition described in the Summary of the Invention (including but not limited to the compositions of any one of Embodiments 1 to 258 and A to K), wherein component (b) comprises at least one compound that is (b42) Thiocarbamate fungicides such as methasulfocarb.

Embodiment B43. The composition described in the Summary of the Invention (including but not limited to the compositions of any one of Embodiments 1 to 258 and A to K), wherein component (b) comprises at least one compound that is Selected from (b43) benzalkonium fungicides such as fluopicolide and fluopimide.

Embodiment B44. The composition described in the Summary of the Invention (including but not limited to the compositions of any one of Embodiments 1 to 258 and A to K), wherein component (b) comprises at least one compound that is (b44) Microbial fungicides such as Bacillus amyloliquefaciens strains QST713, FZB24, MB1600, D747, F727, TJ100 (also known as 1 BE strain; disclosed from EP2962568), and the fungicides they produce lipopeptide.

Embodiment B45. The composition described in the Summary of the Invention (including but not limited to the compositions of any one of Embodiments 1 to 258 and A to K), wherein component (b) comprises at least one compound that is Selected from (b45) quinone lateral inhibitors, stastatin conjugated fungicides such as ametoctradin.

Embodiment B46. The composition described in the Summary of the Invention (including but not limited to the compositions of any one of Embodiments 1 to 258 and A to K), wherein component (b) comprises at least one compound that is Selected from (b46) botanical extract fungicides such as Melaleuca alternifolia , eugenol, geraniol and thymol.

Embodiment B47. The composition described in the Summary of the Invention (including but not limited to the compositions of any one of Embodiments 1 to 258 and A to K), wherein component (b) comprises at least one compound that is Selected from (b47) cyanoacrylate fungicides such as phenacril.

Embodiment B48. The composition described in the Summary of the Invention (including but not limited to the compositions of any one of Embodiments 1 to 258 and A to K), wherein component (b) comprises at least one compound that is Selected from (b48) polyethylene fungicides such as natamycin.

Embodiment B49. The composition described in the Summary of the Invention (including but not limited to the compositions of any one of Embodiments 1 to 258 and A to K), wherein component (b) comprises at least one compound that is Selected from (b49) oxysterol binding protein inhibitors such as oxathiapiprolin and fluoxapiprolin.

Embodiment B50. The composition described in the Summary of the Invention (including but not limited to the compositions of any one of Embodiments 1 to 258 and A to K), wherein component (b) comprises at least one compound that is Selected from (b50) aryl-phenyl-one fungicides such as metrafenone and pyriofenone.

Embodiment B51. The composition described in the Summary of the Invention (including but not limited to the compositions of any one of Embodiments 1 to 258 and A to K), wherein component (b) comprises at least one compound that is Selected from (b51) host plant defense inducing fungicides such as acibenzolar-S-methyl, probenazole, tiadinil, isotianil , laminarin, Mushroom extract from Reynoutria Sachalinensis , and cell walls of Bacillus mycoides isolate J and Saccharomyces Cerevisiae strain LAS117.

Embodiment B52. The composition described in the Summary of the Invention (including but not limited to the compositions of any one of Embodiments 1 to 258 and A to K), wherein component (b) comprises at least one compound that is Selected from (b52) multi-site active fungicides such as copper oxychloride, copper sulfate, copper hydroxide, Bordeaux composition (copper tribasic sulfate), elemental sulfur, ferbam, mancozeb ), maneb, metiram, propineb, thiram, zinc thiazole, zineb, ziram, Folpet, captan, captafol, chlorothalonil, dichlofluanid, tolyfluanid, grejing ( guazatine), iminoctadine albesilate, imnoctadine triacetate, anilazine, dithianon, quinomethionate, and fluoroimide .

Embodiment B53. The composition described in the Summary of the Invention (including but not limited to the compositions of any one of Embodiments 1 to 258 and A to K), wherein component (b) comprises at least one compound that is Selected from (b53) biofungicides with multiple modes of action, such as extracts from lupin leaflets.

Embodiment B54. The composition described in the Summary of the Invention (including but not limited to the compositions of any one of Embodiments 1 to 258 and A to K), wherein component (b) comprises at least one compound that is Fungicides selected from (b54) other than the fungicides of component (a) and components (b1) to (b53), such as cyflufenamid, bethoxazin, ferric arsenic acid Ammonium (neo-asozin), pyrrolnitrin, tebufloquin, dodine, flutianil, ferimzone, picarbutrazox , benzothiazole fungicides dichlobentiazox (registration number 957144-77-3), dipymetitrone (registration number 16114-35-5), flometoquin, tolnifanide ) (Registration No. 304911-98-6), N'-[4-[4-chloro-3-(trifluoromethyl)phenoxy]-2,5-dimethylphenyl] -N -ethyl - N -methylformamide, 5-fluoro-2-[(4-fluorophenyl)methoxy]-4-pyrimidinamine and 4-fluorophenyl N-[1-[[[1-(4 -Cyanophenyl]ethyl]sulfonyl]methyl]propyl]carbamate (XR-539).

Embodiment B55. The composition described in the Summary of the Invention (including but not limited to the compositions of any of Embodiments 1 to 258 and A to K), wherein component (b) comprises ( 1S )-2 ,2-Bis(4-fluorophenyl)-1-methylethyl N -[[[3-(acetoxy)-4-methoxy-2-pyridyl]carbonyl]-L-alanine salt (Provisional generic name is florylpicoxamid).

Embodiment B56. The composition described in the Summary of the Invention (including but not limited to the compositions of any one of Embodiments 1 to 258 and A to K), wherein component (b) comprises 1-[2-[ [[1-(4-Chlorophenyl) -1H -pyrazol-3-yl]oxy]methyl]-3-methylphenyl]-1,4-dihydro-4-methyl-5 H -tetrazol-5-one (provisional generic name metyltetraprole).

Embodiment B57. The composition described in the Summary of the Invention (including but not limited to the compositions of any of Embodiments 1 to 258 and A to K), wherein component (b) comprises 3-chloro-4- (2,6-Difluorophenyl)-6-methyl-5-phenylpyridazine (provisional generic name pyridachlometyl).

Embodiment B58. The composition described in the Summary of the Invention (including but not limited to the compositions of any one of Embodiments 1 to 258 and A to K), wherein component (b) comprises (4-phenoxybenzene) base) methyl 2-amino-6-methyl-pyridine-3-carboxylate (provisional generic name is aminopyrifen).

其中 每個R^b10 與R^b11 獨立地為鹵素；以及 R⁶ 為H、鹵素、C₁ -C₃ 烷基、C₁ -C₃ 鹵代烷基或C₃ -C₆ 環烷基。Embodiment B59. The composition described in the Summary of the Invention (including but not limited to the compositions of any one of Embodiments 1 to 258 and A to K), wherein component (b) comprises at least one compound that is selected from (b54.11) (ie, formula b54.11 )

wherein each R ^b10 and R ^b11 is independently halogen; and R ⁶ is H, halogen, C ₁ -C ₃ alkyl, C ₁ -C ₃ haloalkyl, or C ₃ -C ₆ cycloalkyl.

Specific Embodiment B60. The composition of Specific Embodiment B59, wherein component (b) comprises at least one fungicidal compound selected from the group consisting of: methyl N -[[5-[1-(2,6- Difluoro-4-carboxyphenyl )-1H-pyrazol-3-yl]-2-methylphenyl]methyl]carbamate, methyl N - [[5-[1- (4-Cyclopropyl-2,6-dichlorophenyl )-1H-pyrazol-3-yl]-2-methylphenyl]methyl]carbamate, methyl N - [[ 5-[1-(4-Chloro-2,6-difluorophenyl ) -1H-pyrazol-3-yl]-2-methylphenyl]methyl]carbamate, methyl N -[[5-[1-(4-Cyclopropyl-2,6-difluorophenyl)-1H-pyrazol-3-yl]-2-methylphenyl]methyl]carbamic acid Ester, methyl N -[[5-[1-[2,6-difluoro-4-(1-methylethyl)phenyl] -1H -pyrazol-3-yl]-2-methyl Phenyl]methyl]carbamate and methyl N -[[5-[1-[2,6-difluoro-4-(trifluoromethyl)phenyl] -1H -pyrazole-3 -yl]-2-methylphenyl]methyl]carbamate.

其中 R^b4 為

  

； R^b6 為C₂ -C₄ 烷氧羰基或C₂ -C₄ 鹵代烷基胺基羰基； L為CH₂ 或CH₂ O，其中右側的原子連接式b54.12中的苯基環；以及 R^b5 為

。 Embodiment B61. The composition described in the Summary of the Invention (including but not limited to the compositions of any one of Embodiments 1 to 258 and A to K), wherein component (b) comprises at least one compound that is is selected from (b54.12) (ie, formula b54.12 )

where R ^b4 is

; R ^b6 is C ₂ -C ₄ alkoxycarbonyl or C ₂ -C ₄ haloalkylaminocarbonyl; L is CH ₂ or CH ₂ O, wherein the atom on the right is connected to the phenyl ring in formula b54.12; and R ^b5 for

.

Specific Embodiment B62. The composition of Specific Embodiment B61, wherein component (b) comprises at least one fungicidal compound selected from the group consisting of: N- (2,2,2-trifluoroethyl)-2 -[[4-[5-(Trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]-4-oxazolecarboxamide and ethyl 1-[[ 4-[5-(Trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenoxy]methyl] -1H -pyrazole-4-carboxylate.

其中 每個R^b7 、R^b8 與R^b9 獨立地為H、鹵素或氰基；以及 每個R^b10 與R^b11 獨立地為H、鹵素、C₁ -C₃ 烷基或C₁ -C₃ 甲氧基。Embodiment B63. The composition described in the Summary of the Invention (including but not limited to the compositions of any one of Embodiments 1 to 258 and A to K), wherein component (b) comprises at least one compound that is selected from (b54.13) (ie, formula b54.13 )

wherein each R ^b7 , R ^b8 and R ^b9 is independently H, halogen or cyano; and each R ^b10 and R ^b11 is independently H, halogen, C ₁ -C ₃ alkyl or C ₁ -C ₃ methyl Oxygen.

Specific Embodiment B64. The composition of Specific Embodiment B63, wherein component (b) comprises at least one fungicidal compound selected from the group consisting of: 4-(2-chloro - 4-fluorophenyl)-N- (2-Fluoro-4-methyl-6-nitrobenzene)-1,3-dimethyl- 1H -pyrazol-5-amine, 4-(2-chloro-4-fluorophenyl) -N -(2-Fluoro-6-nitrobenzene)-1,3-dimethyl- 1H -pyrazol-5-amine, 3,5-difluoro-4-[5-[(4-methoxy -2-Nitrophenyl)amino]-1,3-dimethyl- 1H -pyrazol-4-yl]-benzonitrile and N- (2-chloro-4-fluoro-6-nitrobenzene) -4-(2-Chloro-4-fluorophenyl)-1,3-dimethyl- 1H -pyrazol-5-amine.

Embodiment B65. The composition described in the Summary of the Invention (including but not limited to the compositions of any of Embodiments 1 to 258 and A to K), wherein component (b) comprises at least one fungicidal compound ( fungicide) is selected from the group consisting of: azoxystrobin, benzovindiflupyr, boscalid (or nicobifen), bixafen, bromocrizole Bromuconazole, carbendazim, chlorothalonil, copper hydroxide, cyflufenamid, cyproconazole, difenoconazole, dimoxystrobin , epoxiconazole, famoxadone, fenbuconazole, fenpropidin, fenpropimorph, fluindapyr, flusilazole ), flutriafol, fluxapyroxad, hexaconazole, ipconazole, kresoxim-methyl, manzate, metconazole, benzene Metominostrobin, metrafenone, myclobutanil, penconazole, penthiopyrad, picoxystrobin, prochloraz, general Propiconazole, proquinazid, prothioconazole, pydiflumetofen, pyraclostrobin, pyrametostrobin, pyraoxystrobin, pyriofenone, quinoxyfen, tebuconazole, trifloxystrobin, triticonazole, methyl N -[[5-[1-[2, 6-Difluoro-4-(1-methylethyl)phenyl] -1H -pyrazol-3-yl]-2-methylphenyl]methyl]carbamate, methyl N- [ [5-[1-[2,6-Difluoro-4-(trifluoromethyl)phenyl] -1H -pyrazol-3-yl]-2-methylphenyl]methyl]aminomethane acid ester, N- (2,2,2-trifluoroethyl)-2-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazole-3-yl]phenyl ]methyl]-4-oxazolecarboxamide, ethyl 1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenoxy]methyl yl] -1H -pyrazole-4-carboxylate, 4-(2-chloro-4-fluorophenyl)-N-(2-fluoro - 4-methyl-6-nitrobenzene)-1, 3-Dimethyl-1 H -pyrazol-5-amine, 4-(2-chloro-4-fluorophenyl)-N-(2-fluoro-6-nitrobenzene)-1,3- dimethyl yl- 1H -pyrazol-5-amine and 3,5-difluoro-4-[5-[(4-methoxy-2-nitrophenyl)amino]-1,3-dimethyl- 1 H -Pyrazole-4-yl]-benzonitrile.

Embodiment B66. The composition of Embodiment B65, wherein component (b) comprises at least one compound selected from the group consisting of: azoxystrobin, benzovindiflupyr, biphenyl Bixafen, chlorothalonil, copper hydroxide, cyflufenamid, cyproconazole, difenoconazole, dimoxystrobin, eprazole Epoxiconazole, famoxadone, fenpropidin, fenpropimorph, fluindapyr, flusilazole, flutriafol, sterilant (fluxapyroxad), kresoxim-methyl, manzate, metconazole, metminostrobin, metrafenone, myclobutanil, pyrethy Penthiopyrad, picoxystrobin, propiconazole, proquinazid, prothioconazole, pydiflumetofen, pyraclostrobin, pyrametostrobin, pyraoxystrobin, pyriofenone, quinoxyfen, tebuconazole, trifloxystrobin, triticonazole ), methyl N -[[5-[1-[2,6-difluoro-4-(1-methylethyl)phenyl] -1H -pyrazol-3-yl]-2-methyl Phenyl]methyl]carbamate, methyl N -[[5-[1-[2,6-difluoro-4-(trifluoromethyl)phenyl] -1H -pyrazole-3 -yl]-2-methylphenyl]methyl]carbamate, N- (2,2,2-trifluoroethyl)-2-[[4-[5-(trifluoromethyl) -1,2,4-oxadiazol-3-yl]phenyl]methyl]-4-oxazolecarboxamide, ethyl 1-[[4-[5-(trifluoromethyl)-1, 2,4-oxadiazol-3-yl]phenoxy]methyl] -1H -pyrazole-4-carboxylate, 4-(2-chloro - 4-fluorophenyl)-N-(2 -Fluoro-4-methyl-6-nitrobenzene)-1,3-dimethyl- 1H -pyrazol-5-amine, 4-(2-chloro - 4-fluorophenyl)-N-( 2-Fluoro-6-nitrobenzene)-1,3-dimethyl- 1H -pyrazol-5-amine and 3,5-difluoro-4-[5-[(4-methoxy-2 -Nitrophenyl)amino]-1,3-dimethyl- 1H -pyrazole-4-yl]-benzonitrile.

Embodiment B67. The composition of Embodiment B66, wherein component (b) comprises at least one compound selected from the group consisting of: azoxystrobin, benzovindiflupyr, biphenyl Bixafen, chlorothalonil, copper hydroxide, cyproconazole, difenoconazole, epoxiconazole, fenpropidin, fenpro fenpropimorph), fluindapyr, flutriafol, fluxapyroxad, manzate, metominostrobin, picoxystrobin, proxa Prothioconazole, pydiflumetofen, pyraclostrobin, tebuconazole, trifloxystrobin, methyl N -[[5-[1-[ 2,6-Difluoro-4-(1-methylethyl)phenyl] -1H -pyrazol-3-yl]-2-methylphenyl]methyl]carbamate, methyl N -[[5-[1-[2,6-Difluoro-4-(trifluoromethyl)phenyl] -1H -pyrazol-3-yl]-2-methylphenyl]methyl] Carbamate, N- (2,2,2-trifluoroethyl)-2-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl ]Phenyl]methyl]-4-oxazolecarboxamide, ethyl 1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenoxy yl]methyl] -1H -pyrazole-4-carboxylate, 4-(2-chloro-4-fluorophenyl)-N-(2-fluoro - 4-methyl-6-nitrobenzene) -1,3-Dimethyl- 1H -pyrazol-5-amine, 4-(2-chloro-4-fluorophenyl)-N-(2-fluoro - 6-nitrobenzene)-1,3 -Dimethyl- 1H -pyrazol-5-amine and 3,5-difluoro-4-[5-[(4-methoxy-2-nitrophenyl)amino]-1,3-di Methyl- 1H -pyrazol-4-yl]-benzonitrile.

Embodiment B68. The composition of Embodiment B67, wherein component (b) comprises at least one compound selected from the group consisting of: azoxystrobin, benzovindiflupyr, biphenyl Bixafen, chlorothalonil, copper hydroxide, cyproconazole, epoxiconazole, fenpropidin, fenpropimorph, fluindazole Fluindapyr, Flutriafol, Fluxapyroxad, Manzate, Metominostrobin, Picoxystrobin, Prothioconazole, Fluoxazole hydroxyamine (pydiflumetofen), Bai Kemin (pyraclostrobin), Dekeli (tebuconazole), trifluoromine (trifloxystrobin).

Notably, the composition of any embodiment described herein includes any of Embodiments 1 to 258, A to K, and B1 to B68, wherein Formula 1 includes salts thereof, but not N -oxides thereof ; therefore, the phrase "a compound of formula 1" can be replaced by the phrase "a compound of formula 1 or a salt thereof". In this notable composition, component (a) comprises a compound of formula 1 or a salt thereof.

It is also worth noting that as a specific embodiment, the fungicidal composition of the present invention comprises a fungicidally effective amount of the compositions of specific embodiments 1 to 258, A to K and B1 to B68, and at least one selected from the group consisting of surface active agents Diluents, solid diluents, additional components of liquid diluents.

Embodiments of the present invention further include methods for controlling plant diseases caused by fungal phytopathogens comprising applying to the plant or parts thereof or plant seeds or seedlings a fungicidally effective amount of Embodiments 1 to 258, A A composition of any of K to K and B1 to B68 (eg, as a composition comprising the ingredients of a formulation described herein). Embodiments of the present invention also include methods of protecting plants or plant seeds from diseases caused by fungal pathogens, the method comprising adding a fungicidally effective amount of any of Embodiments 1 to 258, A to K, and B1 to B68 The composition of one is applied to the plant or plant seed.

Some embodiments of the present invention relate to controlling or protecting against plant diseases primarily affecting plant foliage and/or applying the compositions of the present invention to plant foliage (ie, plants rather than seeds). Preferred methods of use include those involving the preferred compositions described above; diseases that are effectively controlled include plant diseases caused by fungal phytopathogens. The combination of fungicides used according to the present invention promotes disease control and delays the development of resistance.

Specific embodiments of the method further include:

Embodiment C1. A method of protecting a plant from a disease selected from rust, powdery mildew and Septoria , comprising applying to the plant a fungicidally effective amount of the amount contained in the Summary of the Invention or Embodiment 1 A composition of components (a) and (b) described in any one of to 258.

Embodiment C2. The method of Embodiment C1, wherein the disease is a rust disease, and component (b) of the composition comprises at least one selected from the group consisting of (b3) demethylation inhibitor (DMI) fungicides, (b5) Amine/morpholine fungicides, (b7) Succinate dehydrogenase inhibitor fungicides, (b11) Quinone external inhibitor (QoI) fungicides, (b13) Methylbenzimidazole amine group Fungicidal compounds of formate fungicides and (b52) multi-site active fungicides.

Embodiment C3. The method of Embodiment C2, wherein component (b) of the composition comprises at least one fungicidal compound selected from the group consisting of (b3) demethylation inhibitor (DMI) fungicides, ( b7) Succinate dehydrogenase inhibitor fungicides and (b11) Quinone external inhibitor (QoI) fungicides.

Embodiment C4. The method of Embodiment C3, wherein component (b) of the composition comprises at least one fungicidal compound selected from the group consisting of: azoxystrobin, cyclocrizole ( cyproconazole), difenoconazole, epoxiconazole, fluindapyr, flutriafol, fluxapyroxad, picoxystrobin, proseconazole (prothioconazole), pyraclostrobin, tebuconazole, and trifloxystrobin.

Embodiment C5. The method of Embodiments C2 to C4, wherein the disease is Asian soybean rust caused by Puccinia recondite .

Embodiment C6. The method of Embodiments C2 to C4, wherein the disease is wheat leaf rust caused by Phakopsora pachyrhizi .

Embodiment C7. The method of Embodiment C1, wherein the disease is powdery mildew, and component (b) of the composition comprises at least one fungicidal compound selected from (b3) demethylation inhibitors ( DMI) fungicides, (b11) Quinone External Inhibitor (QoI) fungicides, and (b13) Azanaphthalene fungicides.

Specific embodiment C8. The method of specific embodiment C7, wherein the disease is wheat powdery mildew.

Embodiment C9. The method of Embodiment C7, wherein the disease is staphylosis.

Specific Embodiment C10. The method of Specific Embodiments C7 to C9, wherein component (b) comprises at least one fungicidal compound selected from (b3) demethylation inhibitor (DMI) fungicides.

Embodiment C11. The method of Embodiment C10, wherein component (b) comprises at least one fungicidal compound selected from the group consisting of: cyproconazole, difenoconazole, eprazole ( epoxiconazole), prothioconazole, and tebuconazole.

Embodiment C12. The method of Embodiment C11, wherein component (b) comprises at least one fungicidal compound selected from the group consisting of cyproconazole, difenoconazole, and proseconazole (prothioconazole).

Specific embodiment C13. The method of specific embodiments C8 to C10, wherein component (b) comprises at least one fungicidal compound selected from (b11) quinone external inhibitor (QoI) fungicidal.

Specific Embodiment C14. The method of Specific Embodiment C12, wherein component (b) comprises at least one fungicidal compound selected from the group consisting of azoxystrobin, picoxystrobin, and picoxystrobin (pyraclostrobin).

Embodiment C15. The method of Embodiment C1, wherein the disease is Septoria disease, and component (b) of the composition comprises at least one fungicidal compound selected from the group consisting of Group: epoxiconazole, metalaxyl (including metalaxyl-M), iprovalicarb, and fenpropimorph.

Specific embodiment C16. The method of specific embodiment C15, wherein the disease is wheat leaf blight.

Specific Embodiment C17. The method of any of Specific Embodiments C1 to C16, wherein the components (a) and (b) are administered in synergistically effective amounts (and synergistic ratios relative to each other).

Of note are the specific embodiments corresponding to specific embodiments C1 to C17, which relate to a method for controlling plant diseases caused by fungal phytopathogens, the method comprising applying to the plant or a part thereof a fungicidally effective amount of the present invention of fungicidal compositions.

As described in the Summary of the Invention, the present invention also relates to compounds of formula 1 or N -oxides or salts thereof. It should also be noted that specific embodiments of the present invention, including specific embodiments 1 to 258, also relate to compounds of formula 1 . Accordingly, the combination of specific embodiments 1 to 258 is further described in the following manner:

Specific embodiment D1. A compound of formula 1 or its N -oxide or its salt, wherein T is T-2; R ¹ is CF ₃ ; X is O; Y is O; R ^2a is H or methyl; R ^2b is C ₃ -C ₁₅ trialkylsilyl group or C ₃ -C ₁₅ halogenated trialkylsilyl group; A ¹ is O; A ² is a direct bond or CH ₂ ; each R ^6a and R ^6b is independently H, cyanohydroxy or methyl; J is J-1 or J-6; q is 0 or 1; L is a direct bond or CH ₂ ; E is E ¹ or E ² ; E ¹ is C _{1 -} C3alkoxy, C2 _{- C3alkylcarbonyl} or C2 _{- C3alkoxycarbonyl} , wherein each carbon atom is optionally selected by up to 1 from R ^10a and up to 3 independently from R ^10b is substituted with a substituent; R ^10a is pyrazolyl, imidazolyl or triazolyl, each optionally substituted on a carbon atom ring member with up to 2 substituents independently selected from R ^11a ; each each R ^10b is independently halogen, C ₁ -C ₂ alkyl, C ₁ -C ₂ haloalkyl, C ₁ -C ₂ alkoxy, or C ₂ -C ₄ alkoxycarbonyl; each R ^11a is independently methyl Oxycarbonyl or ethoxycarbonyl; G is G-1, G-3, G-12 or G-22; x is 1 or 2; each R ¹³ is independently C(=O)NR ^14a R ^14b or -UVQ ; or C ₂ -C ₅ alkoxycarbonyl, C ₃ -C ₅ alkenyloxycarbonyl, C ₃ -C ₅ alkynyloxycarbonyl or C ₄ -C ₆ cycloalkoxycarbonyl, each optionally by up to 3 Replaced by substituents independently selected from R ¹⁹ ; each R ^14a is independently H or C ₁ -C ₂ alkyl; each R ^14b is independently H, C ₁ -C ₃ alkyl, C ₁ -C ₃ haloalkyl, cyclopropylmethyl or C ₂ -C ₄ alkoxyalkyl; each R ¹⁹ is independently cyano, halogen, cyclopropyl, cyclobutyl, methoxy, halomethoxy or Methoxycarbonyl; each U is independently a direct bond or C(=O)O; each V is independently a direct bond or CH ₂ ; each Q is independently phenyl or pyridyl, each optional is substituted with up to 2 substituents independently selected from ^R27 ; each ^R27 is independently halogen, methyl or methoxy; and Z is a direct bond, O, NH, C(=O), C(=O)NH or NHC(=O).

Example D2. Compounds of A Example D1 wherein R ^2a is H or methyl; R ^2b is trimethylsilyl or halotrimethylsilyl; A ² is a direct bond; each R ^6a and R ^6b are H; R ⁸ is F or Cl; E ¹ is C ₁ -C ₂ alkoxy or C ₂ -C ₃ alkoxycarbonyl, wherein each carbon atom is optionally selected from at most 1 R ^10a substituents; R ^10a is pyrazolyl or imidazolyl, each optionally substituted on a carbon atom ring member with up to 2 substituents independently selected from R ^11a ; each R ^11a independently is methoxycarbonyl or ethoxycarbonyl; G is G-1 and the 2nd position of G-1 is attached to Z and its 4th position is attached to R ¹³ ; or G is G-12 and the 1st position of G-12 is attached to Z and Its 4th position is connected to R ¹³ ; or G is G-12 and the 1st position of G-12 is connected to Z and its 3rd position is connected to R ¹³ ; x is 1; R ¹³ is C(=O)NR ^14a R ^14b or -UVQ; or C ₂ -C ₅ alkoxycarbonyl, C ₃ -C ₅ alkynyloxycarbonyl or C ₄ -C ₆ cycloalkoxycarbonyl, each optionally substituted by at most 1 substituent selected from R ¹⁹ Substituted; R ^14a is H; R ^14b is H, methyl or cyclopropylmethyl; R ¹⁹ is cyano, halogen, cyclopropyl or methoxy; U is C(=O)O; V is CH ₂ Q is phenyl optionally substituted with up to 2 substituents independently selected from ^R27 ; and Z is a direct bond, O, NH or C(=O).

Specific Example D3. Compounds of A Specific Example D2 wherein R ^2a is H or methyl; R ^2b is trimethylsilyl; R ⁸ is F; E ¹ is methoxy, which is selected from R ^10a R ^10a is pyrazolyl, which can be optionally substituted by at most 1 substituent selected from R ^11a on the carbon atom ring member; G is G-12 and the first position of G-12 Z is attached and R ¹³ is attached at the 4th position; or G is G-12 and Z is attached at the 1st position of G-12 and R ¹³ is attached at the 3rd position; and R ¹³ is C ₂ -C ₅ alkoxycarbonyl optionally is substituted with up to 1 substituent selected from R ¹⁹ ; R ¹⁹ is cyano, Cl, F, cyclopropyl or methoxy; and Z is a direct bond.

Specific Example D3. Compounds of A Specific Example D3 wherein R ^2a is methyl; J is J-1; q is 0; L is CH ₂ ; E is E ² ; G is G-12 and the first Z is attached at the 1 position and ^R13 is attached at the 4th position; and ^R13 is methoxycarbonyl or ethoxycarbonyl.

Other embodiments include a fungicidal composition comprising: (1) the compound of any one of Embodiments D1 to D3; and (2) at least one additive selected from the group consisting of surfactants, solid diluents, and liquid diluents composition. Other embodiments also include methods for protecting plants or plant seeds from diseases caused by fungal pathogens, the method comprising administering a fungicidally effective amount of a compound of any one of embodiments D1 to D3 (directly or indirectly). ) is applied to the plant (or part thereof) or plant seed, or through the environment (eg growth medium) of the plant or plant seed. Notably, embodiments directed to methods of controlling plant diseases caused by fungal phytopathogens comprise applying to the plant or parts thereof a fungicidally effective amount of a compound of any one of Embodiments D1 to D3.

The present invention also provides fungicidal compositions comprising a compound of Formula 1 (including all stereoisomers, N -oxides, and salts thereof) (ie, in a fungicidally effective amount), and selected from surfactants , at least one of a solid diluent and a liquid diluent. Notably, embodiments of such compositions are compositions comprising a compound corresponding to any of the above-described compound embodiments.

Compounds of Formula 1 can be prepared using one or more of the following methods and variations described in Schemes 1-17. Unless otherwise specified, E, L, A, A ¹ , A ² , J, T, X, Y, R ¹ , R ^2a , R ^2b , R ^2c , R ^2d , The definitions of R ^6a , R ^6b and R ²⁹ are as defined above in the Summary of the Invention. Compounds of formula 1a-1a ¹ , 1b-1b ⁶ and 1c-1c ¹ are various subsets of formula 1, and unless otherwise stated, all substituents of formula 1a-1a ¹ , 1b-1b ⁶ and 1c-1c ¹ As defined above for Equation 1. Since the synthetic literature includes many halomethyl ketones as well as hydrate formation methods that can be readily used to prepare the compounds of the present invention, the following methods in Schemes 1-17 are only a simplified representation of the various methods used to prepare the compounds of Formula 1 Representative examples. For a review of ketone and hydrate formation methods, see, eg, Tetrahedron 1991 , 47 , 3207-3258 and Chem . Communications 2013 , 49 (95), 11133-11148, and references cited therein. See also the method outlined in US Patent No. 6,350,892.

As shown in Scheme ¹ , compounds of formula 1a wherein R1 is _CF3 can be prepared by trifluoroacetation of organometallic compounds of formula 2 (ie, those of formula wherein T is T-1 and W is O 1 compound). Typically, in this method, the ethyl ester of trifluoroacetic acid (ie, ethyl trifluoroacetate) is used as the source of the trifluoroacetate group, but trifluoroacetonitrile as well as various trifluoroacetate salts can also be used. Depending on the reaction conditions, two addition reactions can be performed on the trifluoroacetone compound. Carrying out the reaction at -65°C or better at -78°C reduces the occurrence of traces of double addition adducts, especially when using organometallics of formula 2 where M is Li or MgBr. Many other organometallic species produce similar results. For useful reaction conditions in the method of Scheme 1, as well as other established routes for the synthesis of trifluoromethyl ketones, see, for example, Journal of Organic Chemistry 1987 , 52 (22), 5026-5030; Chemical Communications 2013 , 49 (95), 11133-11148; and Journal of Fluorine Chemistry 1981 , 18 , 117-129. The conditions described in these references can be readily modified to prepare compounds of formula la wherein R1 is not _CF3 (eg, ^a dihalo or trichloro moiety). plan 1

Compounds of formula 1a wherein R1 is _CF3 (ie, compounds of formula ¹ wherein T is T-1 and W is O) can also be obtained by adding ethyl ethyl 4,4,4-trifluoroacetate ( ethyl 4,4,4-trifluoroacetoacetate, ETFAA) is alkylated with compounds of formula 3 wherein La is ^a leaving group such as halogen (eg Cl, Br) or sulfonate (eg mesylate) to prepare. In this method, ETFAA is first treated with a base such as sodium hydride in a polar aprotic solvent such as tetrahydrofuran (THF), THF/hexamethylphosphoramide (HMPA) or acetone. Then, the ETFAA anion displaces the leaving group in the compound of formula 3 to give an intermediate ester in lithium chloride (LiCl) and N,N -dimethylformamide ( N,N- dimethylformamide, DMF) is hydrolyzed and decarboxylated to give the ketone compound of formula 1a. For reaction conditions, see Journal Chemical Society , Chemical Communications 1989 , (2), 83-84; Chemical Communications 2013 , 49 (95), 11133-11148 ; and Journal of Fluorine Chemistry 1989 , 44 , 377-394. Scenario 2

As shown in Scheme 3, compounds of formula 1a wherein R ¹ is CF ₃ can also be prepared by trifluoromethylation of esters of formula 5 with trifluoromethyltrimethylsilane (TMS-CF ₃ ) (ie, compounds of formula 1 wherein T is T-1 and W is O). The reaction is carried out in the presence of a fluoride initiator, such as tetrabutylammonium fluoride, and an anhydrous solvent, such as toluene or dichloromethane, at about -78°C (for reaction conditions, see, for example, Angew.Chem. , Int. Ed. 1998 , 37 (6), 820-821). Cesium fluoride in a solvent such as 1,2-dimethoxyethane (glyme) can also act as an initiator at room temperature (for reaction conditions see e.g. J. Org.Chem ., 1999, 64 , 2873). The reaction proceeds through a trimethyl silicate intermediate, which is hydrolyzed with an aqueous acid solution to yield the desired trifluoromethyl ketone compound of formula 1a. Weinrebamide can also be used in place of the starting ester (see, eg, Chem. Commun. 2012 , 48 , 9610). Scenario 3

As shown in Scheme 4, the acyl chloride of formula 6 can be reacted with trifluoroacetic anhydride (TFAA) and pyridine in a solvent such as dichloromethane or toluene at a temperature of about 0 to 80 °C, and then Hydrolysis is carried out (for reaction conditions, see, for example, Tetrahedron 1995 , 51 , 2573-2584) to prepare compounds of formula 1a ¹ wherein _R is CF and at least one of R ^6a or R ^6b is H (ie, wherein A is A ¹ -A ² -CR ^6a R ^6b compound of formula 1a). Compounds of formula 6 can be prepared from compounds of formula 5 by hydrolysis of the ester to the corresponding carboxylic acid and treatment with oxalic chloride, as known to those skilled in the art. Scenario 4

As shown in Scheme 5, compounds of formula 1b wherein R ^2a X and R ^2b Y are OH (ie, formula 1 wherein T is T-2) can be prepared by oxidizing the alcohol of formula 4 to the corresponding dihydroxyl group compound). The oxidation reaction can be carried out by a variety of methods, such as by treating the alcohol of formula 4 with manganese dioxide, Dess-Martin periodinane, pyridinium chlorochromate, or pyridinium dichromate. See Example 6, Step F and Example 8, Step F for typical reaction conditions. Scenario 5

Scheme 6 illustrates Scheme 5 for the preparation of compounds of formula lb ¹ (ie, formula lb wherein L is CH ₂ , J is phenyl (ie, J-1), A is OCH ₂ , and R ¹ is CF ₃ ) A concrete instance of the generic method. In this method, compounds of formula 4a (ie, wherein L is _CH2 , J is phenyl (ie, J- ₁ ), A is OCH2 and R A compound of formula 4 wherein ¹ is _CF3 ) is reacted with an oxidizing agent such as Dess-Martin periodinane in a solvent such as dichloromethane. The method of Scheme 6 is illustrated in Step C of this Example 1. Option 6

As shown in Scheme 7, compounds of formula 4 can be prepared by reacting compounds of formula ² with R1CHO. For reaction conditions see Tetrahedron Letters 2007 , 48 , 6372-6376. Option 7

As shown in Scheme 8, compounds of formula 4b (ie, ^compounds of formula 4 wherein A is ^OCR6aR6b ) can be prepared by reacting a compound of formula 7 with an epoxide of formula 8. The reaction is usually carried out in a solvent such as acetonitrile at a temperature between about 20 and 80°C in a catalytic amount of a base such as cesium carbonate or potassium carbonate; or in a solvent such as dichloromethane with a catalytic amount The Lewis acid, such as boron trifluoride etherate, is mixed at a temperature of about 0 to 40 °C. Step E of this Example 8 illustrates the method of Scheme 8. Those skilled in the art will recognize that the method of Scheme 8 can also be ^performed when A is ^SCR6aR6b or N( ^R7a ) ^{CR6aR6b to} provide other compounds of formula 4b.

Compounds of formula 7 and formula 8 are available from commercial sources and can be readily prepared using commercial precursors and known methods. This Example 1, Step A, Example 6, Step D, and Example 8, Step D illustrate the preparation of compounds of formula 7. Scenario 8

Scheme 9 illustrates the preparation of compounds of formula 4b ¹ (ie, one of formula 4b wherein L is CH ₂ , J is phenyl (ie, J-1), R ^6a and R ^6b are H, and R ¹ is CF ₃ A specific example of the general method of Scheme 8 of compound). In this method, a compound of formula 7a (ie, wherein L is _CH and J is phenyl) is prepared in the presence of cesium carbonate in a solvent such as acetonitrile at a temperature between about 60 and 80°C. (ie, compound of formula 7 of J-1)) is reacted with 2-(trifluoromethyl)oxirane (ie, formula 8a). The method of Scheme 9 is illustrated in Step B of this Example 1. Option 9

As shown in Scheme 10, a ketone of formula 1a (ie, a compound of formula 1 wherein T is T-1 and W is O) may correspond to its corresponding formula 1b wherein R ^2a X and R ^2b Y are OH (ie, The ketone hydrate (ie, the dihydroxy group) of the compound of formula 1 wherein T is T-2 exists in equilibrium. The advantages of Formula 1a or Formula 1b depend on several factors, such as environment and structure. For example, in an aqueous environment, a ketone of formula la can react with water to form a ketone hydrate of formula lb (also known as 1,1-dimethyldiol). Conversion back to the ketone form is usually possible by treatment with a dehydrating agent such as magnesium sulfate or molecular sieves. When the ketone moiety is in close proximity to ^an electron withdrawing group, such as when R1 is trifluoromethyl, the equilibrium generally favors the dihydrate form. In this case, conversion back to the ketone form may require a powerful dehydrating agent such as phosphorus pentoxide (P ₂ O ₅ ). For reaction conditions, see, eg, Eur. J. Org. Chem. 2013 , 3658-3661; and Chemical Communications 2013 , 49 (95), 11133-11148, and references cited therein. Scenario 10

As shown in Scheme 11, ketones of formula 1a can also be combined with their hemiketals, hemithioketals, and hemiacetals of ^formula 1b2 (ie, compounds of formula 1b wherein ^R2bY is OH and ^R2a is not H). As well as their ketals of formula 1b where R ^2a and R ^2b are not H, thioketal acetals exist in equilibrium. Compounds of formula 1a can be prepared by reacting compounds of formula 1a with compounds of formula R ^2a XH (e.g., where the alcohol of X is O, the thiol of X is S or the amine of X is NR ^5a ) to prepare compounds of formula 1b ² , typically in Bronsted ( protic) acid or Lewis acid (eg, _BF3 ) (see, eg, Master OrganicChemistry (Online), On Acetals and Hemiacetals, May 28, 2010, www.masterorganic-chemistry.com/2010/05/28 /on-acetals-and-hemiacetals). In a subsequent step, compounds of formula R ^2b YH (e.g., where the alcohol of Y is O and the thiol of Y is S or Y, can be obtained under dehydrating conditions or by other means of removing water that shifts the equilibrium of the reaction to the right). where the amine is NR ^5b ) compounds of formula 1b ² are treated to provide compounds of formula 1b wherein R ^2a and R ^2b are not H. Alternatively, a ketone of formula 1a can be first treated with two equivalents (or excess) of an alcohol, thiol, or amine in the presence of catalysis and a dehydrating agent to provide a compound of formula 1b directly (see, e.g., in U.S. Pat. Methanol and trimethyl orthoformate are used to prepare dimethyl ketal in US 6,350,892). Scenario 11

As shown in Scheme 12, a halohydrin (eg, 2-chloroethanol or 2-bromopropanol) to treat the corresponding ketone of formula 1a to prepare formula ^1b3 (ie, wherein X and Y are O and ^R2a and ^R2b together form a 5- to 7-membered ring cyclic ketal of compound 1b). For reaction conditions see Organic Letters 2006 8 (17), 3745-3748. Scenario 12

The method of Scheme 12 was also used to prepare cyclic ketals from the corresponding ketone hydrate forms. Scheme 13 illustrates a specific example wherein formula ^1b4 (ie, wherein L is _CH2 and J is benzene) in the presence of potassium carbonate dissolved in acetonitrile at a temperature between about 25 and 70°C (i.e., J- ¹ ), A is ^{OCH2, R2aX and R2bY} _are ^OH , R1 is _CF3 , the ketone hydrate of the compound of formula 1b) is reacted with 2-chloroethanol to provide formula 1b A compound of ⁵ (ie, wherein L is CH ₂ , J is phenyl (ie, J-1), A is OCH ₂ , X and Y are O, R ^2a and R ^2b together form a 5-membered ring, and Compounds of formula 1b in which R ¹ is CF ₃ ). This Example 2 illustrates the method of Scheme 13. Scenario 13

As shown in Scheme 14, this can be achieved by making wherein A ¹ is O, S or N(R ^7a ) and A ² is a direct bond, or wherein A ¹ is CR ^6c R ^6d and A ² is O, S or N(R ^7b ) The compound of formula 9 is reacted with a compound of formula 10 to prepare wherein A ¹ is N(R ^7a ), O or S, and A ² is a direct bond, or wherein A ¹ is CR ^6c R ^6d , and A ² A compound of formula 1b ⁶ that is N(R ^7b ), O, or S (ie, a compound of formula 1b wherein A is A ¹ -A ² -CR ^6a R ^6b ). The reaction is typically carried out in a solvent such as N,N -dimethylformamide (DMF) or dimethylsulfoxide with a base such as cesium carbonate or potassium carbonate or sodium hydride at a temperature between about 20 and 80°C conduct. The method of Scheme 14 is illustrated in Example 4, Step D. Scenario 14

Compounds of formula 10 can be prepared using commercial precursors and known methods. For example, as shown in Scheme 15, under basic conditions (eg, potassium tert-butoxide in a solvent such as N,N -dimethylformamide or tetrahydrofuran), compounds of formula 11 can be combined with halogenated Alcohols (eg, 2-chloroethanol or 3-bromopropanol) are reacted to prepare compounds of formula 10a (that is, wherein R ^6a and R ^6b are H, X and Y are O, and R ^2a and R ^2b together form a 5-membered ring compounds of formula 10) to provide compounds of formula 12. The chemical literature discloses a variety of methods for converting ketones to cyclic ketals that can be readily used to prepare compounds of formula 12 (see, e.g., G. Hilgetag and A. Martini, Ed., Preparative Organic Chemistry, pp 381-387: Wiley, New York, 1972, and references therein; see also this Example 4, Step A). The resulting ester moiety of the cyclic ketal of formula 12 can be reduced to the corresponding alcohol of formula 13 by standard methods known to those skilled in the art (Example 4, Step B illustrates a typical method). The hydroxyl moiety in compounds of formula 13 can then be converted to various ^R29 groups to provide compounds of formula 10a. For example, it can be treated with methanesulfonyl chloride (methanesulfonyl chloride) or 4 - Tosyl chloride (toluenesulfonyl chloride) treats the alcohol to add mesylate or tosylate groups. As shown in Example ₄ , Step C, the triflate group can be added by treating the alcohol with trifluoromethanesulfonic anhydride (CF3SO2 _{) 2O} . Compounds of formula 11 are known and can be prepared by methods known to those skilled in the art. Scenario 15

As shown in Scheme 16, a compound of formula 1a wherein at least one of R ^6a and R ^6b is H (ie, formula 1 wherein T is T-1 and W is O) can be combined with formula 14 in the presence of a base compound of formula 1c (ie, the compound of formula 1 wherein T is T-3 and X is O). Suitable bases include cesium carbonate or potassium carbonate in a solvent such as N,N -dimethylformamide (DMF) or dimethylsulfoxide at temperatures between about 20 and 80°C. In some cases, the method of Scheme 16 produces a mixture of O-alkylated products (usually a mixture of ( E )- and ( Z )-isomers), as well as C-alkylated products. Purification can be carried out using standard techniques such as column chromatography (see Magnetic Resonance in Chemistry 1991 , 29 , 675-678). Compounds of formula 14 are commercially available and can be readily synthesized by general methods known to those skilled in the art. Scenario 16

The method of Scheme 16 can also be used to prepare compounds of formula 1c from the corresponding ketone hydrates. Scheme 17 illustrates a specific example in which a ketone hydrate of formula 1b ⁴ (i.e., wherein L is CH ₂ , J is phenyl (i.e., J-1), A is OCH ₂ , R ^2a X and R ^2b Y is OH, and R ¹ is CF ₃ ) is reacted with iodoethane to provide ^A compound of formula 1c1 (ie, wherein L is _CH2 , J is phenyl (ie, J- ¹ ), _A is O, ^R2d is H, ^XR2c is _OCH2CH3 , and R1 is _CF3 compound of formula 1c). This Example 5 illustrates the method of Scheme 17. Option 17

Compounds of formula 1 wherein T is T-1 and W is S can be prepared from the corresponding compounds wherein W is O by passing phosphorus pentasulfide or 2,4- Bis(4-methoxyphenyl)-1,3-dithio-2,4-diphosphine-2,4-disulfide (Lawesson reagent) treatment. Those skilled in the art will also recognize that compounds of formula 1 wherein T is T-1 and W is NR can be prepared from compounds of formula ¹ wherein T is T-1 and W is O or S by dehydration under dehydration conditions It is carried out with an amine treatment of ^formula _R3NH2 .

The E-L- moieties present in the compounds of formula 1 and the intermediate compounds of formulas 2 to 7 and 9 are common organic functional groups, the preparation of which has been described in the literature. Those skilled in the art will recognize that these well-known chemical classes (esters, amides, sulfonamides, sulfonamides, ethers, carbamates, ureas, heterocycles) can be readily prepared by various methods (see, e.g., PCT Patent Publication Nos. WO 2018/080859, WO 2018/118781, WO 2018/187553, and WO 2019/010192).

It is recognized that some of the reagents and reaction conditions described above for the preparation of compounds of formula 1 may be incompatible with certain functional groups present in the intermediates. In these cases, interconversion of protecting/deprotecting sequences or functional groups into the synthesis will assist in obtaining the desired product. The use and choice of protecting groups will be readily apparent to those skilled in the art of chemical synthesis (see, eg, TW Greene and PGM Wuts, Protective Groups in organic Synthesis, 2nd ed.; Wiley Press, New York, 1991). Those skilled in the art will recognize that in some cases, following the introduction of a given reagent as shown in any individual scheme, it may be necessary to perform additional conventional synthetic steps not described in detail to complete the compound of formula 1 Synthesis. Those skilled in the art will also recognize that it may be necessary to perform the combinations of steps shown in the above schemes in an order other than that suggested by the specific order presented for the preparation of the compounds of Formula 1 .

Those skilled in the art will also recognize that the compounds of Formula 1 and the intermediates described herein can undergo various electrophilic, nucleophilic, radical, organometallic, oxidation, and reduction reactions to add substituents or modify existing substituents.

Without further elaboration, it is believed that one skilled in the art, using the preceding description, can utilize the present invention to its fullest extent. Accordingly, the following examples are to be construed as illustrative only and are not intended to limit the present case in any way. The steps in the following examples illustrate the procedures for each step in a comprehensive synthetic transformation, and the starting materials for each step may not necessarily be prepared by the specific preparations of the procedures described in other examples or steps. Percentages are by weight unless solvent mixtures are chromatographed or otherwise stated. Parts and percentages of chromatographic solvent mixtures are by volume unless otherwise indicated. ^1H NMR spectra are reported in ppm downfield from tetramethylsilane; "s" for singlet, "brS" for broad singlet, "d" for doublet, "dd" for doublet of doublet, "t"" indicates a triplet, "q" indicates a quartet, and "m" indicates a multiplet. ^19F NMR spectra are reported in ppm using trichlorofluoromethane as a reference. Example 1 Ethyl 1-[[4-(3,3,3-trifluoro-2,2-dihydroxypropoxy)phenyl]methyl] -1H -pyrazole-4-carboxylate Preparation (Compound 1) Step A: Preparation of Ethyl 1-[(4-hydroxyphenyl)methyl] -1H -pyrazole-4-carboxylate

Combine ethyl 1H -pyrazole-4-carboxylate (1.40 g, 10 mmol), 4-(chloromethyl acetate) in N,N -dimethylformamide (10 mL) at room temperature (2.0 g, 11 mmol) and potassium carbonate (1.6 g, 11 mmol) were stirred for 16 h. Ethanol (10 mL) was added and the reaction mixture was heated at 65°C for 16 hours, cooled and poured into ice water. The resulting precipitate was collected by filtration, washed with water and air-dried. The resulting solid (2.0 g) was crystallized from acetonitrile to give the title compound as a white solid melting at 113-115°C. ¹ H NMR (CDCl ₃ ): δ 1.32 (t, 3H), 3.10 (d, 1H), 4.10-4.40 (m, 5H), 5.24 (s, 2H), 6.91 (d, 2H), 7.22 (d, 2H), 7.83 (s, 1H), 7.93 (s, 1H). Step B: Preparation of Ethyl 1-[[4-(3,3,3-Trifluoro-2-hydroxypropoxy)phenyl]methyl] -1H -pyrazole-4-carboxylate

Ethyl 1-[(4-hydroxyphenyl)methyl] -1H -pyrazole-4-carboxylate (ie, the product of Step A) (2.36 g, 9.6 g) in acetonitrile (20 mL) mmol), 2-(trifluoromethyl)oxirane (1.3 g, 11.6 mmol), and cesium carbonate (50 mg, 0.15 mmol) were heated at 65 °C. After 3 days, the reaction mixture was cooled and concentrated under reduced pressure. The resulting material was purified by silica gel chromatography (eluting with a gradient of 0 to 50% ethyl acetate in hexanes) to give the title compound as a white solid (2.46 g). ¹ H NMR (CDCl ₃ ): δ 1.33 (t, 3H), 4.29 (q, 2H), 5.21 (s, 2H), 5.95 (brS, 1H), 6.76 (d, 2H), 7.09 (d, 2H) , 7.84 (s, 1H), 7.95 (s, 1H). ¹⁹ F NMR (CDCl ₃ ): δ -77.54. Step C : Ethyl 1-[[4-(3,3,3-trifluoro-2,2-dihydroxypropoxy)phenyl]methyl]-1H-pyrazole-4-carboxylate preparation

Ethyl 1-[[4-( 3,3,3 -trifluoro-2-hydroxypropoxy)phenyl]methyl]-1H- in dichloromethane (20 mL) at room temperature A mixture of pyrazole-4-carboxylate (ie, the product of Step B) (1.23 g, 3.4 mmol) and Dess-Martin periodinane (2.2 g, 5.2 mmol) was stirred for 16 h, then concentrated under reduced pressure . The resulting material was dissolved in ethyl acetate and washed with sodium bisulfite solution (2M in water), then saturated aqueous sodium bicarbonate. The organic layer was dried, filtered and the filtrate was concentrated under reduced pressure. The resulting tan solid (1.77 g) was crystallized from acetonitrile to provide the title compound, a compound of the invention, as solid needles melting at 120-123°C. ¹ H NMR (CDCl ₃ ): δ 1.32 (t, 3H), 3.80 (brS, 1.7H), 4.18 (s, 2H), 4.28 (q, 2H), 5.25 (s, 2H), 6.95 (d, 2H) ), 7.22 (d, 2H), 7.82 (s, 1H), 7.95 (s, 1H). ¹⁹ F NMR (CDCl ₃ ): δ -84.92. Example 2 Ethyl 1-[[4-[[2-(trifluoromethyl)-1,3-dioxolan-2-yl]methoxy]phenyl]methyl] -1H -pyridine Preparation of oxazole-4-carboxylate (compound 32)

Ethyl 1-[[4-(3,3,3-trifluoro-2,2-dihydroxypropoxyl in N,N -dimethylformamide (3.5 mL) at room temperature )phenyl]methyl] -1H -pyrazole-4-carboxylate (ie, the product of Example 1) (1.07 g, 3.0 mmol), 2-chloroethanol (0.24 g, 3.0 mmol), and carbonic acid A mixture of potassium (0.5 g, 3.6 mmol) was stirred for 16 hours and then heated (briefly) at 65°C. After cooling to room temperature, the reaction mixture was concentrated under reduced pressure. The resulting material was diluted with ether and washed with saturated aqueous sodium chloride. The organic layer was dried, filtered, and the filtrate was concentrated under reduced pressure to give the title compound, a compound of the present invention, as a colorless oil (1.06 g). ¹ H NMR (CDCl ₃ ): δ 1.32 (t, 3H), 4.21 (s, 4H), 4.23 (s, 2H), 4.27 (q, 2H), 5.24 (s, 2H), 6.94 (d, 2H) , 7.20 (d, 2H), 7.81 (s, 1H), 7.93 (s, 1H). ¹⁹ F NMR (CDCl ₃ ): δ -81.39. Example 3 Ethyl 1-[[4-[[4,4-dimethyl-2-(trifluoromethyl)-1,3-dioxolan-2-yl]methoxy]phenyl] Preparation of methyl] -1H -pyrazole-4-carboxylate (compound 12)

The title compound was prepared by a method analogous to Example 2. ¹ H NMR (CDCl ₃ ): δ 1.32(t, 3H), 1.13(s, 3H), 1.45(s, 3H), 3.95(d, 1H), 4.00(d, 1H), 4.18(m, 2H) , 4.27(q, 2H), 5.24(s, 2H), 6.94(d, 2H), 7.20(d, 2H), 7.81(s, 1H), 7.93(s, 1H). ¹⁹ F NMR (CDCl ₃ ): δ -81.01. Example 4 Ethyl 1-[[4-[[2-(trifluoromethyl)-1,3-dioxolan-2-yl]methoxy]phenyl]-methyl] -1H- Alternative Preparation of Pyrazole-4-Carboxylate (Compound 32) Step A: Preparation of Methyl 2-(trifluoromethyl)-1,3-dioxolane-2-carboxylate

To a mixture of methyl 3,3,3-trifluoro-2-oxopropionate (31.2 g, 200 mmol) in petroleum ether (100 mL) was added 2-bromoethanol over a period of 15 min (25.0 g, 200 mmol). The reaction mixture was stirred at room temperature for 30 minutes, then cooled to 5 °C and potassium carbonate (28 g, 200 mmol) was added with vigorous stirring. Stirring was continued for an additional 4 hours at 5 °C, then the reaction mixture was allowed to warm to room temperature, diluted with ether (100 mL) and filtered. The filtrate was concentrated under reduced pressure, and the resulting material was dissolved in diethyl ether (200 mL) and washed with saturated aqueous sodium chloride solution (3 times). The organic layer was dried over magnesium sulfate, filtered, and the filtrate was concentrated under reduced pressure to give the title compound as a colorless oil (29 g). ¹ H NMR (CDCl ₃ ): δ 3.80 (s, 3H), 4.30 (m, 4H). ¹⁹ F NMR (CDCl ₃ ): δ -80.52. Step B: Preparation of 2-(trifluoromethyl)-1,3-dioxolane-2-methanol

A mixture of methyl 2-(trifluoromethyl)-1,3-dioxolane-2-carboxylate (ie, the product of Step A) (5 g, 25 mmol) in tetrahydrofuran (75 mL) Add sodium bis(2-methoxyethoxy)aluminum hydride (60% in toluene) (12.2 mL, 37.5 mmol). The reaction mixture was heated at 40 °C for 1.5 hours, then cooled to room temperature and a solution of ethyl acetate (3.30 g, 37.5 mmol) in tetrahydrofuran (15 mL) was added dropwise over 15 minutes. The reaction mixture was stirred for 45 minutes and then concentrated under reduced pressure. The resulting material was diluted with ether (400 mL), washed with saturated aqueous sodium chloride (2x), dried over magnesium sulfate and filtered. The filtrate was concentrated under reduced pressure to give the title compound as an oil (3.8 g). ¹ H NMR (CDCl ₃ ): δ 2.59 (t, 1H), 3.82 (d, 2H), 4.19 (m, 4H). ¹⁹ F NMR (CDCl ₃ ): δ -81.50. Step C: Preparation of [2-(trifluoromethyl)-1,3-dioxolan-2-yl]methyl 1,1,1-trifluoro-methanesulfonate

Combine 2-(trifluoromethyl)-1,3-dioxolane-2-methanol (ie, the product of Step B) (1.67 g, 9.70 mmol) and trifluoromethane in dichloromethane (50 mL) A mixture of ethylamine (1.5 mL, 10.8 mmol) was cooled to -78 °C, then a solution of trifluoromethanesulfonic anhydride (1.81 mL, 10.8 mmol) in dichloromethane (50 mL) was added over 30 min. The reaction mixture was stirred at -78 °C for 1.5 hours, then water (50 mL) was added dropwise while the reaction was allowed to warm to room temperature. The resulting mixture was partitioned between dichloromethane-water and the organic layer was washed with water, dried over magnesium sulfate and filtered. The filtrate was concentrated under reduced pressure to give the title compound as a colorless solid (3.0 g). ¹ H NMR (CDCl ₃ ): δ 4.24 (m, 4H), 4.60 (brS, 2H). ¹⁹ F NMR (CDCl ₃ ): δ -74.84, -81.50. Step D : Ethyl 1-[[4-[[2-(trifluoromethyl)-1,3-dioxolan-2-yl]methoxy]phenyl]methyl]-1H-pyridine Preparation of azole-4-carboxylate

For ethyl 1-[(4-hydroxyphenyl)methyl]-1H-pyrazole-4-carboxylate in N,N - dimethylformamide (100 mL) (ie, carry out Example 1 A mixture of the product of Step A) (16.85 g, 68.0 mmol) and cesium carbonate (53.53 g, 164.5 mmol) was added [2-(trifluoromethyl)-1,3-dioxolan-2-yl] Methyl 1,1,1-trifluoromethanesulfonate (ie, product of Step C) (24.9 g, 82.0 mmol). The reaction mixture was stirred at room temperature for 24 hours and then diluted with ether. The organic layer was washed with saturated aqueous sodium chloride solution, dried over magnesium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The resulting material was purified by silica gel chromatography (eluting with a gradient of 0 to 60% ethyl acetate in hexanes) to give the title compound, the compound of the present invention, as a white solid (23 g), mp 59 -60°C. ¹ H NMR (CDCl ₃ ): δ 1.32 (t, 3H), 4.21 (s, 4H), 4.23 (s, 2H), 4.27 (q, 2H), 5.24 (s, 2H), 6.94 (d, 2H) , 7.20 (d, 2H), 7.81 (s, 1H), 7.93 (s, 1H). ¹⁹ F NMR (CDCl ₃ ): δ -81.39. Example 5 Ethyl 1-[[4-[[( 1Z )-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]phenyl]methyl] Preparation of -1H -pyrazole-4-carboxylate (Compound 64)

Ethyl 1-[[4-(3,3,3-trifluoro-2,2- dihydroxypropoxy )phenyl]methyl]-1H in dimethylsulfoxide (10 mL) - Pyrazole-4-carboxylate (ie, the product of Example 1) (1.0 g, 2.67 mmol), iodoethane (2.5 g, 16 mmol) and a mixture of cesium carbonate (1.75 g, 5.37 mmol) in Heated at 40°C for 45 minutes. The reaction mixture was diluted with ether, washed with water and saturated aqueous sodium chloride, dried and filtered. The filtrate was concentrated under reduced pressure to give the title compound, the compound of the present invention, as a white solid (0.80 g). A portion of the solid was further purified by silica gel chromatography (with a gradient of 0 to 50% ethyl acetate in hexanes) to provide a solid melt at 59-60°C. A nuclear Overhauser effect (NOE) was observed between the trifluoromethyl moiety and the vinyl proton, indicating a cis configuration. ¹ H NMR (CDCl ₃ ): δ 1.30-1.40 (m, 6H), 4.17 (q, 2H), 4.27 (q, 2H), 5.28 (s, 2H), 6.78 (q, 1H), 7.05 (m, 2H), 7.29 (m, 2H), 7.86 (s, 1H), 7.94 (s, 1H). ¹⁹ F NMR (CDCl ₃ ): δ -70.13. Example 6 Ethyl 1-[[3-(3,3,3-trifluoro-2,2-dihydroxypropoxy)phenyl]methyl] -1H -pyrazole-4-carboxylate Preparation (Compound 266) Step A: Preparation of 3-(bromomethyl)phenol

A mixture of 1-(bromomethyl)-3-methoxybenzene (15.48 g, 76.99 mmol) in dichloromethane (150 mL) was cooled to -78 °C, then boron tribromide (in dichloromethane) was added dropwise. 1 M solution in methane). The reaction mixture was warmed to room temperature, stirred for 2 hours, then cooled to -20 °C and methanol (150 mL) was added dropwise. After warming to room temperature, the reaction mixture was concentrated under reduced pressure and the resulting material was diluted with dichloromethane and washed with saturated aqueous sodium bicarbonate. The organic layer was dried over magnesium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The resulting material was purified by silica gel chromatography (gradient 0 to 100% ethyl acetate in hexanes) to give the title compound as a white solid (14.16 g). ¹ H NMR (CDCl ₃ ): δ 4.44 (s, 2H), 4.89 (s, 1H), 6.76 (dd, 1H), 6.87 (s, 1H), 6.95 (d, 1H), 7.19-7.23 (t, 1H). Step B: Preparation of 3-(bromomethyl)phenylacetate

A solution of 3-(bromomethyl)phenol (ie, the product of Step A) (14.16 g, 75.7 mmol) in dichloromethane (130 mL) was cooled to 0 °C, then acetic anhydride (12.96 g, 12 mmol) was added mL, 126.9 mmol), then concentrated with concentrated sulfuric acid (5 drops). The reaction mixture was allowed to warm to room temperature, stirred for 1 hour, and then saturated aqueous sodium bicarbonate solution (300 mL, 318 mmol) was added. The organic layer was separated, washed with water, dried over magnesium sulfate, filtered, and the filtrate was concentrated under reduced pressure to give the title compound as a solid (16.68 g). ¹ H NMR (CDCl ₃ ): δ 4.47 (s, 2H), 7.02-7.04 (m, 1H), 7.14 (s, 1H), 7.25 (m, 1H), 7.35 (t, 1H). Step C : Preparation of Ethyl 1-[[3-(Acetyloxy)phenyl]methyl]-1H-pyrazole-4-carboxylate

To a mixture of 3-(bromomethyl)phenylacetate (ie, the product of Step B) (16.68 g, 72.8 mmol) in acetonitrile (300 mL) was added ethyl 1H -pyrazole-4-carboxylate ( 10.61 g, 75.7 mmol) followed by potassium carbonate (19.35 g, 140 mmol). The reaction mixture was heated at 70°C overnight, cooled to room temperature and filtered. The filtrate was concentrated under reduced pressure to give the title compound as a yellow oil (20.5 g). ¹ H NMR (CDCl ₃ ): δ 2.30 (s, 3H), 4.47 (s, 2H), 7.02 (dd, 1H), 7.15 (s, 1H), 7.25 (m, 1H). Step D : Preparation of Ethyl 1-[(3-hydroxyphenyl)methyl]-1H-pyrazole-4-carboxylate

p-Ethyl 1-[[3-(acetyloxy)phenyl]methyl]-1H-pyrazole-4-carboxylate in ethanol (ie, the product of Step C ) (20.5 g, 72.8 mmol) was added potassium carbonate (10.1 g, 73 mmol). The reaction mixture was heated to reflux for 3 hours, cooled to room temperature and filtered. The filtrate was concentrated under reduced pressure and the resulting material was purified by MPLC silica gel chromatography (eluting with a gradient of 0 to 100% ethyl acetate in hexanes) to give the title compound as a white solid (10.02 g). ¹ H NMR (CDCl ₃ ): δ 1.33 (t, 3H) 4.29 (q, 2H), 5.20 (brS, 1H), 5.25 (s, 2H), 6.66 (m, 1H), 6.78-6.81 (m, 2H) ), 7.21-7.24 (m, 1H), 7.87 (s, 1H), 7.94 (s, 1H). Step E: Preparation of Ethyl 1-[[3-(3,3,3-Trifluoro-2-hydroxypropoxy)phenyl]methyl] -1H -pyrazole-4-carboxylate

p-Ethyl 1-[(3-hydroxyphenyl)methyl]-1H-pyrazole-4-carboxylate (ie, product of Step D ) in acetonitrile (100 mL) (2.38 g 9.66 mmol) To the mixture was added 3-bromo-1,1,1-trifluoro-2-propanol (1.93 g, 1.04 mL, 10 mmol) followed by potassium carbonate (2.86 g, 20.7 mmol). The reaction mixture was heated to reflux for 48 hours, cooled to room temperature, filtered and the filtrate concentrated under reduced pressure. The resulting material was purified by MPLC silica gel chromatography (with a gradient of 0 to 100% ethyl acetate in hexanes) to give the title compound as a solid (2.75 g). ¹ H NMR (CDCl ₃ ): δ 1.33 (q, 3H), 4.1-4.4 (m, 5H), 5.27 (s, 2H), 6.80 (m, 1H), 6.87-6.89 (m, 2H), 7.28- 7.31 (m, 1H), 7.88 (s, 1H), 7.94 (s, 1H). ¹⁹ F NMR (CDCl ₃ ): δ -77.53. Step F : Ethyl 1-[[3-(3,3,3-trifluoro-2,2-dihydroxypropoxy)phenyl]methyl]-1H-pyrazole-4-carboxylate preparation

p-Ethyl 1-[[3-(3,3,3-trifluoro-2-hydroxypropoxy)phenyl]methyl] -1H -pyrazole-4 in dichloromethane (300 mL) - Carboxylate (ie, product of Step E) (5.7 g, 14.9 mmol) To the mixture was added Dess-Martin periodinane (9.13 g, 20.3 mmol). After 3 hours, the reaction mixture was concentrated under reduced pressure, diluted with ethyl acetate, and washed with sodium bisulfite solution (10% aqueous solution), saturated aqueous sodium bicarbonate solution, and saturated aqueous sodium chloride solution. The organic layer was dried over magnesium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The resulting material was triturated with 1-chlorobutane to give the title compound, a compound of the present invention, as a white solid (4.89 g). ¹ H NMR (DMSO- d ₆ ): δ 1.27 (t, 3H), 4.01 (s, 2H), 4.20 (m, 2H), 5.33 (s, 2H), 6.86-6.92 (m, 3H), 7.26- 7.29 (m, 1H), 7.31 (s, 2H, ), 7.87 (s, 1H), 8.48 (s, 1H). ¹⁹ F NMR (DMSO- d ₆ ): δ -81.82. Example 7 Ethyl 1-[[3-[[( 1Z )-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]phenyl]methyl] Preparation of -1H -pyrazole-4-carboxylate (compound 265)

p-Ethyl 1-[[3-(3,3,3-trifluoro-2,2-dihydroxypropoxy)phenyl]methyl] -1H -pyridine in dimethylsulfoxide (24 mL) A mixture of oxazole-4-carboxylate (ie, the product of Example 6) (2.94 g, 7.85 mmol) was added iodoethane (2.39 g, 15.3 mmol). The reaction mixture was heated at 65 °C and cesium carbonate (4.21 g, 12.92 mmol) was added. After 45 minutes, the reaction mixture was cooled to room temperature and poured into ether/water (400 mL, 1:1 ratio). The organic layer was separated and washed with water, saturated aqueous sodium chloride, dried over magnesium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The resulting material was purified by silica gel chromatography (with a gradient of 0 to 100% ethyl acetate in hexanes) to give the title compound, the compound of the invention, as a white solid (2.59 g) at 41- Melted at 43°C. ¹ H NMR (CDCl ₃ ): δ 1.32 (m, 6H), 4.16 (m, 2H), 4.30 (m, 2H), 5.31 (s, 2H), 6.76 (s, 1H), 6.93 (m, 1H) , 7.00-7.03 (m, 2H), 7.34-7.37 (m, 1H), 7.90 (s, 1H), 7.95 (s, 1H). ¹⁹ F NMR (CDCl ₃ ): δ -70.09. Example 8 Ethyl 1-[[4-(3,3,3-trifluoro-2,2-dihydroxypropoxy)phenoxy]methyl] -1H -pyrazole-4-carboxylate Preparation of (Compound 366) Step A: Preparation of Ethyl 1-(hydroxymethyl) -1H -pyrazole-4-carboxylate

A mixture of ethyl1H -pyrazole-4-carboxylate (6.0 g, 43 mmol), formaldehyde (37% aqueous solution, 12 mL) and ethanol (50 mL) was heated to reflux overnight. The reaction mixture was cooled to room temperature and concentrated under reduced pressure. The resulting material was triturated with 1-chlorobutane to give the title compound as a white solid (6.2 g). ¹ H NMR (DMSO- d ₆ ): δ 1.27 (t, 3H) 4.22 (q, 2H), 5.41 (s, 2H), 7.89 (s, 1H), 8.36 (s, 1H). Step B: Preparation of Ethyl 1-(chloromethyl) -1H -pyrazole-4-carboxylate

To a mixture of ethyl 1-(hydroxymethyl) -1H -pyrazole-4-carboxylate (ie, the product of Step A) (6.2 g, 36 mmol) in dichloroethane (100 mL) N,N -Dimethylformamide (2 drops) was added, followed by thionyl chloride (5.3 mL, 73 mmol) dropwise. After 3 hours, the reaction mixture was concentrated under reduced pressure to give the title compound as a yellow solid (6.2 g). ¹ H NMR (CDCl ₃ ): δ 1.35 (t, 3H), 4.31 (q, 2H), 5.85 (s, 2H), 7.99 (s, 1H), 8.11 (s, 1H). Step C : Preparation of Ethyl 1-[(4-Methoxyphenoxy)methyl]-1H-pyrazole-4-carboxylate

At room temperature, stir ethyl 1-(chloromethyl) -1H -pyrazole-4-carboxylate (ie, the product of Step B) (2.0 g, 11 mmol), 4-methoxyphenol (1.24 g, 10 mmol), potassium carbonate (2.8 g, 20 mmol) and N,N -dimethylformamide (25 mL). After 3 days, the reaction mixture was poured into ice water (150 mL) and extracted with ether (2 x 100 mL). The combined organic layers were washed with water (50 mL), saturated aqueous sodium chloride solution (25 mL), dried over magnesium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The resulting material was purified by silica gel chromatography (eluting with a gradient of 10 to 100% ethyl acetate in hexanes) to give the title compound as a colorless oil (2.7 g). ¹ H NMR (CDCl ₃ ): δ 1.34 (t, 3H), 3.78 (s, 3H), 4.29 (q, 2H), 5.90 (s, 2H), 6.80-6.84 (m, 2H), 6.88-6.91 ( m, 2H), 7.96 (s, 1H), 8.05 (s, 1H). Step D : Preparation of Ethyl 1-[(4-Hydroxyphenoxy)methyl]-1H-pyrazole-4-carboxylate

p-Ethyl 1-[(4-methoxyphenoxy)methyl]-1H-pyrazole-4-carboxylate in dichloromethane (3 mL) (ie, the product of Step C ) (1.7 g, 6.2 mmol) to the mixture was added boron tribromide solution (1 M in dichloromethane, 12.4 mL, 12.4 mmol). After 4 hours, saturated aqueous ammonium chloride solution (25 mL) was added to the reaction mixture and stirring was continued for an additional 15 minutes. The reaction mixture was diluted with dichloromethane (25 mL) and saturated aqueous ammonium chloride (25 mL). The organic layer was separated and washed with saturated aqueous sodium bicarbonate (25 mL) and saturated aqueous sodium chloride (25 mL), dried over magnesium sulfate and filtered. The filtrate was concentrated under reduced pressure to give the title compound as a solid (1.65 g). ¹ H NMR (DMSO- d ₆ ): δ 1.26 (t, 3H), 4.21 (q, 2H), 5.76 (s, 1H), 5.96 (s, 2H), 6.62-6.71 (m, 2H), 6.82- 6.88 (m, 2H), 7.93 (d, 1H), 8.48 (d, 1H). Step E: Preparation of Ethyl 1-[[4-(3,3,3-Trifluoro-2-hydroxypropoxy)phenoxy]methyl] -1H -pyrazole-4-carboxylate

p-Ethyl 1-[(4-hydroxyphenoxy)methyl]-1H-pyrazole-4-carboxylate (ie, product of Step D ) (6.2 mmol) in acetonitrile (20 mL) To the mixture was added 2-(trifluoromethyl)oxirane (0.62 mL, 7.6 mmol) and cesium carbonate (about 10 mg). The reaction mixture was heated at 75°C overnight, then cooled to room temperature and concentrated under reduced pressure. The resulting material was purified by silica gel chromatography (eluting with a gradient of 10 to 100% ethyl acetate in hexanes) to give the title compound as a white solid (0.95 g). ¹ H NMR (DMSO- d ₆ ): δ 1.26 (t, 3H), 3.96-4.08 (m, 1H), 4.12 (dd, 1H), 4.22 (q, 2H), 4.33-4.36 (m, 1H), 6.04 (s, 2H), 6.62 (d, 1H), 6.88-6.97 (m, 2H), 7.00-7.03 (m, 2H), 7.95 (s, 1H), 8.54 (s, 1H). Step F: Ethyl 1-[[4-(3,3,3-Trifluoro-2,2-dihydroxypropoxy)phenoxy]-methyl]-1H-pyrazole-4-carboxylic acid Preparation of salt

p-Ethyl 1-[[4-(3,3,3-trifluoro-2-hydroxypropoxy)phenoxy]methyl] -1H -pyrazole-4 in dichloromethane (25 mL) - Carboxylate (ie, product of Step E) (0.95 g, 2.5 mmol) To the mixture was added one portion of Dess-Martin periodinane (1.5 g, 3.5 mmol). The reaction mixture was stirred for 2.5 hours, then saturated aqueous sodium thiosulfate solution (30 mL) was added, and the mixture was concentrated under reduced pressure. The resulting mixture was extracted with ethyl acetate (150 mL), and the combined organic layers were washed with saturated aqueous sodium thiosulfate (50 mL), saturated aqueous sodium bicarbonate (50 mL), and saturated aqueous sodium chloride (25 mL) Washed, dried over magnesium sulfate and filtered. The filtrate was concentrated under reduced pressure, and the resulting material was triturated with dichloromethane to give the title compound, a compound of the present invention, as a solid (0.65 g). ¹ H NMR (DMSO- d ₆ ): δ 1.26 (t, 3H), 3.98 (s, 2H), 4.21 (q, 2H), 6.03 (s, 2H), 6.86-6.94 (m, 2H), 6.95- 7.06 (m, 2H), 7.27 (s, 2H), 7.94 (s, 1H), 8.53 (s, 1H). Example 9 Ethyl 1-[[4-[[(1 Z )-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]phenoxy]methyl Preparation of ] -1H -pyrazole-4-carboxylate (Compound 364)

A mixture of iodoethane (2.7 mL, 34 mmol), potassium carbonate (0.84 g, 6.1 mmol), and dimethylsulfite (7 mL) was stirred at room temperature for 20 minutes, then mixed in dimethylsulfite ( 7 mL) in ethyl 1-[[4-(3,3,3-trifluoro-2,2-dihydroxypropoxy)phenoxy]methyl] -1H -pyrazole-4-carboxylate The acid salt solution (ie, the product of Example 8) (0.64 g, 1.6 mmol) was added portionwise over 20 minutes. After stirring at room temperature for 1.5 hours, the reaction mixture was poured into ice water (150 mL) and extracted with ethyl acetate (125 mL). The organic layer was washed with water (2 x 50 mL) and saturated aqueous sodium chloride solution (50 mL), dried over magnesium sulfate and filtered. The filtrate was concentrated under reduced pressure, and the resulting material was purified by silica gel chromatography (with a gradient of 10 to 100% ethyl acetate in hexanes) to give the title compound, the compound of the invention, as a colorless oil ( 0.46 g). ¹ H NMR (DMSO- d ₆ ): δ 1.23-1.27 (m, 6H), 4.11 (q, 2H), 4.22 (q, 2H), 6.10 (s, 2H), 7.07-7.24 (m, 4H) 7.95 (s, 1H) 8.58 (s, 1H).

The compounds of Tables 1, 1A-48A, 2, and 1B-48B below can be prepared by the methods described herein, as well as methods known in the art. The following abbreviations are used in the table: t for tertiary, s for secondary, n for normal, i for iso, c for cyclic, Me for methyl, Et for ethyl, Pr for propyl, i -Pr for isopropyl , c -Pr represents cyclopropyl, Bu represents butyl, i -Bu represents isobutyl, t -Bu represents tert-butyl, and Ph represents phenyl. Table 1

In the above formula, E equals ^E2 , ^E2 equals GZ-, and G is optionally substituted with ^R13 . G is defined as in Schedule A of the above embodiment. In column G, numbers in parentheses indicate the point of attachment of the G ring to Z. The column (R ¹³ ) _x refers to the substituent attached to the G ring, as shown in Schedule A above. (R ¹³ ) A dash "-" in the _x column indicates that the R ¹³ substituent is absent and the remaining valences on the G ring are occupied by hydrogen atoms. J is J-1, L is CH ₂ and Z is a direct bond J is J-1, L is CH ₂ and Z is a direct bond G (R ¹³ ) _x G (R ¹³ ) _x G-1 (4) – G-12 (1) – G-1 (4) 2-Me G-12 (1) 4-Me G-1 (4) 2-Et G-12 (1) 4-Et G-1 (4) 2- n -Pr G-12 (1) 4- n -Pr G-1 (4) 2- i -Pr G-12 (1) 4- i -Pr G-1 (4) 2- c -Pr G-12 (1) 4- c -Pr G-1 (4) 2- n -Bu G-12 (1) 4- n -Bu G-1 (4) 2- i -Bu G-12 (1) 4- i -Bu G-1 (4) 2- t -Bu G-12 (1) 4- t -Bu G-1 (4) 2-F G-12 (1) 4-F G-1 (4) 2-Cl G-12 (1) 4-Cl G-1 (4) 2-Br G-12 (1) 4-Br G-1 (4) 2- _CF3 G-12 (1) 4-CF ₃ G-1 (4) 2-HO G-12 (1) 4-HO G-1 (4) 2-N≡C G-12 (1) 4-N≡C G-1 (4) 2-N≡CCH ₂ G-12 (1) 4-N≡CCH ₂ G-1 (4) 2-(MeO) G-12 (1) 4-(MeO) G-1 (4) 2-(MeOCH ₂ ) G-12 (1) 4-(MeOCH ₂ ) G-1 (4) 2-(EtOCH ₂ ) G-12 (1) 4-(EtOCH ₂ ) G-1 (4) 2-(CH(=O)) G-12 (1) 4-(CH(=O)) G-1 (4) 2-(HOC(=O)) G-12 (1) 4-(HOC(=O)) G-1 (4) 2-(MeOC(=O)) G-12 (1) 4-(MeOC(=O)) G-1 (4) 2-(EtOC(=O)) G-12 (1) 4-(EtOC(=O)) G-1 (4) 2-( i -PrOC(=O)) G-12 (1) 4-( i -PrOC(=O)) G-1 (4) 2-( n -PrOC(=O)) G-12 (1) 4-( n -PrOC(=O)) G-1 (4) 2-(BuOC(=O)) G-12 (1) 4-(BuOC(=O)) G-1 (4) 2-( i -BuOC(=O)) G-12 (1) 4-( i -BuOC(=O)) G-1 (4) 2-( t -BuOC(=O)) G-12 (1) 4-( t -BuOC(=O)) G-1 (4) 2-(CF ₃ CH ₂ OC(=O) G-12 (1) 4-(CF ₃ CH ₂ OC(=O) G-1 (4) 2-(CH ₂ =CHOC(=O)) G-12 (1) 4-(CH ₂ =CHOC(=O)) G-1 (4) 2-(CH ₂ =CHCH ₂ OC(=O)) G-12 (1) 4-(CH ₂ =CHCH ₂ OC(=O)) G-1 (4) 2-(CH ₂ =CBrCH ₂ OC(=O)) G-12 (1) 4-(CH ₂ =CBrCH ₂ OC(=O)) G-1 (4) 2-(CH ₂ =CHCF ₂ OC(=O)) G-12 (1) 4-(CH ₂ =CHCF ₂ OC(=O)) G-1 (4) 2-(Me ₂ C=CHCH ₂ OC(=O)) G-12 (1) 4-(Me ₂ C=CHCH ₂ OC(=O)) G-1 (4) 2-(CH ₂ =C(Me)CH ₂ OC(=O)) G-12 (1) 4-(CH ₂ =C(Me)CH ₂ OC(=O)) G-1 (4) 2-(CH≡CCH ₂ OC(=O)) G-12 (1) 4-(CH≡CCH ₂ OC(=O)) G-1 (4) 2-(N≡CCH ₂ OC(=O)) G-12 (1) 4-(N≡CCH ₂ OC(=O)) G-1 (4) 2-(MeNHC(=O)) G-12 (1) 4-(MeNHC(=O)) G-1 (4) 2-(Me ₂ NC(=O)) G-12 (1) 4-(Me ₂ NC(=O)) G-1 (4) 2-(MeNHC(=O)) G-12 (1) 4-(MeNHC(=O)) G-1 (4) 2-(EtNHC(=O)) G-12 (1) 4-(EtNHC(=O)) G-1 (4) 2-(PrNHC(=O)) G-12 (1) 4-(PrNHC(=O)) G-1 (4) 2-( i -PrNHC(=O)) G-12 (1) 4-( i -PrNHC(=O)) G-1 (4) 2-(BuNHC(=O)) G-12 (1) 4-(BuNHC(=O)) G-1 (4) 2-( t -BuNHC(=O)) G-12 (1) 4-( t -BuNHC(=O)) G-1 (4) 2-( i -BuNHC(=O)) G-12 (1) 4-( i -BuNHC(=O)) G-1 (4) 2-(CF ₃ CH ₂ NHC(=O)) G-12 (1) 4-(CF ₃ CH ₂ NHC(=O)) G-1 (4) 2-( c -PrCH ₂ NHC(=O)) G-12 (1) 4-( c -PrCH ₂ NHC(=O)) G-1 (4) 2-(MeOCH ₂ NHC(=O)) G-12 (1) 4-(MeOCH ₂ NHC(=O)) G-1 (4) 2-(MeOCH ₂ CH ₂ NHC(=O)) G-12 (1) 4-(MeOCH ₂ CH ₂ NHC(=O)) G-1 (4) 2-(CH ₂ =CHCH ₂ NHC(=O)) G-12 (1) 4-(CH ₂ =CHCH ₂ NHC(=O)) G-1 (4) 2-(N≡CCH ₂ NHC(=O)) G-12 (1) 4-(N≡CCH ₂ NHC(=O)) G-1 (4) 2-(OH-N=CH) G-12 (1) 4-(OH-N=CH) G-1 (4) 2-(Me ₂ NN=CH) G-12 (1) 4-(Me ₂ NN=CH) G-1 (4) 2-(MeOC(=O)NHN=CH) G-12 (1) 4-(MeOC(=O)NHN=CH) G-1 (4) 2-(OHC(=O)CH ₂ ON=CH) G-12 (1) 4-(OHC(=O)CH ₂ ON=CH) G-1 (2) – G-12 (1) 5-Me, 3-(EtOC(=O)) G-1 (2) 4-Me G-12 (1) 3-Me G-1 (2) 4-Et G-12 (1) 3-Et G-1 (2) 4- n -Pr G-12 (1) 3- n -Pr G-1 (2) 4- i -Pr G-12 (1) 3- i -Pr G-1 (2) 4- c -Pr G-12 (1) 3- c -Pr G-1 (2) 4- n -Bu G-12 (1) 3- n -Bu G-1 (2) 4- i -Bu G-12 (1) 3- i -Bu G-1 (2) 4- t -Bu G-12 (1) 3- t -Bu G-1 (2) 4-F G-12 (1) 3-F G-1 (2) 4-Cl G-12 (1) 3-Cl G-1 (2) 4-Br G-12 (1) 3-Br G-1 (2) 4-CF ₃ G-12 (1) 3- _CF3 G-1 (2) 4-HO G-12 (1) 3-HO G-1 (2) 4-N≡C G-12 (1) 3-N≡C G-1 (2) 4-N≡CCH ₂ G-12 (1) 3-N≡CCH ₂ G-1 (2) 4-(MeO) G-12 (1) 3-(MeO) G-1 (2) 4-(MeOCH ₂ ) G-12 (1) 3-(MeOCH ₂ ) G-1 (2) 4-(EtOCH ₂ ) G-12 (1) 3-(EtOCH ₂ ) G-1 (2) 4-(CH(=O)) G-12 (1) 3-(CH(=O)) G-1 (2) 4-(HOC(=O)) G-12 (1) 3-(HOC(=O)) G-1 (2) 4-(MeOC(=O)) G-12 (1) 3-(MeOC(=O)) G-1 (2) 4-(EtOC(=O)) G-12 (1) 3-(EtOC(=O)) G-1 (2) 4-( i -PrOC(=O)) G-12 (1) 3-( i -PrOC(=O)) G-1 (2) 4-( n -PrOC(=O)) G-12 (1) 3-( n -PrOC(=O)) G-1 (2) 4-(BuOC(=O)) G-12 (1) 3-(BuOC(=O)) G-1 (2) 4-( i -BuOC(=O)) G-12 (1) 3-( i -BuOC(=O)) G-1 (2) 4-( t -BuOC(=O)) G-12 (1) 3-( t -BuOC(=O)) G-1 (2) 4-(CF ₃ CH ₂ OC(=O) G-12 (1) 3-(CF ₃ CH ₂ OC(=O) G-1 (2) 4-(CH ₂ =CHOC(=O)) G-12 (1) 3-(CH ₂ =CHOC(=O)) G-1 (2) 4-(CH ₂ =CHCH ₂ OC(=O)) G-12 (1) 3-(CH ₂ =CHCH ₂ OC(=O)) G-1 (2) 4-(CH ₂ =CBrCH ₂ OC(=O)) G-12 (1) 3-(CH ₂ =CBrCH ₂ OC(=O)) G-1 (2) 4-(CH ₂ =CHCF ₂ OC(=O)) G-12 (1) 3-(CH ₂ =CHCF ₂ OC(=O)) G-1 (2) 4-(Me ₂ C=CHCH ₂ OC(=O)) G-12 (1) 3-(Me ₂ C=CHCH ₂ OC(=O)) G-1 (2) 4-(CH ₂ =C(Me)CH ₂ OC(=O)) G-12 (1) 3-(CH ₂ =C(Me)CH ₂ OC(=O)) G-1 (2) 4-(CH≡CCH ₂ OC(=O)) G-12 (1) 3-(CH≡CCH ₂ OC(=O)) G-1 (2) 4-(N≡CCH ₂ OC(=O)) G-12 (1) 3-(N≡CCH ₂ OC(=O)) G-1 (2) 4-(MeNHC(=O)) G-12 (1) 3-(MeNHC(=O)) G-1 (2) 4-(Me ₂ NC(=O)) G-12 (1) 3-(Me ₂ NC(=O)) G-1 (2) 4-(MeNHC(=O)) G-12 (1) 3-(MeNHC(=O)) G-1 (2) 4-(EtNHC(=O)) G-12 (1) 3-(EtNHC(=O)) G-1 (2) 4-(PrNHC(=O)) G-12 (1) 3-(PrNHC(=O)) G-1 (2) 4-( i -PrNHC(=O)) G-12 (1) 3-( i -PrNHC(=O)) G-1 (2) 4-(BuNHC(=O)) G-12 (1) 3-(BuNHC(=O)) G-1 (2) 4-( t -BuNHC(=O)) G-12 (1) 3-( t -BuNHC(=O)) G-1 (2) 4-( i -BuNHC(=O)) G-12 (1) 3-( i -BuNHC(=O)) G-1 (2) 4-(CF ₃ CH ₂ NHC(=O)) G-12 (1) 3-(CF ₃ CH ₂ NHC(=O)) G-1 (2) 4-( c -PrCH ₂ NHC(=O)) G-12 (1) 3-( c -PrCH ₂ NHC(=O)) G-1 (2) 4-(MeOCH ₂ NHC(=O)) G-12 (1) 3-(MeOCH ₂ NHC(=O)) G-1 (2) 4-(MeOCH ₂ CH ₂ NHC(=O)) G-12 (1) 3-(MeOCH ₂ CH ₂ NHC(=O)) G-1 (2) 4-(CH ₂ =CHCH ₂ NHC(=O)) G-12 (1) 3-(CH ₂ =CHCH ₂ NHC(=O)) G-1 (2) 4-(N≡CCH ₂ NHC(=O)) G-12 (1) 3-(N≡CCH ₂ NHC(=O)) G-1 (2) 4-(OH-N=CH) G-12 (1) 3-(OH-N=CH) G-1 (2) 4-(Me ₂ NN=CH) G-12 (1) 3-(Me ₂ NN=CH) G-1 (2) 4-(MeOC(=O)NHN=CH) G-12 (1) 3-(MeOC(=O)NHN=CH) G-1 (2) 4-(OHC(=O)CH ₂ ON=CH) G-12 (1) 3-(OHC(=O)CH ₂ ON=CH) G-3 (1) – G-13 (1) – G-3 (1) 4-Me G-13 (1) 5-Me G-3 (1) 4-Et G-13 (1) 5-Et G-3 (1) 4- n -Pr G-13 (1) 5- n -Pr G-3 (1) 4- i -Pr G-13 (1) 5- i -Pr G-3 (1) 4- c -Pr G-13 (1) 5- c -Pr G-3 (1) 4- n -Bu G-13 (1) 5- n -Bu G-3 (1) 4- i -Bu G-13 (1) 5- i -Bu G-3 (1) 4- t -Bu G-13 (1) 5- t -Bu G-3 (1) 4-F G-13 (1) 5-F G-3 (1) 4-Cl G-13 (1) 5-Cl G-3 (1) 4-Br G-13 (1) 5-Br G-3 (1) 4-CF ₃ G-13 (1) 5- _CF3 G-3 (1) 4-HO G-13 (1) 5-HO G-3 (1) 4-N≡C G-13 (1) 5-N≡C G-3 (1) 4-N≡CCH ₂ G-13 (1) 5-N≡CCH ₂ G-3 (1) 4-(MeO) G-13 (1) 5-(MeO) G-3 (1) 4-(MeOCH ₂ ) G-13 (1) 5-(MeOCH ₂ ) G-3 (1) 4-(EtOCH ₂ ) G-13 (1) 5-(EtOCH ₂ ) G-3 (1) 4-(CH(=O)) G-13 (1) 5-(CH(=O)) G-3 (1) 4-(HOC(=O)) G-13 (1) 5-(HOC(=O)) G-3 (1) 4-(MeOC(=O)) G-13 (1) 5-(MeOC(=O)) G-3 (1) 4-(EtOC(=O)) G-13 (1) 5-(EtOC(=O)) G-3 (1) 4-( i -PrOC(=O)) G-13 (1) 5-( i -PrOC(=O)) G-3 (1) 4-( n -PrOC(=O)) G-13 (1) 5-( n -PrOC(=O)) G-3 (1) 4-(BuOC(=O)) G-13 (1) 5-(BuOC(=O)) G-3 (1) 4-( i -BuOC(=O)) G-13 (1) 5-( i -BuOC(=O)) G-3 (1) 4-( t -BuOC(=O)) G-13 (1) 5-( t -BuOC(=O)) G-3 (1) 4-(CF ₃ CH ₂ OC(=O) G-13 (1) 5-(CF ₃ CH ₂ OC(=O) G-3 (1) 4-(CH ₂ =CHOC(=O)) G-13 (1) 5-(CH ₂ =CHOC(=O)) G-3 (1) 4-(CH ₂ =CHCH ₂ OC(=O)) G-13 (1) 5-(CH ₂ =CHCH ₂ OC(=O)) G-3 (1) 4-(CH ₂ =CBrCH ₂ OC(=O)) G-13 (1) 5-(CH ₂ =CBrCH ₂ OC(=O)) G-3 (1) 4-(CH ₂ =CHCF ₂ OC(=O)) G-13 (1) 5-(CH ₂ =CHCF ₂ OC(=O)) G-3 (1) 4-(Me ₂ C=CHCH ₂ OC(=O)) G-13 (1) 5-(Me ₂ C=CHCH ₂ OC(=O)) G-3 (1) 4-(CH ₂ =C(Me)CH ₂ OC(=O)) G-13 (1) 5-(CH ₂ =C(Me)CH ₂ OC(=O)) G-3 (1) 4-(CH≡CCH ₂ OC(=O)) G-13 (1) 5-(CH≡CCH ₂ OC(=O)) G-3 (1) 4-(N≡CCH ₂ OC(=O)) G-13 (1) 5-(N≡CCH ₂ OC(=O)) G-3 (1) 4-(MeNHC(=O)) G-13 (1) 5-(MeNHC(=O)) G-3 (1) 4-(Me ₂ NC(=O)) G-13 (1) 5-(Me ₂ NC(=O)) G-3 (1) 4-(MeNHC(=O)) G-13 (1) 5-(MeNHC(=O)) G-3 (1) 4-(EtNHC(=O)) G-13 (1) 5-(EtNHC(=O)) G-3 (1) 4-(PrNHC(=O)) G-13 (1) 5-(PrNHC(=O)) G-3 (1) 4-( i -PrNHC(=O)) G-13 (1) 5-( i -PrNHC(=O)) G-3 (1) 4-(BuNHC(=O)) G-13 (1) 5-(BuNHC(=O)) G-3 (1) 4-( t -BuNHC(=O)) G-13 (1) 5-( t -BuNHC(=O)) G-3 (1) 4-( i -BuNHC(=O)) G-13 (1) 5-( i -BuNHC(=O)) G-3 (1) 4-(CF ₃ CH ₂ NHC(=O)) G-13 (1) 5-(CF ₃ CH ₂ NHC(=O)) G-3 (1) 4-( c -PrCH ₂ NHC(=O)) G-13 (1) 5-( c -PrCH ₂ NHC(=O)) G-3 (1) 4-(MeOCH ₂ NHC(=O)) G-13 (1) 5-(MeOCH ₂ NHC(=O)) G-3 (1) 4-(MeOCH ₂ CH ₂ NHC(=O)) G-13 (1) 5-(MeOCH ₂ CH ₂ NHC(=O)) G-3 (1) 4-(CH ₂ =CHCH ₂ NHC(=O)) G-13 (1) 5-(CH ₂ =CHCH ₂ NHC(=O)) G-3 (1) 4-(N≡CCH ₂ NHC(=O)) G-13 (1) 5-(N≡CCH ₂ NHC(=O)) G-3 (1) 4-(OH-N=CH) G-13 (1) 5-(OH-N=CH) G-3 (1) 4-(Me ₂ NN=CH) G-13 (1) 5-(Me ₂ NN=CH) G-3 (1) 4-(MeOC(=O)NHN=CH) G-13 (1) 5-(MeOC(=O)NHN=CH) G-3 (1) 4-(OHC(=O)CH ₂ ON=CH) G-13 (1) 5-(OHC(=O)CH ₂ ON=CH) G-9 (1) – G-17 (1) – G-9 (1) 3-Me G-17 (1) 4-Me G-9 (1) 3-Et G-17 (1) 4-Et G-9 (1) 3- n -Pr G-17 (1) 4- n -Pr G-9 (1) 3- i -Pr G-17 (1) 4- i -Pr G-9 (1) 3- c -Pr G-17 (1) 4- c -Pr G-9 (1) 3- n -Bu G-17 (1) 4- n -Bu G-9 (1) 3- i -Bu G-17 (1) 4- i -Bu G-9 (1) 3- t -Bu G-17 (1) 4- t -Bu G-9 (1) 3-F G-17 (1) 4-F G-9 (1) 3-Cl G-17 (1) 4-Cl G-9 (1) 3-Br G-17 (1) 4-Br G-9 (1) 3- _CF3 G-17 (1) 4-CF ₃ G-9 (1) 3-HO G-17 (1) 4-HO G-9 (1) 3-N≡C G-17 (1) 4-N≡C G-9 (1) 3-N≡CCH ₂ G-17 (1) 4-N≡CCH ₂ G-9 (1) 3-(MeO) G-17 (1) 4-(MeO) G-9 (1) 3-(MeOCH ₂ ) G-17 (1) 4-(MeOCH ₂ ) G-9 (1) 3-(EtOCH ₂ ) G-17 (1) 4-(EtOCH ₂ ) G-9 (1) 3-(CH(=O)) G-17 (1) 4-(CH(=O)) G-9 (1) 3-(HOC(=O)) G-17 (1) 4-(HOC(=O)) G-9 (1) 3-(MeOC(=O)) G-17 (1) 4-(MeOC(=O)) G-9 (1) 3-(EtOC(=O)) G-17 (1) 4-(EtOC(=O)) G-9 (1) 3-( i -PrOC(=O)) G-17 (1) 4-( i -PrOC(=O)) G-9 (1) 3-( n -PrOC(=O)) G-17 (1) 4-( n -PrOC(=O)) G-9 (1) 3-(BuOC(=O)) G-17 (1) 4-(BuOC(=O)) G-9 (1) 3-( i -BuOC(=O)) G-17 (1) 4-( i -BuOC(=O)) G-9 (1) 3-( t -BuOC(=O)) G-17 (1) 4-( t -BuOC(=O)) G-9 (1) 3-(CF ₃ CH ₂ OC(=O) G-17 (1) 4-(CF ₃ CH ₂ OC(=O) G-9 (1) 3-(CH ₂ =CHOC(=O)) G-17 (1) 4-(CH ₂ =CHOC(=O)) G-9 (1) 3-(CH ₂ =CHCH ₂ OC(=O)) G-17 (1) 4-(CH ₂ =CHCH ₂ OC(=O)) G-9 (1) 3-(CH ₂ =CBrCH ₂ OC(=O)) G-17 (1) 4-(CH ₂ =CBrCH ₂ OC(=O)) G-9 (1) 3-(CH ₂ =CHCF ₂ OC(=O)) G-17 (1) 4-(CH ₂ =CHCF ₂ OC(=O)) G-9 (1) 3-(Me ₂ C=CHCH ₂ OC(=O)) G-17 (1) 4-(Me ₂ C=CHCH ₂ OC(=O)) G-9 (1) 3-(CH ₂ =C(Me)CH ₂ OC(=O)) G-17 (1) 4-(CH ₂ =C(Me)CH ₂ OC(=O)) G-9 (1) 3-(CH≡CCH ₂ OC(=O)) G-17 (1) 4-(CH≡CCH ₂ OC(=O)) G-9 (1) 3-(N≡CCH ₂ OC(=O)) G-17 (1) 4-(N≡CCH ₂ OC(=O)) G-9 (1) 3-(MeNHC(=O)) G-17 (1) 4-(MeNHC(=O)) G-9 (1) 3-(Me ₂ NC(=O)) G-17 (1) 4-(Me ₂ NC(=O)) G-9 (1) 3-(MeNHC(=O)) G-17 (1) 4-(MeNHC(=O)) G-9 (1) 3-(EtNHC(=O)) G-17 (1) 4-(EtNHC(=O)) G-9 (1) 3-(PrNHC(=O)) G-17 (1) 4-(PrNHC(=O)) G-9 (1) 3-( i -PrNHC(=O)) G-17 (1) 4-( i -PrNHC(=O)) G-9 (1) 3-(BuNHC(=O)) G-17 (1) 4-(BuNHC(=O)) G-9 (1) 3-( t -BuNHC(=O)) G-17 (1) 4-( t -BuNHC(=O)) G-9 (1) 3-( i -BuNHC(=O)) G-17 (1) 4-( i -BuNHC(=O)) G-9 (1) 3-(CF ₃ CH ₂ NHC(=O)) G-17 (1) 4-(CF ₃ CH ₂ NHC(=O)) G-9 (1) 3-( c -PrCH ₂ NHC(=O)) G-17 (1) 4-( c -PrCH ₂ NHC(=O)) G-9 (1) 3-(MeOCH ₂ NHC(=O)) G-17 (1) 4-(MeOCH ₂ NHC(=O)) G-9 (1) 3-(MeOCH ₂ CH ₂ NHC(=O)) G-17 (1) 4-(MeOCH ₂ CH ₂ NHC(=O)) G-9 (1) 3-(CH ₂ =CHCH ₂ NHC(=O)) G-17 (1) 4-(CH ₂ =CHCH ₂ NHC(=O)) G-9 (1) 3-(N≡CCH ₂ NHC(=O)) G-17 (1) 4-(N≡CCH ₂ NHC(=O)) G-9 (1) 3-(OH-N=CH) G-17 (1) 4-(OH-N=CH) G-9 (1) 3-(Me ₂ NN=CH) G-17 (1) 4-(Me ₂ NN=CH) G-9 (1) 3-(MeOC(=O)NHN=CH) G-17 (1) 4-(MeOC(=O)NHN=CH) G-9 (1) 3-(OHC(=O)CH ₂ ON=CH) G-17 (1) 4-(OHC(=O)CH ₂ ON=CH)

The present invention also includes Tables 1A through 48A, each of which is constructed identically to Table 1 above, except for the row headings in Table 1 (ie, "J is J-1, L is _CH and Z is a direct bond" ) with the corresponding row headings shown below. surface row header surface row header 1A J is J _{- 1} , L is CH2CH2 and Z is a direct bond. 25A J is J-10, L is _CH2 and Z is a direct bond. 2A J is J-1, L is _CH2 (Me) and Z is a direct bond. 26A J is J _{- 10} , L is CH2CH2 and Z is a direct bond. 3A J is J-1, L is (CH ₂ ) ₃ and Z is a direct bond. 27A J is J-10, L is _CH2 (Me) and Z is a direct bond. 4A J is J-1, L is _CH2 and Z is O. 28A J is J-10, L is (CH ₂ ) ₃ and Z is a direct bond. 5A J is J-2, L is _CH2 and Z is a direct bond. 29A J is J-10, L is _CH2 and Z is O. 6A J is J _{- 2} , L is CH2CH2 and Z is a direct bond. 30A J is J-14, L is _CH2 and Z is a direct bond. 7A J is J-2, L is _CH2 (Me) and Z is a direct bond. 31A J is J _{- 14} , L is CH2CH2 and Z is a direct bond. 8A J is J-2, L is (CH ₂ ) ₃ and Z is a direct bond. 32A J is J-14, L is _CH2 (Me) and Z is a direct bond. 9A J is J-2, L is _CH2 and Z is O. 33A J is J-14, L is (CH ₂ ) ₃ and Z is a direct bond. 10A J is J-6, L is _CH2 and Z is a direct bond. 34A J is J-14, L is _CH2 and Z is O. 11A J is J _{- 6} , L is CH2CH2 and Z is a direct bond. 35A J is J-3, L is _CH2 and Z is a direct bond. 12A J is J-6, L is _CH2 (Me) and Z is a direct bond. 36A J is J _{- 3} , L is CH2CH2 and Z is a direct bond. 13A J is J-6, L is (CH ₂ ) ₃ and Z is a direct bond. 37A J is J-3, L is _CH2 (Me) and Z is a direct bond. 14A J is J-6, L is _CH2 and Z is O. 38A J is J-3, L is (CH ₂ ) ₃ and Z is a direct bond. 15A J is J-7, L is _CH2 and Z is a direct bond. 39A J is J-3, L is _CH2 and Z is O. 16A J is J _{- 7} , L is CH2CH2 and Z is a direct bond. 40A J is J-4, L is _CH2 and Z is a direct bond. 17A J is J-7, L is _CH2 (Me) and Z is a direct bond. 41A J is J _{- 4} , L is CH2CH2 and Z is a direct bond. 18A J is J-7, L is (CH ₂ ) ₃ and Z is a direct bond. 42A J is J-4, L is _CH2 (Me) and Z is a direct bond. 19A J is J-7, L is _CH2 and Z is O. 43A J is J-4, L is (CH ₂ ) ₃ and Z is a direct bond. 20A J is J-8, L is _CH2 and Z is a direct bond. 44A J is J-4, L is _CH2 and Z is O. 21A J is J _{- 8} , L is CH2CH2 and Z is a direct bond. 45A J is J-5, L is _CH2 and Z is a direct bond. 22A J is J-8, L is _CH2 (Me) and Z is a direct bond. 46A J is J _{- 5} , L is CH2CH2 and Z is a direct bond. 23A J is J-8, L is (CH ₂ ) ₃ and Z is a direct bond. 47A J is J-5, L is _CH2 (Me) and Z is a direct bond. 24A J is J-8, L is _CH2 and Z is O. 48A J is J-5, L is (CH ₂ ) ₃ and Z is a direct bond. Table 2

In the above formula, E equals ^E2 , ^E2 equals GZ-, and G is optionally substituted with ^R13 . The definition of G is as shown in Schedule A in the above-mentioned embodiment. In column G, the numbers in parentheses indicate the point of attachment of the G ring to the Z. The column (R ¹³ ) _x represents the substituent attached to the G ring, as shown in Figure A above. (R ¹³ ) A dash "-" in the _x column indicates that the R ¹³ substituent is absent and the remaining valences on the G ring are occupied by hydrogen atoms. J is J-1, L is _CH2 and Z is a direct bond. J is J-1, L is _CH2 and Z is a direct bond. G (R ¹³ ) _x G (R ¹³ ) _x G-1 (4) – G-12 (1) – G-1 (4) 2-Me G-12 (1) 4-Me G-1 (4) 2-Et G-12 (1) 4-Et G-1 (4) 2- n -Pr G-12 (1) 4- n -Pr G-1 (4) 2- i -Pr G-12 (1) 4- i -Pr G-1 (4) 2- c -Pr G-12 (1) 4- c -Pr G-1 (4) 2- n -Bu G-12 (1) 4- n -Bu G-1 (4) 2- i -Bu G-12 (1) 4- i -Bu G-1 (4) 2- t -Bu G-12 (1) 4- t -Bu G-1 (4) 2-F G-12 (1) 4-F G-1 (4) 2-Cl G-12 (1) 4-Cl G-1 (4) 2-Br G-12 (1) 4-Br G-1 (4) 2- _CF3 G-12 (1) 4-CF ₃ G-1 (4) 2-HO G-12 (1) 4-HO G-1 (4) 2-N≡C G-12 (1) 4-N≡C G-1 (4) 2-N≡CCH ₂ G-12 (1) 4-N≡CCH ₂ G-1 (4) 2-(MeO) G-12 (1) 4-(MeO) G-1 (4) 2-(MeOCH ₂ ) G-12 (1) 4-(MeOCH ₂ ) G-1 (4) 2-(EtOCH ₂ ) G-12 (1) 4-(EtOCH ₂ ) G-1 (4) 2-(CH(=O)) G-12 (1) 4-(CH(=O)) G-1 (4) 2-(HOC(=O)) G-12 (1) 4-(HOC(=O)) G-1 (4) 2-(MeOC(=O)) G-12 (1) 4-(MeOC(=O)) G-1 (4) 2-(EtOC(=O)) G-12 (1) 4-(EtOC(=O)) G-1 (4) 2-( i -PrOC(=O)) G-12 (1) 4-( i -PrOC(=O)) G-1 (4) 2-( n -PrOC(=O)) G-12 (1) 4-( n -PrOC(=O)) G-1 (4) 2-(BuOC(=O)) G-12 (1) 4-(BuOC(=O)) G-1 (4) 2-( i -BuOC(=O)) G-12 (1) 4-( i -BuOC(=O)) G-1 (4) 2-( t -BuOC(=O)) G-12 (1) 4-( t -BuOC(=O)) G-1 (4) 2-(CF ₃ CH ₂ OC(=O) G-12 (1) 4-(CF ₃ CH ₂ OC(=O) G-1 (4) 2-(CH ₂ =CHOC(=O)) G-12 (1) 4-(CH ₂ =CHOC(=O)) G-1 (4) 2-(CH ₂ =CHCH ₂ OC(=O)) G-12 (1) 4-(CH ₂ =CHCH ₂ OC(=O)) G-1 (4) 2-(CH ₂ =CBrCH ₂ OC(=O)) G-12 (1) 4-(CH ₂ =CBrCH ₂ OC(=O)) G-1 (4) 2-(CH ₂ =CHCF ₂ OC(=O)) G-12 (1) 4-(CH ₂ =CHCF ₂ OC(=O)) G-1 (4) 2-(Me ₂ C=CHCH ₂ OC(=O)) G-12 (1) 4-(Me ₂ C=CHCH ₂ OC(=O)) G-1 (4) 2-(CH ₂ =C(Me)CH ₂ OC(=O)) G-12 (1) 4-(CH ₂ =C(Me)CH ₂ OC(=O)) G-1 (4) 2-(CH≡CCH ₂ OC(=O)) G-12 (1) 4-(CH≡CCH ₂ OC(=O)) G-1 (4) 2-(N≡CCH ₂ OC(=O)) G-12 (1) 4-(N≡CCH ₂ OC(=O)) G-1 (4) 2-(MeNHC(=O)) G-12 (1) 4-(MeNHC(=O)) G-1 (4) 2-(Me ₂ NC(=O)) G-12 (1) 4-(Me ₂ NC(=O)) G-1 (4) 2-(MeNHC(=O)) G-12 (1) 4-(MeNHC(=O)) G-1 (4) 2-(EtNHC(=O)) G-12 (1) 4-(EtNHC(=O)) G-1 (4) 2-(PrNHC(=O)) G-12 (1) 4-(PrNHC(=O)) G-1 (4) 2-( i -PrNHC(=O)) G-12 (1) 4-( i -PrNHC(=O)) G-1 (4) 2-(BuNHC(=O)) G-12 (1) 4-(BuNHC(=O)) G-1 (4) 2-( t -BuNHC(=O)) G-12 (1) 4-( t -BuNHC(=O)) G-1 (4) 2-( i -BuNHC(=O)) G-12 (1) 4-( i -BuNHC(=O)) G-1 (4) 2-(CF ₃ CH ₂ NHC(=O)) G-12 (1) 4-(CF ₃ CH ₂ NHC(=O)) G-1 (4) 2-( c -PrCH ₂ NHC(=O)) G-12 (1) 4-( c -PrCH ₂ NHC(=O)) G-1 (4) 2-(MeOCH ₂ NHC(=O)) G-12 (1) 4-(MeOCH ₂ NHC(=O)) G-1 (4) 2-(MeOCH ₂ CH ₂ NHC(=O)) G-12 (1) 4-(MeOCH ₂ CH ₂ NHC(=O)) G-1 (4) 2-(CH ₂ =CHCH ₂ NHC(=O)) G-12 (1) 4-(CH ₂ =CHCH ₂ NHC(=O)) G-1 (4) 2-(N≡CCH ₂ NHC(=O)) G-12 (1) 4-(N≡CCH ₂ NHC(=O)) G-1 (4) 2-(OH-N=CH) G-12 (1) 4-(OH-N=CH) G-1 (4) 2-(Me ₂ NN=CH) G-12 (1) 4-(Me ₂ NN=CH) G-1 (4) 2-(MeOC(=O)NHN=CH) G-12 (1) 4-(MeOC(=O)NHN=CH) G-1 (4) 2-(OHC(=O)CH ₂ ON=CH) G-12 (1) 4-(OHC(=O)CH ₂ ON=CH) G-1 (2) – G-12 (1) 5-Me, 3-(EtOC(=O)) G-1 (2) 4-Me G-12 (1) 3-Me G-1 (2) 4-Et G-12 (1) 3-Et G-1 (2) 4- n -Pr G-12 (1) 3- n -Pr G-1 (2) 4- i -Pr G-12 (1) 3- i -Pr G-1 (2) 4- c -Pr G-12 (1) 3- c -Pr G-1 (2) 4- n -Bu G-12 (1) 3- n -Bu G-1 (2) 4- i -Bu G-12 (1) 3- i -Bu G-1 (2) 4- t -Bu G-12 (1) 3- t -Bu G-1 (2) 4-F G-12 (1) 3-F G-1 (2) 4-Cl G-12 (1) 3-Cl G-1 (2) 4-Br G-12 (1) 3-Br G-1 (2) 4-CF ₃ G-12 (1) 3- _CF3 G-1 (2) 4-HO G-12 (1) 3-HO G-1 (2) 4-N≡C G-12 (1) 3-N≡C G-1 (2) 4-N≡CCH ₂ G-12 (1) 3-N≡CCH ₂ G-1 (2) 4-(MeO) G-12 (1) 3-(MeO) G-1 (2) 4-(MeOCH ₂ ) G-12 (1) 3-(MeOCH ₂ ) G-1 (2) 4-(EtOCH ₂ ) G-12 (1) 3-(EtOCH ₂ ) G-1 (2) 4-(CH(=O)) G-12 (1) 3-(CH(=O)) G-1 (2) 4-(HOC(=O)) G-12 (1) 3-(HOC(=O)) G-1 (2) 4-(MeOC(=O)) G-12 (1) 3-(MeOC(=O)) G-1 (2) 4-(EtOC(=O)) G-12 (1) 3-(EtOC(=O)) G-1 (2) 4-( i -PrOC(=O)) G-12 (1) 3-( i -PrOC(=O)) G-1 (2) 4-( n -PrOC(=O)) G-12 (1) 3-( n -PrOC(=O)) G-1 (2) 4-(BuOC(=O)) G-12 (1) 3-(BuOC(=O)) G-1 (2) 4-( i -BuOC(=O)) G-12 (1) 3-( i -BuOC(=O)) G-1 (2) 4-( t -BuOC(=O)) G-12 (1) 3-( t -BuOC(=O)) G-1 (2) 4-(CF ₃ CH ₂ OC(=O) G-12 (1) 3-(CF ₃ CH ₂ OC(=O) G-1 (2) 4-(CH ₂ =CHOC(=O)) G-12 (1) 3-(CH ₂ =CHOC(=O)) G-1 (2) 4-(CH ₂ =CHCH ₂ OC(=O)) G-12 (1) 3-(CH ₂ =CHCH ₂ OC(=O)) G-1 (2) 4-(CH ₂ =CBrCH ₂ OC(=O)) G-12 (1) 3-(CH ₂ =CBrCH ₂ OC(=O)) G-1 (2) 4-(CH ₂ =CHCF ₂ OC(=O)) G-12 (1) 3-(CH ₂ =CHCF ₂ OC(=O)) G-1 (2) 4-(Me ₂ C=CHCH ₂ OC(=O)) G-12 (1) 3-(Me ₂ C=CHCH ₂ OC(=O)) G-1 (2) 4-(CH ₂ =C(Me)CH ₂ OC(=O)) G-12 (1) 3-(CH ₂ =C(Me)CH ₂ OC(=O)) G-1 (2) 4-(CH≡CCH ₂ OC(=O)) G-12 (1) 3-(CH≡CCH ₂ OC(=O)) G-1 (2) 4-(N≡CCH ₂ OC(=O)) G-12 (1) 3-(N≡CCH ₂ OC(=O)) G-1 (2) 4-(MeNHC(=O)) G-12 (1) 3-(MeNHC(=O)) G-1 (2) 4-(Me ₂ NC(=O)) G-12 (1) 3-(Me ₂ NC(=O)) G-1 (2) 4-(MeNHC(=O)) G-12 (1) 3-(MeNHC(=O)) G-1 (2) 4-(EtNHC(=O)) G-12 (1) 3-(EtNHC(=O)) G-1 (2) 4-(PrNHC(=O)) G-12 (1) 3-(PrNHC(=O)) G-1 (2) 4-( i -PrNHC(=O)) G-12 (1) 3-( i -PrNHC(=O)) G-1 (2) 4-(BuNHC(=O)) G-12 (1) 3-(BuNHC(=O)) G-1 (2) 4-( t -BuNHC(=O)) G-12 (1) 3-( t -BuNHC(=O)) G-1 (2) 4-( i -BuNHC(=O)) G-12 (1) 3-( i -BuNHC(=O)) G-1 (2) 4-(CF ₃ CH ₂ NHC(=O)) G-12 (1) 3-(CF ₃ CH ₂ NHC(=O)) G-1 (2) 4-( c -PrCH ₂ NHC(=O)) G-12 (1) 3-( c -PrCH ₂ NHC(=O)) G-1 (2) 4-(MeOCH ₂ NHC(=O)) G-12 (1) 3-(MeOCH ₂ NHC(=O)) G-1 (2) 4-(MeOCH ₂ CH ₂ NHC(=O)) G-12 (1) 3-(MeOCH ₂ CH ₂ NHC(=O)) G-1 (2) 4-(CH ₂ =CHCH ₂ NHC(=O)) G-12 (1) 3-(CH ₂ =CHCH ₂ NHC(=O)) G-1 (2) 4-(N≡CCH ₂ NHC(=O)) G-12 (1) 3-(N≡CCH ₂ NHC(=O)) G-1 (2) 4-(OH-N=CH) G-12 (1) 3-(OH-N=CH) G-1 (2) 4-(Me ₂ NN=CH) G-12 (1) 3-(Me ₂ NN=CH) G-1 (2) 4-(MeOC(=O)NHN=CH) G-12 (1) 3-(MeOC(=O)NHN=CH) G-1 (2) 4-(OHC(=O)CH ₂ ON=CH) G-12 (1) 3-(OHC(=O)CH ₂ ON=CH) G-3 (1) – G-13 (1) – G-3 (1) 4-Me G-13 (1) 5-Me G-3 (1) 4-Et G-13 (1) 5-Et G-3 (1) 4- n -Pr G-13 (1) 5- n -Pr G-3 (1) 4- i -Pr G-13 (1) 5- i -Pr G-3 (1) 4- c -Pr G-13 (1) 5- c -Pr G-3 (1) 4- n -Bu G-13 (1) 5- n -Bu G-3 (1) 4- i -Bu G-13 (1) 5- i -Bu G-3 (1) 4- t -Bu G-13 (1) 5- t -Bu G-3 (1) 4-F G-13 (1) 5-F G-3 (1) 4-Cl G-13 (1) 5-Cl G-3 (1) 4-Br G-13 (1) 5-Br G-3 (1) 4-CF ₃ G-13 (1) 5- _CF3 G-3 (1) 4-HO G-13 (1) 5-HO G-3 (1) 4-N≡C G-13 (1) 5-N≡C G-3 (1) 4-N≡CCH ₂ G-13 (1) 5-N≡CCH ₂ G-3 (1) 4-(MeO) G-13 (1) 5-(MeO) G-3 (1) 4-(MeOCH ₂ ) G-13 (1) 5-(MeOCH ₂ ) G-3 (1) 4-(EtOCH ₂ ) G-13 (1) 5-(EtOCH ₂ ) G-3 (1) 4-(CH(=O)) G-13 (1) 5-(CH(=O)) G-3 (1) 4-(HOC(=O)) G-13 (1) 5-(HOC(=O)) G-3 (1) 4-(MeOC(=O)) G-13 (1) 5-(MeOC(=O)) G-3 (1) 4-(EtOC(=O)) G-13 (1) 5-(EtOC(=O)) G-3 (1) 4-( i -PrOC(=O)) G-13 (1) 5-( i -PrOC(=O)) G-3 (1) 4-( n -PrOC(=O)) G-13 (1) 5-( n -PrOC(=O)) G-3 (1) 4-(BuOC(=O)) G-13 (1) 5-(BuOC(=O)) G-3 (1) 4-( i -BuOC(=O)) G-13 (1) 5-( i -BuOC(=O)) G-3 (1) 4-( t -BuOC(=O)) G-13 (1) 5-( t -BuOC(=O)) G-3 (1) 4-(CF ₃ CH ₂ OC(=O) G-13 (1) 5-(CF ₃ CH ₂ OC(=O) G-3 (1) 4-(CH ₂ =CHOC(=O)) G-13 (1) 5-(CH ₂ =CHOC(=O)) G-3 (1) 4-(CH ₂ =CHCH ₂ OC(=O)) G-13 (1) 5-(CH ₂ =CHCH ₂ OC(=O)) G-3 (1) 4-(CH ₂ =CBrCH ₂ OC(=O)) G-13 (1) 5-(CH ₂ =CBrCH ₂ OC(=O)) G-3 (1) 4-(CH ₂ =CHCF ₂ OC(=O)) G-13 (1) 5-(CH ₂ =CHCF ₂ OC(=O)) G-3 (1) 4-(Me ₂ C=CHCH ₂ OC(=O)) G-13 (1) 5-(Me ₂ C=CHCH ₂ OC(=O)) G-3 (1) 4-(CH ₂ =C(Me)CH ₂ OC(=O)) G-13 (1) 5-(CH ₂ =C(Me)CH ₂ OC(=O)) G-3 (1) 4-(CH≡CCH ₂ OC(=O)) G-13 (1) 5-(CH≡CCH ₂ OC(=O)) G-3 (1) 4-(N≡CCH ₂ OC(=O)) G-13 (1) 5-(N≡CCH ₂ OC(=O)) G-3 (1) 4-(MeNHC(=O)) G-13 (1) 5-(MeNHC(=O)) G-3 (1) 4-(Me ₂ NC(=O)) G-13 (1) 5-(Me ₂ NC(=O)) G-3 (1) 4-(MeNHC(=O)) G-13 (1) 5-(MeNHC(=O)) G-3 (1) 4-(EtNHC(=O)) G-13 (1) 5-(EtNHC(=O)) G-3 (1) 4-(PrNHC(=O)) G-13 (1) 5-(PrNHC(=O)) G-3 (1) 4-( i -PrNHC(=O)) G-13 (1) 5-( i -PrNHC(=O)) G-3 (1) 4-(BuNHC(=O)) G-13 (1) 5-(BuNHC(=O)) G-3 (1) 4-( t -BuNHC(=O)) G-13 (1) 5-( t -BuNHC(=O)) G-3 (1) 4-( i -BuNHC(=O)) G-13 (1) 5-( i -BuNHC(=O)) G-3 (1) 4-(CF ₃ CH ₂ NHC(=O)) G-13 (1) 5-(CF ₃ CH ₂ NHC(=O)) G-3 (1) 4-( c -PrCH ₂ NHC(=O)) G-13 (1) 5-( c -PrCH ₂ NHC(=O)) G-3 (1) 4-(MeOCH ₂ NHC(=O)) G-13 (1) 5-(MeOCH ₂ NHC(=O)) G-3 (1) 4-(MeOCH ₂ CH ₂ NHC(=O)) G-13 (1) 5-(MeOCH ₂ CH ₂ NHC(=O)) G-3 (1) 4-(CH ₂ =CHCH ₂ NHC(=O)) G-13 (1) 5-(CH ₂ =CHCH ₂ NHC(=O)) G-3 (1) 4-(N≡CCH ₂ NHC(=O)) G-13 (1) 5-(N≡CCH ₂ NHC(=O)) G-3 (1) 4-(OH-N=CH) G-13 (1) 5-(OH-N=CH) G-3 (1) 4-(Me ₂ NN=CH) G-13 (1) 5-(Me ₂ NN=CH) G-3 (1) 4-(MeOC(=O)NHN=CH) G-13 (1) 5-(MeOC(=O)NHN=CH) G-3 (1) 4-(OHC(=O)CH ₂ ON=CH) G-13 (1) 5-(OHC(=O)CH ₂ ON=CH) G-9 (1) – G-17 (1) – G-9 (1) 3-Me G-17 (1) 4-Me G-9 (1) 3-Et G-17 (1) 4-Et G-9 (1) 3- n -Pr G-17 (1) 4- n -Pr G-9 (1) 3- i -Pr G-17 (1) 4- i -Pr G-9 (1) 3- c -Pr G-17 (1) 4- c -Pr G-9 (1) 3- n -Bu G-17 (1) 4- n -Bu G-9 (1) 3- i -Bu G-17 (1) 4- i -Bu G-9 (1) 3- t -Bu G-17 (1) 4- t -Bu G-9 (1) 3-F G-17 (1) 4-F G-9 (1) 3-Cl G-17 (1) 4-Cl G-9 (1) 3-Br G-17 (1) 4-Br G-9 (1) 3- _CF3 G-17 (1) 4-CF ₃ G-9 (1) 3-HO G-17 (1) 4-HO G-9 (1) 3-N≡C G-17 (1) 4-N≡C G-9 (1) 3-N≡CCH ₂ G-17 (1) 4-N≡CCH ₂ G-9 (1) 3-(MeO) G-17 (1) 4-(MeO) G-9 (1) 3-(MeOCH ₂ ) G-17 (1) 4-(MeOCH ₂ ) G-9 (1) 3-(EtOCH ₂ ) G-17 (1) 4-(EtOCH ₂ ) G-9 (1) 3-(CH(=O)) G-17 (1) 4-(CH(=O)) G-9 (1) 3-(HOC(=O)) G-17 (1) 4-(HOC(=O)) G-9 (1) 3-(MeOC(=O)) G-17 (1) 4-(MeOC(=O)) G-9 (1) 3-(EtOC(=O)) G-17 (1) 4-(EtOC(=O)) G-9 (1) 3-( i -PrOC(=O)) G-17 (1) 4-( i -PrOC(=O)) G-9 (1) 3-( n -PrOC(=O)) G-17 (1) 4-( n -PrOC(=O)) G-9 (1) 3-(BuOC(=O)) G-17 (1) 4-(BuOC(=O)) G-9 (1) 3-( i -BuOC(=O)) G-17 (1) 4-( i -BuOC(=O)) G-9 (1) 3-( t -BuOC(=O)) G-17 (1) 4-( t -BuOC(=O)) G-9 (1) 3-(CF ₃ CH ₂ OC(=O) G-17 (1) 4-(CF ₃ CH ₂ OC(=O) G-9 (1) 3-(CH ₂ =CHOC(=O)) G-17 (1) 4-(CH ₂ =CHOC(=O)) G-9 (1) 3-(CH ₂ =CHCH ₂ OC(=O)) G-17 (1) 4-(CH ₂ =CHCH ₂ OC(=O)) G-9 (1) 3-(CH ₂ =CBrCH ₂ OC(=O)) G-17 (1) 4-(CH ₂ =CBrCH ₂ OC(=O)) G-9 (1) 3-(CH ₂ =CHCF ₂ OC(=O)) G-17 (1) 4-(CH ₂ =CHCF ₂ OC(=O)) G-9 (1) 3-(Me ₂ C=CHCH ₂ OC(=O)) G-17 (1) 4-(Me ₂ C=CHCH ₂ OC(=O)) G-9 (1) 3-(CH ₂ =C(Me)CH ₂ OC(=O)) G-17 (1) 4-(CH ₂ =C(Me)CH ₂ OC(=O)) G-9 (1) 3-(CH≡CCH ₂ OC(=O)) G-17 (1) 4-(CH≡CCH ₂ OC(=O)) G-9 (1) 3-(N≡CCH ₂ OC(=O)) G-17 (1) 4-(N≡CCH ₂ OC(=O)) G-9 (1) 3-(MeNHC(=O)) G-17 (1) 4-(MeNHC(=O)) G-9 (1) 3-(Me ₂ NC(=O)) G-17 (1) 4-(Me ₂ NC(=O)) G-9 (1) 3-(MeNHC(=O)) G-17 (1) 4-(MeNHC(=O)) G-9 (1) 3-(EtNHC(=O)) G-17 (1) 4-(EtNHC(=O)) G-9 (1) 3-(PrNHC(=O)) G-17 (1) 4-(PrNHC(=O)) G-9 (1) 3-( i -PrNHC(=O)) G-17 (1) 4-( i -PrNHC(=O)) G-9 (1) 3-(BuNHC(=O)) G-17 (1) 4-(BuNHC(=O)) G-9 (1) 3-( t -BuNHC(=O)) G-17 (1) 4-( t -BuNHC(=O)) G-9 (1) 3-( i -BuNHC(=O)) G-17 (1) 4-( i -BuNHC(=O)) G-9 (1) 3-(CF ₃ CH ₂ NHC(=O)) G-17 (1) 4-(CF ₃ CH ₂ NHC(=O)) G-9 (1) 3-( c -PrCH ₂ NHC(=O)) G-17 (1) 4-( c -PrCH ₂ NHC(=O)) G-9 (1) 3-(MeOCH ₂ NHC(=O)) G-17 (1) 4-(MeOCH ₂ NHC(=O)) G-9 (1) 3-(MeOCH ₂ CH ₂ NHC(=O)) G-17 (1) 4-(MeOCH ₂ CH ₂ NHC(=O)) G-9 (1) 3-(CH ₂ =CHCH ₂ NHC(=O)) G-17 (1) 4-(CH ₂ =CHCH ₂ NHC(=O)) G-9 (1) 3-(N≡CCH ₂ NHC(=O)) G-17 (1) 4-(N≡CCH ₂ NHC(=O)) G-9 (1) 3-(OH-N=CH) G-17 (1) 4-(OH-N=CH) G-9 (1) 3-(Me ₂ NN=CH) G-17 (1) 4-(Me ₂ NN=CH) G-9 (1) 3-(MeOC(=O)NHN=CH) G-17 (1) 4-(MeOC(=O)NHN=CH) G-9 (1) 3-(OHC(=O)CH ₂ ON=CH) G-17 (1) 4-(OHC(=O)CH ₂ ON=CH)

The present invention also includes Tables 1B through 48B, each of which is identical to Table 2 above (i.e., "J is J-1 , L is CH ₂ , and Z is a direct bond") identically constructed. surface row header surface row header 1B J is J _{- 1} , L is CH2CH2 and Z is a direct bond. 25B J is J-10, L is _CH2 and Z is a direct bond. 2B J is J-1, L is _CH2 (Me) and Z is a direct bond. 26B J is J _{- 10} , L is CH2CH2 and Z is a direct bond. 3B J is J-1, L is (CH ₂ ) ₃ and Z is a direct bond. 27B J is J-10, L is _CH2 (Me) and Z is a direct bond. 4B J is J-1, L is _CH2 and Z is O. 28B J is J-10, L is (CH ₂ ) ₃ and Z is a direct bond. 5B J is J-2, L is _CH2 and Z is a direct bond. 29B J is J-10, L is _CH2 and Z is O. 6B J is J _{- 2} , L is CH2CH2 and Z is a direct bond. 30B J is J-14, L is _CH2 and Z is a direct bond. 7B J is J-2, L is _CH2 (Me) and Z is a direct bond. 31B J is J _{- 14} , L is CH2CH2 and Z is a direct bond. 8B J is J-2, L is (CH ₂ ) ₃ and Z is a direct bond. 32B J is J-14, L is _CH2 (Me) and Z is a direct bond. 9B J is J-2, L is _CH2 and Z is O. 33B J is J-14, L is (CH ₂ ) ₃ and Z is a direct bond. 10B J is J-6, L is _CH2 and Z is a direct bond. 34B J is J-14, L is _CH2 and Z is O. 11B J is J _{- 6} , L is CH2CH2 and Z is a direct bond. 35B J is J-3, L is _CH2 and Z is a direct bond. 12B J is J-6, L is _CH2 (Me) and Z is a direct bond. 36B J is J _{- 3} , L is CH2CH2 and Z is a direct bond. 13B J is J-6, L is (CH ₂ ) ₃ and Z is a direct bond. 37B J is J-3, L is _CH2 (Me) and Z is a direct bond. 14B J is J-6, L is _CH2 and Z is O. 38B J is J-3, L is (CH ₂ ) ₃ and Z is a direct bond. 15B J is J-7, L is _CH2 and Z is a direct bond. 39B J is J-3, L is _CH2 and Z is O. 16B J is J _{- 7} , L is CH2CH2 and Z is a direct bond. 40B J is J-4, L is _CH2 and Z is a direct bond. 17B J is J-7, L is _CH2 (Me) and Z is a direct bond. 41B J is J _{- 4} , L is CH2CH2 and Z is a direct bond. 18B J is J-7, L is (CH ₂ ) ₃ and Z is a direct bond. 42B J is J-4, L is _CH2 (Me) and Z is a direct bond. 19B J is J-7, L is _CH2 and Z is O. 43B J is J-4, L is (CH ₂ ) ₃ and Z is a direct bond. 20B J is J-8, L is _CH2 and Z is a direct bond. 44B J is J-4, L is _CH2 and Z is O. 21B J is J _{- 8} , L is CH2CH2 and Z is a direct bond. 45B J is J-5, L is _CH2 and Z is a direct bond. 22B J is J-8, L is _CH2 (Me) and Z is a direct bond. 46B J is J _{- 5} , L is CH2CH2 and Z is a direct bond. 23B J is J-8, L is (CH ₂ ) ₃ and Z is a direct bond. 47B J is J-5, L is _CH2 (Me) and Z is a direct bond. 24B J is J-8, L is _CH2 and Z is O. 48B J is J-5, L is (CH ₂ ) ₃ and Z is a direct bond. Recipe/Application

Compounds of formula 1 of the present invention (including N -oxides and salts thereof), or mixtures (ie, compositions) comprising such compounds and at least one additional fungicidal compound as described in the Summary of the Invention, will generally be used as A fungicidally active ingredient in a composition, ie, a formulation, wherein at least one additional component is selected from the group consisting of a surfactant, a solid diluent, and a liquid diluent as a carrier. The formulation or composition ingredients are selected to be consistent with the physical properties of the active ingredient, the mode of application, and environmental factors, such as soil type, humidity, and temperature.

Component (a) (ie, at least one compound of formula 1, its N -oxide, or salts thereof) and component (b) (eg, selected from (b1) to (b54) above and salts thereof) mixtures and/or one or more other biologically active compounds or agents (i.e., insecticides, other fungicides, nematicides, acaricides, herbicides, and other biological agents) can be formulated in a variety of ways, including: ( i) Component (a), Component (b) and/or one or more other biologically active compounds or agents may be formulated separately and administered separately or simultaneously in appropriate weight ratios, for example as a tank mix; or (ii) Component (a), component (b) and/or one or more other biologically active compounds or agents may be formulated together in appropriate weight ratios.

Useful formulations include liquid as well as solid compositions. Liquid compositions include solutions (including emulsifiable concentrates), suspensions, emulsions (including microemulsions, oil-in-water emulsions, flowable concentrates, and/or suspoemulsions), etc., which can optionally be thickened into gels. Typical types of aqueous liquid compositions are soluble concentrates, suspension concentrates, capsule suspensions, concentrated emulsions, microemulsions, oil-in-water emulsions, flowable concentrates, and suspoemulsions. Typical types of non-aqueous liquid compositions are emulsifiable concentrates, microemulsifiable concentrates, dispersible concentrates, and oil dispersions.

Typical types of solid compositions are water-dispersible ("wettable") or water-soluble powders, powders, granules, pellets, pellets, pellets, tablets, filled films (including seed coatings), and the like. Films and coatings formed from film-forming solutions or flowable suspensions are particularly useful for seed treatment. The active ingredient may be (micro)encapsulated and further formed into a suspension or solid formulation; or the entire formulation of the active ingredient may be encapsulated (or "overcoated"). Encapsulation can control or delay the release of the active ingredient. Emulsifiable granules combine the advantages of emulsifiable concentrate formulations as well as dry granule formulations. High strength compositions are primarily used as intermediates for further formulation.

Of note are composition embodiments wherein particles of a solid composition comprising a compound of formula 1 (or an N -oxide or salt thereof) are mixed with particles of a solid composition comprising component (b). These mixtures can be further mixed with granules containing other agricultural protectants. Alternatively, two or more agricultural protective agents (eg, a compound of component (a) (Formula 1), a compound of component (b), an agricultural protective agent other than component (a) or (b)) may be combined The solid ingredients combined into one set of granules are then mixed with one or more sets of solid composition granules comprising one or more other agricultural protectants. These particle mixtures may be in accordance with the general particle mixtures disclosed in PCT Patent Publication No. WO 94/24861, or more preferably, in accordance with the teachings of US Patent No. 6,022,552, as homogeneous particle mixtures.

Spray formulations are usually extended in a suitable medium prior to spraying. Such liquid as well as solid preparations are formulated for ease of dilution in a spray medium, usually water, but occasionally another suitable medium such as aromatic or paraffinic hydrocarbons or vegetable oils. Spraying rates can range from about a thousand to several thousand liters per hectare, but are more typically about ten to several hundred liters per hectare. Sprayable formulations can be tank mixed with water or other suitable medium for foliar treatment by aerial or ground application, or for application to the growth medium of plants. Liquid as well as dry formulations can be metered directly into drip irrigation systems or into furrows during planting. Liquid as well as solid formulations can be applied to the seeds of crops and other desired plants as seed treatments prior to planting to protect developing roots and other subterranean plant parts and/or leaves through systemic absorption.

Formulations generally contain effective amounts of active ingredient, diluent, and surfactant within the following approximate ranges, totaling 100% by weight. weight percentage Active ingredient thinner Surfactant Water-dispersible and water-soluble granules, tablets and powders 0.001–90 0–99.999 0–15 Oil dispersions, suspensions, emulsions, solutions (including emulsifiable concentrates) 1–50 40–99 0–50 dust 1–25 70–99 0–5 Granules and Pills 0.001–95 5–99.999 0–15 high strength composition 90–99 0–10 0–2

Solid diluents include, for example, clays such as bentonite, montmorillonite, attapulgite and kaolin, gypsum, cellulose, titanium dioxide, zinc oxide, starch, dextrin, sugars (eg, lactose, sucrose), silica, Talc, mica, diatomaceous earth, urea, calcium carbonate, sodium carbonate and sodium bicarbonate and sodium sulfate. Typical solid diluents are described in Watkins et al., Handbook of Insecticide Dust Diluents , and Carriers , 2nd Ed., Dorland Books, Caldwell, NJ.

Liquid diluents include, for example, water, N,N -dimethylalkylamide (eg, N,N -dimethylformamide), limonene, dimethylsulfoxide, N -alkylpyrrolidone (eg, N,N-dimethylformamide) , N -methylpyrrolidone), alkyl phosphates (eg, triethyl phosphate), ethylene glycol, triethylene glycol, propylene glycol, dipropylene glycol, polypropylene glycol, propylene carbonate, butylene carbonate, paraffins (eg, white mineral oil, n-paraffins, isoparaffins), alkylbenzenes, alkylnaphthalenes, glycerol, triacetin, sorbitol, aromatic hydrocarbons, alkylnaphthalenes, ketones, such as cyclic Hexanone, heptanone, isophorone and 4-hydroxy-4-methyl-2-pentanone, acetates such as isoamyl acetate, hexyl acetate, heptyl acetate, octyl acetate, nonyl acetate, Tridecyl acetate, and esters such as isobornyl acetate, such as alkylated lactates, dibasic esters, alkyl and aryl benzoates, and gamma-butyrolactone, and can be linear, branched, saturated or unsaturated alcohol methanol, ethanol, n-propanol, isopropanol, n-butanol, isobutanol, n-hexanol, 2-ethylhexanol, n-octanol, decanol, isodecanol, isooctadecanol Alcohol, cetyl alcohol, lauryl alcohol, tridecyl alcohol, oleyl alcohol, cyclohexanol, tetrahydrofurfuryl alcohol, diacetone alcohol, cresol and benzyl alcohol. Liquid diluents also include glycerides of saturated and unsaturated fatty acids (typically _C6 - _C22 ), such as vegetable seed and fruit oils (eg, olive oil, castor oil, linseed oil, sesame oil, corn oil (maize oil) , peanut oil, sunflower oil, grapeseed oil, safflower oil, cottonseed oil, soybean oil, rapeseed oil, coconut oil and palm oil, etc.), fats of animal origin (for example, tallow, lard, lard, cod liver oil, fish oil) and its mixture. Liquid diluents also include alkylated fatty acids (eg, methylated, ethylated, butylated), which fatty acids can be obtained by hydrolysis of glycerides from vegetable as well as animal sources, and can be purified by distillation. Typical liquid diluents are described in Marsden, Solvents Guide , 2nd Ed., Interscience Press, New York, 1950.

The solid and liquid compositions of the present invention generally contain one or more surfactants. When added to a liquid, surfactants (also known as "surfactants") typically alter the surface tension of the liquid, usually lowering the surface tension. Depending on the nature of the hydrophilic and lipophilic groups in the surfactant molecule, surfactants can act as wetting agents, dispersing agents, emulsifiers or defoamers.

Surfactants can be classified as nonionic, anionic or cationic. Nonionic surfactants useful in the compositions of the present invention include, but are not limited to, alcohol alkoxylates, such as those based on natural as well as synthetic alcohols (which may be branched or linear) and composed of alcohols and ethylene oxide, Preparation of propylene oxide, butylene oxide or mixtures thereof; amine ethoxylates, alkanolamides and ethoxylated alkanolamides; alkoxylated triglycerides such as ethoxylated soybean oil , castor oil, and rapeseed oil; alkylphenol alkoxylates such as octylphenol ethoxylate, nonylphenol ethoxylate, dinonylphenol ethoxylate, and dodecylphenol ethoxylate compounds (prepared from phenol and ethylene oxide, propylene oxide, butylene oxide, or mixtures thereof); block polymers and reactive block polymers prepared from ethylene oxide or propylene oxide, in which terminal block Ethoxylated fatty acids; ethoxylated fatty esters and oils; ethoxylated methyl esters; ethoxylated tristyryl phenols (including those made from ethylene oxide, propylene oxide, those prepared from butylene oxide or mixtures thereof); fatty acid esters, glycerides, lanolin-based derivatives, polyethoxylated esters, such as polyethoxylated sorbitan fatty acid esters, polyethoxylated Sorbitan fatty acid esters and polyethoxylated glycerol fatty acid esters; other sorbitan derivatives, for example, sorbitan esters; polymeric surfactants, such as random copolymers, block copolymers , alkyd peg (polyethylene glycol) resins, graft or comb polymers, and star polymers; polyethylene glycols (pegs); polyethylene glycol fatty acid esters; silicon-based surfactants; and sugar derivatives compounds, such as sucrose esters, alkyl polyglycosides, alkyl polysaccharides; and glucoamides, such as mixtures of octyl- N -methyl glucosamine and decyl- N -methyl glucosamine (e.g., Products are available from Clariant under the name Synergen® GA).

Useful anionic surfactants include, but are not limited to: alkylarylsulfonic acids and their salts; carboxylated alcohols or alkylphenol ethoxylates; diphenylsulfonate derivatives; lignin and lignin derivatives sulfonates such as lignosulfonates; maleic or succinic acid or anhydrides thereof; olefin sulfonates; phosphate esters, for example, phosphate esters of alcohol alkoxylates, phosphate esters of alkylphenol alkoxylates and Phosphate esters of styrylphenol ethoxylates; protein-based surfactants; sarcosine derivatives; styrylphenol ether sulfates; sulfates and sulfonates of oils and fatty acids; ethoxylated Sulfates and sulfonates of alkylphenols; sulfates of alcohols; sulfates of ethoxylated alcohols; sulfonates of amines and amides, such as N,N -alkyltaurates sulfonic acid salts of benzocum, alkene, toluene, xylene and dodecyl and tridecylbenzene; condensed naphthalene sulfonates; sulfonates of naphthalene and alkylnaphthalenes; fractionated petroleum sulfonic acids Salts; sulfosuccinates; and sulfosuccinates and derivatives thereof such as dialkyl sulfosuccinate salts.

Useful cationic surfactants include, but are not limited to: amides and ethoxylated amides; amines such as N -alkylpropanediamines, tripropylenetriamines, and dipropylenetetramines, and ethoxylated amines, ethylene Oxylated diamines and propoxylated amines (prepared from amines and ethylene oxide, propylene oxide, butylene oxide or mixtures thereof); amine salts such as amine acetate and diamine salts; quaternary ammonium salts Such as quaternary salts, ethoxylated quaternary salts and bisquaternary salts; and amine oxides such as alkyldimethylamine oxides and bis-(2-hydroxyethyl)-alkylamine oxides.

The compositions of the present invention may also employ mixtures of nonionic and anionic surfactants or mixtures of nonionic and cationic surfactants. Nonionic, anionic, and cationic surfactants and their recommended uses are disclosed in various published references, including McCutcheon's Emulsifiers , and Detergents , annual U.S. and International editions published by McCutcheon's Division, The Manufacturing Confectioner Publishing Company; Sisely and Wood, Encyclopedia of Surface Active Agents , Chemical Publishing Company, New York, 1964; and AS Davidson and B. Milwidsky, Synthetic Detergents , Seventh Edition, John Wiley, and Sons Press, New York, 1987.

The compositions of the present invention may also contain formulation aids and additives known to those skilled in the art as formulation aids (some of which may also act as solid diluents, liquid diluents, or surfactants). The formulation aids and additives control: pH (buffers), foaming during processing (defoamers such as polyorganosiloxanes), settling of active ingredients (suspending agents), viscosity (thixotropic thickeners) , microbial growth in container (antimicrobial), product freezing (antifreeze), color (dye/pigment dispersion), rinse (film former or sticker), evaporation (evaporation blocker), and other formulation attributes. Film formers include, for example, polyvinyl acetate, polyvinyl acetate copolymers, polyvinylpyrrolidone-vinyl acetate copolymers, polyvinyl alcohol, polyvinyl alcohol copolymers, and waxes. Examples of formulation aids and additives include those listed in McCutcheon's Volume 2 : Functional Materials , an annual international and North American edition published by McCutcheon's Division, The Manufacturing Confectioner Publishing Company; and PCT Publication No. WO 03/024222.

The compound of formula 1, as well as any other active ingredients, are generally incorporated into the compositions of the present invention by dissolving the active ingredient in a solvent or by grinding in a liquid or dry diluent. Solutions, including emulsifiable concentrates, can be prepared by simply mixing the ingredients. If the solvent intended for the liquid composition of the emulsifiable concentrate is insoluble in water, an emulsifier is usually added to emulsify the active substance-containing solvent upon dilution with water. Active ingredient slurries with particle sizes up to 2,000 μm can be wet milled using a media mill to obtain particles with an average diameter of less than 3 μm. The aqueous slurry can be made into a finished suspension concentrate (see, eg, US Pat. No. 3,060,084) or further processed by spray drying to form water-dispersible granules. Dry formulations typically require a dry milling process, which yields an average particle size in the range of 2 to 10 μm. Dusts and powders can be prepared by mixing and generally grinding (eg, with a hammer mill or fluid energy pulverizer). Granules and pellets can be prepared by spraying the active substance onto preformed granular carriers or by agglomeration techniques. See Browning, "Agglomeration", Chemical Engineering , December 4, 1967, pp 147-48, Perry's Chemical Engineer's Handbook , 4th Ed., McGraw-Hill Press, New York, 1963, pp 8-57 and later, and WO 91/13546. Pellets can be prepared as described in US Pat. No. 4,172,714. Water-dispersible as well as water-soluble granules can be prepared as taught in US Patent Nos. US 4,144,050, US 3,920,442 and German Patent No. DE 3,246,493. Tablets can be prepared as taught in US Patent Nos. US 5,180,587, US 5,232,701 and US 5,208,030. Films can be prepared as taught in British Patent No. GB 2,095,558 and US Patent No. US 3,299,566.

A specific embodiment of the present invention relates to a method for controlling fungal pathogens, comprising diluting a fungicidal composition of the present invention (a compound of formula 1 or a compound of formula 1 formulated with a surfactant, a solid diluent and a liquid diluent and at least a a formulated mixture of other fungicides), and optionally an adjuvant is added to form a diluted composition, and the fungal pathogen or its environment is contacted with an effective amount of the diluted composition.

Although a spray composition formed by diluting a sufficient concentration of the fungicidal composition of the present invention with water may provide sufficient efficacy against fungal pathogens, separately formulated adjuvant products may also be added to spray tank mixtures. These additional adjuvants are commonly referred to as "spray adjuvants" or "tank mix adjuvants" and include anything that is mixed in a spray tank to improve the performance of the pesticide or change the physical properties of the spray mixture. Adjuvants can be anionic or nonionic surfactants, emulsifiers, petroleum-based crop oils, crop-derived seed oils, acidulants, buffers, thickeners, or defoamers. Adjuvants are used to enhance efficacy (eg, bioavailability, adhesion, penetration, coverage uniformity, and protection persistence), or to minimize or eliminate those associated with incompatibility, foaming, drift, evaporation, volatilization, and degradation spray application problems. For optimum performance, adjuvants are chosen with regard to the properties of the active ingredient, formulation and target (eg crops, pests).

The amount of adjuvant added to the spray mixture is typically in the range of about 0.1% to 2.5% by volume. The adjuvant application rate added to the spray mixture is usually about 1 to 5 liters per hectare. Representative examples of spray adjuvants include: Adigor® (Syngenta Corporation) 47% methylated rapeseed oil in liquid hydrocarbon, Silwet® (Helena Chemical Corporation) polyalkylene oxide modified heptamethyltrisilyl Oxane, and a blend of Assist® (BASF Corporation) 17% surfactant in 83% paraffinic mineral oil.

One method of seed treatment is to spray or dust the seed with a compound of the invention (ie, as a formulated composition) prior to sowing the seed. Compositions formulated for seed treatment typically contain film formers or binders. Thus, the seed coating compositions of the present invention generally comprise a biologically effective amount of a compound of formula 1 and a film former or binder. The seeds can be coated by spraying the flowable suspension concentrate directly into a tumbling bed of seeds and then drying the seeds. Alternatively, other formulation types such as wet powders, solutions, suspoemulsions, emulsifiable concentrates, and aqueous emulsions can be sprayed onto the seeds. This process is particularly useful for applying film coatings on seeds. Various coaters and processes are available to those skilled in the art. Suitable methods include those listed in P. Kosters et al., Seed Treatment : Progress , and Prospects , 1994 BCPC Mongraph No. 57 and the references listed therein.

For further information on formulation techniques, see TS Woods, "The Formulator's Toolbox – Product Forms forRModern Agriculture" in Pesticide Chemistry , and Bioscience , The Food–Environment Challenge, edited by T. Brooks and TR Roberts, Advances at the 9th International Congress on Pesticide Chemistry, Royal Society of Chemistry, Cambridge, 1999, pp. 120-133. See also US Patent Nos. US 3,235,361, Col. 6, line 16 to Col. 7, line 19 and Examples 10-41; US 3,309,192, Col. 5, line 43 to Col. 7, line 62, and Examples 8, 12 , 15, 39, 41, 52, 53, 58, 132, 138-140, 162-164, 166, 167, and 169-182; US Patent No. 2,891,855, col. 3, line 66 to col. 5, line 17 and Examples 1-4; Klingman, WeedControl as aScience , John Wiley, and Sons Corporation, New York, 1961, pp 81-96; Hance et al., WeedControl Handbook , 8th Ed., Blackwell Scientific Press, Oxford, 1989; and Developments in formulation technology , PJB Press, Richmond, UK, 2000.

In the following examples, all percentages are by weight and all formulations were prepared in conventional manner. Active ingredient refers to a compound in Index Table AL disclosed herein. Without further elaboration, it is believed that one skilled in the art can, using the preceding description, utilize the present invention to its fullest. Accordingly, the following examples are to be construed as illustrative only and are not intended to limit the present case in any way. Example A high concentration concentrate Compound 263 98.5% silica aerogel 0.5% Synthetic amorphous fine silica 1.0% Example B Wettable powder Compound 330 65.0% Dodecylphenol polyethylene glycol ether 2.0% Sodium lignosulfonate 4.0% Sodium Aluminosilicate 6.0% Montmorillonite (calcined) 23.0% Example C particles Compound 64 10.0% Particulate (low volatiles, 0.71/0.30 mm; US 25-50 sieve) 90.0% Example D extruded pill Compound 32 25.0% Anhydrous sodium sulfate 10.0% Crude calcium lignosulfonate 5.0% Sodium Alkyl Naphthalene Sulfonate 1.0% Calcium/Magnesium Bentonite 59.0% Example E emulsifiable concentrate Compound 64 10.0% Polyoxyethylene sorbitan caproate 20.0% C ₆ – C ₁₀ fatty acid methyl esters 70.0% Example F microemulsion Compound 331 5.0% Polyvinylpyrrolidone-vinyl acetate copolymer 30.0% Alkyl polyglycoside 30.0% Glycerol monooleate 15.0% water 20.0% Example G seed treatment Compound 297 20.00% Polyvinylpyrrolidone-vinyl acetate copolymer 5.00% Montan acid wax 5.00% calcium lignosulfonate 1.00% Polyoxyethylene/polyoxypropylene block copolymer 1.00% Stearyl alcohol (POE 20) 2.00% polyorganosiloxane 0.20% Colorant red dye 0.05% water 65.75% Example H fertilizer stick Compound 126 2.50% Pyrrolidone-styrene copolymer 4.80% Tristyrylphenyl 16-ethoxylate 2.30% talc 0.80% corn starch 5.00% Slow release fertilizer 36.00% Kaolin 38.00% water 10.60% Embodiment 1 Suspension concentrate Compound 163 35% Butyl polyoxyethylene/polypropylene block copolymer 4.0% Stearic acid/polyethylene glycol copolymer 1.0% Styrene acrylic polymer 1.0% Xanthan Gum 0.1% Propylene Glycol 5.0% Silicon based defoamer 0.1% 1,2-Benzisothiazol-3-one 0.1% water 53.7% Example J lotion in water Compound 71 10.0% Butyl polyoxyethylene/polypropylene block copolymer 4.0% Stearic acid/polyethylene glycol copolymer 1.0% Styrene acrylic polymer 1.0% Xanthan Gum 0.1% Propylene Glycol 5.0% Silicon based defoamer 0.1% 1,2-Benzisothiazol-3-one 0.1% Aromatic Petroleum Based Hydrocarbons 20.0 water 58.7% Example K oil dispersion Compound 229 25% Polyoxyethylene sorbitan hexaoleate 15% Organically modified bentonite 2.5% fatty acid methyl ester 57.5% Example L Suspoemulsion Compound 127 10.0% Imidacloprid 5.0% Butyl polyoxyethylene/polypropylene block copolymer 4.0% Stearic acid/polyethylene glycol copolymer 1.0% Styrene acrylic polymer 1.0% Xanthan Gum 0.1% Propylene Glycol 5.0% Silicon based defoamer 0.1% 1,2-Benzisothiazol-3-one 0.1% Aromatic Petroleum Based Hydrocarbons 20.0% water 53.7%

Water-soluble as well as water-dispersible formulations are typically diluted with water prior to application to form aqueous compositions. Aqueous compositions (eg, spray tank compositions) for direct application to plants or parts thereof typically contain at least about 1 ppm or more (eg, 1 ppm to 100 ppm) of a compound of the present invention.

Seed is typically treated at a rate of about 0.001 g (more typically about 0.1 g) to about 10 g per kilogram of seed (ie, about 0.0001 to 1 wt % seed prior to treatment). Flowable suspensions formulated for seed treatment typically contain from about 0.5 to about 70% active ingredient, about 0.5 to about 30% film-forming binder, about 0.5 to about 20% dispersant, 0 to about 5% Thickener, 0 to about 5% pigment and/or dye, 0 to about 2% antifoam, 0 to about 1% preservative, and 0 to about 75% of a volatile liquid diluent.

The composition of the present invention can be used as a plant disease control agent. Accordingly, the present invention further includes a method for controlling plant diseases caused by fungal phytopathogens, the method comprising applying an effective amount of a compound of the present invention or a compound containing the Fungicide compositions of compounds. The compounds and/or compositions of the present invention provide control of diseases caused by fungal phytopathogens belonging to the phyla Ascomycota, Basidiomycota, Zygomycetes, and the fungal-like Oomycetes. The compounds and/or compositions of the present invention are effective in controlling a wide range of plant diseases, especially foliar pathogens of ornamental, turf, vegetable, field, cereal and fruit crops. These pathogens include, but are not limited to, the pathogens listed in Table 1-1. For Ascomycetes as well as Basidiomycetes, the names of either the sexual/asexual/complete stage or the asexual/asexual/incomplete stage (in parentheses) are listed where they are known. Synonymous names for pathogens are indicated by an equals sign. For example, the sexual/genotype/complete stage name Phaeosphaeria nodorum is followed by the corresponding asexual/asexual/incomplete stage name Sta gnospora nodorum and the synonymous old name Septoria nodorum. Table 1-1 The order Ascomycetes of the order Gesporium include Alternaria Solani, A. alternata , A. brassicae , Guignardia bidwellii ), Apple Venturia inaequalis , Pyrenophora tritici-repentis ( Dreschlera tritici-repentis=Helminthosporium tritici-repentis ), and Pyrenophora teres ( Dreschlera teres=Helminthosporium teres ), cucumber Corynespora Cassiicola, Phaeosphaeria nodorum ( Stagonospora nodorum=Septoria nodorum ), Cochliobolus Carbonum, C. heterostrophus , C. heterostrophus Leptosphaeria biglobosa ) and cabbage black foot fungus ( L. maculans ); Endophyte order Ascomycetes include Mycosphaerella graminicola ( Zymoseptoria tritici=Septoria tritici ), M. berkleyi ( Cercosporidium personatum ), M. arachidis ( M. arachidis ) ( Cercospora arachidicola ), PassaloraSojina ( CercosporaSojina ), Cercospora zeae-maydis and C. beticola ; Ascomycetes in the order Powdery mildew (powder mildew), for example, Blumeria graminis f.sp. tritici and Blumeria graminis f.sp. hordei , Erysiphe polygoni ), grape powdery mildew ( E. necator ) (= Uncinula necator ), melon powdery mildew ( Podosphaera fuliginea ) (= Sphaerotheca fuliginea ), and apple powdery mildew ( Podosphaera leucotricha ) (= Sphaerotheca fuliginea ); In the order Ascomycetes of the order Molluscum, for example, Botryotinia fuckeliana ( Botrytis Cinerea ), Oculimacula yallundae (= Tapesia yallundae ; anamorph Helgardia herpotrichoides=Pseudocercosporella herpetrichoides ), Peach brown rot ( Monilinia fructicola ), Sclerotinia Sclerotiorum ( Sclerotinia S clerotiorum ), Sclerotinia minor ( Sclerotinia minor ) and Sclerotinia homoeocarpa ; In the Ascomycetes of the order Hypocrea, for example, Giberella zeae ( Fusarium graminearum ), G. monoliformis ( Fusarium moniliforme ), Fusarium Solani ( =NeocosmoporaSolani ) and cotton Verticillium dahliae ; In the order Ascomycetes of the order Ascomycetes such as Aspergillus flavus and A. parasiticus ; In the order Ascomycetes of the order Intersciatica, for example, Cryptosphorella viticola (= Phomopsis viticola ), Phomopsis longicola , and Diaporthe phaseolorum ; Other Ascomycetes include Magnaporthe grisea , Gaeumannomyces graminis , Rhynchosporium Secalis, and anthrax pathogens such as Glomerella acutata ( Colletotrichum acutatum ) , G. graminicola ( C. graminicola ) ( C. graminicola ), and G. lagenaria ( C. orbiculare ); Basidiomycetes in the order Puccinia include Puccinia recondita , P. Striiformis , Puccinia hordei , P. graminis, and P. graminis ( P. graminis ). P. arachidis ), Hemileia vastatrix and Phakopsora pachyrhizi ; Basidiomycetes of the order Chaetobacteria, for example, Thanatophorum Cucumeris ( Rhizoctonia Solani) and Ceratobasidium oryzae-sativae ( Rhizoctonia oryzae ); Basidiomycetes in the order of Polypores such as Athelia rolfsii ( Sclerotium rolfsii ); In the order Basidiomycetes of the order Solitaria such as Ustilago maydis ; Zygomycetes such as Rhizopus S tolonifer in the order Mucor; Oomycetes of the order Pythium include Phytophthora infestans , P. megasperma , P. parasitica , P. Sojae, P. .Cinnamomi ) and Solanaceae crop blight ( P.Capsici ), and Pythium pathogens such as Pythium aphanidermatum , P. graminicola , P. irregulare , Pythium Pythium ( P. ultimum ) and Pythium ( P. dissoticum ); Oomycetes of the order Downy mildew such as Plasmopara viticola , P. halstedii , Peronospora hyoscyami ( =Peronospora tabacina ), P. manshurica ), Hyaloperonospora parasitica (= Peronospora parasitica ), Pseudoperonospora Cubansis and Bremia lactucae ; and other genera and species closely related to all the above mentioned pathogens.

In addition to the fungicidal activity of the composition or combination, they also have activity against bacteria such as Erwinia amylovora , Xanthomonas Campestris , Pseudomonas Syringae and other related species . By controlling harmful microorganisms, the compositions of the present invention can be used to improve (i.e., increase) the ratio of beneficial to harmful microorganisms in contact with crops or their propagules (eg, seeds, bulbs, bulbs, tubers, cuttings), or in The environment of the crop or its propagules.

The compositions of the present invention can be used to treat all plants, plant parts and seeds. Plants and seed varieties and cultivars can be obtained by conventional propagation and breeding methods or by genetic engineering methods. A genetically modified plant or seed (transgenic plant or seed) is a transgenic plant or seed in which a heterologous gene (transgene) has been stably integrated into the plant or seed genome. A transgene defined by its specific location in the plant genome is called a transformation or transgenic event.

Transgenic plant cultivars that may be treated according to the present invention include resistance to one or more biotic stresses (pests such as nematodes, insects, mites, fungi, etc.) or abiotic stresses (drought, low temperature, soil salinity, etc.), or contain other desirable feature. Plants can be genetically modified to exhibit traits such as herbicide tolerance, insect resistance, modified oil distribution, or drought tolerance.

Treatment of genetically modified plants as well as seeds with the compounds of the present invention may result in super additive or elevating effects. For example, reduced application rates, increased range of activity, increased tolerance to biotic/abiotic stress, or enhanced storage stability may be more likely than would be expected from the simple additive effects of only applying the compounds of the invention to genetically modified plants and seeds bigger.

The compounds and compositions of the present invention are useful in seed treatments to protect seeds from plant diseases. In the context of the present application and the scope of the patent application, treating seed means contacting the seed with a biologically effective amount of a compound of the invention, which is generally formulated into a composition of the invention. This seed treatment protects the seeds from soil-borne disease pathogens, and often also protects the roots, as well as other plant parts, from soil contact with the seedlings from which the germinated seeds develop. Seed treatment can also provide foliar protection through the translocation of a compound of the invention or a second active ingredient within a developing plant. Seed treatment can be applied to all types of seeds, including those that will germinate from plants transgenic to express particular traits. Representative examples include the expression of proteins that are toxic to invertebrate pests, such as Bacillus thuringiensis toxin, or those that express herbicide resistance, such as glyphosate acetyltransferase, which provides resistance to glyphosate medicinal properties. Seed treatment with the compounds and compositions of the present invention can also increase the vigor of plants from such seeds.

The compounds and compositions of the present invention are particularly suitable for seed treatment of crops including, but not limited to, corn, soybeans, cotton, grains (eg, wheat, oats, barley, rye, and rice), potatoes, vegetables, and canola.

In addition, the compounds and compositions of the present invention can be used to treat postharvest diseases of fruits and vegetables caused by fungi, oomycetes and bacteria. These infections can occur before, during and after harvest. For example, infection can occur before harvest and then remain dormant until some point during maturity (eg, host begins tissue changes in such a way that infection can progress or conditions favor disease development); infection can also be caused by mechanical or insect damage of superficial wounds. In this regard, the compositions of the present invention can reduce losses (ie, losses due to quantity as well as quality) caused by post-harvest disease that can occur at any time from post-harvest to consumption. Treatment of postharvest disease with the compounds of the present invention increases the time that perishable edible plant parts (eg, fruits, seeds, leaves, stems, bulbs, tubers) can be refrigerated or unrefrigerated after harvest and remain edible without significant or Harmful degradation or contamination by fungi or other microorganisms. Treatment of edible plant parts with compounds of the present invention before or after harvesting can also reduce the formation of toxic metabolites of fungi or other microorganisms, eg, mycotoxins such as aflatoxins.

Usually by applying an effective amount of a compound of the invention to the part of the plant to be protected such as roots, stems, leaves, fruit, seeds, tubers or bulbs or to the medium (soil or sand) in which the plant is to be protected, either before or after infection. These compounds can also be used in seeds to protect the seeds and seedlings that develop from the seeds. These compounds can also be used to treat plants through irrigation water. Post-harvest pathogen control of pre-harvest-infected agricultural products is typically accomplished by field application of the compounds of the present invention, and in the event of post-harvest infections, the compounds can be applied to the harvested crops, such as dips, sprays fumigants, fumigants, treated packaging, and box liners.

The compounds and compositions of the present invention can also be administered using an unmanned aerial vehicle (UAV) to dispense the compositions disclosed herein over a planted area. In some embodiments, the planting area is an area containing crops. In certain embodiments, the crop line is selected from a monocotyledonous plant or a dicotyledonous plant. In certain embodiments, the crop is selected from the group consisting of rice, corn, barley, soybean, wheat, vegetables, tobacco, tea trees, fruit trees, and sugar cane. In certain embodiments, the compositions disclosed herein are formulated for ultra-low volume nebulization. Products used by drones can be sprayed with water or oil. Typical spray volumes (including product) for drone applications worldwide are 5.0 liters/ha – 100 liters/ha (approximately 0.5-10 gpa). This includes the range from ultra low spray volume (ULV) to low spray volume (LV). Although uncommon, even lower spray rates, as low as 1.0 L/ha (0.1 gpa), may be used in some cases.

Appropriate application rates (eg, fungicidally effective amounts) of component (a) (that is, at least one compound selected from the group consisting of compounds of formula 1, their N -oxides and their salts) and the Suitable application rates (e.g., biologically effective, fungicidally effective, or insecticidally effective amounts) of the mixtures and compositions of sub (a) may be affected by, for example, the plant disease to be controlled, the plant species to be protected, the pathogen to be controlled. factors such as population structure, environmental humidity and temperature, and should be determined under actual use conditions. The fungicidally effective amount required for plant disease control at the desired level can be readily determined by one skilled in the art through simple experimentation. Leaves are generally protected when treated at rates of less than about 1 g/ha to about 5,000 g/ha active ingredient. Seeds, as well as seedlings, are generally protected when seed is treated at a rate of about 0.001 g (more typically about 0.1 g) to about 10 g per kilogram of seed. Component (a), and mixtures and compositions thereof, can be readily determined by a person skilled in the art by simple experimentation, including in accordance with the present invention to provide the desired range of plant protection and control of plant diseases and other selective application of plant pests dosage.

The compounds and compositions of the present invention can also be used to increase the vigor of crop plants. The method comprises contacting a crop plant (eg, leaves, flowers, fruits, or roots) or seeds of a crop plant with a composition comprising a compound of Formula 1 in an amount sufficient to achieve the desired effect of plant vigor (ie, a biologically effective amount). Typically, the compound of formula 1 is administered in a formulated composition. Although the compound of formula 1 is usually applied directly to the crop plant or its seeds, it can also be applied to the locus of the crop plant, ie the crop plant's environment, especially a part of the environment, close enough to allow the compound of formula 1 to migrate into the crop plant . The site associated with this method most often includes a growth medium (ie, a medium that provides nutrients to the plants), usually the soil in which the plants are grown. Thus, treating a crop plant to increase the vigor of the crop plant includes contacting the crop plant, the seed from which the crop plant is grown, or the locus of the crop plant with a biologically effective amount of a compound of Formula 1.

Increased crop vigor can lead to one or more of the following observed effects: (a) through excellent seed germination, crop emergence, and crop standing demonstrating optimal crop establishment; (b) through rapid and robust leaf growth (e.g., through leaf Area index measurement), plant height, number of tillers (e.g., for rice), root mass, and increased crop growth as evidenced by total dry weight of crop vegetative bodies; (c) by flowering time, flowering duration, number of flowers , total biomass accumulation (i.e., yield) and/or fruit or grain-grade marketability of the product (i.e., yield quality) demonstrated to increase crop yield; (d) improved crop resistance or prevention of plant disease infection and arthropod , nematode or mollusk infestation; and (e) increased ability of crops to withstand environmental stress, such as exposure to extreme temperatures, suboptimal moisture or phytotoxic chemicals.

By preventing and/or treating plant diseases caused by fungal phytopathogens in the plant environment, the compounds and compositions of the present invention can increase the viability of treated plants compared to untreated plants. In the absence of such control of plant disease, the disease reduces plant vigor by consuming plant tissue or sap or transmitting plant pathogens, such as viruses. Even in the absence of fungal phytopathogens, the compounds of the present invention can increase plant vigor by altering plant metabolism. Generally, if the plant is grown in a non-ideal environment, ie an environment that contains one or more aspects that are unfavorable to the plant, to its full genetic potential, the vigor of the crop plant will be greatly increased by treatment of the plant with the compounds of the present invention, which live in To show dynamism in an ideal environment.

Notably, a method of increasing the vigor of a crop plant, wherein the crop plant is grown in an environment comprising plant diseases caused by fungal phytopathogens. Also of note are methods of increasing the vigor of crop plants, wherein the crop plants are grown in an environment that does not contain plant diseases caused by fungal phytopathogens. Also of note are methods of increasing the vigor of a crop plant wherein the crop plant is grown in an environment containing less than an ideal amount of moisture to support the growth of the crop plant.

The compounds and compositions of the present invention may also be mixed with one or more other biologically active compounds or agents, including fungicides, insecticides, nematicides, bactericides, acaricides, herbicides pesticides, herbicide safeners, growth regulators such as insect molt inhibitors and rooting stimulants, chemical sterilizers, repellants, attractants, pheromones, feeding stimulants, phytonutrients, other biologically active compounds or insects Pathogenic bacteria, viruses or fungi, forming multi-component pesticides that provide broader agricultural protection. Accordingly, the present invention also relates to compositions comprising a compound of formula 1 (in a fungicidally effective amount) and at least one additional biologically active compound or agent (a biologically effective amount), and may further comprise surfactants, solid diluents or liquid thinner. Other biologically active compounds or agents can be formulated in compositions comprising at least one of surfactants, solid or liquid diluents. For the mixtures of the present invention, one or more other biologically active compounds or agents may be formulated with the compound of formula 1 to form a premix, or one or more other biologically active compounds or agents may be combined with formula 1, and prior to administration Formulations that are combined (eg, in a spray can), or alternatively administered sequentially.

As described in the Summary of the Invention, one aspect of the present invention is a fungicidal composition comprising a mixture or combination of a compound of formula 1, an N -oxide thereof, or a salt thereof (ie, component (a)) and at least one Other fungicides (ie, component (b)). Of note are combinations in which the other fungicidally active ingredient has a different site of action than the compound of formula 1 . In some cases, a combination with at least one other fungicidally active ingredient having a similar range of control but a different site of action will be particularly advantageous for antimicrobial resistance management. Accordingly, the compositions of the present invention may further comprise a fungicidally effective amount of at least one other fungicidally active ingredient having a similar control range but different sites of action.

Examples of component (b) fungicides include acibenzolar-S-methyl, aldimorph, ametoctradin, amisulbrom ), anilazine, azaconazole, azoxystrobin, benalaxyl (including benalaxyl-M), benodanil, benomyl ( benomyl), benthiavalicarb (including benthiavali-isopropyl), benzovindiflupyr, bethoxazin, binapacryl, biphenyl ), bitertanol, bixafen, blasticidin-S, boscalid, bromuconazole, bupirimate, Buthiobate, captafol, captan, carbendazim, carboxin, carpropamid, chloroneb, tetrachloride Isobenzene (chlorothalonil), chlozolinate, clotrimazole, copper hydroxide, copper oxychloride, copper sulfate, coumoxystrobin, cyazofamid, siffen rice ( cyflufenamid, cymoxanil, cyproconazole, cyprodinil, dichlofluanid, diclocymet, diclomezine, diclomezine dicloran, diethofencarb, difenoconazole, diflumetorim, dimethirimol, dimethomorph, dimoxystrobin, diniconazole ) (including denizole-M), dinocap, dithianon, dithiolanes, dodemorph, dodine, large Fenbutasone (dipymetitrone), econazole (e conazole), edifenphos, enoxastrobin (also known as enestroburin), epoxiconazole, etaconazole, ethaboxam , ethirimol, etridiazole, famoxadone, fenamidone, fenarimol, fenaminstrobin, fenbuconazole , fenfuram, fenhexamid, fenoxanil, fenpiclonil, fenpropidin, fenpropimorph, diphenhydramine fenpyrazamine, fentin acetate, fentin chloride, fentin hydroxide, ferbam, ferimzone, flumetoxone ( flometoquin, florylpicoxamid, fluazinam, fludioxonil, flufenoxystrobin, fluindapyr, flumorph , Fluopicolide, Fluopimide, Fluopyram, Flouroimide, Fluoxastrobin, Fluquinconazole , Flusilazole, Flusulfamide, Flutianil, Flutolanil, Flutriafol, Fluxapyroxad, Folpet, fthalide, fuberidazole, furalaxyl, furametpyr, guazatine, hexaconazole, hymexazole, imiter Imazalil, imibenconazole, iminoctadine albesilate, iminoctadine albesilate noctadine triacetate, iodocarb, ipconazole, ipfentrifluconazole, iprobenfos, iprodione, iprovalicarb, isoconazole, isofetamid, isoprothiolane, isoflucypram, isopyrazam, isothiazide Isotianil, kasugamycin, kresoxim-methyl, mancozeb, mandepropamid, mandestrobin, manganese (maneb), mepanipyrim, mepronil, meptyldinocap, metalaxyl (including metalaxyl-M/mefenoxam), mefenoxam Mefentrifluconazole, metconazole, methasulfocarb, metiram, metminostrobin, metrafenone, miconazole, Mike Myclobutanil, naftifine, neo-asozin, nuarimol, octhilinone, ofurace, orysastrobin ), oxadixyl, oxathiapiprolin, oxolinic acid, oxpoconazole, oxycarboxin, oxytetracycline, rice blast pefurazoate, penconazole, pencycuron, penflufen, penthiopyrad, phosphorous acid (including its salts such as aluminum triethylphosphonate) , picarbutrazox, picoxystrobin, piperalin, polyoxin, probenazo le), prochloraz, procymidone, propamacarb, propiconazole, propineb, proquinazid, prothiocarb , prothioconazole, pyraclostrobin, pyrametostrobin, pyraoxystrobin, pyrazophos, pyribencarb, pyributicarb , pyrifenox, pyrimethanil, pyriofenone, pyrisoxazole, pyroquilon, pyrrolnitrin, oxazoquinone (quinconazole), quinofumelin (registration number 861647-84-9), quinomethionate, quinoxyfen, pentachloronitrobenzene (quintozene), cyclamate ( sedaxane, silthiofam, simeconazole, spiroxamine, streptomycin, sulfur, tebuconazole, tebufloquin, gram teclofthalam, tecnazene, terbinafine, tetraconazole, thiabendazole, thifluzamide, thiophanate, thiophanate-methyl, thiram, tiadinil, tolclofos-methyl, tolnifanide, carbamate fungicide tolprocarb, methyl methacrylate Tolyfluanid, triadimefon, triadimenol, triarimol, triticonazole, triazoxide, tribasic copper sulfate, tricyclazole ), triclopyricarb, tridemorp h), trifloxystrobin, triflumizole, triforine, trimorphamide, uniconazole, uniconazole P, validamycin ), valifenalate (also known as valiphenal), vinclozolin, zineb, ziram, zoxamide, N [ 2-( 1S , 2R )-[1,1'-bicyclopropyl]-2-ylphenyl]-3-(difluoromethyl)-1-methyl- 1H -pyrazole-4 -Carboxamide , α-(1-chlorocyclopropyl)-α-[2-(2,2-dichlorocyclopropyl)ethyl]-1H-1,2,4-triazole-1- Ethanol, (α S )-[3-(4-chloro-(2,4-difluorophenyl)-4-isoxazolyl]-3-pyridinemethanol, rel -1-[[(2 R ,3 S )-3-(2-chlorophenyl)-2-(2,4-difluorophenyl)-difluorophenyl)-2- oxiranyl ]methyl]-1H-1,2 ,4-triazole, rel -2-[[( 2R , 3S )-3-(2-chlorophenyl)-2-difluorophenyl)-2-oxiranyl]methyl]- 1,2-Dihydro- 3H -1,2,4-triazole-3-thione, rel -1-[[( 2R , 3S )-3-(2-(2,4-difluoro phenyl)-2-epoxyethyl]methyl]-5-(2-propen-1- ylthio )-1H-1,2,4-triazole, N- [2-[4-[ [3-(4-Chlorophenyl)propyn-1-yl]oxy]-3-methoxyphenyl]ethyl]-3-methyl-2-[(methylsulfonyl)amino ]butanamide, N- [2-[4-[[3-(4-phenyl)-2-propyn-1-yl]oxy]-3-methoxyphenyl]ethyl]-3 -Methyl-2-[(ethylsulfonyl)amino]butanamide, N '-[4-[4-chloro-3-(trifluoromethyl)phenoxy]-2,5-di Methylphenyl] -N -ethyl- N -methyl-formimidamide, N -[[(cyclopropyl-methoxy)-amino][6-(difluoromethoxy)- 2,3-Difluorophenyl]methylene]phenethylamine, N- [2-(2,4-dichlorophenyl)-2-methoxy-1-methylethyl]-3- (Difluoromethyl)-1-methyl-1 H -pyrazol-4-carboxamide, N- (3',4'-difluoro[1,1'-biphenyl]-2-yl)- 3-(Trifluoromethyl)-2 - pyrazinecarboxamide, 3-(difluoromethyl)-N-(2,3-dihydro-1,1,3-trimethyl-1H-indene- 4-yl)-1-methyl- 1H -pyrazol-4- Carboxamide, 5,8-Difluoro- N- [2-[3-methoxy-4-[[4-(trifluoromethyl)-2-pyridyl]oxy]phenyl]-ethyl ]-4-quinazolinamine, 1-[4-[4-[5 R -[(2,6-difluorophenoxy)methyl]-4,5-dihydro-3-isoxazolyl ]-2-thiazolyl]-1-piperidinyl]-2-[5-methyl-3-(trifluoromethyl)-1 H -pyrazol-1-yl]ethanone, 4-fluorophenyl N-[1-[[[1-(4-Cyanophenyl)ethyl]sulfonyl]methyl]propyl]carbamate, 5-fluoro-2-[(4-fluorophenyl) Methoxy]-4-pyrimidinamine, α(methoxyimino) -N -methyl-2-[[[1-[3-(trifluoromethyl)phenyl]ethoxy]imine yl]methyl]phenethylamine, and [[4-methoxy-2-[[[(3 S ,7 R ,8 R ,9 S )-9-methyl-8-(2-methyl) -Oxopropoxy)-2,6-dioxo-7-(phenylmethyl)-1,5-dioxan-3-yl]amino]carbonyl]-3-pyridyl ]oxy]methyl 2-methylpropionate. Therefore, it is worth noting that fungicides comprising as component (a) a compound of formula 1 (or an N -oxide or salt thereof) and at least one fungicide selected from the above list as component (b) combination.

Of particular note are compounds of formula 1 (or N -oxides or salts thereof) (ie, component (a) in the composition) in combination with a compound of component (b) selected from the group consisting of: Aminopyrifen (registration number 1531626-08-0), azoxystrobin, benzovindiflupyr, bixafen, captan, plus Carpropamid, chlorothalonil, copper hydroxide, copper oxychloride, copper sulfate, cymoxanil, cyproconazole, cyprodinil, benzothiazole bactericidal Agents dichlobentiazox (registration number 957144-77-3), diethofencarb, difenoconazole, dimethomorph, dipymetitrone, epoxiconazole, thiazolidine Ethaboxam, fenarimol, fenhexamid, fluazinam, fludioxonil, fluindapyr, fluopyram ), flusilazole, flutianil, flutriafol, fluxapyroxad, folpet, ipflufenoquin (Registration No. 1314008-27-9), iprodione, isofetamid, isoflucypram, isopyrazam, kresoxim-methyl, manganese mancozeb, mandestrobin, meptyldinocap, metalaxyl (including metalaxyl-M/metalaxyl), mefentrifluconazole, metconazole, metrafenone, metyltetraprole (Registration No. 1472649-01-6), myclobutanil, oxathiapiprolin, flufenox (penflufen), penthiopyrad, phosphorous acid (including its salts such as aluminum triethylphosphonate), picoxystrobin, propiconazole, proquinazid, prothioconazole, pyridachlometyl ( Registration number 1358061-55-8), pyraclostrobin, pyrapropoyne (registration number 1803108-03-3), pyrimethanil, sedaxaneSpiroxamine, Sulfur, tebuconazole, thiophanate-methyl, trifloxystrobin, zoxamide, α-(1-chlorocyclopropyl)-α-[2-( 2,2-Diethyl]-1 H -1,2,4-triazole-1-ethanol, N- [2-(2,4-dichlorophenyl)-2-methoxy-1-methan ylethyl]-3-(difluoromethyl)-1-methyl- 1H -pyrazole - 4-(difluoromethyl)-N-(2,3-dihydro-1,1,3- Trimethyl-1 H -inden-4-yl)-1-methyl-1 H -pyrazol-4-carboxamide, 1-[4-[4-[5 R- (2,6-difluoro phenyl)-4,5-dihydro-3-isoxazolyl]-2-thiazolyl]-1-piperidinyl]-2-[5-methyl-3-(trifluoromethyl)- 1 H -pyrazol-1-yl]ethanone, N- [6-[[[[(1-methyl-1 H -tetrazol-5-yl)phenylmethylene]amino]oxy] Methyl]-2-pyridyl]carbamate, 5-fluoro-2-[(4-fluorophenyl)-methoxy]-4-pyrimidinamine, (α S )-[3-(4- Chloro-2-fluorophenyl)-5-(2,4-difluorophenyl)-4-isoxazolyl]-3-pyridinemethanol, rel -1-[[(2 R ,3 S )-3 -(2-Chlorophenyl)-2-(2,4-difluorophenyl)-2- oxiranyl ]methyl]-1H-1,2,4-triazole, rel -2- [[( 2R , 3S )-3-(2-chlorophenyl)-2-(2,4-difluorophenyl)-2-oxiranyl]methyl]-1,2-di Hydrogen- 3H -1,2,4-triazole-3-thione, and rel -1-[[( 2R , 3S )-3-(2-chlorophenyl)-2-(2,4 -difluorophenyl)-2-oxiranyl]methyl]-5-(2-propen-1- ylthio )-1H-1,2,4-triazole (that is, as composition composition of sub (b)).

For better control of plant diseases caused by fungal phytopathogens (eg, lower application rates or more phytopathogens can be controlled) or resistance management, compounds of formula 1, their N -oxides or Mixtures of its salts with fungicidal compounds selected from the group consisting of amisulbrom, azoxystrobin, benzovindiflupyr, bixafen, bec Boscalid, carbendazim, carboxin, chlorothalonil, copper hydroxide, cymoxanil, cyproconazole, difenoconazole, Dimethomorph, dimoxystrobin, epoxiconazole, fenpropidin, fenpropimorph, florylpicoxamid, fluazinam, fludioxonil, flufenoxystrobin, fluindapyr, fluquinconazole, fluopicolide, fluoxastrobin, fluoxastrobin Flutriafol, fluxapyroxad, ipconazole, ipfentrifluconazole, iprodione, kresoxim-methyl, manganese (mancozeb), metalaxyl, mefenoxam, mefentrifluconazole, metconazole, metminostrobin, myclobutanil, paclobutrazole , Penflufen, Picoxystrobin, Prothioconazole, Pydiflumetofen, Pyraclostrobin, Pyraclostrobin, Pyraclostrobin Esters (pyraoxystrobin), pyriofenone, sedaxane, silthiofam, dexamethasone tebuconazole, thiabendazole, thiophanate-methyl, thiram, trifloxystrobin, and triticonazole.

In the fungicidal composition of the present invention, component (a) (that is, at least one compound selected from the compound of formula 1, its N -oxide and salts thereof) and component (b) are combined with a fungicidal An effective amount is present. The weight ratio of component (a) to component (b) (ie, one or more other fungicidal compounds) is typically from about 1:3000 to about 3000:1, more typically from about 1:500 to about 500:1 . Notably, compositions wherein the weight ratio of component (a) to component (b) is from about 125:1 to about 1:125. As with many fungicidal compounds of component (b), these compositions are particularly effective for controlling plant diseases caused by fungal phytopathogens. Of particular note are compositions wherein the weight ratio of component (a) to component (b) is from about 25:1 to about 1:25, or from about 5:1 to about 1:5. The desired fungicidal protection and the desired range of fungicidal compound weight ratios and application rates can be readily determined by those skilled in the art through simple experimentation. It will be apparent that the inclusion of other fungicidal compounds in component (b) extends the control of plant diseases beyond that controlled by component (a) alone. Furthermore, Tables A1 to A21 and C1 to C21 verify the weight ratios of the combinations of fungicidal compounds of the present invention. Table B1 lists typical, more typical, and most typical ratio ranges for specific fungicidal compounds in relation to component (b).

Specific mixtures (compound numbers refer to compounds in Index Tables A to L) are listed in Tables A1 to A21. In Table A1, each row under the column headings "Ingredient (a)" and "Ingredient (b)" specifically discloses Component (a) (i.e., Compound 32) and Component (b) fungicidal compound mixture. The entries under the heading "Illustrative Ratios" disclose three specific weight ratios of component (a) to component (b) of the disclosed mixture. For example, the first row of Table A1 discloses a mixture of compound 32 with benzofuran- S -methyl and lists the weight ratio of compound 32 to acibenzolar- S -methyl 1:1, 1:4 or 1:18. Table A1 Component (a) Component (b) Illustrative scale (*) Compound 32 acibenzolar-S-methyl 1:1 1:4 1:18 Compound 32 aldimorph 7:1 3:1 1:1 Compound 32 Metoctradin 3:1 1:1 1:3 Compound 32 Amisulbrom (amisulbrom) 1:1 1:2 1:6 Compound 32 anilazine 22:1 8:1 4:1 Compound 32 posaconazole (azaconazole) 2:1 1:2 1:4 Compound 32 azoxystrobin 3:1 1:1 1:3 Compound 32 benalaxyl 1:1 1:2 1:6 Compound 32 benalaxyl-M (benalaxyl-M) 1:1 1:3 1:8 Compound 32 Benodanil 4:1 2:1 1:2 Compound 32 benomyl 11:1 4:1 1:1 Compound 32 benthiavalicarb 1:1 1:4 1:12 Compound 3 benthiavalicarb-isopropyl 1:1 1:4 1:12 Compound 32 Bethoxazin 15:1 5:1 2:1 Compound 32 100 mite grams (binapacryl) 15:1 5:1 2:1 Compound 32 biphenyl 15:1 5:1 2:1 Compound 32 Bitertanol 3:1 1:1 1:2 Compound 32 bixafen 2:1 1:1 1:3 Compound 32 Blasticidin-S 1:4 1:12 1:30 Compound 32 Bordeaux mixture (tribasic copper sulfate) 45:1 15:1 5:1 Compound 32 boscalid 4:1 2:1 1:2 Compound 32 Bromuconazole 3:1 1:1 1:3 Compound 32 bupirimate 1:3 1:10 1:30 Compound 32 Captafol 15:1 5:1 2:1 Compound 32 captan 15:1 5:1 2:1 Compound 32 carbendazim 11:1 4:1 2:1 Compound 32 carboxin 4:1 2:1 1:2 Compound 32 Carpropamid 3:1 1:1 1:3 Compound 32 chloroneb 100:1 35:1 14:1 Compound 32 Tetrachloroisobenzene (chlorothalonil) 15:1 5:1 2:1 Compound 32 Chlozolinate 11:1 4:1 2:1 Compound 32 Clotrimazole 3:1 1:1 1:3 Compound 32 copper hydroxide 45:1 15:1 5:1 Compound 32 copper oxychloride 45:1 15:1 5:1 Compound 32 Cyazofamid 1:1 1:2 1:6 Compound 32 Cyflufenamid 1:2 1:6 1:24 Compound 32 cymoxanil 1:1 1:2 1:5 Compound 32 Cyproconazole 1:1 1:2 1:6 Compound 32 Cyprodinil 4:1 2:1 1:2 Compound 32 Dichlofluanid 15:1 5:1 2:1 Compound 32 diclocymet 15:1 5:1 2:1 Compound 32 Diclomezine 3:1 1:1 1:3 Compound 32 dicloran 15:1 5:1 2:1 Compound 32 Diethofencarb 7:1 2:1 1:2 Compound 32 To be clear (difenoconazole) 1:1 1:3 1:12 Compound 32 Diflumetorim 15:1 5:1 2:1 Compound 32 Dimethirimol 1:3 1:8 1:30 Compound 32 Dimethomorph 3:1 1:1 1:2 Compound 32 Dimoxystrobin 2:1 1:1 1:4 Compound 32 diniconazole 1:1 1:3 1:8 Compound 32 diniconazole-M (diniconazole M) 1:1 1:3 1:12 Compound 32 White powder gram (dinocap) 2:1 1:1 1:3 Compound 32 dithianon 5:1 2:1 1:2 Compound 32 Dodemorph 7:1 3:1 1:1 Compound 32 dodine 10:1 4:1 2:1 Compound 32 edifenphos 3:1 1:1 1:3 Compound 32 enestroburin 2:1 1:1 1:4 Compound 32 Eprazole (epoxiconazole) 1:1 1:3 1:7 Compound 32 etaconazole 1:1 1:3 1:7 Compound 32 Ethaboxam 2:1 1:1 1:3 Compound 32 Ethirimol 7:1 3:1 1:1 Compound 32 Etridiazole 7:1 2:1 1:2 Compound 32 Where to kill the same (famoxadone) 2:1 1:1 1:4 Compound 32 Fenamidone 2:1 1:1 1:4 Compound 32 Fenaminstrobin 3:1 1:1 1:3 Compound 32 Fenarimol 1:2 1:7 1:24 Compound 32 Fenbuconazole 1:1 1:3 1:10 Compound 32 Fenfuram (fenfuram) 4:1 1:1 1:2 Compound 32 fenhexamid 10:1 4:1 2:1 Compound 32 blastamide (fenoxanil) 15:1 4:1 1:1 Compound 32 Seed dressing (fenpiclonil) 15:1 5:1 2:1 Compound 32 Fenpropidin 7:1 2:1 1:1 Compound 32 fenpropimorph 7:1 2:1 1:1 Compound 32 Fenpyrazamine 3:1 1:1 1:3 Compound 32 Fentin salts such as fentin acetate, fentin chloride or fentin hydroxide 3:1 1:1 1:3 Compound 32 Ferbam 30:1 10:1 4:1 Compound 32 Ferimzone 7:1 2:1 1:2 Compound 32 fluazinam 3:1 1:1 1:2 Compound 32 Fludioxonil 2:1 1:1 1:4 Compound 32 Ethylene morpholine (flumetover) 3:1 1:1 1:2 Compound 32 flumorph 3:1 1:1 1:3 Compound 32 fluopicolide 1:1 1:2 1:6 Compound 32 Fluopyram 3:1 1:1 1:3 Compound 32 fluoroimide 37:1 14:1 5:1 Compound 32 Fluoxastrobin 1:1 1:2 1:6 Compound 32 Fluquinconazole 1:1 1:2 1:4 Compound 32 flusilazole 3:1 1:1 1:3 Compound 32 Flusulfamide 15:1 5:1 2:1 Compound 32 Flutianil 1:1 1:2 1:6 Compound 32 Flutolanil 4:1 1:1 1:2 Compound 32 Flutriafol 1:1 1:2 1:4 Compound 32 Sterilization Dan (fluxapyroxad) 2:1 1:1 1:3 Compound 32 Folpet 15:1 5:1 2:1 Compound 32 Fosetyl-aluminum 30:1 12:1 5:1 Compound 32 fuberidazole 11:1 4:1 2:1 Compound 32 furalaxyl 1:1 1:2 1:6 Compound 32 furametpyr 15:1 5:1 2:1 Compound 32 guazatine 15:1 5:1 2:1 Compound 32 Fickley (hexaconazole) 1:1 1:2 1:5 Compound 32 hymexazole 75:1 25:1 9:1 Compound 32 Imazalil 1:1 1:2 1:5 Compound 32 imibenconazole 1:1 1:2 1:5 Compound 32 Imnoctadine 15:1 4:1 1:1 Compound 32 Iodopropynyl butylcarbamate (iodocarb) 15:1 5:1 2:1 Compound 32 ipconazole 1:1 1:2 1:5 Compound 32 Propylsiloxane (iprobenfos) 15:1 5:1 2:1 Compound 32 iprodione 15:1 5:1 2:1 Compound 32 iprovalicarb 2:1 1:1 1:3 Compound 32 isopyrazine (isoprothiolane) 45:1 15:1 5:1 Compound 32 isopyrazam 2:1 1:1 1:3 Compound 32 isotianil 2:1 1:1 1:3 Compound 32 Kasugamycin 1:2 1:7 1:24 Compound 32 Kresoxim-methyl 2:1 1:1 1:4 Compound 32 Mancozeb 22:1 7:1 3:1 Compound 32 mandipropamid 2:1 1:1 1:4 Compound 32 Maneb (maneb) 22:1 7:1 3:1 Compound 32 mepanipyrim 6:1 2:1 1:1 Compound 32 Mepronil 1:1 1:2 1:6 Compound 32 Meptyldinocap 2:1 1:1 1:3 Compound 32 metalaxyl 1:1 1:2 1:6 Compound 32 Metalaxyl-M (metalaxyl-M) 1:1 1:4 1:12 Compound 32 metconazole 1:1 1:2 1:6 Compound 32 Methasulfocarb 15:1 5:1 2:1 Compound 32 lest it rot (metiram) 15:1 5:1 2:1 Compound 32 Metominostrobin 3:1 1:1 1:3 Compound 32 Metrafenone 2:1 1:1 1:4 Compound 32 myclobutanil 1:1 1:3 1:8 Compound 32 Naftifine 15:1 5:1 2:1 Compound 32 Ammonium iron arsenate (neo-asozin) 15:1 5:1 2:1 Compound 32 Fluoropyrimidol (nuarimol) 3:1 1:1 1:3 Compound 32 octhilinone 15:1 4:1 1:1 Compound 32 Furamide (ofurace) 1:1 1:2 1:6 Compound 32 orysastrobin 3:1 1:1 1:3 Compound 32 oxadixyl 1:1 1:2 1:6 Compound 32 oxolinic acid 7:1 2:1 1:2 Compound 32 Oxpoconazole 1:1 1:2 1:5 Compound 32 oxycarboxin 4:1 1:1 1:2 Compound 32 Oxytetracycline 3:1 1:1 1:3 Compound 32 pefurazoate 15:1 5:1 2:1 Compound 32 penconazole 1:2 1:6 1:15 Compound 32 pencycuron 11:1 4:1 2:1 Compound 32 Flufenapyr (penflufen) 2:1 1:1 1:3 Compound 32 penthiopyrad 2:1 1:1 1:3 Compound 32 Phosphorous acid or its salts 15:1 6:1 2:1 Compound 32 Tetrachlorophthalide (phthalide) 15:1 6:1 2:1 Compound 32 Picoxystrobin 1:1 1:2 1:5 Compound 32 Piperalin 3:1 1:1 1:3 Compound 32 Polyoxin 3:1 1:1 1:3 Compound 32 Cull fever (probenazole) 3:1 1:1 1:3 Compound 32 Poker Pull (prochloraz) 7:1 2:1 1:2 Compound 32 Procymidone 11:1 4:1 2:1 Compound 32 propamocarb or propamocarb-hydrochloride 10:1 4:1 2:1 Compound 32 Propiconazole (propiconazole) 1:1 1:2 1:5 Compound 32 Methyl Zinc Napo (propineb) 11:1 4:1 2:1 Compound 32 Proquinazid 1:1 1:3 1:12 Compound 32 prothiocarb 3:1 1:1 1:3 Compound 32 Prothioconazole 1:1 1:2 1:5 Compound 32 Pyraclostrobin 2:1 1:1 1:4 Compound 32 Pyraclostrobin (pyrametostrobin) 2:1 1:1 1:4 Compound 32 Pyraclostrobin (pyraoxystrobin) 2:1 1:1 1:4 Compound 32 white powder pine (pyrazophos) 15:1 4:1 1:1 Compound 32 pyribencarb 4:1 1:1 1:2 Compound 32 pyributicarb 15:1 4:1 1:1 Compound 32 pyrifenox 3:1 1:1 1:3 Compound 32 pyrimethanil 3:1 1:1 1:2 Compound 32 pyriofenone 2:1 1:1 1:4 Compound 32 pyrisoxazole 3:1 1:1 1:3 Compound 32 pyroquilon 3:1 1:1 1:3 Compound 32 pyrrolnitrin 15:1 5:1 2:1 Compound 32 quinconazole 1:1 1:2 1:4 Compound 32 quinomethionate 15:1 5:1 2:1 Compound 32 Quinoxyfen 1:1 1:2 1:6 Compound 32 Pentachloronitrobenzene (quintozene) 15:1 5:1 2:1 Compound 32 Silthiofam 2:1 1:1 1:4 Compound 32 simeconazole 1:1 1:2 1:5 Compound 32 Spiroxamine 5:1 2:1 1:2 Compound 32 streptomycin 3:1 1:1 1:3 Compound 32 sulfur 75:1 25:1 9:1 Compound 32 Dekeli (tebuconazole) 1:1 1:2 1:5 Compound 32 Tebufloquin 3:1 1:1 1:3 Compound 32 tecloftalam 15:1 5:1 2:1 Compound 32 Tetrachloronitrobenzene (tecnazene) 15:1 5:1 2:1 Compound 32 Terbinafine 15:1 5:1 2:1 Compound 32 Tetraconazole 1:1 1:2 1:5 Compound 32 thiabendazole 11:1 4:1 2:1 Compound 32 Thifluzamide 3:1 1:1 1:3 Compound 32 Multi-purification (thiophanate) 11:1 4:1 2:1 Compound 32 thiophanate-methyl 11:1 4:1 2:1 Compound 32 land of grace (thiram) 37:1 14:1 5:1 Compound 32 tiadinil 2:1 1:1 1:3 Compound 32 Tolclofos-methyl 37:1 14:1 5:1 Compound 32 tolnifanide 3:1 1:1 1:3 Compound 32 tolylfluanid 15:1 5:1 2:1 Compound 32 Triadimefon 1:1 1:2 1:5 Compound 32 triadimenol 1:1 1:2 1:5 Compound 32 Azoxymethanol (triarimol) 1:2 1:7 1:24 Compound 32 Imidazosin (triazoxide) 15:1 5:1 2:1 Compound 32 tricyclazole 3:1 1:1 1:3 Compound 32 Tridemorph 7:1 2:1 1:1 Compound 32 Trifloxystrobin 2:1 1:1 1:4 Compound 32 Triflumizole 3:1 1:1 1:3 Compound 32 triforine 3:1 1:1 1:3 Compound 32 Trimorphamide 7:1 2:1 1:2 Compound 32 Triticonazole 1:1 1:2 1:5 Compound 32 uniconazole 1:1 1:2 1:5 Compound 32 Validamycin 3:1 1:1 1:3 Compound 32 valifenalate 2:1 1:1 1:4 Compound 32 Vinclozolin 15:1 6:1 2:1 Compound 32 Zinc (zineb) 37:1 14:1 5:1 Compound 32 Zinc (ziram) 37:1 14:1 5:1 Compound 32 Zoxamide 2:1 1:1 1:4 Compound 32 5-Chloro-6-(2,4,6-trifluorophenyl)-7-(4-methylpiperidin-1-yl)[1,2,4]triazolazole[1,5-a] Pyrimidine (DPX-BAS600F) 1:1 1:2 1:6 Compound 32 N- [2-[4-[[3-(4-Chlorophenyl)-2-propyn-1-yl]oxy]-3-methoxyphenyl]ethyl]-3-methyl- 2-[(Methylsulfonyl)amino]butanamide 2:1 1:1 1:4 Compound 32 N- [2-[4-[[3-(4-Chlorophenyl)-2-propyn-1-yl]oxy]-3-methoxyphenyl]ethyl]-3-methyl- 2-[(Ethylsulfonyl)amino]butanamide 2:1 1:1 1:4 Compound 32 4-Fluorophenyl N- [1-[[[1-(4-cyanophenyl]ethyl]sulfonyl]methyl]propyl]carbamate 2:1 1:1 1:4 Compound 32 N -[[(Cyclopropylmethoxy)amino][6-(difluoromethoxy)-2,3-difluorophenyl]methylene]phenethylamine 1:2 1:7 1:24 Compound 32 α-[Methoxyimino] -N -methyl-2-[[[1-[3-(trifluoromethyl)phenyl]ethoxy]imino]methyl]phenethylamine 3:1 1:1 1:3 Compound 32 N '-[4-[4-Chloro-3-(trifluoromethyl)phenoxy]-2,5-dimethylphenyl] -N -ethyl- N -methylformamide 3:1 1:1 1:3 (*) Weight ratio of component (a) to component (b).

Each of Tables A2 to A21 is the same as Table A1 above, except that the entry below the "Component (a)" column heading is replaced with the corresponding "Component (a)" column entry shown below. Thus, for example, in Table A2, the entries under the column "Composition (a)" are all marked "Compound 64", and the first row under the column heading of Table A2 specifically discloses Compound 64 and thiadiazolin S-methyl (acibenzolar- S -methyl) mixture. Tables A3 to A21 are constructed in a similar manner. table number Component (a) entry table number Component (a) entry A2 Compound 64 A12 Compound 221 A3 Compound 71 A13 Compound 229 A4 Compound 126 A14 Compound 231 A5 Compound 127 A15 Compound 262 A6 Compound 132 A16 Compound 263 A7 Compound 162 A17 Compound 265 A8 Compound 163 A18 Compound 297 A9 Compound 171 A19 Compound 330 A10 Compound 186 A20 Compound 331 A11 Compound 218 A21 Compound 364

Table B1 lists specific combinations of component (b) compounds and component (a) illustrating the mixtures, compositions and methods of the present invention. The first column of Table B1 lists specific component (b) compounds (eg, "acibenzolar-S-methyl" in the first row). The second, third and fourth columns of Table B1 list the range of weight ratios at which the compound of component (a) is typically applied to field crops relative to component (b). Thus, for example, the first row of Table B1 discloses that the compound of component (a) and the thiadiazole are generally applied in a ratio by weight of component (a) to component (b) of 2:1 to 1:180 A combination of acibenzolar-S-methyl. The remaining rows of Table B1 should be interpreted similarly. Of particular note is the inclusion of any of the compounds listed in Specific Example 238 as component (a) to the compounds listed in column component (b) of Table B1 according to the weight ratios disclosed in Table B1 The composition of the mixture. Accordingly, Table B1 supplements the specific ratios disclosed in Tables A1 to A21 with these combined ratio ranges. Table B1 Component (b) Typical weight ratio Typical weight ratio most typical weight ratio acibenzolar-S-methyl 2:1 to 1:180 1:1 to 1:60 1:1 to 1:18 aldimorph 30:1 to 1:3 10:1 to 1:1 7:1 to 1:1 Metoctradin 9:1 to 1:18 3:1 to 1:6 3:1 to 1:3 Amisulbrom (amisulbrom) 6:1 to 1:18 2:1 to 1:6 1:1 to 1:6 anilazine 90:1 to 2:1 30:1 to 4:1 22:1 to 4:1 posaconazole (azaconazole) 7:1 to 1:18 2:1 to 1:6 2:1 to 1:4 azoxystrobin 9:1 to 1:12 3:1 to 1:4 3:1 to 1:3 benalaxyl 4:1 to 1:18 1:1 to 1:6 1:1 to 1:6 benalaxyl-M (benalaxyl-M) 4:1 to 1:36 1:1 to 1:12 1:1 to 1:8 Benodanil 18:1 to 1:6 6:1 to 1:2 4:1 to 1:2 benomyl 45:1 to 1:4 15:1 to 1:1 11:1 to 1:1 benthiavalicarb or benthiavalicarb-isopropyl 2:1 to 1:36 1:1 to 1:12 1:1 to 1:12 Bethoxazin 150:1 to 1:36 50:1 to 1:12 15:1 to 2:1 100 mite grams (binapacryl) 150:1 to 1:36 50:1 to 1:12 15:1 to 2:1 biphenyl 150:1 to 1:36 50:1 to 1:12 15:1 to 2:1 Bitertanol 15:1 to 1:5 5:1 to 1:2 3:1 to 1:2 bixafen 12:1 to 1:9 4:1 to 1:3 2:1 to 1:3 Blasticidin-S 3:1 to 1:90 1:1 to 1:30 1:4 to 1:30 boscalid 18:1 to 1:6 6:1 to 1:2 4:1 to 1:2 Bromuconazole 15:1 to 1:9 5:1 to 1:3 3:1 to 1:3 bupirimate 3:1 to 1:90 1:1 to 1:30 1:3 to 1:30 Captafol 90:1 to 1:4 30:1 to 1:2 15:1 to 2:1 captan 90:1 to 1:4 30:1 to 1:2 15:1 to 2:1 carbendazim 45:1 to 1:4 15:1 to 1:2 11:1 to 2:1 carboxin 18:1 to 1:6 6:1 to 1:2 4:1 to 1:2 Carpropamid 15:1 to 1:9 5:1 to 1:3 3:1 to 1:3 chloroneb 300:1 to 2:1 100:1 to 4:1 100:1 to 14:1 Tetrachloroisobenzene (chlorothalonil) 90:1 to 1:4 30:1 to 1:2 15:1 to 2:1 Chlozolinate 45:1 to 1:2 15:1 to 2:1 11:1 to 2:1 Clotrimazole 15:1 to 1:9 5:1 to 1:3 3:1 to 1:3 Copper salts such as Bordeaux mixture (tribasic copper sulfate), copper oxychloride, copper sulfate and copper hydroxide 450:1 to 1:1 150:1 to 4:1 45:1 to 5:1 Cyazofamid 4:1 to 1:18 1:1 to 1:6 1:1 to 1:6 Cyflufenamid 1:1 to 1:90 1:2 to 1:30 1:2 to 1:24 cymoxanil 6:1 to 1:18 2:1 to 1:6 1:1 to 1:5 Cyproconazole 4:1 to 1:18 1:1 to 1:6 1:1 to 1:6 Cyprodinil 22:1 to 1:9 7:1 to 1:3 4:1 to 1:2 Dichlofluanid 150:1 to 1:36 50:1 to 1:12 15:1 to 2:1 diclocymet 150:1 to 1:36 50:1 to 1:12 15:1 to 2:1 Diclomezine 15:1 to 1:9 5:1 to 1:3 3:1 to 1:3 dicloran 150:1 to 1:36 50:1 to 1:12 15:1 to 2:1 Diethofencarb 22:1 to 1:9 7:1 to 1:3 7:1 to 1:2 To be clear (difenoconazole) 4:1 to 1:36 1:1 to 1:12 1:1 to 1:12 Diflumetorim 150:1 to 1:36 50:1 to 1:12 15:1 to 2:1 Dimethirimol 3:1 to 1:90 1:1 to 1:30 1:3 to 1:30 Dimethomorph 9:1 to 1:6 3:1 to 1:2 3:1 to 1:2 Dimoxystrobin 9:1 to 1:18 3:1 to 1:6 2:1 to 1:4 diniconazole 3:1 to 1:36 1:1 to 1:12 1:1 to 1:8 diniconazole-M (diniconazole-M) 3:1 to 1:90 1:1 to 1:30 1:1 to 1:12 White powder gram (dinocap) 7:1 to 1:9 2:1 to 1:3 2:1 to 1:3 dithianon 15:1 to 1:4 5:1 to 1:2 5:1 to 1:2 Dodemorph 30:1 to 1:3 10:1 to 1:1 7:1 to 1:1 dodine 30:1 to 1:2 10:1 to 2:1 10:1 to 2:1 edifenphos 30:1 to 1:9 10:1 to 1:3 3:1 to 1:3 enestroburin 9:1 to 1:18 3:1 to 1:6 2:1 to 1:4 Eprazole (epoxiconazole) 3:1 to 1:36 1:1 to 1:12 1:1 to 1:7 etaconazole 3:1 to 1:36 1:1 to 1:12 1:1 to 1:7 Ethaboxam 7:1 to 1:9 2:1 to 1:3 2:1 to 1:3 Ethirimol 30:1 to 1:3 10:1 to 1:1 7:1 to 1:1 Etridiazole 30:1 to 1:9 10:1 to 1:3 7:1 to 1:2 Where to kill the same (famoxadone) 9:1 to 1:18 3:1 to 1:6 2:1 to 1:4 Fenamidone 6:1 to 1:18 2:1 to 1:6 2:1 to 1:4 Fenaminstrobin 9:1 to 1:18 3:1 to 1:6 3:1 to 1:3 Fenarimol 3:1 to 1:90 1:1 to 1:30 1:2 to 1:24 Fenbuconazole 3:1 to 1:30 1:1 to 1:10 1:1 to 1:10 Fenfuram (fenfuram) 18:1 to 1:6 6:1 to 1:2 4:1 to 1:2 fenhexamid 30:1 to 1:2 10:1 to 2:1 10:1 to 2:1 blastamide (fenoxanil) 150:1 to 1:36 50:1 to 1:12 15:1 to 1:1 Seed dressing (fenpiclonil) 75:1 to 1:9 25:1 to 1:3 15:1 to 2:1 Fenpropidin 30:1 to 1:3 10:1 to 1:1 7:1 to 1:1 fenpropimorph 30:1 to 1:3 10:1 to 1:1 7:1 to 1:1 Fenpyrazamine 100:1 to 1:100 10:1 to 1:10 3:1 to 1:3 Fentine salts, such as fentin acetate, fentin chloride, or fentin hydroxide 15:1 to 1:9 5:1 to 1:3 3:1 to 1:3 Ferbam 300:1 to 1:2 100:1 to 2:1 30:1 to 4:1 Ferimzone 30:1 to 1:5 10:1 to 1:2 7:1 to 1:2 fluazinam 22:1 to 1:5 7:1 to 1:2 3:1 to 1:2 Fludioxonil 7:1 to 1:12 2:1 to 1:4 2:1 to 1:4 Ethylene morpholine (flumetover) 9:1 to 1:6 3:1 to 1:2 3:1 to 1:2 flumorph 9:1 to 1:18 3:1 to 1:6 3:1 to 1:3 fluopicolide 3:1 to 1:18 1:1 to 1:6 1:1 to 1:6 Fluopyram 15:1 to 1:90 5:1 to 1:30 3:1 to 1:3 Fluorimide 150:1 to 2:1 50:1 to 4:1 37:1 to 5:1 Fluoxastrobin 4:1 to 1:18 1:1 to 1:6 1:1 to 1:6 Fluquinconazole 4:1 to 1:12 1:1 to 1:4 1:1 to 1:4 flusilazole 15:1 to 1:9 5:1 to 1:3 3:1 to 1:3 Flusulfamide 90:1 to 1:2 30:1 to 2:1 15:1 to 2:1 Flutianil 7:1 to 1:36 2:1 to 1:12 1:1 to 1:6 Flutolanil 18:1 to 1:6 6:1 to 1:2 4:1 to 1:2 Flutriafol 4:1 to 1:12 1:1 to 1:4 1:1 to 1:4 Sterilization Dan (fluxapyroxad) 12:1 to 1:9 4:1 to 1:3 2:1 to 1:3 Folpet 90:1 to 1:4 30:1 to 1:2 15:1 to 2:1 Fosetyl-aluminum 225:1 to 2:1 75:1 to 5:1 30:1 to 5:1 fuberidazole 45:1 to 1:4 15:1 to 1:2 11:1 to 2:1 furalaxyl 15:1 to 1:45 5:1 to 1:15 1:1 to 1:6 furametpyr 150:1 to 1:36 50:1 to 1:12 15:1 to 2:1 guazatine or imnoctadine 150:1 to 1:36 50:1 to 1:12 15:1 to 2:1 Fickley (hexaconazole) 15:1 to 1:36 5:1 to 1:12 1:1 to 1:5 hymexazole 225:1 to 2:1 75:1 to 4:1 75:1 to 9:1 Imazalil 7:1 to 1:18 2:1 to 1:6 1:1 to 1:5 imibenconazole 15:1 to 1:36 5:1 to 1:12 1:1 to 1:5 Iodopropynyl butylcarbamate (iodocarb) 150:1 to 1:36 50:1 to 1:12 15:1 to 2:1 ipconazole 15:1 to 1:36 5:1 to 1:12 1:1 to 1:5 Propylsiloxane (iprobenfos) 150:1 to 1:36 50:1 to 1:12 15:1 to 2:1 iprodione 120:1 to 1:2 40:1 to 2:1 15:1 to 2:1 iprovalicarb 9:1 to 1:9 3:1 to 1:3 2:1 to 1:3 isopyrazine (isoprothiolane) 150:1 to 2:1 50:1 to 4:1 45:1 to 5:1 isopyrazam 12:1 to 1:9 4:1 to 1:3 2:1 to 1:3 isotianil 12:1 to 1:9 4:1 to 1:3 2:1 to 1:3 Kasugamycin 7:1 to 1:90 2:1 to 1:30 1:2 to 1:24 Kresoxim-methyl 7:1 to 1:18 2:1 to 1:6 2:1 to 1:4 Mancozeb 180:1 to 1:3 60:1 to 2:1 22:1 to 3:1 mandipropamid 6:1 to 1:18 2:1 to 1:6 2:1 to 1:4 Maneb (maneb) 180:1 to 1:3 60:1 to 2:1 22:1 to 3:1 mepanipyrim 18:1 to 1:3 6:1 to 1:1 6:1 to 1:1 Mepronil 7:1 to 1:36 2:1 to 1:12 1:1 to 1:6 Meptyldinocap 7:1 to 1:9 2:1 to 1:3 2:1 to 1:3 metalaxyl 15:1 to 1:45 5:1 to 1:15 1:1 to 1:6 Metalaxyl-M (metalaxyl-M) 7:1 to 1:90 2:1 to 1:30 1:1 to 1:12 metconazole 3:1 to 1:18 1:1 to 1:6 1:1 to 1:6 Methasulfocarb 150:1 to 1:36 50:1 to 1:12 15:1 to 1:1 lest it rot (metiram) 150:1 to 1:36 50:1 to 1:12 15:1 to 1:1 Metominostrobin 9:1 to 1:12 3:1 to 1:4 3:1 to 1:3 Metrafenone 6:1 to 1:12 2:1 to 1:4 2:1 to 1:4 myclobutanil 5:1 to 1:26 1:1 to 1:9 1:1 to 1:8 Naftifine 150:1 to 1:36 50:1 to 1:12 15:1 to 2:1 Ammonium iron arsenate (neo-asozin) 150:1 to 1:36 50:1 to 1:12 15:1 to 2:1 Fluoropyrimidol (nuarimol) 15:1 to 1:9 5:1 to 1:3 3:1 to 1:3 octhilinone 150:1 to 1:36 50:1 to 1:12 15:1 to 1:1 Furamide (ofurace) 15:1 to 1:45 5:1 to 1:15 1:1 to 1:6 orysastrobin 9:1 to 1:12 3:1 to 1:4 3:1 to 1:3 oxadixyl 15:1 to 1:45 5:1 to 1:15 1:1 to 1:6 oxolinic acid 30:1 to 1:9 10:1 to 1:3 7:1 to 1:2 Oxpoconazole 15:1 to 1:36 5:1 to 1:12 1:1 to 1:5 oxycarboxin 18:1 to 1:6 6:1 to 1:2 4:1 to 1:2 Oxytetracycline 15:1 to 1:9 5:1 to 1:3 3:1 to 1:3 pefurazoate 150:1 to 1:36 50:1 to 1:12 15:1 to 2:1 penconazole 1:1 to 1:45 1:2 to 1:15 1:2 to 1:15 pencycuron 150:1 to 1:2 50:1 to 2:1 11:1 to 2:1 Flufenapyr (penflufen) 12:1 to 1:9 4:1 to 1:3 2:1 to 1:3 penthiopyrad 12:1 to 1:9 4:1 to 1:3 2:1 to 1:3 Phosphorous acid and its salts 150:1 to 1:36 50:1 to 1:12 15:1 to 2:1 Tetrachlorophthalide (phthalide) 150:1 to 1:36 50:1 to 1:12 15:1 to 2:1 Picoxystrobin 7:1 to 1:18 2:1 to 1:6 1:1 to 1:5 Piperalin 15:1 to 1:9 5:1 to 1:3 3:1 to 1:3 Polyoxin 15:1 to 1:9 5:1 to 1:3 3:1 to 1:3 Cull fever (probenazole) 15:1 to 1:9 5:1 to 1:3 3:1 to 1:3 Poker Pull (prochloraz) 22:1 to 1:4 7:1 to 1:1 7:1 to 1:2 Procymidone 45:1 to 1:3 15:1 to 1:1 11:1 to 2:1 propamocarb or propamocarb-hydrochloride 30:1 to 1:2 10:1 to 2:1 10:1 to 2:1 Propiconazole (propiconazole) 4:1 to 1:18 1:1 to 1:6 1:1 to 1:5 Methyl Zinc Napo (propineb) 45:1 to 1:2 15:1 to 2:1 11:1 to 2:1 Proquinazid 3:1 to 1:36 1:1 to 1:12 1:1 to 1:12 prothiocarb 9:1 to 1:18 3:1 to 1:6 3:1 to 1:3 Prothioconazole 6:1 to 1:18 2:1 to 1:6 1:1 to 1:5 Pyraclostrobin 9:1 to 1:18 3:1 to 1:6 2:1 to 1:4 Pyraclostrobin (pyrametostrobin) 9:1 to 1:18 3:1 to 1:6 2:1 to 1:4 Pyraclostrobin (pyraoxystrobin) 9:1 to 1:18 3:1 to 1:6 2:1 to 1:4 white powder pine (pyrazophos) 150:1 to 1:36 50:1 to 1:12 15:1 to 1:1 pyribencarb 15:1 to 1:6 5:1 to 1:2 4:1 to 1:2 pyrifenox 15:1 to 1:9 5:1 to 1:3 3:1 to 1:3 pyrimethanil 30:1 to 1:6 10:1 to 1:2 3:1 to 1:2 pyriofenone 6:1 to 1:12 2:1 to 1:4 2:1 to 1:4 pyrisoxazole 15:1 to 1:9 5:1 to 1:3 3:1 to 1:3 pyroquilon 15:1 to 1:9 5:1 to 1:3 3:1 to 1:3 pyrrolnitrin 150:1 to 1:36 50:1 to 1:12 15:1 to 2:1 quinconazole 4:1 to 1:12 1:1 to 1:4 1:1 to 1:4 Quethionate 150:1 to 1:36 50:1 to 1:12 15:1 to 2:1 Quinoxyfen 4:1 to 1:18 1:1 to 1:6 1:1 to 1:6 Pentachloronitrobenzene (quintozene) 150:1 to 1:36 50:1 to 1:12 15:1 to 2:1 Silthiofam 7:1 to 1:18 2:1 to 1:6 2:1 to 1:4 simeconazole 15:1 to 1:36 5:1 to 1:12 1:1 to 1:5 Spiroxamine 22:1 to 1:4 7:1 to 1:2 5:1 to 1:2 streptomycin 15:1 to 1:9 5:1 to 1:3 3:1 to 1:3 sulfur 300:1 to 3:1 100:1 to 9:1 75:1 to 9:1 Dekeli (tebuconazole) 7:1 to 1:18 2:1 to 1:6 1:1 to 1:5 Tebufloquin 100:1 to 1:100 10:1 to 1:10 3:1 to 1:3 tecloftalam 150:1 to 1:36 50:1 to 1:12 15:1 to 2:1 Tetrachloronitrobenzene (tecnazene) 150:1 to 1:36 50:1 to 1:12 15:1 to 2:1 Terbinafine 150:1 to 1:36 50:1 to 1:12 15:1 to 2:1 Tetraconazole 15:1 to 1:36 5:1 to 1:12 1:1 to 1:5 thiabendazole 45:1 to 1:4 15:1 to 1:2 11:1 to 2:1 Thifluzamide 15:1 to 1:9 5:1 to 1:3 3:1 to 1:3 Multi-purification (thiophanate) 45:1 to 1:3 15:1 to 2:1 11:1 to 2:1 thiophanate-methyl 45:1 to 1:3 15:1 to 2:1 11:1 to 2:1 land of grace (thiram) 150:1 to 1:2 50:1 to 2:1 37:1 to 5:1 tiadinil 12:1 to 1:9 4:1 to 1:3 2:1 to 1:3 Tolclofos-methyl 150:1 to 1:2 50:1 to 2:1 37:1 to 5:1 tolnifanide 15:1 to 1:18 5:1 to 1:6 3:1 to 1:3 tolylfluanid 150:1 to 1:36 50:1 to 1:12 15:1 to 2:1 Triadimefon 15:1 to 1:36 5:1 to 1:12 1:1 to 1:5 triadimenol 15:1 to 1:36 5:1 to 1:12 1:1 to 1:5 Azoxymethanol (triarimol) 3:1 to 1:90 1:1 to 1:30 1:2 to 1:24 Imidazosin (triazoxide) 150:1 to 1:36 50:1 to 1:12 15:1 to 2:1 tricyclazole 15:1 to 1:9 5:1 to 1:3 3:1 to 1:3 Tridemorph 30:1 to 1:3 10:1 to 1:1 7:1 to 1:1 Trifloxystrobin 6:1 to 1:18 2:1 to 1:6 2:1 to 1:4 Triflumizole 15:1 to 1:9 5:1 to 1:3 3:1 to 1:3 triforine 15:1 to 1:9 5:1 to 1:3 3:1 to 1:3 Trimorphamide 45:1 to 1:9 15:1 to 1:3 7:1 to 1:2 Triticonazole 15:1 to 1:36 5:1 to 1:12 1:1 to 1:5 uniconazole 15:1 to 1:36 5:1 to 1:12 1:1 to 1:5 Validamycin 150:1 to 1:36 50:1 to 1:12 3:1 to 1:3 valifenalate 6:1 to 1:18 2:1 to 1:6 2:1 to 1:4 Vinclozolin 120:1 to 1:2 40:1 to 2:1 15:1 to 2:1 Zinc (zineb) 150:1 to 1:2 50:1 to 2:1 37:1 to 5:1 Zinc (ziram) 150:1 to 1:2 50:1 to 2:1 37:1 to 5:1 Zoxamide 6:1 to 1:18 2:1 to 1:6 2:1 to 1:4 5-Chloro-6-(2,4,6-trifluorophenyl)-7-(4-methylpiperidin-1-yl)[1,2,4]triazolazole[1,5-a] Pyrimidine (DPX-BAS600F) 15:1 to 1:36 5:1 to 1:12 1:1 to 1:6 N- [2-[4-[[3-(4-Chlorophenyl)-2-propyn-1-yl]oxy]-3-methoxyphenyl]ethyl]-3-methyl- 2-[(Methylsulfonyl)amino]butanamide 6:1 to 1:18 2:1 to 1:6 2:1 to 1:4 N- [2-[4-[[3-(4-Chlorophenyl)-2-propyn-1-yl]oxy]-3-methoxyphenyl]ethyl]-3-methyl- 2-[(Ethylsulfonyl)amino]butanamide 6:1 to 1:18 2:1 to 1:6 2:1 to 1:4 4-Fluorophenyl N- [1-[[[1-(4-cyanophenyl]ethyl]sulfonyl]methyl]propyl]carbamate 6:1 to 1:18 2:1 to 1:6 2:1 to 1:4 N -[[(Cyclopropylmethoxy)amino][6-(difluoromethoxy)-2,3-difluorophenyl]methylene]phenethylamine 1:1 to 1:90 1:2 to 1:30 1:2 to 1:24 α-[Methoxyimino] -N -methyl-2-[[[1-[3-(trifluoromethyl)phenyl]ethoxy]imino]methyl]phenethylamine 9:1 to 1:18 3:1 to 1:6 3:1 to 1:3 N '-[4-[4-Chloro-3-(trifluoromethyl)phenoxy]-2,5-dimethylphenyl] -N -ethyl- N -methylformamide 15:1 to 1:18 5:1 to 1:6 3:1 to 1:3

As described above, the present invention includes a fungicidal compound wherein in the composition comprising the components (a) and (b), the component (b) comprises at least one selected from the two groups of (b1) to (b54). specific examples. Tables C1 to C21 list specific mixtures (compound numbers refer to compounds in Index Tables A to L) to illustrate specific examples, wherein component (b) comprises a compound selected from the two groups of (b1) to (b54). at least one fungicidal compound. In Table C1, each row under the column headings "Component (a)" and "Component (b)" specifically discloses the difference between component (a), which is compound 32, and at least two components (b) A mixture of fungicides. The entries under the heading "Illustrative Ratios" disclose, in turn, three specific weight ratios of component (a) to each component (b) fungicidal compound for the disclosed mixtures. For example, the first row discloses a mixture of compound 32 with cyproconazole and azoxystrobin, and lists the weight ratio of compound 32 with cyproconazole and azoxystrobin as 1: 1:1, 2:1:1 or 3:1:1. Table C1 Composition (a) Component (b) Illustrative scale (*) Compound 32 Cyproconazole azoxystrobin 1:1:1 2:1:1 3:1:1 Compound 32 Cyproconazole Kresoxim-methyl 1:1:1 2:1:1 3:1:1 Compound 32 Cyproconazole Picoxystrobin 1:1:1 2:1:1 3:1:1 Compound 32 Cyproconazole Pyraclostrobin 1:1:1 2:1:1 3:1:1 Compound 32 Cyproconazole Pyrametrostrobin 1:1:1 2:1:1 3:1:1 Compound 32 Cyproconazole Pyraclostrobin (pyraoxystrobin) 1:1:1 2:1:1 3:1:1 Compound 32 Cyproconazole Trifloxystrobin 1:1:1 2:1:1 3:1:1 Compound 32 Cyproconazole bixafen 1:1:2 2:1:2 3:1:2 Compound 32 Cyproconazole boscalid 1:1:2 2:1:2 3:1:2 Compound 32 Cyproconazole Cyflufenamid 1:2:1 2:2:1 3:2:1 Compound 32 Cyproconazole Fluopyram 1:1:2 2:1:2 3:1:2 Compound 32 Cyproconazole isopyrazam 1:1:2 2:1:2 3:1:2 Compound 32 Cyproconazole Metrafenone 1:1:2 2:1:2 3:1:2 Compound 32 Cyproconazole penthiopyrad 1:1:2 2:1:2 3:1:2 Compound 32 Cyproconazole Proquinazid 1:1:1 2:1:1 3:1:1 Compound 32 Cyproconazole pyriofenone 1:1:2 2:1:2 3:1:2 Compound 32 Cyproconazole Quinoxyfen 1:1:1 2:1:1 3:1:1 Compound 32 Cyproconazole Sedaxane 1:1:2 2:1:2 3:1:2 Compound 32 Cyproconazole Picoxystrobin Proquinazid 1:1:1:1 2:1:1:1 3:1:1:1 Compound 32 Cyproconazole Trifloxystrobin Proquinazid 1:1:1:1 2:1:1:1 3:1:1:1 Compound 32 Difenoconazole azoxystrobin 1:1:1 2:1:1 3:1:1 Compound 32 Difenoconazole Kresoxim-methyl 1:1:1 2:1:1 3:1:1 Compound 32 Difenoconazole Picoxystrobin 1:1:1 2:1:1 3:1:1 Compound 32 Difenoconazole Pyraclostrobin 1:1:1 2:1:1 3:1:1 Compound 32 Difenoconazole Pyraclostrobin (pyrametostrobin) 1:1:1 2:1:1 3:1:1 Compound 32 To be clear (difenoconazole) Pyraclostrobin (pyraoxystrobin) 1:1:1 2:1:1 3:1:1 Compound 32 Difenoconazole Trifloxystrobin 1:1:1 2:1:1 3:1:1 Compound 32 Difenoconazole bixafen 1:1:2 2:1:2 3:1:2 Compound 32 Difenoconazole boscalid 1:1:2 2:1:2 3:1:2 Compound 32 Difenoconazole Cyflufenamid 1:2:1 2:2:1 3:2:1 Compound 32 Difenoconazole Fluopyram 1:1:2 2:1:2 3:1:2 Compound 32 Difenoconazole isopyrazam 1:1:2 2:1:2 3:1:2 Compound 32 Difenoconazole Metrafenone 1:1:2 2:1:2 3:1:2 Compound 32 Difenoconazole penthiopyrad 1:1:2 2:1:2 3:1:2 Compound 32 Difenoconazole Proquinazid 1:1:1 2:1:1 3:1:1 Compound 32 Difenoconazole pyriofenone 1:1:2 2:1:2 3:1:2 Compound 32 Difenoconazole Quinoxyfen 1:1:1 2:1:1 3:1:1 Compound 32 Difenoconazole Sedaxane 1:1:2 2:1:2 3:1:2 Compound 32 Difenoconazole Picoxystrobin Proquinazid 1:1:1:1 2:1:1:1 3:1:1:1 Compound 32 Difenoconazole Trifloxystrobin Proquinazid 1:1:1:1 2:1:1:1 3:1:1:1 Compound 32 Eprazole (epoxiconazole) azoxystrobin 1:1:1 2:1:1 3:1:1 Compound 32 Eprazole (epoxiconazole) Kresoxim-methyl 1:1:1 2:1:1 3:1:1 Compound 32 Eprazole (epoxiconazole) Picoxystrobin 1:1:1 2:1:1 3:1:1 Compound 32 Eprazole (epoxiconazole) Pyraclostrobin 1:1:1 2:1:1 3:1:1 Compound 32 Eprazole (epoxiconazole) Pyraclostrobin (pyrametostrobin) 1:1:1 2:1:1 3:1:1 Compound 32 Eprazole (epoxiconazole) Pyraclostrobin (pyraoxystrobin) 1:1:1 2:1:1 3:1:1 Compound 32 Eprazole (epoxiconazole) Trifloxystrobin 1:1:1 2:1:1 3:1:1 Compound 32 Eprazole (epoxiconazole) bixafen 1:1:2 2:1:2 3:1:2 Compound 32 Eprazole (epoxiconazole) boscalid 1:1:2 2:1:2 3:1:2 Compound 32 Eprazole (epoxiconazole) Cyflufenamid 1:2:1 2:2:1 3:2:1 Compound 32 Eprazole (epoxiconazole) Fluopyram 1:1:2 2:1:2 3:1:2 Compound 32 Eprazole (epoxiconazole) isopyrazam 1:1:2 2:1:2 3:1:2 Compound 32 Eprazole (epoxiconazole) Metrafenone 1:1:2 2:1:2 3:1:2 Compound 32 Eprazole (epoxiconazole) penthiopyrad 1:1:2 2:1:2 3:1:2 Compound 32 Eprazole (epoxiconazole) Proquinazid 1:1:1 2:1:1 3:1:1 Compound 32 Eprazole (epoxiconazole) pyriofenone 1:1:2 2:1:2 3:1:2 Compound 32 Eprazole (epoxiconazole) Quinoxyfen 1:1:1 2:1:1 3:1:1 Compound 32 Eprazole (epoxiconazole) Sedaxane 1:1:2 2:1:2 3:1:2 Compound 32 Eprazole (epoxiconazole) Picoxystrobin Proquinazid 1:1:1:1 2:1:1:1 3:1:1:1 Compound 32 Eprazole (epoxiconazole) Trifloxystrobin Proquinazid 1:1:1:1 2:1:1:1 3:1:1:1 Compound 32 metconazole azoxystrobin 1:1:1 2:1:1 3:1:1 Compound 32 metconazole Kresoxim-methyl 1:1:1 2:1:1 3:1:1 Compound 32 metconazole Picoxystrobin 1:1:1 2:1:1 3:1:1 Compound 32 metconazole Pyraclostrobin 1:1:1 2:1:1 3:1:1 Compound 32 metconazole Pyraclostrobin (pyrametostrobin) 1:1:1 2:1:1 3:1:1 Compound 32 metconazole Pyraclostrobin (pyraoxystrobin) 1:1:1 2:1:1 3:1:1 Compound 32 metconazole Trifloxystrobin 1:1:1 2:1:1 3:1:1 Compound 32 metconazole bixafen 1:1:2 2:1:2 3:1:2 Compound 32 metconazole boscalid 1:1:2 2:1:2 3:1:2 Compound 32 metconazole Cyflufenamid 1:2:1 2:2:1 3:2:1 Compound 32 metconazole Fluopyram 1:1:2 2:1:2 3:1:2 Compound 32 metconazole isopyrazam 1:1:2 2:1:2 3:1:2 Compound 32 metconazole Metrafenone 1:1:2 2:1:2 3:1:2 Compound 32 metconazole penthiopyrad 1:1:2 2:1:2 3:1:2 Compound 32 metconazole Proquinazid 1:1:1 2:1:1 3:1:1 Compound 32 metconazole pyriofenone 1:1:2 2:1:2 3:1:2 Compound 32 metconazole Quinoxyfen 1:1:1 2:1:1 3:1:1 Compound 32 metconazole Sedaxane 1:1:2 2:1:2 3:1:2 Compound 32 metconazole Picoxystrobin Proquinazid 1:1:1:1 2:1:1:1 3:1:1:1 Compound 32 metconazole Trifloxystrobin Proquinazid 1:1:1:1 2:1:1:1 3:1:1:1 Compound 32 myclobutanil azoxystrobin 1:1:1 2:1:1 3:1:1 Compound 32 myclobutanil Kresoxim-methyl 1:1:1 2:1:1 3:1:1 Compound 32 myclobutanil Picoxystrobin 1:1:1 2:1:1 3:1:1 Compound 32 myclobutanil Pyraclostrobin 1:1:1 2:1:1 3:1:1 Compound 32 myclobutanil Pyraclostrobin (pyrametostrobin) 1:1:1 2:1:1 3:1:1 Compound 32 myclobutanil Pyraclostrobin (pyraoxystrobin) 1:1:1 2:1:1 3:1:1 Compound 32 myclobutanil Trifloxystrobin 1:1:1 2:1:1 3:1:1 Compound 32 myclobutanil bixafen 1:1:2 2:1:2 3:1:2 Compound 32 myclobutanil boscalid 1:1:2 2:1:2 3:1:2 Compound 32 myclobutanil Cyflufenamid 1:2:1 2:2:1 3:2:1 Compound 32 myclobutanil Fluopyram 1:1:2 2:1:2 3:1:2 Compound 32 myclobutanil isopyrazam 1:1:2 2:1:2 3:1:2 Compound 32 myclobutanil Metrafenone 1:1:2 2:1:2 3:1:2 Compound 32 myclobutanil penthiopyrad 1:1:2 2:1:2 3:1:2 Compound 32 myclobutanil Proquinazid 1:1:1 2:1:1 3:1:1 Compound 32 myclobutanil pyriofenone 1:1:2 2:1:2 3:1:2 Compound 32 myclobutanil Quinoxyfen 1:1:1 2:1:1 3:1:1 Compound 32 myclobutanil Sedaxane 1:1:2 2:1:2 3:1:2 Compound 32 myclobutanil Picoxystrobin Proquinazid 1:1:1:1 2:1:1:1 3:1:1:1 Compound 32 myclobutanil Trifloxystrobin Proquinazid 1:1:1:1 2:1:1:1 3:1:1:1 Compound 32 Prothioconazole azoxystrobin 1:1:1 2:1:1 3:1:1 Compound 32 Prothioconazole Kresoxim-methyl 1:1:1 2:1:1 3:1:1 Compound 32 Prothioconazole Picoxystrobin 1:1:1 2:1:1 3:1:1 Compound 32 Prothioconazole Pyraclostrobin 1:1:1 2:1:1 3:1:1 Compound 32 Prothioconazole Pyraclostrobin (pyrametostrobin) 1:1:1 2:1:1 3:1:1 Compound 32 Prothioconazole Pyraclostrobin (pyraoxystrobin) 1:1:1 2:1:1 3:1:1 Compound 32 Prothioconazole Trifloxystrobin 1:1:1 2:1:1 3:1:1 Compound 32 Prothioconazole bixafen 1:1:2 2:1:2 3:1:2 Compound 32 Prothioconazole boscalid 1:1:2 2:1:2 3:1:2 Compound 32 Prothioconazole Cyflufenamid 1:2:1 2:2:1 3:2:1 Compound 32 Prothioconazole Fluopyram 1:1:2 2:1:2 3:1:2 Compound 32 Prothioconazole isopyrazam 1:1:2 2:1:2 3:1:2 Compound 32 Prothioconazole Metrafenone 1:1:2 2:1:2 3:1:2 Compound 32 Prothioconazole penthiopyrad 1:1:2 2:1:2 3:1:2 Compound 32 Prothioconazole Proquinazid 1:1:1 2:1:1 3:1:1 Compound 32 Prothioconazole pyriofenone 1:1:2 2:1:2 3:1:2 Compound 32 Prothioconazole Quinoxyfen 1:1:1 2:1:1 3:1:1 Compound 32 Prothioconazole Sedaxane 1:1:2 2:1:2 3:1:2 Compound 32 Prothioconazole Picoxystrobin Proquinazid 1:1:1:1 2:1:1:1 3:1:1:1 Compound 32 Prothioconazole Trifloxystrobin Proquinazid 1:1:1:1 2:1:1:1 3:1:1:1 Compound 32 Dekeli (tebuconazole) azoxystrobin 1:1:1 2:1:1 3:1:1 Compound 32 Dekeli (tebuconazole) Kresoxim-methyl 1:1:1 2:1:1 3:1:1 Compound 32 Dekeli (tebuconazole) Picoxystrobin 1:1:1 2:1:1 3:1:1 Compound 32 Dekeli (tebuconazole) Pyraclostrobin 1:1:1 2:1:1 3:1:1 Compound 32 Dekeli (tebuconazole) Pyraclostrobin (pyrametostrobin) 1:1:1 2:1:1 3:1:1 Compound 32 Dekeli (tebuconazole) Pyraclostrobin (pyraoxystrobin) 1:1:1 2:1:1 3:1:1 Compound 32 Dekeli (tebuconazole) Trifloxystrobin 1:1:1 2:1:1 3:1:1 Compound 32 Dekeli (tebuconazole) bixafen 1:1:2 2:1:2 3:1:2 Compound 32 Dekeli (tebuconazole) boscalid 1:1:2 2:1:2 3:1:2 Compound 32 Dekeli (tebuconazole) Cyflufenamid 1:2:1 2:2:1 3:2:1 Compound 32 Dekeli (tebuconazole) Fluopyram 1:1:2 2:1:2 3:1:2 Compound 32 Dekeli (tebuconazole) isopyrazam 1:1:2 2:1:2 3:1:2 Compound 32 Dekeli (tebuconazole) Metrafenone 1:1:2 2:1:2 3:1:2 Compound 32 Dekeli (tebuconazole) penthiopyrad 1:1:2 2:1:2 3:1:2 Compound 32 Dekeli (tebuconazole) Proquinazid 1:1:1 2:1:1 3:1:1 Compound 32 Dekeli (tebuconazole) pyriofenone 1:1:2 2:1:2 3:1:2 Compound 32 Dekeli (tebuconazole) Quinoxyfen 1:1:1 2:1:1 3:1:1 Compound 32 Dekeli (tebuconazole) Sedaxane 1:1:2 2:1:2 3:1:2 Compound 32 Dekeli (tebuconazole) Picoxystrobin Proquinazid 1:1:1:1 2:1:1:1 3:1:1:1 Compound 32 Dekeli (tebuconazole) Trifloxystrobin Proquinazid 1:1:1:1 2:1:1:1 3:1:1:1 (*) Weight ratio of component (a) to component (b).

Each of Tables C2 to C21 is the same as Table C1 above, except that the entries under the "Component (a)" column heading are replaced with the corresponding "Component (a)" column entries shown below. Thus, for example, in Table C2, the entries under the column "Composition (a)" are all marked "Compound 64", and the first row under the column heading of Table C2 specifically discloses compound 64 with cyproconazole and sub-compound 64. Exemplary weight ratios of azoxystrobin, and Compound 64: cyproconazole: azoxystrobin are 1:1:1, 2:1:1, and 3:1:1. Tables C3 to C21 are constructed in a similar manner. table number Component (a) entry table number Component (a) entry C2 Compound 64 C12 Compound 221 C3 Compound 71 C13 Compound 229 C4 Compound 126 C14 Compound 231 C5 Compound 127 C15 Compound 262 C6 Compound 132 C16 Compound 263 C7 Compound 162 C17 Compound 265 C8 Compound 163 C18 Compound 297 C9 Compound 171 C19 Compound 330 C10 Compound 186 C20 Compound 331 C11 Compound 218 C21 Compound 364

Of note are compositions of the present invention comprising a compound of formula 1 (or an N -oxide or salt thereof) and at least one other fungicidal compound having a different site of action than the compound of formula 1 . In some cases, a combination with at least one other fungicidal compound having a similar range of control but a different site of action will be particularly beneficial for resistance management. Thus, the compositions of the present invention may advantageously comprise at least one fungicidally active compound selected from (b1) to (b54) as described above, which have a similar range of control but different sites of action.

Composition (a), or a combination of composition (a) and composition (b) may be further mixed with one or more other biologically active compounds or agents, including insecticides, nematicides, bactericides, acaricides herbicides, herbicides, herbicide safeners, growth regulators such as insect molt inhibitors and rooting stimulants, chemical sterilizers, repellants, attractants, pheromones, feeding stimulants, phytonutrients, other biological activities Compounds or entomopathogenic bacteria, viruses or fungi, forming multi-component pesticides that provide broader agricultural protection. Accordingly, the present invention also relates to compositions comprising a fungicidally effective amount of composition (a), or a mixture of composition (a) and composition (b), and a biologically effective amount of at least one additional biologically active compound or a composition of agents, and may further comprise a surfactant, a solid diluent, or a liquid diluent. Other biologically active compounds or agents may also be formulated in compositions comprising at least one of surfactants, solid or liquid diluents, respectively. For the compositions of the present invention, one or more other biologically active compounds or agents may be formulated with one or both of compositions (a) and (b) to form a premix, or one or more other biologically active compounds may be combined The compound or agent is formulated separately from compositions (a) and (b), combined (eg, in a spray tank) prior to administration, or administered sequentially.

Examples of such biologically active compounds that can be formulated with component (a), or a combination of component (a) and component (b) are: insecticides such as abamectin, acephate, acequinocyl , acetamiprid, acrinathrin , acynonapyr , afidopyropen ([(3S,4R,4aR,6S, 6a S ,12 R ,12a S ,12b S )-3-[(cyclopropylcarbonyl)oxy]-1,3,4,4a,5,6,6a,12,12a,12b-decahydro-6 ,12-Dihydroxymethyl- 4,6a ,12b-trimethyl-11-oxo-9-(3-pyridyl)-2H, 11H -naphtho[2,1- b ]pyrano [3,4-e]pyran-4-yl]methylcyclopropanecarboxylate), amidoflumet, amitraz, avermectin, azadirachtin ), azinphos-methyl, benfuracarb, bensultap, benzpyrimoxan, bifenthrin, kappa-bifenthrin , bifenazate, bistrifluron, boric acid, broflanilide, buprofezin, cadusafos, carbaryl, carbaryl Carbofuran, cartap, carzol, chlorantraniliprole, chlorfenapyr, chlorfluazuron, chloroprallethrin ), chlorpyrifos, chlorpyrifos-e, chlorpyrifos-methyl, chromafenozide, clofentezin, chloroprallethrin, Clothianidin, cyantraniliprole (3-chloro-2-pyridyl)-N-[4-cyano-2-methyl - 6-[(methylamino)carbonyl]benzene base]-1 H -pyrazol-5-carboxamide), cyclobromine ( cyclaniliprole) (3-bromo- N- [2-bromo-4-chloro-6-[[(1-cyclopropylethyl)amino]carbonyl]phenyl]-1-(3-chloro-2-pyridine base)-1H-pyrazol-5-carboxamide), cycloprothrin, cycloxaprid (( 5S , 8R )-1-[(6-chloro-3- pyridyl)methyl]-2,3,5,6,7,8-hexahydro-9-nitro-5,8-epoxy- 1H -imidazo[1,2- a ]aza), Cyenopyrafen, cyflumetofen, cyfluthrin, beta-cyfluthrin, cyhalodiamide, cyhalothrin, gamma Marcellonin (gamma-cyhalothrin), lambda-cyhalothrin, cypermethrin, alpha-cypermethrin, zeta-cypermethrin, cypermethrin (cyromazine), deltamethrin, diafenthiuron, diazinon, dicloromesotiaz, dieldrin, diflubenzuron, tetrafluoromethyl ether Dimefluthrin, Dimehypo, Dimethoate, Dimpropyridaz, Dinotefuran, Diofenolan, Emamectin, Dinotefuran Emamectin benzoate, endosulfan, esfenvalerate, ethiprole, etofenprox, epsilon-metofluthrin , etoxazole, fenbutatin oxide, fenitrothion, fenothiocarb, fenoxycarb, fenpropathrin, fenvalerate, fen Fipronil, flometoquin (2-ethyl-3,7-dimethyl-6-[4-(trifluoromethoxy)phenoxy]-4-quinolyl methyl carbonate) ),fluorine Flonicamid, fluazaindolizine, flubendiamide, flucythrinate, flufenerim, flufenoxuron, flufenoxystrobin ) (methyl(α E )-2-[[2-chloro-4-(trifluoromethyl)phenoxy]methyl]-α-(methoxymethylene)phenylacetate, methyl fluoride Fluensulfone (5-chloro-2-[(3,4,4-trifluoro-3-buten-1-yl)sulfonyl]thiazole), fluhexafon, fluopyram ), flupiprole (1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-5-[(2-methyl-2-propen-1-yl)amino) ]-4-[(Trifluoromethyl)sulfinyl]-1H-pyrazole-3-carbonitrile), flupyradifurone (4-[[(6-chloro-3-pyridyl)methyl ](2,2-difluoroethyl)amino]-2(5H)-furanone), flupyrimin, fluvalinate, tau-fluvalinate, fluoroethyl Fluxametamide, fonophos, formetanate, fosthiazate, gamma-cyhalothrin, halofenozide, heptafluthrin ([2,3,5,6-Tetrafluoro-4-(methoxymethyl)phenyl]methyl-2,2-dimethyl-3-[( 1Z )-3,3,3- Trifluoro-1-propen-1-yl]cyclopropane), hexaflumuron, hexythiazox, hydramethylnon, imidacloprid, indoxacarb, Insect soap, isofenphos, isocycloseram, kappa-tefluthrin, lambda-cyhalothrin, lufenuron, malathion, chlorine meperfluthrin ([2,3,5,6-tetrafluoro-4-(methoxymethyl)phenyl]methyl( 1R , 3S )-3-(2,2-dichloroethylene) base)-2,2-dimethylcyclopropanecarboxylate), metaflumizone, metaldehyde ), methamidophos, methidathion, methiocarb, methomyl, methoprene, methoxychlor, metofluthrin, methoxyfenozide, epsilon-metofluthrin, epsilon-momfluorothrin, monocrotophos, monofluorothrin ([2,3,5,6-tetrafluoro-4-(methoxy) Methyl)phenyl]methyl 3-(2-cyano-1-propen-1-yl)-2,2-dimethylcyclopropanecarboxylate), nicotine, nitenpyram ), nithiazine, novaluron, novoflumuron, oxamyl, oxazosulfyl, parathion, methylparathion Pine (parathion‑methyl), permethrin, phorate, phosalone, phosmet, phosphamidon, pirimicarb, buffysone (profenofos), profluthrin, propargite, protrifenbute, pyflubumide (1,3,5-trimethyl-N-(2-methyl) yl-1-oxopropyl)-N-[3-(2-methylpropyl)-4-[2,2,2-trifluoro-1-methoxy-1-(trifluoromethyl) ethyl]phenyl]-1H-pyrazole-4-carboxamide), pymetrozine, this, pyrafluprole, pyrethrin, pyridaben, pyridine Pyridalyl, pyrifluquinazon, pyriminostrobin (methyl(α E )-2-[[[2-[(2,4-dichlorophenyl)amino] -6-(trifluoromethyl)-4-pyrimidinyl]oxy]methyl]-α-(methoxymethylene)-phenylacetate methyl ester), pyriprole, pyriproxyfen , rotenone, ryanodine, silafluofen, spinetoram, Spinosad, Spirodiclofen, Spiromesifen, Spiropidion, Spirotetramat, Sulprofos, Quick Kill Fluorine (sulfoxaflor), ( N- [methyloxy[1-[6-(trifluoromethyl)-3-pyridyl]ethyl]-λ4-sulfinyl]cyanamide), Delfinol ( tebufenozide, tebufenpyrad, teflubenzuron, tefluthrin, kappa-tefluthrin, terbufos, tetrachlorantraniliprole, Tetrachlorvinphos, tetramethrin, tetramethylfluthrin ([2,3,5,6-tetrafluoro-4-(methoxymethyl)phenyl]2, 2,3,3-tetramethylcyclopropanecarboxylate), tetraniliprole, thiacloprid, thiamethoxam, thiodicarb, thiodicarb ( thiosultap-sodium), tioxazafen (3-phenyl-5-(2-thienyl)-1,2,4-oxadiazole), tolfenpyrad, tralomethrin, pyricarb ( triazamate, trichlorfon, triflumezopyrim (2,4-dioxo-1-(5-pyrimidinylmethyl)-3-[3-(trifluoromethyl)phenyl] -2H-pyrido[1,2- a ]pyrimidine inner salt), triflumuron , tyclopyrazoflor, zeta-cypermethrin, Bacillus thuringiensis ) delta-endotoxin, entomopathogenic bacteria, entomopathogenic viruses, or entomopathogenic fungi.

One specific example of a biological agent for use in admixture with the compounds of the present invention includes entomopathogenic bacteria, such as Bacillus thuringiensis , and entrapped thuringiensis delta-endotoxins, such as those prepared by the ^CellCap® method MVP ^® and MVPII ^® bioinsecticides (CellCap ^® , MVP ^® and MVPII ^® are trademarks of Mycogen Corporation, Indianapolis, IN, USA); entomopathogenic fungi, such as green muscarinic fungi; entomopathogenic fungi Sexual (naturally occurring and genetically modified) viruses, including baculoviruses, nucleopolyhedro virus (NPV) such as Helicoverpa zea nucleopolyhedrovirus (HzNPV), celery armyworm ( Anagrapha falcifera ) ) nuclear polyhedrosis virus (AfNPV); and granulosis virus (GV) such as Cydia pomonella granulosis virus (CpGV).

General references for these pesticide protectants (ie, insecticides, fungicides, nematicides, acaricides, herbicides, and biologicals) include The Pesticide Manual , 13th Edition, edited by CDS Tomlin, Crop Protection UK Commission, Farnham, Surrey, UK, 2003, and The BioPesticide Manual , 2nd Edition, edited by LGCopping, UK Crop Protection Council, Farnham, Surrey, UK, 2001.

For embodiments in which one or more of these different mixing partners are used, the weight ratio of these different mixing partners (total) to component (a) or the mixture of component (a) and component (b) is typically in the range of about 1 : between 3000 and about 3000:1. Notably, a weight ratio between about 1:100 and about 3000:1, or between about 1:30 and about 300:1 (eg, a ratio between about 1:1 and about 30:1). Clearly, the inclusion of these additional components expands the range of diseases controlled beyond those controlled by component (a) alone or a mixture of components (a) and (b).

Component (a) compounds and/or combinations thereof with component (b) compounds and/or one or more other biologically active compounds or agents may be used for genetic transformation to express proteins that are toxic to invertebrate pests (e.g. delta-endotoxin) plants. The effect of exogenously administered component (a) alone or in combination with component (b) may be synergistic with the expressed toxin protein.

Notably, a combination or composition comprising component (a) or components (a) and (b) as described in the Summary of the Invention further comprises at least one invertebrate pest control compound or medicament (e.g. agents, acaricides). Of particular note are compositions comprising component (a) and at least one (ie, one or more) invertebrate pest control compounds or agents, which can then be subsequently combined with component (b) to provide components comprising Components (a) and (b) and one or more invertebrate pest control compounds or agents. Alternatively, without first mixing with component (b), a biologically effective amount of a composition comprising component (a) and at least one invertebrate pest control agent may be applied to the plant or plant seed (either directly or through the plant). or the environment of plant seeds) to protect plants or plant seeds from diseases caused by fungal pathogens as well as invertebrate pests.

For embodiments in which one or more invertebrate pest control compounds are used, the weight ratio of these compounds (total) to component (a) compounds is typically between about 1:3000 and about 3000:1. Notably, a weight ratio of about 1:300 to about 300:1 (eg, a ratio between about 1:30 to about 30:1). A person skilled in the art can easily determine the biologically effective amount of active ingredient required for the desired range of biological activity by simple experimentation.

Of note is the composition of the present invention which, in addition to the compound of component (a), alone or in combination with component (b), comprises at least one invertebrate pest control compound selected from the group consisting of Or medicines: abamectin, acetamiprid, acrinathrin, acynonapyr, afidopyropen, amitraz, avermectin, Azadirachtin, benfuracarb, bensultap, bifenthrin, buprofezin, broflanilide, cadusafos, carbaryl ( carbaryl, cartap, chlorantraniliprole, chloroprallethrin, chlorfenapyr, chlorpyrifos, clothianidin, cyanogen cyantraniliprole, cyclaniliprole, cycloprothrin, cyfluthrin, beta-cyfluthrin, cyhalothrin, gamma gamma-cyhalothrin, lambda-cyhalothrin, cypermethrin, alpha-cypermethrin, zeta-cypermethrin, cypermethrin cyromazine), (deltamethrin), dieldrin, dinotefuran, diofenolan, emamectin, endosulfan, epsilon epsilon-metofluthrin, esfenvalerate, ethiprole, etofenprox, etoxazole, fenitrothion, fenothiocarb, fenoxycarb, fenvalerate, fipronil, flometoquin, fluxametam ide), flonicamid, flubendiamide, fluensulfone, flufenoxuron, flufenoxystrobin, flufensulfone, flupirtine flupiprole, flupyrimin, flupyradifurone, fluvalinate, formetanate, fosthiazate, gamma-cyhalothrin, sevoflurane Heptafluthrin, hexaflumuron, hydramethylnon, imidacloprid, indoxacarb, isocycloseram, kappa-tefluthrin, beta-cyhalothrin lambda-cyhalothrin, lufenuron, meperfluthrin, metaflumizone, methiodicarb, methomyl, methoprene , methoxyfenozide, metofluthrin, monofluorothrin, nitenpyram, nithiazine, novaluron, oxamyl, fluorine spray pyflubumide, pymetrozine, pyrethrin, pyridaben, pyridalyl, pyriminostrobin, pyriproxyfen , ryanodine, spinetoram, spinosad, spirodiclofen, spiromesifen, spirotetramat, sulfoxaflor , tebufenozide, tetramethrin, tetramethylfluthrin, thiacloprid, thiamethoxam, thiodicarb, thiosultap -sod ium), tralomethrin, triazamate, triflumezopyrim, triflumuron, tyclopyrazoflor, zeta-cypermethrin , Bacillus thuringiensis delta-endotoxin, all thuringiensis strains, and all strains of Nucleo polyhydrosis .

In some cases, the compounds of component (a) of the present invention, alone or in admixture with component (b), in combination with other biologically active (particularly fungicidal) compounds or agents (ie, active ingredients) may result in Greater than additive (ie, synergistic) effects. Reducing the amount of active ingredients released into the environment while ensuring effective pest control has always been the goal. This combination may be beneficial for reducing crop production costs as well as reducing environmental burden when increased efficiency of fungicidally active ingredients occurs when application rates reach agriculturally satisfactory fungal control rates.

Table D1 lists specific combinations of invertebrate pest control agents with compound 32 as component (a) (compound numbers refer to compounds in index Tables A to L), which exemplify mixtures comprising these active ingredients and Compositions and methods of using them in accordance with the present invention are invented. The second column of Table D1 lists specific invertebrate pest control agents (eg, "avermectin" in the first row). The third column of Table D1 lists the mode of action (if known) or chemical class of the invertebrate pest control agent. The fourth column of Table D1 lists specific examples of weight ratio ranges relative to the proportions at which Compound 32 alone or in combination with component (b) is typically applied as an invertebrate pest control agent (eg, Avi The weight ratio of avermectin to compound 32 was "50:1 to 1:50"). Thus, for example, the first row of Table D1 specifically discloses that the combination of Compound 32 and avermectin is typically administered in a weight ratio of 50:1 to 1:50. The remaining rows of Table D1 will be interpreted similarly. Thus, for example, the first row of Table D1 specifically discloses that the combination of Compound 32 and avermectin is typically administered in a weight ratio of 50:1 to 1:50. The remaining rows of Table D1 will be interpreted similarly. Form D1 table number Invertebrate pest control reagents Mode of action or chemical classification Typical weight ratio Compound 32 avermectin Macrocyclic lactones 50:1 to 1:50 Compound 32 Acetamiprid Neonicotines (neonicotinoids) 150:1 to 1:200 Compound 32 Amitraz (Amitraz) Octopamine receptor ligand 200:1 to 1:100 Compound 32 Avermectin Macrocyclic lactones 50:1 to 1:50 Compound 32 Azadirachtin ecdysone binding agent 100:1 to 1:120 Compound 32 Beta-cyfluthrin Sodium Channel Modulator 150:1 to 1:200 Compound 32 Bifenthrin Sodium Channel Modulator 100:1 to 1:10 Compound 32 Buprofezin Chitin synthesis inhibitor 500:1 to 1:50 Compound 32 Pedan (Cartap) Neurotoxin (nereistoxin) analogs 100:1 to 1:200 Compound 32 Chlorantraniliprole ryanodine receptor modulator 100:1 to 1:120 Compound 32 Chlorfenapyr mitochondrial electron transport inhibitor 300:1 to 1:200 Compound 32 Chlorpyrifos Cholinesterase inhibitors 500:1 to 1:200 Compound 32 Clothianidin Neonicotines (neonicotinoids) 100:1 to 1:400 Compound 32 Cyantraniliprole ryanodine receptor modulator 100:1 to 1:120 Compound 32 Cyfluthrin Sodium Channel Modulator 150:1 to 1:200 Compound 32 Cyhalothrin Sodium Channel Modulator 150:1 to 1:200 Compound 32 Cypermethrin Sodium Channel Modulator 150:1 to 1:200 Compound 32 Cyromazine Chitin synthesis inhibitor 400:1 to 1:50 Compound 32 Deltamethrin Sodium Channel Modulator 50:1 to 1:400 Compound 32 Dieldrin Cyclodiene insecticide 200:1 to 1:100 Compound 32 Dinotefuran Neonicotines (neonicotinoids) 150:1 to 1:200 Compound 32 Diofenolan molting inhibitor 150:1 to 1:200 Compound 32 Emamectin Macrocyclic lactones 50:1 to 1:10 Compound 32 Endosulfan Cyclodiene insecticide 200:1 to 1:100 Compound 32 Esfenvalerate Sodium Channel Modulator 100:1 to 1:400 Compound 32 Fenprole (Ethiprole) GABA-regulated chloride channel antagonists 200:1 to 1:100 Compound 32 Fenothiocarb 150:1 to 1:200 Compound 32 Fenoxycarb Youth hormone simulation 500:1 to 1:100 Compound 32 Fenvalerate Sodium Channel Modulator 150:1 to 1:200 Compound 32 Fipronil GABA-regulated chloride channel antagonists 150:1 to 1:100 Compound 32 Flonicamide 200:1 to 1:100 Compound 32 Flubendiamide ryanodine receptor modulator 100:1 to 1:120 Compound 32 Flufenoxuron Chitin synthesis inhibitor 200:1 to 1:100 Compound 32 Hexaflumuron Chitin synthesis inhibitor 300:1 to 1:50 Compound 32 Hydramethylnon mitochondrial electron transport inhibitor 150:1 to 1:250 Compound 32 Imidacloprid Neonicotines (neonicotinoids) 1000:1 to 1:1000 Compound 32 Indoxacarb Sodium Channel Modulator 200:1 to 1:50 Compound 32 Lambda-cyhalothrin Sodium Channel Modulator 50:1 to 1:250 Compound 32 Lufenuron Chitin synthesis inhibitor 500:1 to 1:250 Compound 32 Meperfluthrin Sodium Channel Modulator 100:1 to 1:400 Compound 32 Metaflumizone 200:1 to 1:200 Compound 32 Methomyl Cholinesterase inhibitors 500:1 to 1:100 Compound 32 Methoprene Youth hormone simulation 500:1 to 1:100 Compound 32 Methoxyfenozide ecdysone binding agent 50:1 to 1:50 Compound 32 Nitenpyram Neonicotines (neonicotinoids) 150:1 to 1:200 Compound 32 Nithiazine Neonicotines (neonicotinoids) 150:1 to 1:200 Compound 32 Novaluron Chitin synthesis inhibitor 500:1 to 1:150 Compound 32 Oxamyl Cholinesterase inhibitors 200:1 to 1:200 Compound 32 Pymetrozine 200:1 to 1:100 Compound 32 Pyrethrin Sodium Channel Modulator 100:1 to 1:10 Compound 32 Pyridaben mitochondrial electron transport inhibitor 200:1 to 1:100 Compound 32 Pyridalyl 200:1 to 1:100 Compound 32 Pyriproxyfen Youth hormone simulation 500:1 to 1:100 Compound 32 Ryanodine ryanodine receptor modulator 100:1 to 1:120 Compound 32 Spinetoram Macrocyclic lactones 150:1 to 1:100 Compound 32 Spinosad Macrocyclic lactones 500:1 to 1:10 Compound 32 Spirodiclofen Lipid biosynthesis inhibitor 200:1 to 1:200 Compound 32 Spiromesifen Lipid biosynthesis inhibitor 200:1 to 1:200 Compound 32 Sulfoxaflor 200:1 to 1:200 Compound 32 Tebufenozide ecdysone binding agent 500:1 to 1:250 Compound 32 Tetramethylfluthrin Sodium Channel Modulator 100:1 to 1:40 Compound 32 Thiacloprid Neonicotines (neonicotinoids) 100:1 to 1:200 Compound 32 Thiamethoxam Neonicotines (neonicotinoids) 1250:1 to 1:1000 Compound 32 Thiodicarb Cholinesterase inhibitors 500:1 to 1:400 Compound 32 Insecticidal double (Thiosultap-sodium) 150:1 to 1:100 Compound 32 Tralomethrin Sodium Channel Modulator 150:1 to 1:200 Compound 32 Triazamate Cholinesterase inhibitors 250:1 to 1:100 Compound 32 Triflumuron Chitin synthesis inhibitor 200:1 to 1:100 Compound 32 Bacillus thuringiensis biological reagent 50:1 to 1:10 Compound 32 thuringiensis delta-endotoxin biological reagent 50:1 to 1:10 Compound 32 NPV (eg Gemstar) biological reagent 50:1 to 1:10

Each of Tables D2 to D21 is the same as Table D1 above, except that the entries below the column heading "Component (a)" are replaced by the corresponding "Column Entry for Components (a)" shown below replace. Thus, for example, in Table D2, the entries under the column "Composition (a)" are all marked "Compound 64", and the first row under the column heading of Table D2 specifically discloses the relationship between Compound 64 and abamectin. mixture. Tables D3 to D21 are constructed in a similar manner. table number Component (a) entry table number Component (a) entry D2 Compound 64 D12 Compound 221 D3 Compound 71 D13 Compound 229 D4 Compound 126 D14 Compound 231 D5 Compound 127 D15 Compound 262 D6 Compound 132 D16 Compound 263 D7 Compound 162 D17 Compound 265 D8 Compound 163 D18 Compound 297 D9 Compound 171 D19 Compound 330 D10 Compound 186 D20 Compound 331 D11 Compound 218 D21 Compound 364

Compositions comprising a compound of formula 1 useful in seed treatment may further comprise bacteria and fungi capable of preventing the deleterious effects of phytopathogenic fungi or bacteria and/or soil animals such as nematodes. Bacteria that exhibit nematicidal properties may include, but are not limited to, Bacillus firmus , B. Cereus, B. Subtiliis , and Pasteuria penetrans ). A suitable B. firmus strain is the strain CNCM I-1582 (GB-126) available under the trade name BioNem ^™ . A suitable Bacillus cereus strain is the NCMM I-1592 strain. Both strains of Bacillus are disclosed in US Pat. No. 6,406,690. Other suitable bacteria exhibiting nematicidal activity are B. amyloliquefaciens IN937a and B. subtilis strain GB03. Bacteria exhibiting fungicidal properties may include, but are not limited to, B. pumilus strain GB34. Fungal species exhibiting nematicidal properties may include, but are not limited to, Myrothecium verrucaria , Paecilomyces lilacinus , and Purpureocillium lilacinum .

The seed treatment may also include one or more nematicides of natural origin, such as a trigger protein called harpin, which is isolated from certain bacterial plant pathogens such as Erwinia amylovora . An example is the Harpin-N-Tek seed treatment technology, commercially available as N-Hibit ^™ GoldCST.

The seed treatment may also include one or more legume rhizobia, such as the microsymbiotic nitrogen-fixing bacterium Bradyrhizobium japonicum . These inoculants optionally include one or more lipo-chitooligosaccharides (LCOs), which are nodulation (Nod) factors produced by rhizobia during the onset of nodulation of legume roots. For example, Optimize® brand seed treatment technology combines LCO PromoteR Technology ^TM with an inoculant.

The seed treatment may also include one or more isoflavones, which increase root colonization by mycorrhizal fungi. Mycorrhizal fungi improve plant growth by increasing root uptake of nutrients such as water, sulfates, nitrates, phosphates, and metals. Examples of isoflavones include, but are not limited to, genistein, chickpea sprouts A, formononetin, daidzein, glycidin, hesperetin, naringenin, and plastase. Formononetin can be used, for example, as an active ingredient in PHC Colonize® AG mycorrhizal inoculation products.

The seed treatment may also include one or more plant activators that induce systemic acquired resistance in the plant upon contact with the pathogen. An example of a plant activator that induces this protective mechanism is acitophen- S -methyl.

In the present fungicidal composition, the compound of formula 1 of component (a) can act synergistically with other fungicidal compounds of component (b) to provide beneficial effects such as widening the range of plant diseases controlled, prolonged prevention and Duration of therapeutic protection, and inhibition of proliferation of resistant fungal pathogens. In certain specific embodiments, compositions are provided in accordance with the present invention comprising a ratio of component (a) to component (b) that is particularly useful for controlling specific fungal diseases (eg, Alternaria Solani ) , Blumeria graminis f.Sp. tritici , Botrytis Cinerea, Puccinia recondita f.Sp. tritici , Rhizoctonia Solani, Rhizoctonia Solani Septoria nodorum ), wheat leaf spot ( Septoria tritici ).

Mixtures of fungicides can also provide better disease control than would be expected based on the activity of the individual constituent components. This synergy has been described as "the synergy of the two components in the mixture so that the total effect is greater or longer than the sum of the two (or more) actions taken independently" (see PML Tames, Neth. J. Plant Pathology 1964 , 70 , 73–80). In a method of providing plant disease control, a synergistic effect is exhibited from a combination of active ingredients (eg, fungicidal compounds) applied to a plant or seed, in a synergistic weight ratio and synergistically (ie, synergistically effective) amount of active ingredient applied. The measures for disease prevention, suppression and prevention cannot exceed 100%. Thus, the expression of substantial synergy generally requires the use of application rates of active ingredients, where the active ingredients each provide far less than 100% effect, and thus their additive effect is substantially less than 100%, to allow for increased effect due to synergy possibility. On the other hand, an application rate of the active ingredient that is too low may show that, even in the case of a synergistic effect, not much activity is shown in the mixture. Those skilled in the art can readily identify and optimize the weight ratios and application rates (ie, application rates) of fungicidal compounds that provide synergistic effects through simple experimentation.

。The existence of synergy between the two active ingredients was determined by means of the Colby equation (see Colby, SR "Calculating Synergistic and Antagonistic Responses of Herbicide Combinations", Weeds , (1967), 15, 20‑22):

.

Using Colby's method, it can be determined that there is a synergistic interaction between the two active ingredients by first calculating the predicted activity p of the mixture based on the activities of the two components administered separately. If p is lower than the experimentally determined effect, then synergy has occurred. In the above equation, A is the fungicidal activity in percent control of one of the constituents applied alone at the ratio x. Item B is the fungicidal activity in percent control of the second set of components applied at rate y. This equation estimates p, the expected fungicidal activity of a mixture of A at ratio x and the fungicidal activity of a mixture of B at ratio y, if their effects are strictly additive and no interaction occurs.

化合物編號 R¹³ L A NMR 分子量 1 (實施例1) EtOC(=O) CH₂ OCH₂ *    5 EtOC(=O) CH₂ OCH(Me) *    35 EtOC(=O) CH(Me) OCH₂ *    36 c -PrCH₂ NHC(=O) CH₂ OCH₂ * 400 (M+1) 37 MeOC(=O) CH₂ OCH₂ * 361 (M+1) 38 CH₂ =CHCF₂ OC(=O) CH₂ OCH₂    423 (M+1) 39 i -PrOC(=O) CH₂ OCH₂ * 389 (M+1) 40 CH₂ =C(Me)CH₂ OC(=O) CH₂ OCH₂ * 401 (M+1) 42 n -PrOC(=O) CH₂ OCH₂ * 389 (M+1) 43 CH₂ =CHCH₂ OC(=O) CH₂ OCH₂ * 387 (M+1) 44 HC≡CCH₂ OC(=O) CH₂ OCH₂ * 385 (M+1) 45 CF₃ CH₂ OC(=O) CH₂ OCH₂ * 429 (M+1) 46 CF₃ CF₂ CH₂ OC(=O) CH₂ OCH₂ * 479 (M+1) 47 PhCH₂ OC(=O) CH₂ OCH₂ * 437 (M+1) 48 CH₃ (CH₂ )₅ OC(=O) CH₂ OCH₂ * 431 (M+1) 49 3,4-di-Cl-PhCH₂ OC(=O) CH₂ OCH₂ * 505 (M+1) 50 3,4-di-F-PhCH₂ OC(=O) CH₂ OCH₂ * 473 (M+1) 51 EtOC(=O) CH₂ CH(OH)CH₂ *    66 EtOC(=O) CH₂ CH₂ CH₂ * 355 (M+1) 131 EtOC(=O) CH₂ CH₂ OCH₂ *    206 N≡C CH₂ OCH₂ *    227 EtOC(=O) CH₂ OCF₂ *    286 EtOC(=O) (CH₂ )₃ OCH₂ * 403 (M+1) 322 Br CH₂ OCH₂ * 383 (M+1) 329 HOC(=O) CH₂ OCH₂ * 327 (M-1) 381 EtOC(=O) CH₂ N(C≡N)CH₂    381 (M+1) 388 CF₃ CH₂ OCH₂    351 (M-1) 389 NO₂ CH₂ OCH₂    346 (M-1) *有關¹⁹ F NMR數據，請參閱索引表M。 索引表 A1

化合物編號 R¹³ L (R⁸ )_q NMR 分子量 264 EtOC(=O) CH₂ 3-F *    376 EtOC(=O) CH₂ 2-F    393 (M+1) 409 EtOC(=O) CH₂ 3-I    501 (M+1) 431 EtOC(=O) CH₂ 2,3-di-F    411 (M+1) 444 EtOC(=O) CH₂ 3-Me    389 (M+1) 455 NO₂ CH₂ 3-F    346 (M-1) 456 CF₃ CH₂ 3-F    369 (M-1) 459 EtOC(=O) CH₂ 3-Cl    409 (M+1) 465 EtOC(=O) CH₂ 2,3,5,6-四氟    447 (M+1) *有關¹⁹ F NMR數據，請參閱索引表M。 索引表 A2

化合物編號 R¹³ L A 分子量 熔點(℃) 68 CF₃ CH₂ NHC(=O) CH₂ OCH₂ 445 (M+1) 116-120 69 c -PrCH₂ NHC(=O) CH₂ OCH₂ 417 (M+1)    135

CH₂ OCH₂ 453 (M+1)    136 EtOC(=O) CH₂ OCH₂ 392 (M+1)    215

CH₂ OCH₂ 403 (M+1) 140-144 223 MeOCH₂ CH₂ NHC(=O) CH₂ OCH₂ 421 (M+1)    索引表 B

L欄中的破折號「–」代表L為一直接鍵。 化合物 編號 E L A NMR 分子量 熔點(℃) 2 CF₃ C(OH)₂ CH₂ O – OCH₂ *    105-109 29 CH₃ CH₂ S(=O)₂ CH₂ OCH₂ *       30 1-吲哚基 CH₂ CH₂ CH₂    332 (M+1)    31 MeS(=O)₂ – OCH₂ *    102-106 33 MeOC(=O)NHN=CH – OCH₂ *    140-145 34 Me₂ NS(=O)₂ – OCH₂ *    142-146 41 3-(Me₂ NC(=O))-4,5-二氫-5-異噁唑基 – OCH₂ *       80 CH₃ C(=O) – OCH₂ *       97 EtOC(=O)CH=CHCH₂ O – OCH₂ *       142 N≡C – OCH₂ *       177 HC(=O) – OCH₂ *       229 MeOC(=O) – OCH₂    279 (M-1)    233 3-(EtOC(=O))-1H -吡唑-1-基 CH₂ OCH₂ *       234 5-(EtOC(=O))-1H -吡唑-1-基 CH₂ OCH₂ *       247 5-(c -PrCH₂ NHC(=O))-2-噁唑基 CH₂ OCH₂    401 (M+1)    256 5-(c -PrCH₂ NHC(=O))-2-噻唑基 CH₂ OCH₂    417 (M+1) 126-130 274 5-(CF₃ CH₂ NHC(=O))-2-噁唑基 CH₂ OCH₂    429 (M+1) 75-79 277 5-(CF₃ CH₂ NHC(=O))-2-噻唑基 CH₂ OCH₂    445 (M+1) 110-114 280 NO₂ – OCH₂ *       295 5-(F₂ CHCH₂ NHC(=O))-2-噻唑基 CH₂ OCH₂    427 (M+1)    366 (實施例8) 4-(EtOC(=O))-1H -吡唑-1-基-CH₂ O – OCH₂ **       369 CH₃ – OCH(C(=O)OMe *       384

– OCH₂    320 (M+1)    387 CF₃ – OCH₂    271 (M-1)    396 CH₃ – OCH₂ *       432 MeO CH₂ OCH₂ *       *有關¹⁹ F NMR數據，請參閱索引表M。 **有關¹ H NMR數據，請參閱索引表N。 索引表C

化合物編號 R¹³ L A M NMR 分子量 3 n -PrOC(=O) CH₂ OCH₂ CH₂ * 415 (M+1) 4 EtOC(=O) CH₂ OCH₂ C(=O) * 415 (M+1) 6 EtOC(=O) CH₂ OCH(Me) CH₂ *    7 [註 1] EtOC(=O) CH₂ OCH₂ CH(Me) *    8 [註 2] EtOC(=O) CH₂ OCH₂ CH(Me) *    12 (實施例3) EtOC(=O) CH₂ OCH₂ C(Me)₂ *    13 MeOC(=O) CH₂ OCH₂ CH₂ * 387 (M+1) 14 i -PrOC(=O) CH₂ OCH₂ CH₂ * 415 (M+1) 15 HC≡CCH₂ OC(=O) CH₂ OCH₂ CH₂ * 411 (M+1) 16 CH₃ (CH₂ )₅ OC(=O) CH₂ OCH₂ CH₂ * 457 (M+1) 17 3,4-di-Cl-PhCH₂ OC(=O) CH₂ OCH₂ CH₂ * 531 (M+1) 18 3,4-di-F-PhCH₂ OC(=O) CH₂ OCH₂ CH₂ * 499 (M+1) 26 EtOC(=O) CH(CH₃ ) OCH₂ CH₂ * 413 (M-1) 32 (實施例2)以及(實施例4) EtOC(=O) CH₂ OCH₂ CH₂ *    67 EtOC(=O) CH₂ CH₂ CH₂ CH₂ * 397 (M-1) 93 HOC(=O) CH₂ OCH₂ CH₂ *    115 EtOC(=O) CH₂ SCH₂ CH₂    417 (M+1) 125 n- BuOC(=O) CH₂ OCH₂ CH₂    429 (M+1) 126 i- BuOC(=O) CH₂ OCH₂ CH₂ * 429 (M+1) 127 c- PrCH₂ OC(=O) CH₂ OCH₂ CH₂ * 427 (M+1) 133 EtOC(=O) CH₂ CH₂ OCH₂ CH₂ *    134 CF₃ CH₂ OC(=O) CH₂ OCH₂ CH₂ * 453 (M-1) 141 EtOC(=O) CH₂ CH₂ OCH₂ CH₂ *    161 Cl(CH₂ )₃ OC(=O) CH₂ OCH₂ CH₂ * 449 (M+1) 162 MeOCH₂ CH₂ OC(=O) CH₂ OCH₂ CH₂ * 431 (M+1) 163 CH₃ C≡CCH₂ OC(=O) CH₂ OCH₂ CH₂ * 425 (M+1) 164 N≡CCH₂ NHC(=O) CH₂ OCH₂ CH₂ * 411 (M+1) 169 CH₃ C(=O)CH₂ OC(=O) CH₂ OCH₂ CH₂ * 429 (M+1) 170 PhC(=O)CH₂ OC(=O) CH₂ OCH₂ CH₂ * 491 (M+1) 171 N≡C(CH₂ )₃ OC(=O) CH₂ OCH₂ CH₂ * 440 (M+1) 172 N≡CCH₂ OC(=O) CH₂ OCH₂ CH₂ *    188 CH₂ =CHCH₂ OC(=O) CH₂ OCH₂ CH₂    413 (M+1) 197 CF₃ CH₂ NHC(=O) CH₂ OCH₂ CH₂ * 454 (M+1) 198 Me₂ NC(=O) CH₂ OCH₂ CH₂ * 400 (M+1) 199 2-吡啶基-CH₂ OC(=O) CH₂ OCH₂ CH₂ * 464 (M+1) 200 3-吡啶基-CH₂ OC(=O) CH₂ OCH₂ CH₂ * 464 (M+1) 201 4-吡啶基-CH₂ OC(=O) CH₂ OCH₂ CH₂ * 464 (M+1) 202 c -己基-C(=O)CH₂ OC(=O) CH₂ OCH₂ CH₂ * 497 (M+1) 203 MeOC(=O)CH₂ OC(=O) CH₂ OCH₂ CH₂ * 445 (M+1) 204 1,3-二氧戊環-2-基-CH₂ OC(=O) CH₂ OCH₂ CH₂ * 459 (M+1) 209 N≡C CH₂ OCH₂ CH₂ *    228 CH₂ =C(CH₃ )CH₂ OC(=O) CH₂ OCH₂ CH₂ * 427 (M+1) 240 EtOCH₂ CH₂ OCH₂ CH₂ * 387 (M+1) 249 c -BuCH₂ OC(=O) CH₂ OCH₂ CH₂ * 441 (M+1) 272 c -己基-CH₂ OC(=O) CH₂ OCH₂ CH₂ * 469 (M+1) 284 c -戊基-CH₂ OC(=O) CH₂ OCH₂ CH₂ * 455 (M+1) 285 [註 4] CH₃ CH=CHCH₂ OC(=O) CH₂ OCH₂ CH₂ * 427 (M+1) 296 EtOC(=O) (CH₂ )₃ OCH₂ CH₂ * 429 (M+1) 318 c- BuOC(=O) CH₂ OCH₂ CH₂ * 427 (M+1) 319 EtOC(=O) CH₂ OCF₂ CH₂ * 437 (M+1) 443 EtOC(=O) CH₂ NHCH₂ CH₂ *    *有關¹⁹ F NMR數據，請參閱索引表M。 註1： 87:13 非鏡像異構物之混合物。 註2： 33:67 非鏡像異構物之混合物。 註4： 60:40順反異構物之混合物。 索引表 D

化合物編號 T NMR 分子量 9

*    10

*    20

*    21

* 400 (M+1) 52

*    187

   429 (M+1) *有關¹⁹ F NMR數據，請參閱索引表M。 索引表 E

L欄中的破折號「–」代表L為一直接鍵。 化合物編號 E L A NMR 分子量 22 3-(Me₂ NC(=O))-4,5-二氫-5-異噁唑基 – OCH₂ *    23 CH₃ CH₂ S(=O)₂ CH₂ OCH₂ *    24 CH₃ S(=O)₂ – OCH₂ *    25 (Me)₂ NS(=O)₂ – OCH₂ *    27 MeOC(=O)NHN=CH – OCH₂ *    28

– OCH₂ *    76 i -BuS(=O)₂ NH CH₂ OCH₂    396 (M-1) 77 c -己基-NHC(=S)NH CH₂ OCH₂    419 (M+1) 78 EtOC(=O)NH CH₂ OCH₂    350 (M+1) 98 N≡C – OCH₂ * 274 (M+1) 112 i -BuOC(=O)NH CH₂ OCH₂ *    160 5-(EtOC(=O)-1-吲唑基 CH₂ OCH₂ *    166 NO₂ – OCH₂ *    173 5-(CF₃ )-1,2,4-惡二唑-3-基 – OCH₂    385 (M+1) 174 NH₂ CH₂ OCH₂ *    175 i -PrC(=O)NH CH₂ OCH₂    348 (M+1) 176 c -PrC(=O)NH CH₂ OCH₂ *    178 OH CH₂ OCH₂    301 (M+23) 179 3-CF₃ -PhC(=O)NH CH₂ OCH₂ *    189 MeOC(=O) – OCH₂ * 307 (M+1) 190 Ph – OCH₂ *    191 PhO – OCH₂ *    192 Ph CH₂ OCH₂ *    207 CF₃ S(=O)₂ NH CH₂ OCH₂    408 (M-1) 212 CF₃ CH₂ C(=O)NH CH₂ OCH₂    388 (M+1) 214 MeOCH(CH₃ )C(=O)NH CH₂ OCH₂ *    232 3-(EtOC(=O))-1H -吡唑-1-基 CH₂ OCH₂ *    235 i -PrC(=O)N(OMe) CH₂ OCH₂ *    236 c -PrC(=O)N(OMe) CH₂ OCH₂ *    237 n -PrC(=O)N(OMe) CH₂ OCH₂ *    238 t -BuOC(=O)N(OMe) CH₂ OCH₂    430 (M+23) 239 N≡C CH₂ OCH₂ *    281 2-(MeS)-4-嘧啶基 CH₂ OCH₂    387 (M+1) 282 2-(MeS(=O)₂ )-4-嘧啶基 CH₂ OCH₂    419 (M+1) 283 2-(F₂ CHCH₂ O)-4-嘧啶基 CH₂ OCH₂    421 (M+1) 289

CH₂ OCH₂ *    290

CH₂ OCH₂ *    314              

CH₂ OCH₂    457 (M+1) 372

– OCH₂    346 (M+1) 382

– OCH₂    396 (M+1) 411

– OCH₂    375 (M+1) *有關¹⁹ F NMR數據，請參閱索引表M。 索引表 E1

化合物編號 R¹³ M L A 分子量 熔點(℃) 70 4-(CF₃ CH₂ NHC(=O)) S CH₂ OCH₂ 471 (M+1)    71 4-(c -PrCH₂ NHC(=O)) S CH₂ OCH₂ 443 (M+1) 88-92 137 4-(EtOC(=O)) S CH₂ OCH₂ 418 (M+1) 74-78 248 5-(c -PrCH₂ NHC(=O)) O CH₂ OCH₂ 427 (M+1)    257 5-(CF₃ CH₂ NHC(=O)) O CH₂ OCH₂ 455 (M+1) 99-103 259 5-(c -PrCH₂ NHC(=O)) S CH₂ OCH₂ 443 (M+1) 117-121 275 5-(CF₃ CH₂ NHC(=O)) S CH₂ OCH₂ 471(M+1)    索引表 F

R¹³ 欄中的破折號「–」表示R¹³ 取代基不存在，且剩餘的碳價被氫原子佔據。L欄中的破折號「–」表示L為一直接鍵。除非另有說明，否則上述結構中雙鍵周圍的取代基之結構如結構所示。 化合物 編號 R¹³ L A R^2c NMR 分子量 (M+1) 熔點(℃) 53 EtOC(=O) CH₂ O CH₃ *       54 EtOC(=O) CH₂ O CH₂ CH₂ OMe *       55 EtOC(=O) CH₂ O CH₂ CH=CH₂ *       56 EtOC(=O) CH₂ O CH₂ C≡CH *       57 EtOC(=O) CH₂ O CH(CH₃ )₂ *       64 (實施例5) EtOC(=O) CH₂ O CH₂ CH₃ *    58-59 65 EtOC(=O) CH₂ O CH₂ CH₂ CH₃ *       89 t -BuOC(=O) CH₂ O CH₂ CH₃ *       106 CF₃ CH₂ NHC(=O) CH₂ O CH₂ CH₃       109-113 107 N≡CCH₂ NHC(=O) CH₂ O CH₂ CH₃       114-118 116 HOC(=O) CH₂ O CH₂ CH₃ *    127-131 117 c -PrCH₂ NHC(=O) CH₂ O CH₂ CH₃       106-110 118 i -PrNHC(=O) CH₂ O CH₂ CH₃       114-118 132 EtOC(=O) (CH₂ )₂ O CH₂ CH₃ *       138 MeOC(=O) CH₂ O CH₂ CH₃       105-109 139 i -PrOC(=O) CH₂ O CH₂ CH₃    399    140 EtOC(=O) CH₂ CH₂ CH₂ CH₃ *       145 EtOC(=O) CH₂ O CH₂ CH₂ OH *       151 – CH₂ O CH₂ CH₃ *       167 EtOC(=O) CH₂ CH₂ O CH₂ CH₃ *       180 Cl CH₂ O CH₂ CH₃ *       182 CF₃ CH₂ O CH₂ CH₃ *       183 Br CH₂ O CH₂ CH₃ *       185 CH≡CCH₂ OC(=O) CH₂ O CH₂ CH₃       69-73 186 PhCH₂ OC(=O) CH₂ O CH₂ CH₃       63-67 205 N≡C CH₂ O CH₂ CH₃ *       216 MeC(=O)CH₂ OC(=O) CH₂ O CH₂ CH₃       64-68 217 n- PrOC(=O) CH₂ O CH₂ CH₃    399    218 n- BuOC(=O) CH₂ O CH₂ CH₃    413    219 i- BuOC(=O) CH₂ O CH₂ CH₃    413    220 c- PrCH₂ OC(=O) CH₂ O CH₂ CH₃    411    221 Cl(CH₂ )₃ OC(=O) CH₂ O CH₂ CH₃    433    222 MeOCH₂ CH₂ OC(=O) CH₂ O CH₂ CH₃       79-83 242 CH₂ =C(Me)CH₂ OC(=O) CH₂ O CH₂ CH₃    411    243 CH₃ C≡CCH₂ OC(=O) CH₂ O CH₂ CH₃       105-109 244 PhC(=O)CH₂ OC(=O) CH₂ O CH₂ CH₃       114-118 245 N≡CCH₂ CH₂ OC(=O) CH₂ O CH₂ CH₃ *    81-85 246 CH₂ =CHCH₂ OC(=O) CH₂ O CH₂ CH₃    397    267 EtOC(=O) CH(Me) O CH₂ CH₃ *       294 EtOC(=O) (CH₂ )₃ O CH₂ CH₃ * 413    298 EtOC(=O) CH₂ O CH₂ CF₃ *       316 EtOC(=O) – O CH₂ CH₃    371    328 HOC(=O) (CH₂ )₂ O CH₂ CH₃ *       354 MeOC(=O) (CH₂ )₂ O CH₂ CH₃ * 385    380 EtOC(=O) CH₂ N(C≡N) CH₂ CH₃    371    400 EtOC(=O) CH₂ O CH₂ C≡N    396    413 c -丙基-NHC(=O) CH₂ O CH₂ CH₃    396    414 CH₃ NHC(=O) CH₂ O CH₂ CH₃    370    422 EtOC(=O) CH₂ O S(=O)₂ CF₃    489    427 MeOC(=O)CH₂ NHC(=O) CH₂ O CH₂ CH₃    428    428 c -戊基-NHC(=O) CH₂ O CH₂ CH₃    424    435 2-嘧啶基-CH₂ NHC(=O) CH₂ O CH₂ CH₃    448    436 CF₂ HCH₂ NHC(=O) CH₂ O CH₂ CH₃    420    437 CH₃ CH₂ NHC(=O) CH₂ O CH₂ CH₃    384    438 (CH₃ CH₂ )₂ NC(=O) CH₂ O CH₂ CH₃    412    *有關¹⁹ F NMR數據，請參閱索引表M。 索引表 F1

除非另有說明，否則上述結構中雙鍵周圍的取代基之結構如結構所示。 化合物編號 R¹³ L (R⁸ )_q R^2c NMR 分子量 (M+1) 熔點(℃) 262 EtOC(=O) CH₂ 3-F CH₂ CH₃ *       344 EtOC(=O) CH₂ 3-Br CH₂ CH₃ * 463 88-89 374 EtOC(=O) CH₂ 3-I CH₂ CH₃    511    375 EtOC(=O) CH₂ 2-F CH₂ CH₃    403    410 EtOC(=O) CH₂ 3-Me CH₂ CH₃    399    416 EtOC(=O) CH₂ 3-C≡N CH₂ CH₃    410    430 EtOC(=O) CH₂ 2,3-di-F CH₂ CH₃    421    458 EtOC(=O) CH₂ 3-Cl CH₂ CH₃    419    464 EtOC(=O) CH₂ 2,3,5,6-四氟 CH₂ CH₃    457    *有關¹⁹ F NMR數據，請參閱索引表M。 索引表 G

L欄中的破折號「–」表示L為一直接鍵。除非另有說明，否則上述結構中雙鍵周圍的取代基之結構如結構所示。 化合物編號 E L A R^2d R^2c NMR 分子量 58

– O H CH₂ CH₃ *    60 CH₃ S(=O)₂ – O H CH₂ CH₃ *    61 (Me)₂ NS(=O)₂ – O H CH₂ CH₃ *    62 CH₃ CH₂ S(=O)₂ CH₂ O H CH₂ CH₃ *    72 HOC(=O) – O H CH₂ CH₃ * 275 (M-1) 73 i -PrOC(=O) – O H CH₂ CH₃ * 318 (M+1) 74 CH₂ =CHCH₂ OC(=O) – O H CH₂ CH₃ * 317 (M+1) 75 CH≡CCH₂ OC(=O) – O H CH₂ CH₃ * 313 (M-1) 79 CH₃ C(=O) – O H CH₂ CH₃ *    83

CH₂ O H CH₂ CH₃ * 401 (M+1) 84

CH₂ O H CH₂ CH₃ * 401 (M+1) 85 5-(CH₃ OC(=O))-1H -咪唑-1-基 CH₂ O H CH₂ CH₃ * 371 (M+1) 86 4-(CH₃ OC(=O))-1H -咪唑-1-基 CH₂ O H CH₂ CH₃ * 371 (M+1) 87

CH₂ O H CH₂ CH₃ * 364 (M+1) 88

CH₂ O H CH₂ CH₃ * 364 (M+1) 90 3-(EtOC(=O)-5-(MeO))-1H -吡唑-1-yl CH₂ O H CH₂ CH₃ * 415 (M+1) 91

CH₂ O H CH₂ CH₃ * 420 (M+1) 92

CH₂ O H CH₂ CH₃ * 360 (M+1) 94 n -PrOC(=O) – O H CH₂ CH₃ *    95 EtOC(=O) – O H CH₂ CH₃ * 305 (M+1) 96 EtOC(=O)CH=CHCH₂ O – O H CH₂ CH₃ *    99 NH₂ C(=O) – O H CH₂ CH₃ * 274 (M+1) 100 c -PrNHC(=O) – O H CH₂ CH₃ * 316 (M+1) 101 i- PrNHC(=O) – O H CH₂ CH₃ * 318 (M+1) 102 CH≡CCH₂ NHC(=O) – O H CH₂ CH₃ * 314 (M+1) 103 CH₂ =CHCH₂ NHC(=O) – O H CH₂ CH₃ * 316 (M+1) 104 n -PrNHC(=O) – O H CH₂ CH₃ * 318 (M+1) 105 MeNHC(=O) – O H CH₂ CH₃ * 290 (M+1) 109 t- BuOC(=O)NH CH₂ O H CH₂ CH₃    261 (M+1) 110 NH₂ CH₂ O H CH₂ CH₃    262 (M+1) 111 EtOC(=O)NH CH₂ O H CH₂ CH₃ *    113 CF₃ CH₂ C(=O)NH CH₂ O H CH₂ CH₃ *    114 MeOCH(CH₃ )C(=O)NH CH₂ O H CH₂ CH₃ *    119

CH₂ O H CH₂ CH₃ * 386 (M+1) 120

CH₂ O H CH₂ CH₃ * 386 (M+1) 121

CH₂ O H CH₂ CH₃ * 386 (M+1) 143

– O H CH₂ CH₃ *    144 N≡C – O H CH₂ CH₃ *    148 HC(=O) – O H CH₂ CH₃       149 EtS(=O)₂ NH CH₂ O H CH₂ CH₃ *    150 EtC(=O)NH CH₂ O H CH₂ CH₃ *    152 3,5-di-Me-1H -吡唑-1-基 CH₂ O H CH₂ CH₃ * 341 (M+1) 153 4-(EtOC(=O))-1H -咪唑-1-基 CH₂ O H CH₂ CH₃ * 385 (M+1) 154 N≡C CH₂ O H CH₂ CH₃ *    155 N≡CS CH₂ O H CH₂ CH₃ *    156 1H -咪唑-1-基 CH₂ O H CH₂ CH₃ * 313 (M+1) 184

CH₂ O H CH₂ CH₃ *    193 NH₂ C(=O)O CH₂ O H CH₂ CH₃ *    195 OH CH₂ O H CH₂ CH₃ *    196 EtNHC(=O)O CH₂ O H CH₂ CH₃ *    210 i- PrC(=O)NH CH₂ O H CH₂ CH₃ * 332 (M+1) 211 c- PrC(=O)NH CH₂ O H CH₂ CH₃    331 (M+1) 224

CH₂ O H CH₂ CH₃ * 330 (M+1) 225

CH₂ O H CH₂ CH₃ * 358 (M+1) 226

CH₂ O H CH₂ CH₃ * 380 (M+1) 230 MeOC(=O) – O H CH₂ CH₃ * 291 (M+1) 268 4-(EtOC(=O))-1-哌啶基 CH₂ O H CH₂ CH₃ * 402 (M+1) 269 3-(EtOC(=O))-1-哌啶基 CH₂ O H CH₂ CH₃ * 402 (M+1) 270 [註 7] 4-(EtOC(=O))-吡啶-1-基 CH₂ O H CH₂ CH₃ *    271 [註 7] 3-(EtOC(=O))-吡啶-1-基 CH₂ O H CH₂ CH₃ *    278

– O H CH₂ CH₃ *    279 NO₂ – O H CH₂ CH₃ *    287

CH₂ O H CH₂ CH₃ *    288

CH₂ O H CH₂ CH₃ *    297 4-(EtOC(=O))-1H -吡唑-1-基-CH₂ O CH₂ O H CH₂ CH₃ * 412 (M-1) 306

CH₂ O H CH₂ CH₃    405 (M+1) 307

CH₂ O H CH₂ CH₃    403 (M+1) 308

CH₂ O H CH₂ CH₃    371 (M+1) 309 4-(MeOC(=O))-1-哌啶基 CH₂ O H CH₂ CH₃ * 388 (M+1) 310 3-(MeOC(=O))-1-吡咯烷基 CH₂ O H CH₂ CH₃ * 374 (M+1) 311 4-(N≡C)-1-哌啶基 CH₂ O H CH₂ CH₃ * 355 (M+1) 312 4-(MeO)-1-哌啶基 CH₂ O H CH₂ CH₃ * 360 (M+1) 313             

CH₂ O H CH₂ CH₃    441 (M+1) 364 (實施例9) 4-(EtOC(=O))-1H -吡唑-1-基-CH₂ O – O H CH₂ CH₃    401 (M+1) 371 c -PrC(=O)NH – O H CH₂ CH₃    316 (M+1) 373

– O H CH₂ CH₃    330 (M+1) 379 2-F-PhC(=O)O – O H CH₂ CH₃    371 (M+1) 383

– O H CH₂ CH₃    380 (M+1) 412

– O H CH₂ CH₃    359 (M+1) 426 4-(2,4-di-F-PhNHC(=O))-1H -吡唑-1-基 – O    CH₂ CH₃    468 (M+1) 433 MeO CH₂ O H CH₂ CH₃ *    434 ClCH₂ – O H CH₂ CH₃ **    445 MeC(=O)S CH₂ O H CH₂ CH₃ *    461 2-F-PhC(=O)NH – O H CH₂ CH₃    370 (M+1) *有關¹⁹ F NMR數據，請參閱索引表M。 **有關¹ H NMR數據，請參閱索引表N。 註7：HBr鹽類。 索引表 H

除非另有說明，否則上述結構中雙鍵周圍的取代基之結構如結構所示。 化合物編號 R¹³ L A R^2d R^2c NMR 分子量 158 3-CH₃ CH₂ O H CH₂ CH₃ * 371 (M+1) 181 3-CF₃ CH₂ O H CH₂ CH₃ * 379 (M-1) 231 3-(EtOC(=O)) CH₂ O H CH₂ CH₃ *    241 5-(EtOC(=O)) CH₂ O H CH₂ CH₃ *    250 5-(MeOC(=O)) CH₂ O H CH₂ CH₃ * 371 (M+1) 251 3-(MeOC(=O)) CH₂ O H CH₂ CH₃ * 371 (M+1) 252 5-(t -BuOC(=O)) CH₂ O H CH₂ CH₃ * 411 (M-1) 253 3-(t -BuOC(=O)) CH₂ O H CH₂ CH₃ * 411 (M-1) 291 3-(CH₂ =CHCH₂ OC(=O)) CH₂ O H CH₂ CH₃ * 397 (M+1) 292 3-(n -PrOC(=O)) CH₂ O H CH₂ CH₃ * 399 (M+1) 293 3-(CH₃ C≡CCH₂ OC(=O)) CH₂ O H CH₂ CH₃ * 409 (M+1) 299 3-(HOC(=O)) CH₂ O H CH₂ CH₃ *    325 3-(HC≡CCH₂ OC(=O)) CH₂ O H CH₂ CH₃ * 395 (M+1) 326 3-(CH₃ CH₂ C≡CCH₂ OC(=O)) CH₂ O H CH₂ CH₃ * 423 (M+1) 327 3-(i -PrOC(=O)) CH₂ O H CH₂ CH₃ * 399 (M+1) 356 3-(n -BuOC(=O)) CH₂ O H CH₂ CH₃ * 413 (M+1) 357 3-(i -BuOC(=O)) CH₂ O H CH₂ CH₃ * 413 (M+1) 358 3-(CH₂ =C(Me)CH₂ OC(=O)) CH₂ O H CH₂ CH₃ * 411 (M+1) 359 3-(CH₃ C(=O)CH₂ OC(=O)) CH₂ O H CH₂ CH₃ * 413 (M+1) 360 3-(MeOCH₂ CH₂ OC(=O)) CH₂ O H CH₂ CH₃ * 415 (M+1) 361 3-(c -BuCH₂ OC(=O)) CH₂ O H CH₂ CH₃ * 425 (M+1) 362 3-(ClCH₂ CH₂ CH₂ OC(=O)) CH₂ O H CH₂ CH₃ * 433 (M+1) *有關¹⁹ F NMR數據，請參閱索引表M。 索引表 I

R¹³ 欄中的破折號「–」表示R¹³ 取代基不存在，且剩餘的碳價被氫原子佔據。除非另有說明，否則上述結構中雙鍵周圍的取代基之結構如結構所示。 化合物編號 R¹³ L A R^2d R^2c NMR 分子量 81 5-CN CH₂ O H CH₂ CH₃ * 337 (M-1) 82 3-CN CH₂ O H CH₂ CH₃ * 337 (M-1) 122 5-(MeOC(=O)) CH₂ O H CH₂ CH₃ * 370 (M-1) 123 3-(MeOC(=O)) CH₂ O H CH₂ CH₃ * 370 (M-1) 157 – CH₂ O H CH₂ CH₃ * 312 (M-1) 260 5-MeS CH₂ O H CH₂ CH₃ * 358 (M-1) 261 3-MeS CH₂ O H CH₂ CH₃ * 360 (M+1) *有關¹⁹ F NMR數據，請參閱索引表M。 索引表 J

除非另有說明，否則上述結構中雙鍵周圍的取代基之結構如結構所示。 化合物編號 R¹³ M L A R^2d R^2c NMR 分子量 129 4-(CF₃ CH₂ NHC(=O)) S CH₂ O H CH₂ CH₃ *    130 4-(c -PrCH₂ NHC(=O)) S CH₂ O H CH₂ CH₃ *    254 5-(c -PrCH₂ NHC(=O)) S CH₂ O H CH₂ CH₃    427 (M+1) 255 5-(CHF₂ CH₂ NHC(=O)) O CH₂ O H CH₂ CH₃    421 (M+1) 258 5-(c -PrCH₂ NHC(=O)) O CH₂ O H CH₂ CH₃    411 (M+1) 276 5-(CHF₂ CH₂ NHC(=O)) S CH₂ O H CH₂ CH₃    437 (M+1) *有關¹⁹ F NMR數據，請參閱索引表M。 索引表 K

L欄中的破折號「–」代表L為一直接鍵。除非另有說明，否則上述結構中雙鍵周圍的取代基之結構如結構所示。 化合物編號 R¹³ L R^2d R^2c NMR 分子量 265 (實施例7) EtOC(=O) CH₂ H CH₂ CH₃ * 385 (M+1) 300 CH₃ C≡CCH₂ OC(=O) CH₂ H CH₂ CH₃ * 409 (M+1) 304 EtOC(=O) CH(Me) H CH₂ CH₃    399 (M+1) 317 EtOC(=O) – H CH₂ CH₃    371 (M+1) 323 HOC(=O) CH₂ H CH₂ CH₃ * 357 (M+1) 324 EtOC(=O) CH₂ H n -Pr    399 (M+1) 330 MeOC(=O) CH₂ H CH₂ CH₃ * 371 (M+1) 331 n -PrOC(=O) CH₂ H CH₂ CH₃ * 399 (M+1) 332 i -PrOC(=O) CH₂ H CH₂ CH₃ * 399 (M+1) 333 CH₂ =CHCH₂ OC(=O) CH₂ H CH₂ CH₃ * 397 (M+1) 334 i -BuOC(=O) CH₂ H CH₂ CH₃ * 413 (M+1) 335 CH₂ =C(Me)CH₂ OC(=O) CH₂ H CH₂ CH₃ * 411 (M+1) 336 CH≡CCH₂ OC(=O) CH₂ H CH₂ CH₃ * 395 (M+1) 337 CH₃ C(=O)CH₂ OC(=O) CH₂ H CH₂ CH₃ * 413 (M+1) 338 Cl(CH₂ )₃ OC(=O) CH₂ H CH₂ CH₃ * 433 (M+1) 339 n -BuOC(=O) CH₂ H CH₂ CH₃ * 413 (M+1) 340 CH₃ O(CH₂ )₂ OC(=O) CH₂ H CH₂ CH₃ * 415 (M+1) 341 c -PrCH₂ OC(=O) CH₂ H CH₂ CH₃ * 411 (M+1) 342 c -BuCH₂ OC(=O) CH₂ H CH₂ CH₃ * 425 (M+1) 343 EtNHC(=O) CH₂ H CH₂ CH₃ * 382 (M-1) 345 EtOC(=O) CH₂ CH₂ H CH₂ CH₃ * 399 (M+1) 347 CHF₂ CH₂ OC(=O) CH₂ H CH₂ CH₃ * 421 (M+1) 348 CF₃ CH₂ CH₂ OC(=O) CH₂ H CH₂ CH₃ * 453 (M+1) 349 CF₂ =CFCH₂ CH₂ OC(=O) CH₂ H CH₂ CH₃ * 465 (M+1) 350 (Me)₂ CH(CH₂ )₂ OC(=O) CH₂ H CH₂ CH₃ *    351 CH₃ O(CH₂ )₃ OC(=O) CH₂ H CH₂ CH₃ * 429 (M+1) 352 CF₃ O(CH₂ )₂ OC(=O) CH₂ H CH₂ CH₃ * 469 (M+1) 355 CF₃ (CH₂ )₃ OC(=O) CH₂ H CH₂ CH₃ * 467 (M+1) 365 EtOC(=O) CH₂ H CH₃ *    390 c -戊基-NHC(=O) CH₂ H CH₂ CH₃    424 (M+1) 391 c -丙基-NHC(=O) CH₂ H CH₂ CH₃    396 (M+1) 393 c -丙基-CH₂ NHC(=O) CH₂ H CH₂ CH₃    410 (M+1) 394 CF₂ HCH₂ NHC(=O) CH₂ H CH₂ CH₃    420 (M+1) 401 CF₃ CH₂ NHC(=O) CH₂ H CH₂ CH₃    438 (M+1) 402 2-嘧啶基-CH₂ NHC(=O) CH₂ H CH₂ CH₃    448 (M+1) 403 CH₃ NHC(=O) CH₂ H CH₂ CH₃    370 (M+1) 404 (CH₃ CH₂ )₂ NC(=O) CH₂ H CH₂ CH₃    412 (M+1) 415 i -PrNHC(=O) CH₂ H CH₂ CH₃    398 (M+1) 421 EtOC(=O) (CH₂ )₃ H CH₂ CH₃    413 (M+1) *有關¹⁹ F NMR數據，請參閱索引表M。 索引表 K1

R⁸ 欄中的破折號「–」表示R⁸ 取代基不存在，且剩餘的碳價被氫原子佔據。除非另有說明，否則上述結構中雙鍵周圍的取代基之結構如結構所示。 化合物編號 R¹³ L R⁸ R^2c 分子量 301 4-(EtOC(=O)) CH₂ 2-F CH₂ CH₃ 403 (M+1) 302 4-(EtOC(=O)) CH₂ 6-F CH₂ CH₃ 403 (M+1) 303 4-(EtOC(=O)) CH₂ 2-Me CH₂ CH₃ 399 (M+1) 378 3-(EtOC(=O)) CH₂ 5-MeO CH₂ CH₃ 415 (M+1) 405 3-(EtOC(=O)) CH₂ 5-Me CH₂ CH₃ 399 (M+1) 406 4-(EtOC(=O)) CH₂ 5-Me CH₂ CH₃ 399 (M+1) 407 3-(EtOC(=O)) CH₂ 4-MeO CH₂ CH₃ 415 (M+1) 408 4-(EtOC(=O)) CH₂ 4-MeO CH₂ CH₃ 415 (M+1) 418 4-(EtOC(=O)) CH₂ 4-F CH₂ CH₃ 403 (M+1) 419 5-(EtOC(=O)) CH₂ 4-F CH₂ CH₃ 403 (M+1) 420 3-(EtOC(=O)) CH₂ 4-F CH₂ CH₃ 403 (M+1) 448 5-(EtOC(=O)) CH₂ – CH₂ CH₃ 386 (M+1) 449 3-(EtOC(=O)) CH₂ – CH₂ CH₃ 386 (M+1) 451 4-(EtOC(=O)) CH₂ 6-Me CH₂ CH₃ 399 (M+1) 462 5-(EtOC(=O)) CH₂ 5-Me CH₂ CH₃ 399 (M+1) 463 5-(EtOC(=O)) CH₂ 4-MeO CH₂ CH₃ 415  +1) 索引表 L 化合物 編號 結構 NMR 分子量 熔點(℃) 63 [註 6]

*       124

   402 (M+1)    146

* 401 (M+1)    147

* 274 (M+1)    165

*       168

   402 (M+1)    263

*       266 (實施例6)

*       273

**       305

*       320

   391 (M+1)    321

*       346

* 389 (M+1)    353

* 417 (M+1)    367

*       368

   349 (M+1) 81-84 370

   403 (M+1)    377

   455 (M+1)    385

*       386

*    83.7-86.5 392

   473 (M+1) 59-62 395

*       398

   437 (M+1)    399

   385 (M+1)    417

   403 (M+1)    423

*       424

   409 (M+1)    425

   419 (M+1)    439

   289 (M-1)    440

   339 (M-1)    441

   272 (M-1)    442

   279 (M-1)    446

*       447

*       450

   373 (M+1)    452

   369 (M-1)    453

   365 (M+1)    454

   419 (M+1)    457

   417 (M+1)    460

   275 (M-1)    註6：3:2幾何異構物之混合物。 *有關¹⁹ F NMR數據，請參閱索引表M。 **有關¹ H NMR數據，請參閱索引表N。 索引表 M 化合物編號 ¹⁹ F NMR數據^a 化合物編號 ¹⁹ F NMR數據^a 1 δ -84.92 (s). 177 δ -84.85 (s). 2 δ (DMSO-d ₆ ) -81.80 (s). 179 δ -62.79 (s), -81.40 (s). 3 δ -81.39 (s). 180 δ -70.10 (s). 4 δ (DMSO-d ₆ ) -81.50 (s). 181 δ -61.85 (s). 5 δ -82.61 (s), -75.48 (s). 182 δ -56.40 (s). 6 δ -79.03 (s). 183 δ -70.09 (s). 7 δ -81.50 (s), -81.71 (s). 184 δ -70.11 (s). 8 δ -81.50 (s), -81.71 (s). 189 δ -81.42 (s). 9 δ -81.27 (s). 190 δ -81.38 (s). 10 δ -79.64 (s). 191 δ -81.42 (s). 12 δ -81.01 (s). 192 δ -81.39 (s). 13 δ -81.38 (s). 193 δ -70.01 (s). 14 δ -81.39 (s). 195 δ -70.04 (s). 15 δ -81.38 (s). 196 δ -70.08 (s). 16 δ -81.39 (s). 197 δ -72.38 (s), -81.38 (s). 17 δ -81.38 (s). 198 δ -81.38 (s). 18 δ -81.38 (s). 199 δ -81.38 (s). 20 δ -78.49 (s). 200 δ -81.38 (s). 21 δ -80.99 (s). 201 δ -81.38 (s). 22 δ -81.39 (s). 202 δ -81.39 (s). 23 δ -81.37 (s). 203 δ -81.39 (s). 24 δ -81.37 (s). 204 δ -81.38 (s). 25 δ -81.37 (s). 205 δ -70.14 (s). 26 δ -81.39 (s). 206 δ -84.95 (s). 27 δ -81.41 (s). 209 δ -81.36 (s). 28 δ -81.38 (s). 210 δ -70.08 (s). 29 δ -84.92 (s). 214 δ -81.43 (s). 31 δ (DMSO-d ₆ ) -81.91 (s). 224 δ -70.09 (s). 32 δ -81.39 (s). 225 δ -70.08 (s). 33 δ (DMSO-d ₆ ) -81.83 (s). 226 δ -70.10 (s). 34 δ (DMSO-d ₆ ) -81.89 (s). 227 δ -81.57 (s), -84.95 (s). 35 δ -84.94 (s). 228 δ -81.39 (s). 36 δ (DMSO-d ₆ ) -81.37 (s). 230 δ -70.21 (s). 37 δ (DMSO-d ₆ ) -81.82 (s). 231 δ -70.12 (s). 39 δ -84.93 (s). 232 δ -81.39 (s). 40 δ (acetone-d ₆ ) -83.12 (s). 233 δ -84.87 (s). 41 δ -84.81 (s). 234 δ -84.95 (s). 42 δ (DMSO-d ₆ ) -81.82 (s). 235 δ -81.45 (s). 43 δ (DMSO-d ₆ ) -81.82 (s). 236 δ -81.46 (s). 44 δ -84.21 (s). 237 δ -81.44 (s). 45 δ (DMSO-d ₆ ) -81.82 (s), -72.33 (t). 239 δ -81.42 (s). 46 δ (DMSO-d ₆ ) -81.83 (s), -82.96 (s), -122.29 (t). 240 δ -81.39 (s) 47 δ (DMSO-d ₆ ) -81.82 (s). 241 δ -70.11 (s). 48 δ (DMSO-d ₆ ) -81.82 (s). 245 δ -68.61 (s). 49 δ (DMSO-d ₆ ) -81.82 (s). 249 δ -81.39 (s). 50 δ (DMSO-d ₆ ) -81.82 (s), -138.53 (m), -139.66 (m). 250 δ -70.11 (s). 51 δ -87.93 (s). 251 δ -70.13 (s). 52 δ -76.89 (s). 252 δ -70.09 (s). 53 δ -70.09 (s). 253 δ -70.11 (s). 54 δ -69.99 (s). 260 δ -70.12 (s). 55 δ -69.95 (s). 261 δ -70.12 (s). 56 δ -69.73 (s). 262 δ -70.33 (s). 57 δ -69.75 (s). 263 δ -81.60 (s), -132.13 (s). 58 δ -70.10 (s). 264 δ -84.92 (s). 60 δ -70.30 (s). 265 δ -70.09 (s). 61 δ -70.26 (s). 266 δ -84.88 (s). 62 δ -70.15 (s). 267 δ -70.13 (s). 63 δ -63.30 (s), -63.67 (s). 268 δ -70.03 (s). 64 δ -70.13 (s). 269 δ -70.03 (s). 65 δ -70.03 (s). 270 δ -70.12 (s). 66 δ -85.74 (s). 271 δ -70.12 (s). 67 δ -82.36 (s). 272 δ -69.99 (s). 72 δ -70.24 (s). 278 δ -70.11 (s). 73 δ -70.20 (s). 279 δ -70.31 (s). 74 δ -70.22 (s). 280 δ -84.80 (s). 75 δ -70.22 (s). 284 δ -81.38 (s). 79 δ -70.22 (s). 285 δ -81.39 (s). 80 δ -84.87 (s). 286 δ -84.94 (s). 81 δ -70.17 (s). 287 δ -70.05 (s). 82 δ -70.14 (s). 288 δ -70.04 (s). 83 δ -70.17 (s). 289 δ -81.39 (s). 84 δ -70.16 (s). 290 δ -81.37 (s). 85 δ -70.14 (s). 291 δ -70.12 (s). 86 δ -70.12 (s). 292 δ -70.13 (s). 87 δ -70.11 (s). 293 δ -70.13 (s). 88 δ -70.19 (s). 294 δ -70.01 (s). 89 δ -70.13 (s). 296 δ -81.38 (s). 90 δ -70.16 (s). 297 δ -70.01 (s). 91 δ -70.12 (s). 298 δ -70.05 (s), -74.96 (s). 92 δ -70.13 (s). 299 δ -70.12 (s). 93 δ -81.42 (s). 300 δ -70.10 (s). 94 δ -70.21 (s). 305 δ -84.85 (s). 95 δ -70.21 (s). 309 δ -70.02 (s). 96 δ -69.98 (s). 310 δ -70.04 (s). 97 δ -84.95 (s). 311 δ -70.01 (s). 98 δ -81.40 (s). 312 δ -70.03 (s). 99 δ -70.19 (s). 318 δ -81.38 (s). 100 δ -70.16 (s). 319 δ -79.29 (s), 82.67 (s). 101 δ -70.15 (s). 321 δ -68.60 (s). 102 δ -70.18 (s). 322 δ -81.70 (s). 103 δ -70.16 (s). 323 δ -70.10 (s). 104 δ -70.16 (s). 325 δ -70.11 (s). 105 δ -70.16 (s). 326 δ -70.13 (s). 111 δ -70.08 (s). 327 δ -70.13 (s). 112 δ -81.43 (s). 328 δ -68.54 (s). 113 δ -63.01 (s), -70.10 (s). 329 δ -77.08 (s). 114 δ -70.09 (s). 330 δ -70.09 (s). 116 δ -70.14 (s). 331 δ -70.10 (s). 119 δ -70.16 (s). 332 δ -70.08 (s). 120 δ -70.15 (s). 333 δ -70.09 (s). 121 δ -70.16 (s). 334 δ -70.09 (s). 122 δ -70.14 (s). 335 δ -70.09 (s). 123 δ -70.15 (s). 336 δ -70.08 (s). 126 δ -81.38 (s). 337 δ -70.08 (s). 127 δ -81.38 (s). 338 δ -70.06 (s). 129 δ -70.06 (s), -72.25 (s). 339 δ -70.10 (s). 130 δ 70.06 (s). 340 δ -70.09 (s). 131 δ -84.93 (s). 341 δ -70.09 (s). 132 δ -70.05 (s). 342 δ -70.11 (s). 133 δ -81.40 (s). 343 δ -70.11 (s). 134 δ -81.40 (s), -73.70 (s). 344 δ -70.50 (s). 140 δ -69.16 (s). 345 δ -68.59 (s). 164 δ -81.33 (s). 346 δ -81.82 (s). 165 δ -81.34 (s). 347 δ -70.09 (s), -125.54 (s). 166 δ -81.38 (s). 348 δ -64.93 (s), -70.09 (s). 167 δ -69.60 (s). 349 δ -70.13 (s), -103.21 (s), -123.98 (s), -175.15 (s). 141 δ -81.28 (s). 350 δ -70.09 (s). 142 δ -84.83 (s). 351 δ -70.09 (s). 143 δ -60.46(s), -70.25 (s). 352 δ -60.95 (s), -70.12 (s). 144 δ -70.30 (s). 353 δ -81.41 (s). 145 δ -69.79 (s). 354 δ -70.03 (s). 146 δ -81.37 (s). 355 δ -66.44 (s), -70.09 (s). 147 δ -81.36 (s). 356 δ -70.14 (s). 149 δ -70.07 (s). 357 δ -70.13 (s). 150 δ -70.07 (s). 358 δ -70.12 (s). 151 δ -70.09 (s). 359 δ -70.11 (s). 152 δ -70.09 (s). 360 δ -70.12 (s). 153 δ -70.12 (s). 361 δ -70.13 (s). 154 δ -70.10 (s). 362 δ -70.11 (s). 155 δ -70.05 (s). 365 δ -70.05 (s). 156 δ -70.05 (s). 367 δ -70.08 (s). 157 δ -70.19 (s). 369 δ -83.07 (s). 158 δ -70.10 (s). 385 δ -80.30 (s). 160 δ -81.44 (s). 386 δ -84.80 (s). 161 δ -81.38 (s). 395 δ -80.30 (s). 162 δ (DMSO-d ₆ ) -80.02 (s). 396 δ -84.90 (s). 163 δ -81.38 (s). 423 δ -84.80 (s). 169 δ -81.38 (s). 432 δ -84.80 (s). 170 δ -81.38 (s). 433 δ -70.00 (s). 171 δ -81.37 (s). 443 δ -81.72 (s). 172 δ -81.37 (s). 445 δ -70.10 (s). 176 δ -81.40 (s). 447 δ -70.08 (s). ^a 除非另有說明，否則在CDCl₃ 溶液中，相對於CF₃ CCl₃ ，以ppm為單位報告¹⁹ F NMR光譜。以（s）單重態、（t）三重態以及（m）多重態表示耦合。 索引表 N 化合物編號 ¹ H NMR數據^a 273 (CDCl₃ )：δ 1.36-1.32 (t, 3H), 4.21 (s, 6H), 4.32-4.25 (q, 2H), 5.32 (s, 2H), 6.20 (s, 1H), 6.70 (s, 1H), 7.89 (s, 1H), 7.95 (s, 1H)。 366 (DMSO-d ₆ )：δ 1.26 (t, 3H), 3.98 (s, 2H), 4.21 (q, 2H), 6.03 (s, 2H), 6.86-6.94 (m, 2H), 6.95-7.06 (m, 2H), 7.27 (s, 2H), 7.94 (s, 1H), 8.53 (s, 1H)。 434 (CDCl₃ )：δ 1.34 (t, 3H), 4.18 (s, 2H), 4.57 (q, 2H), 6.78 (s, 1H), 7.05 (s, 2H), 7.36 (s, 2H)。 ^a 以來自四甲基矽烷的低磁場ppm為單位報告¹ H NMR數據。以（s）單重態、（t）三重態以及（q）四重態表示耦合。 本發明之生物學實施例The following tests demonstrate the control efficacy of the compounds of the present invention against specific pathogens. However, the protection against pathogens provided by the compounds is not limited to these species. See Index Tables A through L below for compound descriptions. The following abbreviations are used in the index table: Me for methyl, Et for ethyl,n -Pr means n-propyl,i -Pr means isopropyl,c -Pr represents cyclopropyl,n -Bu means n-butyl,i -Bu means isobutyl,c -Bu means cyclobutyl,c -hexyl represents cyclohexyl, Ph represents phenyl, MeO represents methoxy, and EtO represents ethoxy. The abbreviation "Cmpd. No." stands for "Compound No." and the abbreviation "Ex." stands for "Example" followed by a number indicating in which Example the compound was prepared. The abbreviation "m.p." stands for "melting point". The value reported in the column "MS" is the molecular weight of the highest isotopic abundance positively charged parent ion (M+1) formed by the addition of H+ (molecular weight 1) to the molecule with the highest isotopic abundance, or by The highest isotopic abundance negatively charged ion (M-1) is formed by the loss of H+ (molecular weight 1). Not reported to contain one or more isotopes of lower atomic weight (e.g.³⁷ Cl,⁸¹ Br) in the presence of molecular ions. The reported MS peaks were observed by mass spectrometry using electrospray ionization (ESI) or atmospheric pressure chemical ionization (APCI). Index Table A

Compound number R ¹³ L A NMR molecular weight 1 (Example 1) EtOC(=O) CH ₂ OCH ₂ * 5 EtOC(=O) CH ₂ OCH(Me) * 35 EtOC(=O) CH(Me) OCH ₂ * 36 c -PrCH ₂ NHC(=O) CH ₂ OCH ₂ * 400 (M+1) 37 MeOC(=O) CH ₂ OCH ₂ * 361 (M+1) 38 CH ₂ =CHCF ₂ OC(=O) CH ₂ OCH ₂ 423 (M+1) 39 i -PrOC(=O) CH ₂ OCH ₂ * 389 (M+1) 40 CH ₂ =C(Me)CH ₂ OC(=O) CH ₂ OCH ₂ * 401 (M+1) 42 n -PrOC(=O) CH ₂ OCH ₂ * 389 (M+1) 43 CH ₂ =CHCH ₂ OC(=O) CH ₂ OCH ₂ * 387 (M+1) 44 HC≡CCH ₂ OC(=O) CH ₂ OCH ₂ * 385 (M+1) 45 CF ₃ CH ₂ OC(=O) CH ₂ OCH ₂ * 429 (M+1) 46 CF ₃ CF ₂ CH ₂ OC(=O) CH ₂ OCH ₂ * 479 (M+1) 47 PhCH ₂ OC(=O) CH ₂ OCH ₂ * 437 (M+1) 48 CH ₃ (CH ₂ ) ₅ OC(=O) CH ₂ OCH ₂ * 431 (M+1) 49 3,4-di-Cl-PhCH ₂ OC(=O) CH ₂ OCH ₂ * 505 (M+1) 50 3,4-di-F-PhCH ₂ OC(=O) CH ₂ OCH ₂ * 473 (M+1) 51 EtOC(=O) CH ₂ CH(OH)CH ₂ * 66 EtOC(=O) CH ₂ CH ₂ CH ₂ * 355 (M+1) 131 EtOC(=O) CH ₂ CH ₂ OCH ₂ * 206 N≡C CH ₂ OCH ₂ * 227 EtOC(=O) CH ₂ OCF ₂ * 286 EtOC(=O) (CH ₂ ) ₃ OCH ₂ * 403 (M+1) 322 Br CH ₂ OCH ₂ * 383 (M+1) 329 HOC(=O) CH ₂ OCH ₂ * 327 (M-1) 381 EtOC(=O) CH ₂ N(C≡N)CH ₂ 381 (M+1) 388 _CF3 CH ₂ OCH ₂ 351 (M-1) 389 NO ₂ CH ₂ OCH ₂ 346 (M-1) *related¹⁹ For F NMR data, see Index Table M. Index Table A1

Compound number R ¹³ L (R ⁸ ) _q NMR molecular weight 264 EtOC(=O) CH ₂ 3-F * 376 EtOC(=O) CH ₂ 2-F 393 (M+1) 409 EtOC(=O) CH ₂ 3-I 501 (M+1) 431 EtOC(=O) CH ₂ 2,3-di-F 411 (M+1) 444 EtOC(=O) CH ₂ 3-Me 389 (M+1) 455 NO ₂ CH ₂ 3-F 346 (M-1) 456 _CF3 CH ₂ 3-F 369 (M-1) 459 EtOC(=O) CH ₂ 3-Cl 409 (M+1) 465 EtOC(=O) CH ₂ 2,3,5,6-Tetrafluoro 447 (M+1) *related¹⁹ For F NMR data, see Index Table M. Index Table A2

Compound number R ¹³ L A molecular weight Melting point(℃) 68 _CF3CH2NHC ( ₌ O) CH ₂ OCH ₂ 445 (M+1) 116-120 69 c -PrCH ₂ NHC(=O) CH ₂ OCH ₂ 417 (M+1) 135

CH ₂ OCH ₂ 453 (M+1) 136 EtOC(=O) CH ₂ OCH ₂ 392 (M+1) 215

CH ₂ OCH ₂ 403 (M+1) 140-144 223 MeOCH ₂ CH ₂ NHC(=O) CH ₂ OCH ₂ 421 (M+1) index table B

A dash "–" in the L column indicates that L is a direct key. Compound number E L A NMR molecular weight Melting point(℃) 2 CF ₃ C(OH) ₂ CH ₂ O – OCH ₂ * 105-109 29 CH ₃ CH ₂ S(=O) ₂ CH ₂ OCH ₂ * 30 1-Indolyl CH ₂ CH ₂ CH ₂ 332 (M+1) 31 MeS(=O) ₂ – OCH ₂ * 102-106 33 MeOC(=O)NHN=CH – OCH ₂ * 140-145 34 Me ₂ NS(=O) ₂ – OCH ₂ * 142-146 41 3-(Me ₂ NC(=O))-4,5-dihydro-5-isoxazolyl – OCH ₂ * 80 CH ₃ C(=O) – OCH ₂ * 97 EtOC(=O)CH=CHCH ₂ O – OCH ₂ * 142 N≡C – OCH ₂ * 177 HC(=O) – OCH ₂ * 229 MeOC(=O) – OCH ₂ 279 (M-1) 233 3-(EtOC(=O))-1 H -pyrazol-1-yl CH ₂ OCH ₂ * 234 5-(EtOC(=O))-1 H -pyrazol-1-yl CH ₂ OCH ₂ * 247 5-( c -PrCH ₂ NHC(=O))-2-oxazolyl CH ₂ OCH ₂ 401 (M+1) 256 5-( c -PrCH ₂ NHC(=O))-2-thiazolyl CH ₂ OCH ₂ 417 (M+1) 126-130 274 5-(CF ₃ CH ₂ NHC(=O))-2-oxazolyl CH ₂ OCH ₂ 429 (M+1) 75-79 277 5-(CF ₃ CH ₂ NHC(=O))-2-thiazolyl CH ₂ OCH ₂ 445 (M+1) 110-114 280 NO ₂ – OCH ₂ * 295 5-(F ₂ CHCH ₂ NHC(=O))-2-thiazolyl CH ₂ OCH ₂ 427 (M+1) 366 (Example 8) 4-(EtOC(=O))- 1H -pyrazol-1-yl-CH ₂ O – OCH ₂ ** 369 CH ₃ – OCH(C(=O)OMe * 384

– OCH ₂ 320 (M+1) 387 _CF3 – OCH ₂ 271 (M-1) 396 CH ₃ – OCH ₂ * 432 MeO CH ₂ OCH ₂ * *related¹⁹ For F NMR data, see Index Table M. **related¹ H NMR data, see Index Table N. Index table C

Compound number R ¹³ L A M NMR molecular weight 3 n -PrOC(=O) CH ₂ OCH ₂ CH ₂ * 415 (M+1) 4 EtOC(=O) CH ₂ OCH ₂ C(=O) * 415 (M+1) 6 EtOC(=O) CH ₂ OCH(Me) CH ₂ * 7 [Note 1] EtOC(=O) CH ₂ OCH ₂ CH(Me) * 8 [Note 2] EtOC(=O) CH ₂ OCH ₂ CH(Me) * 12 (Example 3) EtOC(=O) CH ₂ OCH ₂ C(Me) ₂ * 13 MeOC(=O) CH ₂ OCH ₂ CH ₂ * 387 (M+1) 14 i -PrOC(=O) CH ₂ OCH ₂ CH ₂ * 415 (M+1) 15 HC≡CCH ₂ OC(=O) CH ₂ OCH ₂ CH ₂ * 411 (M+1) 16 CH ₃ (CH ₂ ) ₅ OC(=O) CH ₂ OCH ₂ CH ₂ * 457 (M+1) 17 3,4-di-Cl-PhCH ₂ OC(=O) CH ₂ OCH ₂ CH ₂ * 531 (M+1) 18 3,4-di-F-PhCH ₂ OC(=O) CH ₂ OCH ₂ CH ₂ * 499 (M+1) 26 EtOC(=O) CH( _CH3 ) OCH ₂ CH ₂ * 413 (M-1) 32 (Example 2) and (Example 4) EtOC(=O) CH ₂ OCH ₂ CH ₂ * 67 EtOC(=O) CH ₂ CH ₂ CH ₂ CH ₂ * 397 (M-1) 93 HOC(=O) CH ₂ OCH ₂ CH ₂ * 115 EtOC(=O) CH ₂ SCH ₂ CH ₂ 417 (M+1) 125 n- BuOC(=O) CH ₂ OCH ₂ CH ₂ 429 (M+1) 126 i- BuOC(=O) CH ₂ OCH ₂ CH ₂ * 429 (M+1) 127 c- PrCH ₂ OC(=O) CH ₂ OCH ₂ CH ₂ * 427 (M+1) 133 EtOC(=O) CH ₂ CH ₂ OCH ₂ CH ₂ * 134 CF ₃ CH ₂ OC(=O) CH ₂ OCH ₂ CH ₂ * 453 (M-1) 141 EtOC(=O) CH ₂ CH ₂ OCH ₂ CH ₂ * 161 Cl(CH ₂ ) ₃ OC(=O) CH ₂ OCH ₂ CH ₂ * 449 (M+1) 162 MeOCH ₂ CH ₂ OC(=O) CH ₂ OCH ₂ CH ₂ * 431 (M+1) 163 CH ₃ C≡CCH ₂ OC(=O) CH ₂ OCH ₂ CH ₂ * 425 (M+1) 164 N≡CCH ₂ NHC(=O) CH ₂ OCH ₂ CH ₂ * 411 (M+1) 169 CH ₃ C(=O)CH ₂ OC(=O) CH ₂ OCH ₂ CH ₂ * 429 (M+1) 170 PhC(=O)CH ₂ OC(=O) CH ₂ OCH ₂ CH ₂ * 491 (M+1) 171 N≡C(CH ₂ ) ₃ OC(=O) CH ₂ OCH ₂ CH ₂ * 440 (M+1) 172 N≡CCH ₂ OC(=O) CH ₂ OCH ₂ CH ₂ * 188 CH ₂ =CHCH ₂ OC(=O) CH ₂ OCH ₂ CH ₂ 413 (M+1) 197 _CF3CH2NHC ( ₌ O) CH ₂ OCH ₂ CH ₂ * 454 (M+1) 198 Me ₂ NC(=O) CH ₂ OCH ₂ CH ₂ * 400 (M+1) 199 2-Pyridyl-CH ₂ OC(=O) CH ₂ OCH ₂ CH ₂ * 464 (M+1) 200 3-Pyridyl-CH ₂ OC(=O) CH ₂ OCH ₂ CH ₂ * 464 (M+1) 201 4-Pyridyl-CH ₂ OC(=O) CH ₂ OCH ₂ CH ₂ * 464 (M+1) 202 c -hexyl-C(=O)CH ₂ OC(=O) CH ₂ OCH ₂ CH ₂ * 497 (M+1) 203 MeOC(=O)CH ₂ OC(=O) CH ₂ OCH ₂ CH ₂ * 445 (M+1) 204 1,3-Dioxolane-2-yl-CH ₂ OC(=O) CH ₂ OCH ₂ CH ₂ * 459 (M+1) 209 N≡C CH ₂ OCH ₂ CH ₂ * 228 CH ₂ =C(CH ₃ )CH ₂ OC(=O) CH ₂ OCH ₂ CH ₂ * 427 (M+1) 240 EtOCH ₂ CH ₂ OCH ₂ CH ₂ * 387 (M+1) 249 c -BuCH ₂ OC(=O) CH ₂ OCH ₂ CH ₂ * 441 (M+1) 272 c -hexyl-CH ₂ OC(=O) CH ₂ OCH ₂ CH ₂ * 469 (M+1) 284 c -pentyl-CH ₂ OC(=O) CH ₂ OCH ₂ CH ₂ * 455 (M+1) 285 [Note 4] CH3CH _{= CHCH2OC} (=O) CH ₂ OCH ₂ CH ₂ * 427 (M+1) 296 EtOC(=O) (CH ₂ ) ₃ OCH ₂ CH ₂ * 429 (M+1) 318 c- BuOC(=O) CH ₂ OCH ₂ CH ₂ * 427 (M+1) 319 EtOC(=O) CH ₂ OCF ₂ CH ₂ * 437 (M+1) 443 EtOC(=O) CH ₂ NHCH ₂ CH ₂ * *related¹⁹ For F NMR data, see Index Table M. Note 1: 87:13 A mixture of diastereoisomers. Note 2: 33:67 A mixture of diastereoisomers. Note 4: 60:40 mixture of cis-trans isomers. index table D

Compound number T NMR molecular weight 9

* 10

* 20

* twenty one

* 400 (M+1) 52

* 187

429 (M+1) *related¹⁹ For F NMR data, see Index Table M. Index table E

A dash "–" in the L column indicates that L is a direct key. Compound number E L A NMR molecular weight twenty two 3-(Me ₂ NC(=O))-4,5-dihydro-5-isoxazolyl – OCH ₂ * twenty three CH ₃ CH ₂ S(=O) ₂ CH ₂ OCH ₂ * twenty four CH ₃ S(=O) ₂ – OCH ₂ * 25 (Me) ₂ NS(=O) ₂ – OCH ₂ * 27 MeOC(=O)NHN=CH – OCH ₂ * 28

– OCH ₂ * 76 i -BuS(=O) ₂ NH CH ₂ OCH ₂ 396 (M-1) 77 c -hexyl-NHC(=S)NH CH ₂ OCH ₂ 419 (M+1) 78 EtOC(=O)NH CH ₂ OCH ₂ 350 (M+1) 98 N≡C – OCH ₂ * 274 (M+1) 112 i -BuOC(=O)NH CH ₂ OCH ₂ * 160 5-(EtOC(=O)-1-indazolyl CH ₂ OCH ₂ * 166 NO ₂ – OCH ₂ * 173 5-(CF ₃ )-1,2,4-oxadiazol-3-yl – OCH ₂ 385 (M+1) 174 _NH2 CH ₂ OCH ₂ * 175 i -PrC(=O)NH CH ₂ OCH ₂ 348 (M+1) 176 c -PrC(=O)NH CH ₂ OCH ₂ * 178 OH CH ₂ OCH ₂ 301 (M+23) 179 3-CF ₃ -PhC(=O)NH CH ₂ OCH ₂ * 189 MeOC(=O) – OCH ₂ * 307 (M+1) 190 Ph – OCH ₂ * 191 PhO – OCH ₂ * 192 Ph CH ₂ OCH ₂ * 207 CF ₃ S(=O) ₂ NH CH ₂ OCH ₂ 408 (M-1) 212 CF ₃ CH ₂ C(=O)NH CH ₂ OCH ₂ 388 (M+1) 214 MeOCH(CH ₃ )C(=O)NH CH ₂ OCH ₂ * 232 3-(EtOC(=O))-1 H -pyrazol-1-yl CH ₂ OCH ₂ * 235 i -PrC(=O)N(OMe) CH ₂ OCH ₂ * 236 c -PrC(=O)N(OMe) CH ₂ OCH ₂ * 237 n -PrC(=O)N(OMe) CH ₂ OCH ₂ * 238 t -BuOC(=O)N(OMe) CH ₂ OCH ₂ 430 (M+23) 239 N≡C CH ₂ OCH ₂ * 281 2-(MeS)-4-pyrimidinyl CH ₂ OCH ₂ 387 (M+1) 282 2-(MeS(=O) ₂ )-4-pyrimidinyl CH ₂ OCH ₂ 419 (M+1) 283 2-(F ₂ CHCH ₂ O)-4-pyrimidinyl CH ₂ OCH ₂ 421 (M+1) 289

CH ₂ OCH ₂ * 290

CH ₂ OCH ₂ * 314

CH ₂ OCH ₂ 457 (M+1) 372

– OCH ₂ 346 (M+1) 382

– OCH ₂ 396 (M+1) 411

– OCH ₂ 375 (M+1) *related¹⁹ For F NMR data, see Index Table M. Index table E1

Compound number R ¹³ M L A molecular weight Melting point(℃) 70 4-(CF ₃ CH ₂ NHC(=O)) S CH ₂ OCH ₂ 471 (M+1) 71 4-( c -PrCH ₂ NHC(=O)) S CH ₂ OCH ₂ 443 (M+1) 88-92 137 4-(EtOC(=O)) S CH ₂ OCH ₂ 418 (M+1) 74-78 248 5-( c -PrCH ₂ NHC(=O)) O CH ₂ OCH ₂ 427 (M+1) 257 5-(CF ₃ CH ₂ NHC(=O)) O CH ₂ OCH ₂ 455 (M+1) 99-103 259 5-( c -PrCH ₂ NHC(=O)) S CH ₂ OCH ₂ 443 (M+1) 117-121 275 5-(CF ₃ CH ₂ NHC(=O)) S CH ₂ OCH ₂ 471(M+1) Index table F

R¹³ A dash "–" in a column means R¹³ Substituents are absent and the remaining carbon valences are occupied by hydrogen atoms. A dash "–" in column L indicates that L is a direct key. The structures of substituents around double bonds in the above structures are shown in the structures unless otherwise specified. Compound number R ¹³ L A R ^2c NMR Molecular weight (M+1) Melting point(℃) 53 EtOC(=O) CH ₂ O CH ₃ * 54 EtOC(=O) CH ₂ O CH ₂ CH ₂ OMe * 55 EtOC(=O) CH ₂ O CH ₂ CH=CH ₂ * 56 EtOC(=O) CH ₂ O CH ₂ C≡CH * 57 EtOC(=O) CH ₂ O CH(CH ₃ ) ₂ * 64 (Example 5) EtOC(=O) CH ₂ O CH ₂ CH ₃ * 58-59 65 EtOC(=O) CH ₂ O CH ₂ CH ₂ CH ₃ * 89 t -BuOC(=O) CH ₂ O CH ₂ CH ₃ * 106 _CF3CH2NHC ( ₌ O) CH ₂ O CH ₂ CH ₃ 109-113 107 N≡CCH ₂ NHC(=O) CH ₂ O CH ₂ CH ₃ 114-118 116 HOC(=O) CH ₂ O CH ₂ CH ₃ * 127-131 117 c -PrCH ₂ NHC(=O) CH ₂ O CH ₂ CH ₃ 106-110 118 i -PrNHC(=O) CH ₂ O CH ₂ CH ₃ 114-118 132 EtOC(=O) (CH ₂ ) ₂ O CH ₂ CH ₃ * 138 MeOC(=O) CH ₂ O CH ₂ CH ₃ 105-109 139 i -PrOC(=O) CH ₂ O CH ₂ CH ₃ 399 140 EtOC(=O) CH ₂ CH ₂ CH ₂ CH ₃ * 145 EtOC(=O) CH ₂ O CH ₂ CH ₂ OH * 151 – CH ₂ O CH ₂ CH ₃ * 167 EtOC(=O) CH ₂ CH ₂ O CH ₂ CH ₃ * 180 Cl CH ₂ O CH ₂ CH ₃ * 182 _CF3 CH ₂ O CH ₂ CH ₃ * 183 Br CH ₂ O CH ₂ CH ₃ * 185 CH≡CCH ₂ OC(=O) CH ₂ O CH ₂ CH ₃ 69-73 186 PhCH ₂ OC(=O) CH ₂ O CH ₂ CH ₃ 63-67 205 N≡C CH ₂ O CH ₂ CH ₃ * 216 MeC(=O)CH ₂ OC(=O) CH ₂ O CH ₂ CH ₃ 64-68 217 n- PrOC(=O) CH ₂ O CH ₂ CH ₃ 399 218 n- BuOC(=O) CH ₂ O CH ₂ CH ₃ 413 219 i- BuOC(=O) CH ₂ O CH ₂ CH ₃ 413 220 c- PrCH ₂ OC(=O) CH ₂ O CH ₂ CH ₃ 411 221 Cl(CH ₂ ) ₃ OC(=O) CH ₂ O CH ₂ CH ₃ 433 222 MeOCH ₂ CH ₂ OC(=O) CH ₂ O CH ₂ CH ₃ 79-83 242 CH ₂ =C(Me)CH ₂ OC(=O) CH ₂ O CH ₂ CH ₃ 411 243 CH ₃ C≡CCH ₂ OC(=O) CH ₂ O CH ₂ CH ₃ 105-109 244 PhC(=O)CH ₂ OC(=O) CH ₂ O CH ₂ CH ₃ 114-118 245 N≡CCH ₂ CH ₂ OC(=O) CH ₂ O CH ₂ CH ₃ * 81-85 246 CH ₂ =CHCH ₂ OC(=O) CH ₂ O CH ₂ CH ₃ 397 267 EtOC(=O) CH(Me) O CH ₂ CH ₃ * 294 EtOC(=O) (CH ₂ ) ₃ O CH ₂ CH ₃ * 413 298 EtOC(=O) CH ₂ O CH ₂ CF ₃ * 316 EtOC(=O) – O CH ₂ CH ₃ 371 328 HOC(=O) (CH ₂ ) ₂ O CH ₂ CH ₃ * 354 MeOC(=O) (CH ₂ ) ₂ O CH ₂ CH ₃ * 385 380 EtOC(=O) CH ₂ N(C≡N) CH ₂ CH ₃ 371 400 EtOC(=O) CH ₂ O CH ₂ C≡N 396 413 c -propyl-NHC(=O) CH ₂ O CH ₂ CH ₃ 396 414 _CH3NHC (=O) CH ₂ O CH ₂ CH ₃ 370 422 EtOC(=O) CH ₂ O S(=O) ₂ CF ₃ 489 427 MeOC(=O)CH ₂ NHC(=O) CH ₂ O CH ₂ CH ₃ 428 428 c -pentyl-NHC(=O) CH ₂ O CH ₂ CH ₃ 424 435 2-Pyrimidyl-CH ₂ NHC(=O) CH ₂ O CH ₂ CH ₃ 448 436 CF ₂ HCH ₂ NHC(=O) CH ₂ O CH ₂ CH ₃ 420 437 CH ₃ CH ₂ NHC(=O) CH ₂ O CH ₂ CH ₃ 384 438 (CH ₃ CH ₂ ) ₂ NC(=O) CH ₂ O CH ₂ CH ₃ 412 *related¹⁹ For F NMR data, see Index Table M. Index table F1

The structures of substituents around double bonds in the above structures are shown in the structures unless otherwise specified. Compound number R ¹³ L (R ⁸ ) _q R ^2c NMR Molecular weight (M+1) Melting point(℃) 262 EtOC(=O) CH ₂ 3-F CH ₂ CH ₃ * 344 EtOC(=O) CH ₂ 3-Br CH ₂ CH ₃ * 463 88-89 374 EtOC(=O) CH ₂ 3-I CH ₂ CH ₃ 511 375 EtOC(=O) CH ₂ 2-F CH ₂ CH ₃ 403 410 EtOC(=O) CH ₂ 3-Me CH ₂ CH ₃ 399 416 EtOC(=O) CH ₂ 3-C≡N CH ₂ CH ₃ 410 430 EtOC(=O) CH ₂ 2,3-di-F CH ₂ CH ₃ 421 458 EtOC(=O) CH ₂ 3-Cl CH ₂ CH ₃ 419 464 EtOC(=O) CH ₂ 2,3,5,6-Tetrafluoro CH ₂ CH ₃ 457 *related¹⁹ For F NMR data, see Index Table M. Index table G

A dash "–" in column L indicates that L is a direct key. The structures of substituents around double bonds in the above structures are shown in the structures unless otherwise specified. Compound number E L A R ^2d R ^2c NMR molecular weight 58

– O H CH ₂ CH ₃ * 60 CH ₃ S(=O) ₂ – O H CH ₂ CH ₃ * 61 (Me) ₂ NS(=O) ₂ – O H CH ₂ CH ₃ * 62 CH ₃ CH ₂ S(=O) ₂ CH ₂ O H CH ₂ CH ₃ * 72 HOC(=O) – O H CH ₂ CH ₃ * 275 (M-1) 73 i -PrOC(=O) – O H CH ₂ CH ₃ * 318 (M+1) 74 CH ₂ =CHCH ₂ OC(=O) – O H CH ₂ CH ₃ * 317 (M+1) 75 CH≡CCH ₂ OC(=O) – O H CH ₂ CH ₃ * 313 (M-1) 79 CH ₃ C(=O) – O H CH ₂ CH ₃ * 83

CH ₂ O H CH ₂ CH ₃ * 401 (M+1) 84

CH ₂ O H CH ₂ CH ₃ * 401 (M+1) 85 5-(CH ₃ OC(=O))-1 H -imidazol-1-yl CH ₂ O H CH ₂ CH ₃ * 371 (M+1) 86 4-(CH ₃ OC(=O))-1 H -imidazol-1-yl CH ₂ O H CH ₂ CH ₃ * 371 (M+1) 87

CH ₂ O H CH ₂ CH ₃ * 364 (M+1) 88

CH ₂ O H CH ₂ CH ₃ * 364 (M+1) 90 3-(EtOC(=O)-5-(MeO))-1 H -pyrazole-1-yl CH ₂ O H CH ₂ CH ₃ * 415 (M+1) 91

CH ₂ O H CH ₂ CH ₃ * 420 (M+1) 92

CH ₂ O H CH ₂ CH ₃ * 360 (M+1) 94 n -PrOC(=O) – O H CH ₂ CH ₃ * 95 EtOC(=O) – O H CH ₂ CH ₃ * 305 (M+1) 96 EtOC(=O)CH=CHCH ₂ O – O H CH ₂ CH ₃ * 99 NH ₂ C(=O) – O H CH ₂ CH ₃ * 274 (M+1) 100 c -PrNHC(=O) – O H CH ₂ CH ₃ * 316 (M+1) 101 i- PrNHC(=O) – O H CH ₂ CH ₃ * 318 (M+1) 102 _CH≡CCH2NHC (=O) – O H CH ₂ CH ₃ * 314 (M+1) 103 CH ₂ =CHCH ₂ NHC(=O) – O H CH ₂ CH ₃ * 316 (M+1) 104 n -PrNHC(=O) – O H CH ₂ CH ₃ * 318 (M+1) 105 MeNHC(=O) – O H CH ₂ CH ₃ * 290 (M+1) 109 t- BuOC(=O)NH CH ₂ O H CH ₂ CH ₃ 261 (M+1) 110 _NH2 CH ₂ O H CH ₂ CH ₃ 262 (M+1) 111 EtOC(=O)NH CH ₂ O H CH ₂ CH ₃ * 113 CF ₃ CH ₂ C(=O)NH CH ₂ O H CH ₂ CH ₃ * 114 MeOCH(CH ₃ )C(=O)NH CH ₂ O H CH ₂ CH ₃ * 119

CH ₂ O H CH ₂ CH ₃ * 386 (M+1) 120

CH ₂ O H CH ₂ CH ₃ * 386 (M+1) 121

CH ₂ O H CH ₂ CH ₃ * 386 (M+1) 143

– O H CH ₂ CH ₃ * 144 N≡C – O H CH ₂ CH ₃ * 148 HC(=O) – O H CH ₂ CH ₃ 149 EtS(=O) ₂ NH CH ₂ O H CH ₂ CH ₃ * 150 EtC(=O)NH CH ₂ O H CH ₂ CH ₃ * 152 3,5-di-Me-1 H -pyrazol-1-yl CH ₂ O H CH ₂ CH ₃ * 341 (M+1) 153 4-(EtOC(=O))-1 H -imidazol-1-yl CH ₂ O H CH ₂ CH ₃ * 385 (M+1) 154 N≡C CH ₂ O H CH ₂ CH ₃ * 155 N≡CS CH ₂ O H CH ₂ CH ₃ * 156 1 H -imidazol-1-yl CH ₂ O H CH ₂ CH ₃ * 313 (M+1) 184

CH ₂ O H CH ₂ CH ₃ * 193 NH ₂ C(=O)O CH ₂ O H CH ₂ CH ₃ * 195 OH CH ₂ O H CH ₂ CH ₃ * 196 EtNHC(=O)O CH ₂ O H CH ₂ CH ₃ * 210 i- PrC(=O)NH CH ₂ O H CH ₂ CH ₃ * 332 (M+1) 211 c- PrC(=O)NH CH ₂ O H CH ₂ CH ₃ 331 (M+1) 224

CH ₂ O H CH ₂ CH ₃ * 330 (M+1) 225

CH ₂ O H CH ₂ CH ₃ * 358 (M+1) 226

CH ₂ O H CH ₂ CH ₃ * 380 (M+1) 230 MeOC(=O) – O H CH ₂ CH ₃ * 291 (M+1) 268 4-(EtOC(=O))-1-piperidinyl CH ₂ O H CH ₂ CH ₃ * 402 (M+1) 269 3-(EtOC(=O))-1-piperidinyl CH ₂ O H CH ₂ CH ₃ * 402 (M+1) 270 [Note 7] 4-(EtOC(=O))-pyridin-1-yl CH ₂ O H CH ₂ CH ₃ * 271 [Note 7] 3-(EtOC(=O))-pyridin-1-yl CH ₂ O H CH ₂ CH ₃ * 278

– O H CH ₂ CH ₃ * 279 NO ₂ – O H CH ₂ CH ₃ * 287

CH ₂ O H CH ₂ CH ₃ * 288

CH ₂ O H CH ₂ CH ₃ * 297 4-(EtOC(=O))- 1H -pyrazol-1-yl-CH ₂ O CH ₂ O H CH ₂ CH ₃ * 412 (M-1) 306

CH ₂ O H CH ₂ CH ₃ 405 (M+1) 307

CH ₂ O H CH ₂ CH ₃ 403 (M+1) 308

CH ₂ O H CH ₂ CH ₃ 371 (M+1) 309 4-(MeOC(=O))-1-piperidinyl CH ₂ O H CH ₂ CH ₃ * 388 (M+1) 310 3-(MeOC(=O))-1-pyrrolidinyl CH ₂ O H CH ₂ CH ₃ * 374 (M+1) 311 4-(N≡C)-1-piperidinyl CH ₂ O H CH ₂ CH ₃ * 355 (M+1) 312 4-(MeO)-1-piperidinyl CH ₂ O H CH ₂ CH ₃ * 360 (M+1) 313

CH ₂ O H CH ₂ CH ₃ 441 (M+1) 364 (Example 9) 4-(EtOC(=O))- 1H -pyrazol-1-yl-CH ₂ O – O H CH ₂ CH ₃ 401 (M+1) 371 c -PrC(=O)NH – O H CH ₂ CH ₃ 316 (M+1) 373

– O H CH ₂ CH ₃ 330 (M+1) 379 2-F-PhC(=O)O – O H CH ₂ CH ₃ 371 (M+1) 383

– O H CH ₂ CH ₃ 380 (M+1) 412

– O H CH ₂ CH ₃ 359 (M+1) 426 4-(2,4-di-F-PhNHC(=O))-1 H -pyrazol-1-yl – O CH ₂ CH ₃ 468 (M+1) 433 MeO CH ₂ O H CH ₂ CH ₃ * 434 ClCH ₂ – O H CH ₂ CH ₃ ** 445 MeC(=O)S CH ₂ O H CH ₂ CH ₃ * 461 2-F-PhC(=O)NH – O H CH ₂ CH ₃ 370 (M+1) *related¹⁹ For F NMR data, see Index Table M. **related¹ H NMR data, see Index Table N. Note 7: HBr salts. Index table H

The structures of substituents around double bonds in the above structures are shown in the structures unless otherwise specified. Compound number R ¹³ L A R ^2d R ^2c NMR molecular weight 158 3- _CH3 CH ₂ O H CH ₂ CH ₃ * 371 (M+1) 181 3- _CF3 CH ₂ O H CH ₂ CH ₃ * 379 (M-1) 231 3-(EtOC(=O)) CH ₂ O H CH ₂ CH ₃ * 241 5-(EtOC(=O)) CH ₂ O H CH ₂ CH ₃ * 250 5-(MeOC(=O)) CH ₂ O H CH ₂ CH ₃ * 371 (M+1) 251 3-(MeOC(=O)) CH ₂ O H CH ₂ CH ₃ * 371 (M+1) 252 5-( t -BuOC(=O)) CH ₂ O H CH ₂ CH ₃ * 411 (M-1) 253 3-( t -BuOC(=O)) CH ₂ O H CH ₂ CH ₃ * 411 (M-1) 291 3-(CH ₂ =CHCH ₂ OC(=O)) CH ₂ O H CH ₂ CH ₃ * 397 (M+1) 292 3-( n -PrOC(=O)) CH ₂ O H CH ₂ CH ₃ * 399 (M+1) 293 3-(CH ₃ C≡CCH ₂ OC(=O)) CH ₂ O H CH ₂ CH ₃ * 409 (M+1) 299 3-(HOC(=O)) CH ₂ O H CH ₂ CH ₃ * 325 3-(HC≡CCH ₂ OC(=O)) CH ₂ O H CH ₂ CH ₃ * 395 (M+1) 326 3-(CH ₃ CH ₂ C≡CCH ₂ OC(=O)) CH ₂ O H CH ₂ CH ₃ * 423 (M+1) 327 3-( i -PrOC(=O)) CH ₂ O H CH ₂ CH ₃ * 399 (M+1) 356 3-( n -BuOC(=O)) CH ₂ O H CH ₂ CH ₃ * 413 (M+1) 357 3-( i -BuOC(=O)) CH ₂ O H CH ₂ CH ₃ * 413 (M+1) 358 3-(CH ₂ =C(Me)CH ₂ OC(=O)) CH ₂ O H CH ₂ CH ₃ * 411 (M+1) 359 3-(CH ₃ C(=O)CH ₂ OC(=O)) CH ₂ O H CH ₂ CH ₃ * 413 (M+1) 360 3-(MeOCH ₂ CH ₂ OC(=O)) CH ₂ O H CH ₂ CH ₃ * 415 (M+1) 361 3-( c -BuCH ₂ OC(=O)) CH ₂ O H CH ₂ CH ₃ * 425 (M+1) 362 3-(ClCH ₂ CH ₂ CH ₂ OC(=O)) CH ₂ O H CH ₂ CH ₃ * 433 (M+1) *related¹⁹ For F NMR data, see Index Table M. Index table I

R¹³ A dash "–" in a column means R¹³ Substituents are absent and the remaining carbon valences are occupied by hydrogen atoms. The structures of substituents around double bonds in the above structures are shown in the structures unless otherwise specified. Compound number R ¹³ L A R ^2d R ^2c NMR molecular weight 81 5-CN CH ₂ O H CH ₂ CH ₃ * 337 (M-1) 82 3-CN CH ₂ O H CH ₂ CH ₃ * 337 (M-1) 122 5-(MeOC(=O)) CH ₂ O H CH ₂ CH ₃ * 370 (M-1) 123 3-(MeOC(=O)) CH ₂ O H CH ₂ CH ₃ * 370 (M-1) 157 – CH ₂ O H CH ₂ CH ₃ * 312 (M-1) 260 5-MeS CH ₂ O H CH ₂ CH ₃ * 358 (M-1) 261 3-MeS CH ₂ O H CH ₂ CH ₃ * 360 (M+1) *related¹⁹ For F NMR data, see Index Table M. Index table J

The structures of substituents around double bonds in the above structures are shown in the structures unless otherwise specified. Compound number R ¹³ M L A R ^2d R ^2c NMR molecular weight 129 4-(CF ₃ CH ₂ NHC(=O)) S CH ₂ O H CH ₂ CH ₃ * 130 4-( c -PrCH ₂ NHC(=O)) S CH ₂ O H CH ₂ CH ₃ * 254 5-( c -PrCH ₂ NHC(=O)) S CH ₂ O H CH ₂ CH ₃ 427 (M+1) 255 5-(CHF ₂ CH ₂ NHC(=O)) O CH ₂ O H CH ₂ CH ₃ 421 (M+1) 258 5-( c -PrCH ₂ NHC(=O)) O CH ₂ O H CH ₂ CH ₃ 411 (M+1) 276 5-(CHF ₂ CH ₂ NHC(=O)) S CH ₂ O H CH ₂ CH ₃ 437 (M+1) *related¹⁹ For F NMR data, see Index Table M. Index table K

A dash "–" in the L column indicates that L is a direct key. The structures of substituents around double bonds in the above structures are shown in the structures unless otherwise specified. Compound number R ¹³ L R ^2d R ^2c NMR molecular weight 265 (Example 7) EtOC(=O) CH ₂ H CH ₂ CH ₃ * 385 (M+1) 300 CH ₃ C≡CCH ₂ OC(=O) CH ₂ H CH ₂ CH ₃ * 409 (M+1) 304 EtOC(=O) CH(Me) H CH ₂ CH ₃ 399 (M+1) 317 EtOC(=O) – H CH ₂ CH ₃ 371 (M+1) 323 HOC(=O) CH ₂ H CH ₂ CH ₃ * 357 (M+1) 324 EtOC(=O) CH ₂ H n -Pr 399 (M+1) 330 MeOC(=O) CH ₂ H CH ₂ CH ₃ * 371 (M+1) 331 n -PrOC(=O) CH ₂ H CH ₂ CH ₃ * 399 (M+1) 332 i -PrOC(=O) CH ₂ H CH ₂ CH ₃ * 399 (M+1) 333 CH ₂ =CHCH ₂ OC(=O) CH ₂ H CH ₂ CH ₃ * 397 (M+1) 334 i -BuOC(=O) CH ₂ H CH ₂ CH ₃ * 413 (M+1) 335 CH ₂ =C(Me)CH ₂ OC(=O) CH ₂ H CH ₂ CH ₃ * 411 (M+1) 336 CH≡CCH ₂ OC(=O) CH ₂ H CH ₂ CH ₃ * 395 (M+1) 337 CH ₃ C(=O)CH ₂ OC(=O) CH ₂ H CH ₂ CH ₃ * 413 (M+1) 338 Cl(CH ₂ ) ₃ OC(=O) CH ₂ H CH ₂ CH ₃ * 433 (M+1) 339 n -BuOC(=O) CH ₂ H CH ₂ CH ₃ * 413 (M+1) 340 CH ₃ O(CH ₂ ) ₂ OC(=O) CH ₂ H CH ₂ CH ₃ * 415 (M+1) 341 c -PrCH ₂ OC(=O) CH ₂ H CH ₂ CH ₃ * 411 (M+1) 342 c -BuCH ₂ OC(=O) CH ₂ H CH ₂ CH ₃ * 425 (M+1) 343 EtNHC(=O) CH ₂ H CH ₂ CH ₃ * 382 (M-1) 345 EtOC(=O) CH ₂ CH ₂ H CH ₂ CH ₃ * 399 (M+1) 347 CHF ₂ CH ₂ OC(=O) CH ₂ H CH ₂ CH ₃ * 421 (M+1) 348 CF ₃ CH ₂ CH ₂ OC(=O) CH ₂ H CH ₂ CH ₃ * 453 (M+1) 349 CF ₂ =CFCH ₂ CH ₂ OC(=O) CH ₂ H CH ₂ CH ₃ * 465 (M+1) 350 (Me) ₂ CH(CH ₂ ) ₂ OC(=O) CH ₂ H CH ₂ CH ₃ * 351 CH ₃ O(CH ₂ ) ₃ OC(=O) CH ₂ H CH ₂ CH ₃ * 429 (M+1) 352 CF ₃ O(CH ₂ ) ₂ OC(=O) CH ₂ H CH ₂ CH ₃ * 469 (M+1) 355 CF ₃ (CH ₂ ) ₃ OC(=O) CH ₂ H CH ₂ CH ₃ * 467 (M+1) 365 EtOC(=O) CH ₂ H CH ₃ * 390 c -pentyl-NHC(=O) CH ₂ H CH ₂ CH ₃ 424 (M+1) 391 c -propyl-NHC(=O) CH ₂ H CH ₂ CH ₃ 396 (M+1) 393 c -propyl-CH ₂ NHC(=O) CH ₂ H CH ₂ CH ₃ 410 (M+1) 394 CF ₂ HCH ₂ NHC(=O) CH ₂ H CH ₂ CH ₃ 420 (M+1) 401 _CF3CH2NHC ( ₌ O) CH ₂ H CH ₂ CH ₃ 438 (M+1) 402 2-Pyrimidyl-CH ₂ NHC(=O) CH ₂ H CH ₂ CH ₃ 448 (M+1) 403 _CH3NHC (=O) CH ₂ H CH ₂ CH ₃ 370 (M+1) 404 (CH ₃ CH ₂ ) ₂ NC(=O) CH ₂ H CH ₂ CH ₃ 412 (M+1) 415 i -PrNHC(=O) CH ₂ H CH ₂ CH ₃ 398 (M+1) 421 EtOC(=O) (CH ₂ ) ₃ H CH ₂ CH ₃ 413 (M+1) *related¹⁹ For F NMR data, see Index Table M. Index table K1

R⁸ A dash "–" in a column means R⁸ Substituents are absent and the remaining carbon valences are occupied by hydrogen atoms. The structures of substituents around double bonds in the above structures are shown in the structures unless otherwise specified. Compound number R ¹³ L ^R8 R ^2c molecular weight 301 4-(EtOC(=O)) CH ₂ 2-F CH ₂ CH ₃ 403 (M+1) 302 4-(EtOC(=O)) CH ₂ 6-F CH ₂ CH ₃ 403 (M+1) 303 4-(EtOC(=O)) CH ₂ 2-Me CH ₂ CH ₃ 399 (M+1) 378 3-(EtOC(=O)) CH ₂ 5-MeO CH ₂ CH ₃ 415 (M+1) 405 3-(EtOC(=O)) CH ₂ 5-Me CH ₂ CH ₃ 399 (M+1) 406 4-(EtOC(=O)) CH ₂ 5-Me CH ₂ CH ₃ 399 (M+1) 407 3-(EtOC(=O)) CH ₂ 4-MeO CH ₂ CH ₃ 415 (M+1) 408 4-(EtOC(=O)) CH ₂ 4-MeO CH ₂ CH ₃ 415 (M+1) 418 4-(EtOC(=O)) CH ₂ 4-F CH ₂ CH ₃ 403 (M+1) 419 5-(EtOC(=O)) CH ₂ 4-F CH ₂ CH ₃ 403 (M+1) 420 3-(EtOC(=O)) CH ₂ 4-F CH ₂ CH ₃ 403 (M+1) 448 5-(EtOC(=O)) CH ₂ – CH ₂ CH ₃ 386 (M+1) 449 3-(EtOC(=O)) CH ₂ – CH ₂ CH ₃ 386 (M+1) 451 4-(EtOC(=O)) CH ₂ 6-Me CH ₂ CH ₃ 399 (M+1) 462 5-(EtOC(=O)) CH ₂ 5-Me CH ₂ CH ₃ 399 (M+1) 463 5-(EtOC(=O)) CH ₂ 4-MeO CH ₂ CH ₃ 415 +1) Index table L Compound number structure NMR molecular weight Melting point(℃) 63 [Note 6]

* 124

402 (M+1) 146

* 401 (M+1) 147

* 274 (M+1) 165

* 168

402 (M+1) 263

* 266 (Example 6)

* 273

** 305

* 320

391 (M+1) 321

* 346

* 389 (M+1) 353

* 417 (M+1) 367

* 368

349 (M+1) 81-84 370

403 (M+1) 377

455 (M+1) 385

* 386

* 83.7-86.5 392

473 (M+1) 59-62 395

* 398

437 (M+1) 399

385 (M+1) 417

403 (M+1) 423

* 424

409 (M+1) 425

419 (M+1) 439

289 (M-1) 440

339 (M-1) 441

272 (M-1) 442

279 (M-1) 446

* 447

* 450

373 (M+1) 452

369 (M-1) 453

365 (M+1) 454

419 (M+1) 457

417 (M+1) 460

275 (M-1) Note 6: 3:2 mixture of geometric isomers. *related¹⁹ For F NMR data, see Index Table M. **related¹ H NMR data, see Index Table N. Index table M Compound number ¹⁹ F NMR ^dataa Compound number ¹⁹ F NMR ^dataa 1 δ -84.92 (s). 177 δ -84.85 (s). 2 δ (DMSO- d ₆ ) -81.80 (s). 179 δ -62.79 (s), -81.40 (s). 3 δ -81.39 (s). 180 δ -70.10 (s). 4 δ (DMSO- d ₆ ) -81.50 (s). 181 δ -61.85 (s). 5 δ -82.61 (s), -75.48 (s). 182 δ -56.40 (s). 6 δ -79.03 (s). 183 δ -70.09 (s). 7 δ -81.50 (s), -81.71 (s). 184 δ -70.11 (s). 8 δ -81.50 (s), -81.71 (s). 189 δ -81.42 (s). 9 δ -81.27 (s). 190 δ -81.38 (s). 10 δ -79.64 (s). 191 δ -81.42 (s). 12 δ -81.01 (s). 192 δ -81.39 (s). 13 δ -81.38 (s). 193 δ -70.01 (s). 14 δ -81.39 (s). 195 δ -70.04 (s). 15 δ -81.38 (s). 196 δ -70.08 (s). 16 δ -81.39 (s). 197 δ -72.38 (s), -81.38 (s). 17 δ -81.38 (s). 198 δ -81.38 (s). 18 δ -81.38 (s). 199 δ -81.38 (s). 20 δ -78.49 (s). 200 δ -81.38 (s). twenty one δ -80.99 (s). 201 δ -81.38 (s). twenty two δ -81.39 (s). 202 δ -81.39 (s). twenty three δ -81.37 (s). 203 δ -81.39 (s). twenty four δ -81.37 (s). 204 δ -81.38 (s). 25 δ -81.37 (s). 205 δ -70.14 (s). 26 δ -81.39 (s). 206 δ -84.95 (s). 27 δ -81.41 (s). 209 δ -81.36 (s). 28 δ -81.38 (s). 210 δ -70.08 (s). 29 δ -84.92 (s). 214 δ -81.43 (s). 31 δ (DMSO- d ₆ ) -81.91 (s). 224 δ -70.09 (s). 32 δ -81.39 (s). 225 δ -70.08 (s). 33 δ (DMSO- d ₆ ) -81.83 (s). 226 δ -70.10 (s). 34 δ (DMSO- d ₆ ) -81.89 (s). 227 δ -81.57 (s), -84.95 (s). 35 δ -84.94 (s). 228 δ -81.39 (s). 36 δ (DMSO- d ₆ ) -81.37 (s). 230 δ -70.21 (s). 37 δ (DMSO- d ₆ ) -81.82 (s). 231 δ -70.12 (s). 39 δ -84.93 (s). 232 δ -81.39 (s). 40 δ (acetone- d ₆ ) -83.12 (s). 233 δ -84.87 (s). 41 δ -84.81 (s). 234 δ -84.95 (s). 42 δ (DMSO- d ₆ ) -81.82 (s). 235 δ -81.45 (s). 43 δ (DMSO- d ₆ ) -81.82 (s). 236 δ -81.46 (s). 44 δ -84.21 (s). 237 δ -81.44 (s). 45 δ (DMSO- d ₆ ) -81.82 (s), -72.33 (t). 239 δ -81.42 (s). 46 δ (DMSO- d ₆ ) -81.83 (s), -82.96 (s), -122.29 (t). 240 δ -81.39 (s) 47 δ (DMSO- d ₆ ) -81.82 (s). 241 δ -70.11 (s). 48 δ (DMSO- d ₆ ) -81.82 (s). 245 δ -68.61 (s). 49 δ (DMSO- d ₆ ) -81.82 (s). 249 δ -81.39 (s). 50 δ (DMSO- d ₆ ) -81.82 (s), -138.53 (m), -139.66 (m). 250 δ -70.11 (s). 51 δ -87.93 (s). 251 δ -70.13 (s). 52 δ -76.89 (s). 252 δ -70.09 (s). 53 δ -70.09 (s). 253 δ -70.11 (s). 54 δ -69.99 (s). 260 δ -70.12 (s). 55 δ -69.95 (s). 261 δ -70.12 (s). 56 δ -69.73 (s). 262 δ -70.33 (s). 57 δ -69.75 (s). 263 δ -81.60 (s), -132.13 (s). 58 δ -70.10 (s). 264 δ -84.92 (s). 60 δ -70.30 (s). 265 δ -70.09 (s). 61 δ -70.26 (s). 266 δ -84.88 (s). 62 δ -70.15 (s). 267 δ -70.13 (s). 63 δ -63.30 (s), -63.67 (s). 268 δ -70.03 (s). 64 δ -70.13 (s). 269 δ -70.03 (s). 65 δ -70.03 (s). 270 δ -70.12 (s). 66 δ -85.74 (s). 271 δ -70.12 (s). 67 δ -82.36 (s). 272 δ -69.99 (s). 72 δ -70.24 (s). 278 δ -70.11 (s). 73 δ -70.20 (s). 279 δ -70.31 (s). 74 δ -70.22 (s). 280 δ -84.80 (s). 75 δ -70.22 (s). 284 δ -81.38 (s). 79 δ -70.22 (s). 285 δ -81.39 (s). 80 δ -84.87 (s). 286 δ -84.94 (s). 81 δ -70.17 (s). 287 δ -70.05 (s). 82 δ -70.14 (s). 288 δ -70.04 (s). 83 δ -70.17 (s). 289 δ -81.39 (s). 84 δ -70.16 (s). 290 δ -81.37 (s). 85 δ -70.14 (s). 291 δ -70.12 (s). 86 δ -70.12 (s). 292 δ -70.13 (s). 87 δ -70.11 (s). 293 δ -70.13 (s). 88 δ -70.19 (s). 294 δ -70.01 (s). 89 δ -70.13 (s). 296 δ -81.38 (s). 90 δ -70.16 (s). 297 δ -70.01 (s). 91 δ -70.12 (s). 298 δ -70.05 (s), -74.96 (s). 92 δ -70.13 (s). 299 δ -70.12 (s). 93 δ -81.42 (s). 300 δ -70.10 (s). 94 δ -70.21 (s). 305 δ -84.85 (s). 95 δ -70.21 (s). 309 δ -70.02 (s). 96 δ -69.98 (s). 310 δ -70.04 (s). 97 δ -84.95 (s). 311 δ -70.01 (s). 98 δ -81.40 (s). 312 δ -70.03 (s). 99 δ -70.19 (s). 318 δ -81.38 (s). 100 δ -70.16 (s). 319 δ -79.29 (s), 82.67 (s). 101 δ -70.15 (s). 321 δ -68.60 (s). 102 δ -70.18 (s). 322 δ -81.70 (s). 103 δ -70.16 (s). 323 δ -70.10 (s). 104 δ -70.16 (s). 325 δ -70.11 (s). 105 δ -70.16 (s). 326 δ -70.13 (s). 111 δ -70.08 (s). 327 δ -70.13 (s). 112 δ -81.43 (s). 328 δ -68.54 (s). 113 δ -63.01 (s), -70.10 (s). 329 δ -77.08 (s). 114 δ -70.09 (s). 330 δ -70.09 (s). 116 δ -70.14 (s). 331 δ -70.10 (s). 119 δ -70.16 (s). 332 δ -70.08 (s). 120 δ -70.15 (s). 333 δ -70.09 (s). 121 δ -70.16 (s). 334 δ -70.09 (s). 122 δ -70.14 (s). 335 δ -70.09 (s). 123 δ -70.15 (s). 336 δ -70.08 (s). 126 δ -81.38 (s). 337 δ -70.08 (s). 127 δ -81.38 (s). 338 δ -70.06 (s). 129 δ -70.06 (s), -72.25 (s). 339 δ -70.10 (s). 130 δ 70.06 (s). 340 δ -70.09 (s). 131 δ -84.93 (s). 341 δ -70.09 (s). 132 δ -70.05 (s). 342 δ -70.11 (s). 133 δ -81.40 (s). 343 δ -70.11 (s). 134 δ -81.40 (s), -73.70 (s). 344 δ -70.50 (s). 140 δ -69.16 (s). 345 δ -68.59 (s). 164 δ -81.33 (s). 346 δ -81.82 (s). 165 δ -81.34 (s). 347 δ -70.09 (s), -125.54 (s). 166 δ -81.38 (s). 348 δ -64.93 (s), -70.09 (s). 167 δ -69.60 (s). 349 δ -70.13 (s), -103.21 (s), -123.98 (s), -175.15 (s). 141 δ -81.28 (s). 350 δ -70.09 (s). 142 δ -84.83 (s). 351 δ -70.09 (s). 143 δ -60.46(s), -70.25(s). 352 δ -60.95 (s), -70.12 (s). 144 δ -70.30 (s). 353 δ -81.41 (s). 145 δ -69.79 (s). 354 δ -70.03 (s). 146 δ -81.37 (s). 355 δ -66.44 (s), -70.09 (s). 147 δ -81.36 (s). 356 δ -70.14 (s). 149 δ -70.07 (s). 357 δ -70.13 (s). 150 δ -70.07 (s). 358 δ -70.12 (s). 151 δ -70.09 (s). 359 δ -70.11 (s). 152 δ -70.09 (s). 360 δ -70.12 (s). 153 δ -70.12 (s). 361 δ -70.13 (s). 154 δ -70.10 (s). 362 δ -70.11 (s). 155 δ -70.05 (s). 365 δ -70.05 (s). 156 δ -70.05 (s). 367 δ -70.08 (s). 157 δ -70.19 (s). 369 δ -83.07 (s). 158 δ -70.10 (s). 385 δ -80.30 (s). 160 δ -81.44 (s). 386 δ -84.80 (s). 161 δ -81.38 (s). 395 δ -80.30 (s). 162 δ (DMSO- d ₆ ) -80.02 (s). 396 δ -84.90 (s). 163 δ -81.38 (s). 423 δ -84.80 (s). 169 δ -81.38 (s). 432 δ -84.80 (s). 170 δ -81.38 (s). 433 δ -70.00 (s). 171 δ -81.37 (s). 443 δ -81.72 (s). 172 δ -81.37 (s). 445 δ -70.10 (s). 176 δ -81.40 (s). 447 δ -70.08 (s). ^a Unless otherwise stated, at CDCl₃ solution, relative to CF₃ CCl₃ , reported in ppm¹⁹ F NMR spectrum. Couplings are expressed as (s) singlet, (t) triplet, and (m) multiplet. index table N Compound number ¹ H NMR ^dataa 273 (CDCl ₃ ): δ 1.36-1.32 (t, 3H), 4.21 (s, 6H), 4.32-4.25 (q, 2H), 5.32 (s, 2H), 6.20 (s, 1H), 6.70 (s, 1H) ), 7.89 (s, 1H), 7.95 (s, 1H). 366 (DMSO- d ₆ ): δ 1.26 (t, 3H), 3.98 (s, 2H), 4.21 (q, 2H), 6.03 (s, 2H), 6.86-6.94 (m, 2H), 6.95-7.06 (m , 2H), 7.27 (s, 2H), 7.94 (s, 1H), 8.53 (s, 1H). 434 (CDCl ₃ ): δ 1.34 (t, 3H), 4.18 (s, 2H), 4.57 (q, 2H), 6.78 (s, 1H), 7.05 (s, 2H), 7.36 (s, 2H). ^a Reported in ppm downfield from tetramethylsilane¹ H NMR data. Couplings are expressed as (s) singlet, (t) triplet, and (q) quadruplet. Biological Examples of the Invention

General protocol for preparing test suspensions for testing AC: first dissolve the test compound in acetone in an amount equal to 3% of the final volume, then suspend the desired concentration (in ppm) in acetone and purified water (50/50). mixture) containing 250 ppm of the surfactant PE G400 (polyol ester). The resulting test suspension was then used for tests A-E. Test A

The test solution was sprayed onto the run-off points of soybean seedlings. The next day, seedlings were inoculated with a spore suspension of Phakopsora pachyrhizi , the causative agent of Asian soybean rust, and incubated at 22°C for 24 hours at saturated air pressure, then moved to a 22°C growth chamber 8 days, after which a visual disease rating was performed. Test B

The test solution was sprayed to the run-off point of the wheat seedlings. The next day, seedlings were inoculated with a spore suspension of Puccinia recondita f.Sp. tritici , the causative agent of wheat leaf rust, and incubated at 20°C for 24 hours at saturated air pressure, then moved to 20°C 6 days in a growth chamber at °C before disease grading. test C

The test solution was sprayed onto the bleed point on the grape seedlings. The next day, seedlings were inoculated with a spore suspension of Uncinula necator , the causative agent of grape powdery mildew, and incubated in a growth chamber at 20°C for 12 days before disease grading. test D

The test solution was sprayed to the run-off point of the wheat seedlings. The next day, seedlings were inoculated with a spore suspension of Zymoseptoria tritici , the causative agent of wheat leaf spot, and incubated at 24°C for 48 hours at saturated air pressure, then moved to 20°C for growth Disease ratings were performed after 17 days in the chamber. test E

The test suspension was sprayed to the run-off point on the wheat seedlings. The next day, Blumeria graminis f.Sp. tritici (also known as Erysiphe graminis f.Sp. tritici , the causative agent of wheat powdery mildew) Seedlings were inoculated with spore powder and incubated in a growth chamber at 20 °C for 8 days, after which visual disease ratings were performed.

The results of Test AE are provided in Table A. In this table, a rating of 100 represents 100% disease control, and a rating of 0 represents no disease control (relative to the control group). An asterisk "*" or a double asterisk "**" or a triple asterisk "***" next to the rating indicates that a 50 ppm, 10 ppm, 250 ppm test suspension was used, respectively. A dash (-) indicates that the compound was not tested. Table A Compound number Ratio in ppm Test A Test B test C test D test E 1 250 100 91 – 97 81 2 10 77 32 – – – 3 10 100 0 – – – 4 10 100 89 100* – – 5 10 0 0 – – – 6 10 0 0 – – – 7 10 94 0 – – – 8 10 96 9 – – – 9 10 98 86 – – – 10 10 100 86 – – – 12 10 13 0 – – – 13 10 99 0 – – – 14 10 100 0 – – – 15 10 100 0 – – – 16 10 99 0 – – – 17 10 100 0 – – – 18 10 100 0 – – – 20 10 98 86 – – – twenty one 10 84 twenty three – – – twenty two 10 38 0 – – – twenty three 10 0 19 – – – twenty four 10 81 91 – – – 25 10 0 0 – – – 26 10 99 0 – – – 27 10 0 0 – – – 28 10 0 0 – – – 29 10 84 28 – 0*** 79*** 30 10 0 0 – – – 31 10 44 93 – – – 32 50 100 68 100** 89*** 97*** 33 10 96 86 – – – 34 10 0 80 – – – 35 10 99 32 – – – 36 10 70 0 – – – 37 10 99 86 – – – 38 10 97 89 – – – 39 10 91 79 – – – 40 10 91 68 – – – 41 10 92 twenty three – – – 42 10 99 85 – – – 43 10 96 60 – – – 44 10 97 85 16*** 98*** 91*** 45 10 87 85 – – – 46 10 64 85 – – – 47 50 100 95 – – – 48 50 100 91 – – – 49 10 0 86 – – – 50 10 54 91 – – – 51 10 0 0 81*** 3*** 0*** 52 10 99 0 – – – 53 50 100 67 – – – 54 10 0 0 – – – 55 10 0 0 – – – 56 10 38 0 – – – 57 250 100 0 64*** 28 95*** 58 10 0 0 – – – 60 10 0 0 – – – 61 10 0 0 – – – 62 10 0 0 – – – 63 10 0 0 – – – 64 250 100 99 100** 73 99 65 10 100 0 – – – 66 50 92 89 – – – 67 50 65 0 – – – 68 10 100 95 – – – 69 10 98 96 – – – 70 250 100 100 86 91 83 71 10 100 96 – – – 72 50 13 0 – – – 73 10 0 0 – – – 74 10 0 0 – – – 75 10 0 0 – – – 76 10 0 0 – – – 77 10 99 0 – – – 78 10 94 0 – – – 79 50 0 0 – – – 80 50 99 100 0 96*** 99*** 81 10 0 0 – – – 82 10 97 0 – – – 83 10 82 0 – – – 84 10 0 0 – – – 85 10 89 0 – – – 86 10 99 0 – – – 87 10 0 0 – – – 88 10 65 0 – – – 89 10 0 0 – – – 90 10 100 0 – – – 91 10 0 0 – – – 92 10 0 0 – – – 93 10 96 0 – – – 94 10 0 0 – – – 95 10 0 0 – – – 96 10 13 0 – – – 97 50 94 0 – – – 98 250 100 100 31 77 0 99 10 0 80 – – – 100 10 0 0 – – – 101 10 0 0 – – – 102 10 0 0 – – – 103 10 0 0 – – – 104 10 0 80 – – – 105 10 0 68 – – – 106 10 0 0 – – – 107 10 0 0 – – – 109 10 0 0 – – – 110 50 79 0 – – – 111 10 0 0 – – – 112 10 0 0 – – – 113 10 0 0 – – – 114 50 44 0 – – – 115 250 0 0 58 19 56 116 10 100 0 – – – 117 10 twenty three 0 – – – 118 50 100 0 77*** 13*** 76*** 119 10 97 0 – – – 120 50 100 0 twenty three 17 98 121 10 100 0 – – – 122 10 0 0 – – – 123 10 98 0 – – – 124 50 100 0 100 92*** 98 125 10 100 0 – – – 126 10 100 0 100* – – 127 10 100 0 100* – – 129 10 100 0 – – – 130 10 100 0 – – – 131 50 99 86 – – – 132 10 100 0 98* – – 133 10 79 0 – – – 134 10 89 32 – – – 135 10 86 61 – – – 136 10 98 83 – – – 137 10 79 0 – – – 138 10 100 0 100* 31*** 99*** 139 10 100 0 – – – 140 10 98 twenty three – – – 141 10 0 0 – – – 142 10 92 100 19*** 100*** 99*** 143 10 0 0 – – – 144 10 78 0 – – – 145 10 82 0 – – – 146 50 60 0 – – – 147 50 77 0 – – – 148 10 0 0 – – – 149 10 0 0 – – – 150 10 33 0 – – – 151 10 0 0 – – – 152 10 0 0 – – – 153 10 100 0 – – – 154 10 0 0 – – – 155 10 0 0 – – – 156 10 0 0 – – – 157 10 0 9 – – – 158 10 0 0 – – – 160 10 13 0 – – – 161 10 100 0 – – – 162 10 100 0 100* – – 163 10 100 0 100* – – 164 10 31 0 – – – 165 10 0 0 – – – 166 10 100 95 – – – 167 10 38 0 – – – 168 10 0 0 – – – 169 10 100 0 – – – 170 10 100 0 100* – – 171 10 100 0 99* – – 172 10 100 0 – – – 173 10 0 0 – – – 174 10 0 0 – – – 175 10 0 0 – – – 176 10 0 0 – – – 177 50 100 89 – – – 178 10 0 0 – – – 179 10 0 0 – – – 180 10 0 0 – – – 181 10 0 0 – – – 182 10 0 0 – – – 183 10 0 0 70*** 66*** 0*** 184 10 0 0 – – – 185 10 100 0 100* 0*** 95*** 186 10 100 0 100* 9*** 84*** 187 10 93 74 – – – 188 10 100 0 – – – 189 10 0 0 – – – 190 10 0 0 – – – 191 10 0 0 – – – 192 10 0 0 – – – 193 10 0 86 – – – 195 10 0 0 – – – 196 10 0 74 – – – 197 10 0 0 – – – 198 10 0 0 – – – 199 10 100 0 – – – 200 10 100 0 – – – 201 10 100 0 – – – 202 10 100 0 – – – 203 10 50 0 – – – 204 10 100 0 – – – 205 10 0 0 – – – 206 50 100 98 34*** 93*** 93*** 207 10 0 0 – – – 209 10 89 0 – – – 210 10 0 0 – – – 211 10 0 0 – – – 212 10 44 0 – – – 214 10 0 0 – – – 215 10 80 55 – – – 216 10 100 0 20*** 37*** 87*** 217 10 100 0 75*** twenty three*** 96*** 218 10 100 0 75*** 53*** 90*** 219 10 100 0 92*** 0*** 83*** 220 10 100 0 85*** 28*** 92*** 221 10 100 0 41*** 10*** 95*** 222 10 100 0 38*** 17*** 90*** 223 10 75 0 – – – 224 10 0 0 – – – 225 10 0 0 – – – 226 10 0 0 – – – 227 10 99 55 – – – 228 10 100 0 – – – 229 50 99 100 – 96*** 99*** 230 10 0 0 – – – 231 10 100 0 – – – 232 10 98 0 – – – 233 50 100 96 – – – 234 50 100 92 – – – 235 10 97 0 – – – 236 10 75 0 – – – 237 10 97 0 – – – 238 10 73 0 – – – 239 10 0 0 – – – 240 10 99 0 – – – 241 10 0 0 – – – 242 10 100 0 87*** 27*** 69*** 243 10 100 0 29*** 0*** 56*** 244 10 100 0 – 0*** 0*** 245 10 100 0 twenty four*** 18*** 76*** 246 10 100 0 85*** 12*** 90*** 247 10 13 0 twenty one*** 79*** twenty one*** 248 10 71 0 62*** 93*** 89*** 249 10 100 0 – – – 250 10 0 0 – – – 251 10 100 9 – – – 252 10 0 0 – – – 253 10 0 0 – – – 254 10 73 0 10*** 67*** 56*** 255 10 89 0 93*** 60*** 64*** 256 10 73 0 15*** 95*** 82*** 257 10 54 0 81*** 35*** 92*** 258 10 96 0 64*** 13*** 53*** 259 10 25 0 31*** 88*** 83*** 260 10 0 0 – – – 261 10 0 0 – – – 262 10 100 0 99* – – 263 10 100 0 100* – – 264 10 99 80 – 95*** 96*** 265 50 100 0 98 – – 266 50 86 74 – – – 267 10 94 0 – – – 268 10 99 0 – – – 269 10 100 0 – – – 270 10 25 0 – – – 271 10 0 0 – – – 272 10 100 0 – – – 273 50 100 0 49*** 20*** 65*** 274 10 48 0 – – – 275 10 0 0 – – – 276 10 13 0 100* 53*** 86*** 277 10 50 45 – – – 278 50 94 0 – – – 279 50 0 0 – – – 280 50 100 100 – 99*** 99*** 281 50 95 98 – – – 282 50 0 0 – – – 283 50 100 99 – – – 284 10 100 0 – – – 285 10 100 0 – – – 286 10 87 55 – – – 287 50 77 0 – – – 288 50 96 0 – – – 289 10 0 0 – – – 290 50 50 19 – – – 291 10 100 0 – – – 292 10 100 0 – – – 293 10 100 0 – – – 294 10 100 0 – – – 295 50 99 80 – – – 296 10 0 0 – – – 297 10 100 0 – – – 298 10 0 0 – – – 299 10 100 0 – – – 300 10 100 0 – – – 301 50 100 0 100* – – 302 50 99 0 – – – 303 50 0 0 – – – 304 50 96 0 – – – 305 10 70 0 – – – 306 50 96 68 – – – 307 50 0 0 – – – 308 50 25 0 – – – 309 10 100 0 – – – 310 10 100 0 – – – 311 10 0 0 – – – 312 10 0 0 – – – 313 50 0 0 – – – 314 50 0 0 – – – 316 50 100 9 100 2 73 317 50 0 0 – – – 318 10 100 0 – – – 319 50 100 41 – – – 320 10 89 68 – 81*** 91*** 321 10 100 0 – – – 322 10 99 86 48*** 100*** 97*** 323 50 100 0 – – – 324 10 0 0 – – – 325 10 100 0 – – – 326 10 100 0 – – – 327 10 100 0 – – – 328 10 100 0 – – – 329 50 100 41 – – – 330 10 100 0 – – – 331 10 100 0 – – – 332 10 100 0 – – – 333 10 100 0 – – – 334 10 100 0 – – – 335 10 100 0 – – – 336 10 100 0 – – – 337 10 100 0 – – – 338 10 100 0 – – – 339 10 100 0 – – – 340 10 100 0 – – – 341 10 100 0 – – – 342 10 100 0 – – – 343 10 0 0 – – – 344 50 100 0 – – – 345 10 0 0 – – – 346 10 0 0 – – – 347 50 100 0 – – – 348 10 100 0 – – – 349 10 100 0 – – – 350 10 100 0 – – – 351 10 100 0 – – – 352 10 100 0 – – – 353 50 0 0 – – – 354 10 100 0 – – – 355 10 100 0 – – – 356 10 100 0 – – – 357 10 100 9 – – – 358 10 100 0 – – – 359 10 100 0 – – 360 10 100 0 – – – 361 10 100 0 – – – 362 10 100 0 – – – 364 50 100 0 100 0 56 365 10 100 0 – – – 366 10 79 55 – – – 367 10 0 0 – – – 368 50 0 0 33*** 0*** 0*** 369 – – – – – – 370 10 0 0 – – – 371 50 0 77 – – – 372 50 97 28 – 99*** 99*** 373 50 81 0 56*** 99*** 98*** 374 50 0 0 – 0*** 76*** 375 50 100 0 66*** 95*** 99*** 376 50 100 92 36 98*** 99*** 377 10 44 0 – – – 378 10 0 0 – – – 379 50 0 0 93*** 0*** twenty one*** 380 10 0 0 – 0*** 56*** 381 10 25 28 – 0*** 69*** 382 50 0 0 twenty two*** 4*** 56*** 383 50 0 0 74*** 0*** 0*** 384 50 99 83 – 48*** 87*** 385 50 100 68 – – – 386 10 84 19 – – – 387 – – – – – – 388 – – – – – – 389 – – – – – – 390 50 0 – – – – 391 50 0 – – – – 392 10 97 19 – – – 393 50 38 0 63*** 69*** 0*** 394 50 0 0 75*** twenty four*** 0*** 395 50 100 100 100 – – 396 50 31 19 – – – 398 10 0 0 – – – 399 50 97 0 – – – 400 50 100 0 – – – 401 10 0 0 35*** 0*** 0*** 402 50 97 – 48*** 5*** 0*** 403 50 54 – 74*** 17*** 0*** 404 50 0 0 44*** 11*** 0*** 405 50 0 0 – – – 406 50 0 0 – – – 407 50 0 0 – – – 408 50 44 0 – – – 409 – – – – 410 10 100 0 88*** 11*** 13*** 411 50 87 0 – – – 412 50 100 0 – – – 413 10 0 0 61*** 90*** 35*** 414 10 45 0 91*** 97*** 90*** 415 10 0 0 9*** 0*** 0*** 416 50 81 0 34*** 0*** 0*** 417 10 0 0 – – – 418 10 0 0 – – – 419 10 0 0 – – – 420 10 0 0 – – – 421 10 0 0 – – – 422 50 100 84 – – – 423 50 87 80 – – – 424 10 97 41 – – – 425 10 100 0 – – – 426 10 0 0 45*** 2*** 43*** 427 10 13 0 5*** 53*** 29*** 428 10 0 0 43*** 2*** 0*** 430 50 100 0 82*** 3*** 99*** 431 250 – – 36 93 96 432 50 100 98 – – – 433 50 0 0 – – – 434 50 0 0 – – – 435 50 96 0 45*** 5*** 81*** 436 50 99 0 48*** – 0*** 437 50 77 0 77*** 78*** 69*** 438 50 73 0 59*** 26*** 98*** 439 – – – – – – 440 – – – – – – 441 – – – – – – 442 50 0 0 – – – 443 50 48 0 – – – 444 – – – – – – 445 50 38 0 – – – 446 10 98 0 – – – 447 10 0 0 – – – 448 10 0 0 – – – 449 50 99 0 – – – 450 50 97 0 – – – 451 50 0 0 – – – 452 – – – – – – 453 10 0 0 – – – 454 10 100 0 100 – – 455 50 99 86 34 43 0 456 50 99 93 6 80 98*** 457 250 89** 0** 73 7 0 458 10 100 0 25*** 41*** 94*** 459 50 100 97 – 37*** 0*** 460 – – – – – – 461 50 0 0 – 53*** 69*** 462 10 0 0 – – – 463 10 0 0 – – – 464 50 100 0 73*** 4*** 99*** 465 50 100 100 73*** 59*** 91***

The test results of the compounds of formula 1 presented in Table A above illustrate the fungicidal activity of component (a) against components comprising component (a) as well as component (b) and optionally at least one other fungicidal activity according to the present invention. The plant disease control effect of the composition of the fungicide compound contributes.

Test F below demonstrates the control effect of the composition of the present invention on Asian soybean rust. The general method for preparing the test compositions for Test F is as follows: Compound 32, Compound 64, azoxystrobin, benzovindiflupyr, bixafen, chlorothalonil , Cyproconazole, epoxiconazole, fenpropidin, fenpropimorph, fluindapyr, flutriafol, Sterilization Dan (fluxapyroxad), phenoxystrobin (metominostrobin), picoxystrobin (picoxystrobin), prothioconazole (prothioconazole), pydiflumetofen (pydiflumetofen), pyraclostrobin (pyraclostrobin), tebuconazole (tebuconazole) and triflumine (trifloxystrobin). The formulations copper hydroxide and mancozeb sold under the trademark KOCIDE 3000 and MANZATE, respectively, were obtained. The unformulated material was first dissolved in acetone, then suspended at the desired concentration (in ppm) in acetone and purified water (50/v/v) containing 250 ppm of the surfactant Trem ^® 014 (polyol ester). 50) in. The formulated materials are dispersed in sufficient water to achieve the desired concentration, and neither organic solvents nor surfactants are added to the suspension. The resulting test mixture was then used in Test F. Tests were performed on four individual plants and results are reported as the average of the four plants.

。A synergy between the two active ingredients was established by means of the Colby equation (see Colby, SR "Calculating Synergistic and Antagonistic Responses of Herbicide Combinations", Weeds , (1967), 15, 20‑22):

.

Using Colby's method, it can be determined that there is a synergistic interaction between the two active ingredients by first calculating the predicted activity p of the mixture based on the activities of the two components administered separately. If p is lower than the experimentally determined effect, then synergy has occurred. In the above equation, A is the fungicidal activity in percent control of one of the constituents applied alone at the ratio x. Item B is the fungicidal activity in percent control of the second set of components applied at rate y. This equation estimates p, the expected fungicidal activity of a mixture of A at ratio x and the fungicidal activity of a mixture of B at ratio y, if their effects are strictly additive and no interaction occurs. Test F

The test mixture was sprayed to the run-off point on soybean seedlings. The next day, seedlings were inoculated with a spore suspension of Phakopsora pachyrhizi , the causative agent of Asian soybean rust, and incubated in a saturated atmosphere at 22°C for 24 hours before being moved to a growth chamber at 22°C After 8 days, visual disease was scored.

Results for Test F are provided in Tables B-1 to 1-1 for Compound 32, and results for Test F for Compound 64 are provided in Tables B-2 to 1-2. Each table corresponds to a set of simultaneous evaluations. In each table, a rating of 100 indicates 100% disease control, and a rating of 0 indicates no disease control (relative to the control). The column labeled "Obsd" represents the mean of the results observed on four individual plants tested. The column labeled "Exp" is the expected value for each treatment mixture using Colby's equation. Table B-1 Observation and expected effect of single application of compound 32 and its mixture with picoxystrobin in the control of Asian soybean rust Application rate (ppm) of compound 32 (ie, component (a)) Component (b) Application rate (ppm) of component (b) Test F observe expected 0 none 0 0 – 1.422 none 0 55 – 2.276 none 0 64 – 0 Picoxystrobin 20.596 73 – 0 Picoxystrobin 33.865 75 – 1.422 Picoxystrobin 20.596 75 88 1.422 Picoxystrobin 33.865 66 89 2.276 Picoxystrobin 20.596 66 90 2.276 Picoxystrobin 33.865 72 91 Table B-2 Observation and expected effect of single application of compound 64 and its mixture with picoxystrobin in the control of Asian soybean rust Application rate (ppm) of compound 64 (ie, component (a)) Component (b) Application rate (ppm) of component (b) Test F observe expected 0 none 0 0 – 0.303 none 0 53 – 0.489 none 0 68 – 0 Picoxystrobin 20.596 73 – 0 Picoxystrobin 33.865 75 – 0.303 Picoxystrobin 20.596 59 87 0.303 Picoxystrobin 33.865 67 88 0.489 Picoxystrobin 20.596 65 91 0.489 Picoxystrobin 33.865 72 92 Table C-1 Observation and expected effect of compound 32 alone and its mixture with bixafen, fluxapyroxad and fluindapyr in controlling Asian soybean rust Application rate (ppm) of compound 32 (ie, component (a)) Component (b) Application rate (ppm) of component (b) Test F observe expected 0 none 0 0 – 1.422 none 0 39 – 2.276 none 0 44 – 0 Bixafen (bixafen) 11.327 54 – 0 Bixafen (bixafen) 19.525 55 – 1.422 Bixafen (bixafen) 11.327 64 72 1.422 Bixafen (bixafen) 19.525 59 72 2.276 Bixafen (bixafen) 11.327 56 75 2.276 Bixafen (bixafen) 19.525 59 74 0 Sterilization Dan (fluxapyroxad) 2.757 19 – 0 Sterilization Dan (fluxapyroxad) 4.748 52 – 1.422 Sterilization Dan (fluxapyroxad) 2.757 68 50 1.422 Sterilization Dan (fluxapyroxad) 4.748 74 70 2.276 Sterilization Dan (fluxapyroxad) 2.757 72 54 2.276 Sterilization Dan (fluxapyroxad) 4.748 82 73 0 Fluindapyr 8.820 61 – 0 Fluindapyr 15.230 79 – 1.422 Fluindapyr 8.820 50 76 1.422 Fluindapyr 15.230 51 87 2.276 Fluindapyr 8.820 64 78 2.276 Fluindapyr 15.230 71 88 Table C-2 Observation and expected effect of compound 64 alone and its mixture with bixafen, fluxapyroxad and fluindapyr in controlling Asian soybean rust Application rate (ppm) of compound 64 (ie, component (a)) Component (b) Application rate (ppm) of component (b) Test F observe expected 0 none 0 0 – 0.303 none 0 34 – 0.489 none 0 63 – 0 Bixafen (bixafen) 11.327 54 – 0 Bixafen (bixafen) 19.525 55 – 0.303 Bixafen (bixafen) 11.327 35 70 0.303 Bixafen (bixafen) 19.525 66 69 0.489 Bixafen (bixafen) 11.327 13 83 0.489 Bixafen (bixafen) 19.525 53 83 0 Sterilization Dan (fluxapyroxad) 2.757 19 – 0 Sterilization Dan (fluxapyroxad) 4.748 52 – 0.303 Sterilization Dan (fluxapyroxad) 2.757 27 46 0.303 Sterilization Dan (fluxapyroxad) 4.748 54 68 0.489 Sterilization Dan (fluxapyroxad) 2.757 53 70 0.489 Sterilization Dan (fluxapyroxad) 4.748 48 82 0 Fluindapyr 8.820 61 – 0 Fluindapyr 15.230 79 – 0.303 Fluindapyr 8.820 64 74 0.303 Fluindapyr 15.230 72 86 0.489 Fluindapyr 8.820 61 86 0.489 Fluindapyr 15.230 65 92 Table D-1 Observation and expected effect of compound 32 alone and its mixture with mancozeb, fenpropimorph and tebuconazole in controlling Asian soybean rust Application rate (ppm) of compound 32 (ie, component (a)) Component (b) Application rate (ppm) of component (b) Test F observe expected 0 none 0 0 – 1.422 none 0 52 – 2.276 none 0 60 – 0 Mancozeb 42.532 70 – 0 Mancozeb 74.012 71 – 1.422 Mancozeb 42.532 94 86 1.422 Mancozeb 74.012 91 86 2.276 Mancozeb 42.532 94 88 2.276 Mancozeb 74.012 73 88 0 fenpropimorph 242.823 33 – 0 fenpropimorph 458.587 44 – 1.422 fenpropimorph 242.823 73 68 1.422 fenpropimorph 458.587 67 73 2.276 fenpropimorph 242.823 79 73 2.276 fenpropimorph 458.587 91 78 0 Dekeli (tebuconazole) 486.921 30 – 0 Dekeli (tebuconazole) 841.166 55 – 1.422 Dekeli (tebuconazole) 486.921 52 66 1.422 Dekeli (tebuconazole) 841.166 76 78 2.276 Dekeli (tebuconazole) 486.921 64 72 2.276 Dekeli (tebuconazole) 841.166 72 82 Table D-2 Observation and expected effect of compound 64 alone and its mixture with mancozeb, fenpropimorph and tebuconazole in controlling Asian soybean rust Application rate (ppm) of compound 64 (ie, component (a)) Component (b) Application rate (ppm) of component (b) Test F observe expected 0 none 0 0 – 0.303 none 0 49 – 0.489 none 0 63 – 0 Mancozeb 42.532 70 – 0 Mancozeb 74.012 71 – 0.303 Mancozeb 42.532 83 85 0.303 Mancozeb 74.012 82 85 0.489 Mancozeb 42.532 92 89 0.489 Mancozeb 74.012 92 89 0 fenpropimorph 242.823 33 – 0 fenpropimorph 458.587 44 – 0.303 fenpropimorph 242.823 64 66 0.303 fenpropimorph 458.587 94 72 0.489 fenpropimorph 242.823 88 75 0.489 fenpropimorph 458.587 92 79 0 Dekeli (tebuconazole) 486.921 30 – 0 Dekeli (tebuconazole) 841.166 55 – 0.303 Dekeli (tebuconazole) 486.921 48 65 0.303 Dekeli (tebuconazole) 841.166 54 77 0.489 Dekeli (tebuconazole) 486.921 50 74 0.489 Dekeli (tebuconazole) 841.166 66 83 Table E-1 Observation and expected effect of compound 32 alone and its mixture with cyproconazole, Azoxystrobin and trifloxystrobin in controlling Asian soybean rust Application rate (ppm) of compound 32 (ie, component (a)) Component (b) Application rate (ppm) of component (b) Test F observe expected 0 none 0 0 – 1.422 none 0 78 – 2.276 none 0 80 – 0 Cyproconazole 37.333 44 – 0 Cyproconazole 64.883 68 – 1.422 Cyproconazole 37.333 80 87 1.422 Cyproconazole 64.883 82 93 2.276 Cyproconazole 37.333 87 88 2.276 Cyproconazole 64.883 87 93 0 azoxystrobin 95.873 70 – 0 azoxystrobin 169.226 88 – 1.422 azoxystrobin 95.873 85 93 1.422 azoxystrobin 169.226 90 97 2.276 azoxystrobin 95.873 87 94 2.276 azoxystrobin 169.226 86 98 0 Trifloxystrobin 20.511 69 – 0 Trifloxystrobin 35.310 86 – 1.422 Trifloxystrobin 20.511 79 93 1.422 Trifloxystrobin 35.310 94 97 2.276 Trifloxystrobin 20.511 92 94 2.276 Trifloxystrobin 35.310 94 97 Table E-2 Observation and expected effect of compound 64 alone and its mixture with cyproconazole, Azoxystrobin and trifloxystrobin in controlling Asian soybean rust Application rate (ppm) of compound 64 (ie, component (a)) Component (b) Application rate (ppm) of component (b) Test F observe expected 0 none 0 0 – 0.303 none 0 78 – 0.489 none 0 77 – 0 Cyproconazole 37.333 44 – 0 Cyproconazole 64.883 68 – 0.303 Cyproconazole 37.333 82 88 0.303 Cyproconazole 64.883 80 93 0.489 Cyproconazole 37.333 86 87 0.489 Cyproconazole 64.883 90 93 0 azoxystrobin 95.873 70 – 0 azoxystrobin 169.226 88 – 0.303 azoxystrobin 95.873 84 93 0.303 azoxystrobin 169.226 85 97 0.489 azoxystrobin 95.873 91 93 0.489 azoxystrobin 169.226 87 97 0 Trifloxystrobin 20.511 69 – 0 Trifloxystrobin 35.310 86 – 0.303 Trifloxystrobin 20.511 90 93 0.303 Trifloxystrobin 35.310 87 97 0.489 Trifloxystrobin 20.511 86 93 0.489 Trifloxystrobin 35.310 82 97 Table F-1 Observation and expected effect of single application of compound 32 and its mixture with epoxiconazole and pydiflumetofen in the control of Asian soybean rust Application rate (ppm) of compound 32 (ie, component (a)) Component (b) Application rate (ppm) of component (b) Test F observe expected 0 none 0 0 – 1.422 none 0 75 – 2.276 none 0 77 – 0 Eprazole (epoxiconazole) 46.795 twenty three – 0 Eprazole (epoxiconazole) 89.631 70 – 1.422 Eprazole (epoxiconazole) 46.795 76 81 1.422 Eprazole (epoxiconazole) 89.631 79 92 2.276 Eprazole (epoxiconazole) 46.795 81 82 2.276 Eprazole (epoxiconazole) 89.631 88 93 0 Fluconazole (pydiflumetofen) 70.950 0 – 0 Fluconazole (pydiflumetofen) 135.850 73 – 1.422 Fluconazole (pydiflumetofen) 70.950 61 75 1.422 Fluconazole (pydiflumetofen) 135.850 81 93 2.276 Fluconazole (pydiflumetofen) 70.950 84 77 2.276 Fluconazole (pydiflumetofen) 135.850 76 94 Table F-2 Observation and expected effect of single application of compound 64 and its mixture with epoxiconazole and pydiflumetofen in the control of Asian soybean rust Application rate (ppm) of compound 64 (ie, component (a)) Component (b) Application rate (ppm) of component (b) Test F observe expected 0 none 0 0 – 0.303 none 0 37 – 0.489 none 0 68 – 0 Eprazole (epoxiconazole) 46.795 twenty three – 0 Eprazole (epoxiconazole) 89.631 70 – 0.303 Eprazole (epoxiconazole) 46.795 58 52 0.303 Eprazole (epoxiconazole) 89.631 68 81 0.489 Eprazole (epoxiconazole) 46.795 69 76 0.489 Eprazole (epoxiconazole) 89.631 73 90 0 Fluconazole (pydiflumetofen) 70.950 0 – 0 Fluconazole (pydiflumetofen) 135.850 73 – 0.303 Fluconazole (pydiflumetofen) 70.950 47 37 0.303 Fluconazole (pydiflumetofen) 135.850 66 83 0.489 Fluconazole (pydiflumetofen) 70.950 63 68 0.489 Fluconazole (pydiflumetofen) 135.850 63 92 Table G-1 Observation and expected effect of compound 32 alone and its mixture with benzovindiflupyr, prothioconazole and chlorothalonil in controlling Asian soybean rust Application rate (ppm) of compound 32 (ie, component (a)) Component (b) Application rate (ppm) of component (b) Test F observe expected 0 none 0 0 – 1.422 none 0 39 – 2.276 none 0 61 – 0 benzovindiflupyr 0.606 67 – 0 benzovindiflupyr 0.980 67 – 1.422 benzovindiflupyr 0.606 70 80 1.422 benzovindiflupyr 0.980 80 80 2.276 benzovindiflupyr 0.606 76 87 2.276 benzovindiflupyr 0.980 80 87 0 Prothioconazole 10.165 7 – 0 Prothioconazole 16.339 65 – 1.422 Prothioconazole 10.165 72 43 1.422 Prothioconazole 16.339 47 79 2.276 Prothioconazole 10.165 71 64 2.276 Prothioconazole 16.339 87 86 0 Tetrachloroisobenzene (chlorothalonil) 138.129 59 – 0 Tetrachloroisobenzene (chlorothalonil) 222.081 85 – 1.422 Tetrachloroisobenzene (chlorothalonil) 138.129 50 75 1.422 Tetrachloroisobenzene (chlorothalonil) 222.081 88 91 2.276 Tetrachloroisobenzene (chlorothalonil) 138.129 57 84 2.276 Tetrachloroisobenzene (chlorothalonil) 222.081 88 94 Table G-2 Observation and expected effect of compound 64 alone and its mixture with benzovindiflupyr, prothioconazole and chlorothalonil in controlling Asian soybean rust Application rate (ppm) of compound 64 (ie, component (a)) Component (b) Application rate (ppm) of component (b) Test F observe expected 0 none 0 0 – 0.303 none 0 52 – 0.489 none 0 50 – 0 benzovindiflupyr 0.606 67 – 0 benzovindiflupyr 0.980 67 – 0.303 benzovindiflupyr 0.606 83 84 0.303 benzovindiflupyr 0.980 79 84 0.489 benzovindiflupyr 0.606 73 83 0.489 benzovindiflupyr 0.980 86 84 0 Prothioconazole 10.165 7 – 0 Prothioconazole 16.339 65 – 0.303 Prothioconazole 10.165 61 55 0.303 Prothioconazole 16.339 69 83 0.489 Prothioconazole 10.165 60 53 0.489 Prothioconazole 16.339 73 82 0 Tetrachloroisobenzene (chlorothalonil) 138.129 59 – 0 Tetrachloroisobenzene (chlorothalonil) 222.081 85 – 0.303 Tetrachloroisobenzene (chlorothalonil) 138.129 34 81 0.303 Tetrachloroisobenzene (chlorothalonil) 222.081 89 93 0.489 Tetrachloroisobenzene (chlorothalonil) 138.129 65 79 0.489 Tetrachloroisobenzene (chlorothalonil) 222.081 91 92 Table H-1 Observation and expected effect of compound 32 alone and its mixture with pydiflumetofen, pyraclostrobin and metminostrobin in controlling Asian soybean rust Application rate (ppm) of compound 32 (ie, component (a)) Component (b) Application rate (ppm) of component (b) Test F observe expected 0 none 0 0 – 1.422 none 0 69 – 2.276 none 0 63 – 0 Fluconazole (pydiflumetofen) 41.364 49 – 0 Fluconazole (pydiflumetofen) 128.793 36 – 1.422 Fluconazole (pydiflumetofen) 41.364 67 84 1.422 Fluconazole (pydiflumetofen) 128.793 72 80 2.276 Fluconazole (pydiflumetofen) 41.364 76 81 2.276 Fluconazole (pydiflumetofen) 128.793 83 76 0 Pyraclostrobin 45.860 35 – 0 Pyraclostrobin 137.503 45 – 1.422 Pyraclostrobin 45.860 43 80 1.422 Pyraclostrobin 137.503 65 83 2.276 Pyraclostrobin 45.860 55 76 2.276 Pyraclostrobin 137.503 78 79 0 Metominostrobin 29.673 13 – 0 Metominostrobin 86.003 37 – 1.422 Metominostrobin 29.673 65 73 1.422 Metominostrobin 86.003 52 80 2.276 Metominostrobin 29.673 63 67 2.276 Metominostrobin 86.003 82 76 Table H-2 Observation and expected effect of compound 64 alone and its mixture with pydiflumetofen, pyraclostrobin and metminostrobin in controlling Asian soybean rust Application rate (ppm) of compound 64 (ie, component (a)) Component (b) Application rate (ppm) of component (b) Test F observe expected 0 none 0 0 – 0.303 none 0 50 – 0.489 none 0 70 – 0 Fluconazole (pydiflumetofen) 41.364 49 – 0 Fluconazole (pydiflumetofen) 128.793 36 – 0.303 Fluconazole (pydiflumetofen) 41.364 64 75 0.303 Fluconazole (pydiflumetofen) 128.793 78 68 0.489 Fluconazole (pydiflumetofen) 41.364 71 84 0.489 Fluconazole (pydiflumetofen) 128.793 67 81 0 Pyraclostrobin 45.860 35 – 0 Pyraclostrobin 137.503 45 – 0.303 Pyraclostrobin 45.860 70 68 0.303 Pyraclostrobin 137.503 80 73 0.489 Pyraclostrobin 45.860 68 80 0.489 Pyraclostrobin 137.503 59 83 0 Metominostrobin 29.673 13 – 0 Metominostrobin 86.003 37 – 0.303 Metominostrobin 29.673 52 57 0.303 Metominostrobin 86.003 69 69 0.489 Metominostrobin 29.673 46 74 0.489 Metominostrobin 86.003 66 81 Table I-1 Observation and expected effect of compound 32 alone and its mixture with copper hydroxide, flutriafol and fenpropidin in controlling Asian soybean rust Application rate (ppm) of compound 32 (ie, component (a)) Component (b) Application rate (ppm) of component (b) Test F observe expected 0 none 0 0 – 1.422 none 0 63 – 2.276 none 0 71 – 0 copper hydroxide 3610.778 87 – 0 copper hydroxide 7371.507 65 – 1.422 copper hydroxide 3610.778 84 95 1.422 copper hydroxide 7371.507 81 87 2.276 copper hydroxide 3610.778 93 96 2.276 copper hydroxide 7371.507 87 90 0 Flutriafol 544.265 13 – 0 Flutriafol 1124.021 52 – 1.422 Flutriafol 544.265 82 68 1.422 Flutriafol 1124.021 87 82 2.276 Flutriafol 544.265 75 75 2.276 Flutriafol 1124.021 88 86 0 Fenpropidin 78.393 45 – 0 Fenpropidin 161.740 68 – 1.422 Fenpropidin 78.393 48 80 1.422 Fenpropidin 161.740 80 88 2.276 Fenpropidin 78.393 83 84 2.276 Fenpropidin 161.740 87 91 Table I-2 Observation and expected effect of compound 64 alone and its mixture with copper hydroxide, flutriafol and fenpropidin in controlling Asian soybean rust Application rate (ppm) of compound 64 (ie, component (a)) Component (b) Application rate (ppm) of component (b) Test F observe expected 0 none 0 0 – 0.303 none 0 50 – 0.489 none 0 81 – 0 copper hydroxide 3610.778 87 – 0 copper hydroxide 7371.507 65 – 0.303 copper hydroxide 3610.778 79 93 0.303 copper hydroxide 7371.507 82 83 0.489 copper hydroxide 3610.778 86 97 0.489 copper hydroxide 7371.507 84 93 0 Flutriafol 544.265 13 – 0 Flutriafol 1124.021 52 – 0.303 Flutriafol 544.265 65 56 0.303 Flutriafol 1124.021 74 76 0.489 Flutriafol 544.265 75 83 0.489 Flutriafol 1124.021 75 91 0 Fenpropidin 78.393 45 – 0 Fenpropidin 161.740 68 – 0.303 Fenpropidin 78.393 37 72 0.303 Fenpropidin 161.740 77 84 0.489 Fenpropidin 78.393 75 90 0.489 Fenpropidin 161.740 82 94

none

none

Claims (15)

A fungicidal composition comprising: (a) at least one compound selected from the group consisting of compounds of formula 1, N -oxides thereof, and salts thereof:

where T is selected from the group consisting of:

,

, T-1 T-2 T-3 The chemical bond extending to the left connects A; R ¹ is CF ₃ , CHF ₂ , CCl ₃ , CHCl ₂ , CF ₂ Cl, CFCl ₂ or CHFCl; W is O, S or NR ³ ; R ³ is H, cyano, Nitro, C(=O)OH, benzyl, C ₁ -C ₄ alkyl, C ₂ -C ₄ alkylcarbonyl, C ₂ -C ₄ haloalkylcarbonyl, OR ^3a or NR ^3b R ^3c ; R ^3a is H, benzyl, C ₁ -C ₄ alkyl, C ₂ -C ₄ alkylcarbonyl or C ₂ -C ₄ haloalkylcarbonyl; R ^3b is H, C ₁ -C ₄ alkyl, C ₂ -C ₄ alkane or C ₂ -C ₄ haloalkylcarbonyl; R ^3c is H or C ₁ -C ₄ alkyl; or R ^3b and R ^3c are taken together to form a 4- to 6-membered fully saturated heterocycle, each ring except the attached nitrogen In addition to atoms, it also contains ring members selected from carbon atoms and up to 2 heteroatoms independently selected from up to 2 O, up to 2 S, and up to 2 N atoms, each ring optionally substituted with up to 2 methyl groups; X is O, S or NR ^5a ; Y is O, S or NR ^5b ; each R ^5a and R ^5b are independently H, hydroxy or C ₁ -C ₄ alkyl; each R ^2a and R ^2b are independently H, C ₁ -C ₄ alkyl, C ₂ -C ₄ alkenyl, C ₃ -C ₁₅ trialkylsilyl, C ₃ -C ₁₅ halotrialkylsilyl group, (CR ^4a R ^4b ) _p -OH, (CR ^4a R ^4b ) _p -SH, (CR ^4a R ^4b ) _p -Cl or (CR ^4a R ^4b ) _p -Br; or R ^2a and R ^2b and their The attached X and Y atoms together form a 5- to 7-membered saturated ring comprising ring members selected from carbon atoms in addition to the X and Y atoms, wherein up to 2 carbon atomic ring members are independently selected from C(=O) and C(=S), the ring optionally having up to 2 of the carbon atom ring members independently selected from the group consisting _of halogen, cyano, _{C1 -} C2 alkyl, _{C1 -} C2 haloalkyl, C1- C ₂ alkoxy and C ₁ -C ₂ haloalkoxy substituents; R ^2c is C ₁ -C ₄ alkyl, C ₁ -C ₄ haloalkyl, C ₂ -C ₄ alkenyl, C ₂ - C ₄ haloalkenyl, C ₂ -C ₄ alkynyl, C ₂ -C ₄ haloalkynyl or trifluoromethylsulfonyl, each optionally by up to 2 independently selected from cyano, hydroxy , SC≡N and C ₁ -C ₂ alkoxy substituents; R ^2d is H, cyano, halogen or C ₁ -C ₄ alkyl; each R ^4a and R ^4b are independently H or C ₁ -C ₄ alkyl; p is 2 or 3; when T is T-1 or T-2, then A is A ¹ -A ² -CR ^6a R ^6b , wherein A ¹ is connected to J, and CR ^6a R ^6b is connected to T; When T is T-3, then A is A ¹ -A ² , wherein A ¹ is connected to J, and A ² is connected to T; A ¹ is CR ^6c R ^6d , N(R ^7a ), O or S; A ² is a direct bond, CR ^6e R ^6f , N(R ^7b ), O or S; each of R ^6a , R ^6b , R ^6c , R ^6d , R ^6e and R ^6f are independently H, cyano, hydroxyl, halogen, C(=O)OCH ₃ or C ₁ -C ₄ alkyl; each R ^7a and R ^7b are independently H, C(=O) H, cyano, C ₁ -C ₄ alkyl or C ₂ -C ₄ alkylcarbonyl; J is selected from the group consisting of:

,

,

,

, J-1 J-2 J-3 J-4

,

,

,

, J-5 J-6 J-7 J-8

,

,

,

, J-9 J-10 J-11 J-12

, J-13 J-14 wherein the bond extending to the left connects L, and the bond extending to the right connects A; each R ^is independently F, Cl, I, Br, cyano, methyl, trifluoromethyl, or methoxy; q is 0, 1, 2, 3 or 4; L is (CR ^9a R ^9b ) _n ; each R ^9a and R ^9b is independently H, halogen, cyano, hydroxy, nitro, C ₁ -C ₃ alkyl, C ₁ -C ₃ haloalkyl, C ₁ -C ₃ alkoxy or C ₁ -C ₃ haloalkoxy; n is 0, 1, 2 or 3; E is C ₁ -C ₆ alkyl or C ₁ -C ₆ haloalkyl; or E is E ¹ or E ² ; E ¹ is amino, cyano, hydroxyl, nitro, CH(=O), C(=O)OH, C(=O)NH ₂ , C( =S)NH ₂ , OC(=O)NH ₂ , OC(=S)NH ₂ , NHC(=O)NH ₂ , NHC(=S)NH ₂ , SC≡N, ‑CH=NNHC(=O) OC ₁ -C ₆ alkyl or -N(OCH ₃ )C(=O)C ₁ -C ₆ alkyl; or E ¹ is C ₁ -C ₆ alkoxy, C ₂ -C ₆ alkenyloxy, C ₂ -C ₆ alkynyloxy, C ₁ -C ₆ alkylthio, C ₂ -C ₆ alkenylthio, C ₂ -C ₆ alkynylthio, C ₁ -C ₆ alkylsulfinyl, C ₂ - C ₆ alkenylsulfinyl, C ₂ -C ₆ alkynylsulfinyl, C ₁ -C ₆ alkylsulfonyl, C ₂ -C ₆ alkenyl sulfonyl, C ₂ -C ₆ alkynyl Sulfonyl, C ₁ -C ₆ alkylsulfonamido, C ₂ -C ₆ alkenylsulfonamido, C ₂ -C ₆ alkynylsulfonamido, C ₁ -C ₆ alkyl Aminosulfonyl, C ₂ -C ₆ dialkylaminosulfonyl, C ₂ -C ₆ alkenylaminosulfonyl, C ₂ -C ₆ alkynylaminosulfonyl, C ₁ -C ₆ alkylaminosulfonamido, C ₂ -C ₆ alkenyl amino sulfonamido, C ₂ -C ₆ alkynyl amino sulfonamido, C ₂ -C ₆ alkylcarbonyl, C3 _{- C6alkenylcarbonyl} , C3 _{- C6alkynylcarbonyl} , C2 _{- C6alkylaminocarbonyl} , C3 _{- C6alkenylaminocarbonyl} , C3 _{- C6alkynylaminocarbonyl} , C ₂ -C ₆ alkylcarbonyl amino, C ₃ -C ₆ alkenyl carbonyl amino, C ₃ -C ₆ alkynyl carbonyl amino, C ₂ -C ₆ alkyl amino carbonyl amino, C ₃ - C ₆ alkenylaminocarbonylamino, C ₃ -C ₆ alkynylaminocarbonylamino, C ₂ -C ₆ alkylcarbonyloxy, C ₃ -C ₆ alkenylcarbonyloxy, C ₃ -C ₆ Alkynylcarbonyloxy, C2 _- C6alkoxycarbonyl, C3 _{- C6alkenyloxycarbonyl} , C3 _{- C6alkynyloxycarbonyl} , _{C2 - C6alkylaminocarbonyloxy} , C _{3 - C6alkenylaminocarbonyloxy} , C3 _{- C6alkynylaminocarbonyloxy} , C2 _{- C6alkoxycarbonylamino} , C3 _{- C6alkenyloxycarbonylamino} , C3 -C ₆ alkynyloxycarbonylamino, C ₂ -C ₆ alkylamino (thiocarbonyl) oxy, C ₃ -C ₆ alkenylamino (thiocarbonyl) oxy, C ₃ -C ₆ alkyne amino (thiocarbonyl) oxy, C ₂ -C ₆ alkoxy (thiocarbonyl) amine, C ₃ -C ₆ alkenyloxy (thiocarbonyl) amine, C ₃ -C ₆ alkynyloxy (thiocarbonyl) amine, C ₂ -C ₆ alkyl (thiocarbonyl), C ₂ -C ₆ (alkylthio) carbonyl, C ₃ -C ₆ alkenyl (thiocarbonyl), C ₃ - C ₆ (alkenylthio) carbonyl, C ₃ -C ₆ alkynyl (thiocarbonyl), C ₃ -C ₆ (alkynylthio) carbonyl, C ₂ -C ₆ alkylamino (thiocarbonyl), C ₃ -C ₆ alkenylamino (thiocarbonyl), C ₃ -C ₆ alkynylamino (thiocarbonyl), C ₂ -C ₆ alkyl (thiocarbonyl) amino, C ₂ -C ₆ ( Alkylthio)carbonylamino, C3 _{- C6alkenyl} (thiocarbonyl)amine, C3 _{- C6} (alkenylthio)carbonylamino, C3 _{- C6alkynyl (} thiocarbonyl)amine group, C ₃ -C ₆ (alkynylthio) carbonylamino, C ₂ -C ₆ alkylamino (thiocarbonyl) amino, C ₃ -C ₆ alkenylamino (thiocarbonyl) amino or C3 _{- C6alkynylamino} (thiocarbonyl)amino, wherein each carbon atom is optionally substituted with up to 1 substituent selected from R ^10a and up to 3 independently selected from R ^10b ; R ^10a is phenyl optionally substituted with up to 3 substituents independently selected from R ^11a ; or a 5- to 6-membered heterocycle comprising ring members selected from carbon atoms and 1 to 4 heteroatoms independently selected from up to 2 O, up to 2 S, and up to 4 N atoms, wherein up to 3 carbon atom ring members are independently selected from C(=O) and C(=S), and the sulfur atom ring members are independently S(=O) _u (=NR ¹² ) _v , each ring is optionally substituted on the carbon atom ring members with up to 3 substituents independently selected from R ^11a , and Optionally substituted on nitrogen ring members with up to 3 substituents independently selected from R ^11b ; each R ^10b is independently amine, cyano, halogen, hydroxy, nitro, SC≡N, - SH, C ₁ -C ₄ alkyl, C ₁ -C ₄ haloalkyl, C ₃ -C ₆ cycloalkyl, C ₃ -C ₆ halocycloalkyl, C ₁ -C ₄ alkoxy, C ₁ ‑ C ₄ haloalkoxy, C ₁ -C ₄ alkylthio, C ₁ -C ₄ alkylsulfinyl, C ₁ -C ₄ alkylsulfonyl, C ₁ -C ₄ haloalkylsulfonyl, C ₁ -C ₄ alkylamino, C ₂ -C ₄ dialkylamine, C ₂ -C ₄ alkylcarbonyl, C ₂ -C ₄ haloalkylcarbonyl, C ₂ -C ₅ alkoxycarbonyl, C ₂ -C ₅ haloalkane Oxycarbonyl, C2 _{- C5} alkylaminocarbonyl, or C3 _{- C5} dialkylaminocarbonyl; each R ^11a is independently halogen, hydroxy, cyano, amino, nitro, _C1 -C ₄ alkyl, C ₁ -C ₄ haloalkyl, C ₂ -C ₄ alkenyl, C ₂ -C ₄ alkynyl, C ₁ -C ₄ hydroxyalkyl, C ₃ -C ₆ cycloalkyl, C ₄ -C ₇ cycloalkylalkyl, C ₁ -C ₄ alkoxy, C ₁ -C ₄ haloalkoxy, C ₂ -C ₄ alkenyloxy, C ₂ -C ₄ alkynyloxy, C ₂ -C ₄ alkoxy Alkyl alkyl, C ₂ -C ₆ alkylcarbonyloxy, C ₁ -C ₄ alkylthio, C ₁ -C ₄ haloalkylthio, C ₂ -C ₆ alkylcarbonylthio, C ₁ -C ₄ alkane sulfinyl, C ₁ -C ₄ haloalkylsulfinyl, C ₁ -C ₄ alkylsulfonyl, C ₁ -C ₄ haloalkylsulfonyl, C ₁ -C ₄ alkylsulfonyl Oxygen, C ₁ -C ₄ alkylamine, C ₂ -C ₈ dialkylamine, C ₃ -C ₆ cycloalkylamine, C ₂ -C ₄ alkylcarbonyl, C ₃ -C ₅ alkene Carbonyl, C ₃ -C ₅ alkynylcarbonyl, C ₄ -C ₇ cycloalkylcarbonyl, C ₅ -C ₈ cycloalkylalkylcarbonyl, C ₂ -C ₆ alkoxycarbonyl, C ₃ -C ₇ alkenyl Oxycarbonyl, C ₃ -C ₇ alkynyloxycarbonyl, C ₄ -C ₇ cycloalkoxycarbonyl, C ₅ -C ₈ cycloalkylalkoxycarbonyl, C ₂ -C ₆ alkylaminocarbonyl, C ₃ -C _{6Alkenylaminocarbonyl} , C3 _{- C6alkynylaminocarbonyl} , _C4 - _{C7cycloalkylaminocarbonyl} , _{C5 - C8cycloalkylalkylaminocarbonyl} , C3- _C8di Alkylaminocarbonyl or C ₃ -C ₆ trialkylsilyl; each R ^11b is independently C(=O)H, C ₁ -C ₃ alkyl, C ₁ -C ₃ alkoxy, C _{2 -} C3 alkylcarbonyl or _{C2 -} C3 alkoxycarbonyl; each ^R12 is independently H, cyano, _{C1 -} C3 alkyl or _{C1 -} C3 haloalkyl; each u and v independently 0, 1, or 2, provided that the sum of u and v is 0, 1, or ² ; E2 is GZ, where Z is attached to L; G is phenyl, optionally selected from up to 3 independently or G is a 5- to 6-membered heteroaromatic ring, each ring comprising ring members selected from carbon atoms and 1 to ⁴ heteroatoms independently selected from up to 2 O , up to 2 S and up to 4 N atoms, each ring optionally substituted with up to ³ substituents independently selected from R; or G is a 3- to 7-membered non-aromatic Aromatic or 8 to 11 membered bicyclic ring systems, each ring or ring system comprising ring members selected from carbon atoms and optionally up to 4 heteroatoms independently selected from up to 2 O, up to 2 S and up to 4 N atoms, wherein up to 2 ring members are independently selected from C(=O), C(=S), S(=O) and S(=O) ₂ , each ring or ring The system is optionally substituted with up to 3 substituents independently selected from R ¹³ ; each R ¹³ is independently cyano, halogen, hydroxyl, nitro, -SH, SF ₅ , CH(=O), C (=O)OH, NR ^14a R ^14b , C(=O)NR ^14a R ^14b , C(=O)C(=O)NR ^14a R ^14b , C(=S)NR ^14a R ^14b , C(R ¹⁵ )=NR ¹⁶ , N=CR ¹⁷ NR ^18a R ^18b or -UVQ; or C ₁ -C ₆ alkyl, C ₂ -C ₆ alkenyl, C ₂ -C ₆ alkynyl, C ₃ -C ₇ cycloalkyl , C ₃ -C ₇ cycloalkenyl, C ₁ -C ₆ alkoxy, C ₂ -C ₆ alkenyloxy, C ₂ -C ₆ alkynyloxy, C ₃ -C ₇ cycloalkoxy, C ₁ - C ₆ alkylthio, C ₁ -C ₆ alkyl sulfinyl, C ₁ -C ₆ alkyl sulfonyl, C ₁ -C ₆ alkylaminosulfinyl, C ₂ -C ₆ dioxane aminosulfinyl, C ₁ -C ₆ alkylsulfonyloxy, C ₁ -C ₆ alkylsulfonylamino, C ₂ -C ₆ alkylcarbonyl, C ₄ -C ₇ cycloalkane carbonyl, C ₂ -C ₆ alkoxycarbonyl, C ₃ -C ₆ alkenyloxycarbonyl, C ₃ -C ₆ alkynyloxycarbonyl, C ₄ -C ₇ cycloalkoxycarbonyl, C ₃ -C ₆ alkoxycarbonyl Carbonyl, C ₂ -C ₆ alkylcarbonyloxy, C ₄ -C ₇ cycloalkylcarbonyloxy, C ₂ -C ₆ alkoxycarbonyloxy, C ₄ -C ₇ cycloalkoxycarbonyloxy, C ₂ -C ₆ alkylaminocarbonyloxy, C ₄ -C ₇ cycloalkylaminocarbonyloxy, C ₂ -C ₆ alkylcarbonylamino, C ₄ -C ₇ cycloalkylcarbonylamino, C ₂ -C6alkoxycarbonylamino, _{C4 - C7cycloalkoxycarbonylamino} , C2 _- C6alkylaminocarbonylamino, _{C4 - C7cycloalkylaminocarbonylamino} or _{C2 -C6} dialkoxyphosphino groups, each optionally substituted with up to 3 substituents independently selected from ^R19 ; each ^R14a independently H, cyano, hydroxy, _C1 -C ₄ alkyl, C ₁ -C ₄ haloalkyl, C ₂ -C ₄ alkenyl, C ₂ -C ₄ haloalkenyl, C ₂ -C ₄ alkynyl, C ₂ -C ₄ haloalkynyl, C ₁ -C ₅ alkoxy, C ₂ -C ₄ alkoxy alkyl, C ₁ -C ₄ alkyl sulfonyl , C ₁ -C ₄ haloalkylsulfonyl, C ₂ -C ₄ alkylthioalkyl, C ₂ -C ₄ alkylsulfonyl alkyl, C ₂ -C ₄ alkylsulfonyl alkyl, C ₂ -C ₄ alkylcarbonyl, C ₂ -C ₄ haloalkylcarbonyl, C ₄ -C ₇ cycloalkylcarbonyl, C ₂ -C ₅ alkoxycarbonyl, C ₃ -C ₅ alkoxycarbonyl alkyl, C ₂ - C ₅ alkylaminocarbonyl or C ₃ -C ₅ dialkylamino carbonyl; each R ^14b is independently H, C ₁ -C ₆ alkyl, C ₁ -C ₆ haloalkyl, C ₂ -C ₆ Alkenyl, C ₂ -C ₆ haloalkenyl, C ₂ -C ₆ alkynyl, C ₂ -C ₆ haloalkynyl, C ₁ -C ₆ hydroxyalkyl, C ₂ -C ₆ cyanoalkyl, C ₃ -C ₈ cycloalkyl, C ₃ -C ₈ halocycloalkyl, C ₃ -C ₈ cycloalkenyl, C ₃ -C ₈ halocycloalkenyl, C ₄ -C ₁₀ alkylcycloalkyl , C ₄ -C ₁₀ cycloalkyl alkyl, C ₄ -C ₁₀ halogenated cycloalkyl alkyl, C ₆ -C ₁₄ cycloalkyl cycloalkyl, C ₅ -C ₁₀ alkyl cycloalkyl alkyl, C ₂ -C ₆ alkoxyalkyl, C ₂ -C ₆ haloalkoxy alkyl, C ₄ -C ₁₀ cycloalkoxy alkyl, C ₃ -C ₈ alkoxyalkoxy alkyl, C ₂ -C ₆ alkylthioalkyl, C ₂ -C ₆ alkylsulfonyl alkyl, C ₂ -C ₆ alkylsulfonyl alkyl, C ₂ -C ₆ alkylaminoalkyl, C ₂ - _C6 haloalkylaminoalkyl, C3 _- C8 dialkylaminoalkyl, or _C4 - _C10 cycloalkylaminoalkyl, each optionally by up to ₁ selected from cyano, hydroxy , nitro, C ₂ -C ₄ alkylcarbonyl, C ₂ -C ₄ alkoxycarbonyl, C ₃ -C ₁₅ trialkylsilyl, C ₃ -C ₁₅ halotrialkylsilyl and pyrimidinyl or R ^14a and R ^14b together form a 4- to 6-membered fully saturated heterocyclic ring, each ring containing, in addition to the nitrogen atom to which it is attached, ring members selected from carbon atoms and up to 2 heterocyclic atoms independently selected from up to 2 O, up to 2 S, and up to 2 N atoms, each ring optionally substituted with up to 3 independently selected from halogen and _{C1 -} C3 alkyl each R ¹⁵ is independently H, cyano, halogen, methyl, methoxy, methylthio or methoxycarbonyl; each R ¹⁶ is independently hydroxyl or NR ^20a R ^20b ; or C ₁ -C ₄ alkoxy, C ₂ -C ₄ alkenyloxy, C ₂ -C ₄ alkynyloxy, C ₂ -C ₄ alkylcarbonyloxy, C ₂ -C ₅ alkoxycarbonyloxy, C ₂ - _C5 alkylaminocarbonyloxy or C3 _{- C5} dialkylaminocarbonyloxy, each optionally with up to 1 selected from cyano, halogen, hydroxy and C (=O) OH substituent; each R ¹⁷ is independently H, methyl, methoxy or methylthio; each R ^18a and R ^18b are independently H or C ₁ -C ₄ alkyl ; or R ^18a and R ^18b together form a 5- to 6-membered fully saturated heterocyclic ring, each ring containing, in addition to the nitrogen atom to which it is attached, ring members selected from carbon atoms and up to 2 heteroatoms, the heteroatoms Independently selected from up to 2 O, up to 2 S, and up to 2 N atoms, each ring is optionally substituted with up to ² methyl groups; each R is independently amine, cyano, halogen, hydroxy , nitro, -SH, C ₁ -C ₄ alkyl, C ₁ -C ₄ haloalkyl, C ₃ -C ₆ cycloalkyl, C ₃ -C ₆ halocycloalkyl, C ₁ -C ₄ alkoxy base, C ₁ -C ₄ haloalkoxy, C ₂ -C ₄ alkoxyalkoxy, C ₁ -C ₄ alkylthio, C ₁ -C ₄ alkylsulfinyl, C ₁ -C ₄ alkane Sulfonyl, C ₁ -C ₄ haloalkylsulfonyl, C ₂ -C ₄ alkylcarbonyl, C ₂ -C ₄ haloalkylcarbonyl, C ₂ -C ₅ alkoxycarbonyl, C ₁ -C ₆ alkyl Amine, C ₂ -C ₆ dialkylamino, C ₂ -C ₅ alkylaminocarbonyl, C ₃ -C ₅ dialkylamino carbonyl, C ₃ -C ₅ alkylthioalkylcarbonyl, C ₃ -C ₁₅ trisilyl group, C ₃ -C ₁₅ halogenated trialkylsilyl group, C(R ²¹ )=NOR ²² or C(R ²³ )=NR ²⁴ ; each U is independently a direct bond, C(=O)O, C(=O)N(R ²⁵ ), or C(=S)N(R ²⁶ ), where the atom on the left connects G and the atom on the right connects V; each V is independently A direct bond; or C ₁ -C ₆ alkylene, C ₂ -C ₆ alkenylene, C ₃ -C ₆ alkynylene, C ₃ -C ₆ cycloalkylene, or C ₃ -C ₆ cycloalkene radicals, wherein up to 1 carbon atom is C(=O), each optionally being up to 3 independently selected from halogen, cyano, nitro, hydroxy, _{C1 -} C2 alkyl, _C1 -C ₂ haloalkyl, C ₁ -C ₂ alkoxy, and C ₁ -C ₂ haloalkoxy substituents; each Q is independently phenyl or phenoxy, each optionally being replaced by up to 2 independently or each Q is independently a 5- to ⁶ -membered heteroaromatic ring, each ring comprising ring members selected from carbon atoms and 1 to 4 heteroatoms independently is independently selected from up to 2 O, up to 2 S, and up to 4 N atoms, each ring is optionally substituted with up to ² substituents independently selected from R; or each Q is independently 3 to 7-membered non-aromatic heterocycle, each ring comprising ring members selected from carbon atoms and 1 to 4 heteroatoms independently selected from up to 2 O, up to 2 S, and up to 4 N atoms, wherein up to 2 ring members are independently selected from C(=O), C(=S), S(=O), and S(=O) ₂ , each ring optionally selected by up to 2 independently Substituted from a substituent of R ²⁷ ; each R ^20a is independently H, C ₁ -C ₄ alkyl or C ₂ -C ₄ alkylcarbonyl; each R ^20b is independently H, cyano, C ₁ - C ₅ alkyl, C ₂ -C ₅ alkylcarbonyl, C ₂ -C ₅ haloalkylcarbonyl, C ₄ -C ₇ cycloalkylcarbonyl, C ₂ -C ₅ alkoxycarbonyl, C ₃ -C ₅ alkoxycarbonyl alkyl, C ₂ -C ₅ alkylaminocarbonyl or C ₃ -C ₅ dialkylaminocarbonyl; or R ^20a and R ^20b together form a 5- to 6-membered fully saturated heterocycle, each ring except the attached In addition to nitrogen atoms, ring members are selected from carbon atoms and up to 2 heteroatoms independently selected from up to 2 O, up to 2 S, and up to 2 N atoms, optionally selected for each ring is substituted with up to 2 methyl groups; each R ²¹ and R ²³ are independently H, cyano, halogen, C ₁ -C ₃ alkyl, C ₁ -C ₃ haloalkyl, C ₃ -C ₆ cycloalkyl or C ₁ -C ₃ alkoxy; or phenyl, optionally substituted with up to 2 substituents independently selected from halogen and C ₁ -C ₃ alkyl; each R ²² is independently H, C ₁ -C ₅ alkyl, C ₁ -C ₅ haloalkyl, C ₂ -C ₅ alkenyl, C ₂ -C ₅ haloalkenyl, C ₂ -C ₅ alkynyl, C ₃ -C ₆ cycloalkyl , C ₃ -C ₆ halocycloalkyl, C ₂ -C ₅ alkylcarbonyl, or C ₂ -C ₅ alkoxycarbonyl; or each R ²² is phenyl, which is optionally selected by up to 2 independently Substituted from halogen and _{C1 -} C3 alkyl substituents; or a 5- to 6-membered fully saturated heterocyclic ring, each ring containing ring members selected from carbon atoms and up to 2 heteroatoms, the heteroatoms independently selected from up to 2 O, up to 2 S, and up to 2 N atoms, each ring is optionally substituted with up to 2 substituents independently selected from halogen and _{C1 -} C3 alkyl; each R ²⁴ is independently H, cyano, C ₁ -C ₃ alkyl, C ₁ -C ₃ haloalkyl, C ₁ -C ₄ alkoxy, C ₂ -C ₄ alkylcarbonyl or C ₂ -C ₄ alkane Oxycarbonyl; each R ²⁵ and R ²⁶ are independently H, cyano, hydroxy, C ₁ -C ₄ alkyl, C ₁ -C ₄ haloalkyl, C ₂ -C ₄ alkylcarbonyl, C ₂ -C ₄ haloalkylcarbonyl, C2 _{- C4alkoxycarbonyl} , or C2 _{- C4haloalkoxycarbonyl} ; each ^R27 is independently halogen, cyano, hydroxy, nitro, _{C1 -} C4alkyl, _C1- C ₄ haloalkyl, C ₂ -C ₄ alkenyl, C ₁ -C ₄ alkoxy, C ₂ -C ₄ alkylcarbonyl or C ₂ -C ₄ alkoxycarbonyl; Z is a direct bond, O, S(=O) _m , N(R ²⁸ ), C(=O), C(=O)O, C(=O)N(R ²⁸ ), NR ²⁸ C(=O), N(R ²⁸ )C(=O)N(R ²⁸ ), N(R ²⁸ )C(=S)N(R ²⁸ ) , OC(=O)N(R ²⁸ ), N(R ²⁸ )C(=O)O, S(O) ₂ N(R ²⁸ ), N(R ²⁸ )S(=O) ₂ or N(R 2 ²⁸ ) S(O) ₂ N(R ²⁸ ), wherein the atom on the right is attached to L; each R ²⁸ is independently H, C ₁ -C ₃ alkyl, C ₁ -C ₃ alkoxy, C ₂ -C ₃ alkylcarbonyl or C ₂ -C ₃ alkoxycarbonyl; and m is 0, 1 or 2; and (b) at least one other fungicidal compound; provided that: (c) when A ¹ is N(R ^7a ), O or S, then A ² is a direct bond or CR ^6e R ^6f ; and when A ² is N(R ^7b ), O or S; then A ¹ is CR ^6c R ^6d . The composition of claim 1, wherein component (a) comprises a compound of formula 1 or a salt thereof, wherein R ¹ is CF ₃ , CCl ₃ or CF ₂ Cl; W is O; each R ^5a and R ^5b is independently H, hydroxy or methyl; each R ^2a and R ^2b is independently H or methyl; or R ^2a and R ^2b together with the X and Y atoms to which they are attached form a 5- to 6-membered saturated ring, It contains ring members, in addition to X and Y atoms, also selected from carbon atoms, wherein at most 1 carbon atom ring member is selected from C(=O), the ring can be optionally separated by up to 2 independent carbon atom ring members is substituted with a substituent selected from halogen, cyano, methyl, halomethyl, methoxy and halomethoxy; R ^2c is C ₁ -C ₂ alkyl, C ₂ -C ₃ alkenyl or C ₂ -C _3alkynyl ; R ^2d is H or methyl; A ¹ is CR ^6c R ^6d or O; A ² is a direct bond, CR ^6e R ^6f or O; each of R ^6a , R ^6b , R ^6c , R ^6d , R ^6e and R ^6f are independently H, cyano, hydroxyl, Br, Cl, F or methyl; J is J-1, J-6 or J-14; each R ⁸ is independently F, Cl or methyl; each R ^9a and R ^9b is independently H, halogen or methyl; n is 0, 1 or 2; E ¹ is C ₁ -C ₆ alkoxy, C ₁ -C ₆ alkylsulfonyl radical, C ₂ -C ₆ alkylcarbonyl or C ₂ -C ₆ alkoxycarbonyl, wherein each carbon atom is optionally replaced by at most 1 substituent selected from R ^10a and at most 3 independently selected from R ^10b Substituted; R ^10a is phenyl, optionally substituted with up to 2 substituents independently selected from R ^11a ; or a 5- to 6-membered heterocycle comprising ring members selected from carbon atoms and 1 to 4 heteroatoms independently selected from up to 2 O, up to 2 S, and up to 4 N atoms, each ring optionally on carbon ring members by up to 2 independently selected from R ^11a Substituents, and optionally substituted on nitrogen ring members with up to 2 substituents independently selected from R ^11b ; each R ^10b is independently halogen, hydroxy, C ₁ -C ₄ alkyl, C ₁ -C ₄ haloalkyl, C ₁ -C ₄ alkoxy, C ₁ -C ₄ haloalkoxy, C ₁ -C ₄ alkylsulfonyl, C ₂ -C ₄ alkylcarbonyl or C ₂ -C ₅ alkoxycarbonyl; each R ^11a is independently halogen, C ₁ -C ₂ alkyl, C ₁ -C ₂ haloalkyl, C ₁ -C ₂ alkoxy, or C ₂ -C ₃ alkoxycarbonyl; each R ^11b is independently methyl, methoxy, methylcarbonyl or methoxycarbonyl; G is selected from the group consisting of:

,

,

,

, G-1 G-2 G-3 G-4

,

,

,

, G-5 G-6 G-7 G-8

,

,

,

, G-9 G-10 G-11 G-12

,

,

,

, G-13 G-14 G-15 G-16

,

,

,

, G-17 G-18 G-19 G-20

,

,

,

, G-21 G-22 G-23 G-24

,

,

,

, G-25 G-26 G-27 G-28

,

,

,

, G-29 G-30 G-31 G-32

,

,

,

, G-33 G-34 G-35 G-36

,

,

,

, G-37 G-38 G-39 G-40

,

,

,

, G-41 G-42 G-43 G-44

,

,

,

, G-45 G-46 G-47 G-48

,

,

,

, G-49 G-50 G-51 G-52

,

,

,

, G-53 G-54 G-55 G-56

,

,

,

, G-57 G-58 G-59 G-60

,

,

,

, G-61 G-62 G-63 G-64

,

,

,

, G-65 G-66 G-67 G-68

,

,

,

, G-69 G-70 G-71 G-72

,

,

,

, G-73 G-74 G-75 G-76

,

,

,

, G-77 G-78 G-79 G-80

,

,

,

, G-81 G-82 G-83 G-84

,

,

,

, G-85 G-86 G-87 G-88

,

,

,

, G-89 G-90 G-91 G-92

,

,

,

, G-93 G-94 G-95 G-96

,

,

,

, G-97 G-98 G-99 G-100

,

,

,

, G-101 G-102 G-103 G-104

,

,

,

, G-105 G-106 G-107 G-108

,

,

,

, G-109 G-110 G-111 G-112

,

,

'

, G-113 G-114 G-115 G-116

, G-117 G-118 wherein the floating bond is attached to Z in Formula 1 through any available carbon or nitrogen atom of the ring or ring system shown; and x is 0, 1, 2, or ³ ; each R is independently C(= O) NR ^14a R ^14b or -UVQ; or C ₁ -C ₆ alkyl, C ₂ -C ₆ alkenyl, C ₂ -C ₆ alkynyl, C ₁ -C ₆ alkoxy, C ₂ -C ₆ alkene Oxy group, C ₂ -C _6alkynyloxy , C ₁ -C ₆ alkylsulfonyl group, C ₁ -C ₆ alkylsulfonyloxy group, C ₁ -C ₆ alkylsulfonylamino group, C ₂ -C ₆ alkylcarbonyl, C ₂ -C ₆ alkoxycarbonyl, C ₃ -C ₆ alkenyloxycarbonyl, C ₃ -C ₆ alkynyloxycarbonyl, C ₄ -C ₆ cycloalkoxycarbonyl or C ₂ - C alkoxycarbonyloxy, each optionally substituted with up to ₃ substituents independently selected from R ¹⁹ ; each R ^14a is independently H, C ₁ -C ₂ alkyl, C ₂ -C ₄ alkenyl, C ₂ -C ₄ alkynyl, C ₂ -C ₄ alkylcarbonyl or C ₂ -C ₄ alkoxycarbonyl; each R ^14b is independently H, C ₁ -C ₄ alkyl, C ₁ - C ₄ haloalkyl, C ₂ -C ₄ alkenyl, C ₂ -C ₄ haloalkenyl, C ₂ -C ₄ alkynyl, C ₃ -C ₅ cycloalkyl, C ₄ -C ₆ cycloalkylalkyl , C2 _{- C4alkoxyalkyl} , C2 _{- C4haloalkoxyalkyl} , C2 _{- C4alkylaminoalkyl} or C3 _{- C5dialkylaminoalkyl} ; or R ^14a and R ^14b together form an azetidinyl, morpholinyl, pyrrolidinyl, piperidinyl, piperazinyl or thiomorpholinyl ring, each ring optionally being selected from up to 2 independently Substituents of halogen or methyl; each R ¹⁹ is independently cyano, halogen, C ₁ -C ₂ alkyl, C ₁ -C ₂ haloalkyl, C ₃ -C ₆ cycloalkyl, C ₁ - C ₂ alkoxy, C ₁ -C ₂ haloalkoxy, C ₂ -C ₃ alkylcarbonyl, C ₂ -C ₃ haloalkylcarbonyl or C ₂ -C ₃ alkoxycarbonyl; each U is independently a direct bond, C(=O)O or C(=O)N(R ²⁵ ); each V is independently a direct bond; or C ₁ -C ₃ alkylene, each optionally by up to 2 independently is substituted with a substituent selected from halogen, hydroxy, C ₁ -C ₂ alkyl, C ₁ -C ₂ alkoxy and C ₁ -C ₂ haloalkoxy; each Q is independently phenyl, which can be selected is substituted with up to ² substituents independently selected from R; or pyridyl, pyrazolyl, imidazolyl, triazolyl, thiazolyl or oxazolyl, each optionally substituted with up to 2 independently substituted with a substituent selected from R ²⁷ ; each R ²⁵ is independently H, cyano, hydroxy or C ₁ -C ₂ alkyl; each R ²⁷ is independently halo and Z is _a direct _bond , _O , _NH , C( ₌ O), C( ₌ O)NH, NHC(=O), NHC(=O)NH, OC(=O)NH, NHC(=O)O, S(=O) ₂ NH, NHS(=O) ₂ or NHS(=O) ) ₂ NH. The composition according to claim 2, wherein composition (a) comprises a compound of formula 1 or a salt thereof, wherein T is T-2 or T-3; R ¹ is CF ₃ ; X is O; Y is O ; each R ^2a and R ^2b is independently H or methyl; or R ^2a and R ^2b together with the X and Y atoms to which they are attached form a 5-membered saturated ring comprising ring members, in addition to the X and Y atoms, Also selected from carbon atoms, the ring is optionally substituted on carbon atom ring members with up to 1 substituent selected from halogen, methyl and halomethyl; R ^2c is methyl or ethyl; R ^2d is H A ¹ is O; A ² is a direct bond or CH ₂ ; Each R ^6a and R ^6b is independently H, cyanohydroxy or methyl; J is J-1 or J-6; q is 0 or 1 ; Each R ^9a and R ^9b are independently H or methyl; E ¹ is C ₁ -C ₃ alkoxy, C ₂ -C ₃ alkylcarbonyl or C ₂ -C ₃ alkoxycarbonyl, wherein each carbon Atoms are optionally substituted with up to 1 substituent selected from R ^10a and up to 3 independently selected from R ^10b ; R ^10a is pyrazolyl, imidazolyl or triazolyl, each on a carbon atom ring member optionally substituted with up to 2 substituents independently selected from R ^11a ; each R ^10b is independently halogen, C ₁ -C ₂ alkyl, C ₁ -C ₂ haloalkyl, C ₁ -C ₂ alkane Oxygen or C ₂ -C ₄ alkoxycarbonyl; G is G-1, G-3, G-12 or G-22; x is 1 or 2; each R ¹³ is independently C(=O)NR ^14a R ^14b or -UVQ; or C ₂ -C ₅ alkoxycarbonyl, C ₃ -C ₅ alkenyloxycarbonyl, C ₃ -C ₅ alkynyloxycarbonyl or C ₄ -C ₆ cycloalkoxycarbonyl, each optional is substituted with up to 3 substituents independently selected from R ¹⁹ ; each R ^14a is independently H or C ₁ -C ₂ alkyl; each R ^14b is independently H, C ₁ -C ₃ alkyl , C ₁ -C ₃ haloalkyl, cyclopropylmethyl or C ₂ -C ₄ alkoxyalkyl; each R ¹⁹ is independently cyano, halogen, cyclopropyl, cyclobutyl, methoxy, halomethoxy or methoxycarbonyl; each U is independently a direct bond or C(=O)O; each V is independently a direct bond or CH ₂ ; each Q is independently phenyl or pyridyl , each optionally substituted with up to 2 substituents independently selected from R ²⁷ ; each R ²⁷ is independently halogen, methyl or methoxy; and Z is a direct bond, O, NH, C (=O), C(=O)NH or NHC(=O). The composition of claim 3, wherein component (a) comprises a compound of formula 1 or a salt thereof, wherein each R ^2a and R ^2b is H; or R ^2a and R ^2b and X and Y to which they are attached The atoms together form a ⁵ -membered saturated ring comprising ring members, in addition to the X and Y atoms, selected from carbon atoms; ^A is a direct bond; each ^R is ^H ; R is F or Cl; L is a direct bond, CH ₂ or CH ₂ CH ₂ ; E ¹ is C ₁ -C ₂ alkoxy or C ₂ -C ₃ alkoxycarbonyl, wherein each carbon atom is optionally selected from at most 1 R ^10a substituents; R ^10a is pyrazolyl or imidazolyl, each optionally substituted on a carbon atom ring member with up to 2 substituents independently selected from R ^11a ; each R ^11a independently is methoxycarbonyl or ethoxycarbonyl; G is G-1 and the 2nd position of G-1 is attached to Z and its 4th position is attached to R ¹³ ; or G is G-12 and the 1st position of G-12 is attached to Z and Its 4th position is connected to R ¹³ ; or G is G-12 and the 1st position of G-12 is connected to Z and its 3rd position is connected to R ¹³ ; x is 1; R ¹³ is C(=O)NR ^14a R ^14b or -UVQ; or C ₂ -C ₅ alkoxycarbonyl, C ₃ -C ₅ alkynyloxycarbonyl or C ₄ -C ₆ cycloalkoxycarbonyl, each optionally substituted by at most 1 substituent selected from R ¹⁹ Substituted; R ^14a is H; R ^14b is H, methyl or cyclopropylmethyl; R ¹⁹ is cyano, halogen, cyclopropyl or methoxy; U is C(=O)O; V is CH ₂ Q is phenyl optionally substituted with up to 2 substituents independently selected from ^R27 ; and Z is a direct bond, O, NH or C(=O). The composition according to claim 4, wherein component (a) comprises a compound of formula 1 or a salt thereof, wherein R ⁸ is F; L is a direct bond or CH ₂ ; E ¹ is a methoxy group, selected Substituted from substituents of R ^10a ; R ^10a is pyrazolyl optionally substituted on carbon atom ring members with up to 1 substituent selected from R ^11a ; G is G-12 and G-12 The 1st position is attached to Z and its 4th position is attached to R ¹³ ; or G is G-12 and the 1st position of G-12 is attached to Z and its 3rd position is attached to R ¹³ ; and R ¹³ is C ₂ -C ₅ alkoxy Carbonyl, optionally substituted with up to 1 substituent selected from R ¹⁹ ; R ¹⁹ is cyano, Cl, F, cyclopropyl or methoxy; and Z is a direct bond. The composition according to claim 5, wherein component (a) comprises a compound of formula 1 or a salt thereof, wherein J is J-1; q is 0; L is CH ₂ ; E is E ² ; G is G -12 and the 1st position of G-12 is attached to Z and its 4th position is attached to R ¹³ ; and R ¹³ is methoxycarbonyl or ethoxycarbonyl. The composition of claim 1, wherein component (a) comprises a compound selected from the group consisting of: ethyl 1-[[4-(3,3,3-trifluoro-2,2-dihydroxypropoxy)alkenyl]methyl] -1H -pyrazole-4-carboxylate; Ethyl 1-[[4-[[2-(trifluoromethyl)-1,3-dioxolan-2-yl]methoxy]phenyl]methyl] -1H -pyrazole-4 - carboxylates; Ethyl 1-[[4-[[(1 Z )-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]phenyl]methyl] -1H - Pyrazole-4-carboxylate; Ethyl 1-[[4-[[(1 Z )-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]phenyl]methyl] -1H - Pyrazole-3-carboxylate; Ethyl 1-[[4-[[(1 Z )-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]-3-fluorophenyl]methyl ] -1H -pyrazole-4-carboxylate; Ethyl 1-[[3-[[(1 Z )-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]phenyl]methyl] -1H - Pyrazole-4-carboxylate; Ethyl 1-[[4-[[(1 Z )-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]phenoxy]methyl]-1 H -pyrazole-4-carboxylate; N- (Cyclopropylmethyl)-2-[[4-[[2-(trifluoromethyl)-1,3-dioxolan-2-yl]methoxy]phenyl]-methyl ] thiazole-4-carboxamide; 2-Methylpropyl 1-[[4-[[2-(trifluoromethyl)-1,3-dioxolan-2-yl]methoxy]phenyl]methyl]-1 H - Pyrazole-4-carboxylate; Cyclopropylmethyl 1-[[4-[[2-(trifluoromethyl)-1,3-dioxolan-2-yl]methoxy]phenyl]methyl] -1H -pyridine oxazole-4-carboxylate; Ethyl 1-[2-[4-[[(1 Z )-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]phenyl]ethyl]- 1 H -pyrazole-4-carboxylate; 2-Methoxyethyl 1-[[4-[[2-(trifluoromethyl)-1,3-dioxolan-2-yl]methoxy]phenyl]methyl]-1 H - Pyrazole-4-carboxylate; 2-Butyn-1-yl 1-[[4-[[2-(trifluoromethyl)-1,3-dioxolan-2-yl]methoxy]phenyl]methyl]-1 H -pyrazole-4-carboxylate; 3-cyanopropyl 1-[[4-[[2-(trifluoromethyl)-1,3-dioxolan-2-yl]methoxy]phenyl]methyl]-1 H -pyridine oxazole-4-carboxylate; Benzyl 1-[[4-[[(1 Z )-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]phenyl]methyl]-1 H -pyrazole-4-carboxylate; Butyl 1-[[4-[[(1 Z )-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]phenyl]methyl] -1H - Pyrazole-4-carboxylate; 3-Chloropropyl 1-[[4-[[( 1Z )-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]phenyl]methyl] -1 H -pyrazole-4-carboxylate; phenyl methyl 4-(3,3,3-trifluoro-2,2-dihydroxypropoxy)carboxylate; Ethyl 1-[[3-Fluoro-4-[[2-(trifluoromethyl)-1,3-dioxolan-2-yl]methoxy]phenyl]methyl]-1 H - Pyrazole-4-carboxylate; Ethyl 1-[[4-[[(1 Z )-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]benzyloxy]methyl]- 1 H -pyrazole-4-carboxylate; Methyl 1-[[3-[[(1 Z )-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]phenyl]methyl] -1H - Pyrazole-4-carboxylate; and Propyl 1-[[3-[[(1 Z )-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]phenyl]methyl] -1H - Pyrazole-4-carboxylate. The composition of any one of claims 1 to 7, wherein component (b) comprises at least one fungicidal compound selected from the group consisting of: (b1) methyl benzimidazole carbamate ( methyl benzimidazole carbamate (MBC) fungicide; (b2) dimethylimide fungicide; (b3) demethylation inhibitor (DMI) fungicide; (b4) phenyl phenylamide (PA) fungicides; (b5) amine/morpholine fungicides; (b6) phospholipid biosynthesis inhibitor fungicides; (b7) succinate dehydrogenase inhibitor (succinate dehydrogenase inhibitor, SDHI) fungicides; (b8) hydroxy(2-amino-)pyrimidine fungicides; (b9) anilinopyrimidine (AP) fungicides; (b10) N -phenylcarbamates fungicides; (b11) quinone outside inhibitor (QoI) fungicides; (b12) phenylpyrrole (PP) fungicides; (b13) azine fungicides; (b14) cells Peroxidation inhibitor fungicides; (b15) Melanin biosynthesis inhibitor-reductase (MBI-R) fungicides; (b16a) Melanin biosynthesis inhibitor-dehydratase (melanin biosynthesis inhibitor) -dehydratase, MBI-D) fungicides; (b16b) melanin biosynthesis inhibitor-polyketide synthase (MBI-P) fungicides; (b17) ketoreductase inhibitors (keto reductase inhibitor, KRI) fungicides; (b18) squalene-epoxidase inhibitor fungicides; (b19) polytoxin fungicides; (b20) phenylurea fungicides; (b21) quinones quinone inside inhibitor (QiI) fungicides; (b22) benzyl amide and thiazole carboxamide fungicides; (b23) allylpyranuronic acid antibiotic fungicides; (b24) hexylpyridine (b25) glucopyranosyl antibiotics: protein synthesis fungicides; (b26) glucopyranosyl antibiotic fungicides; (b27) cyanoacetamidoxime fungicides; ( b28) Carbamate fungicides; (b 29) Oxidative phosphorylation uncoupling fungicides; (b30) Organotin fungicides; (b31) Carboxylic acid fungicides; (b32) Heteroaromatic fungicides; (b33) Phosphonate fungicides; (b34) Phthalic acid fungicides; (b35) Benzotriazine fungicides; (b36) Benzyl sulfonamides fungicides; (b37) pyridoxine fungicides; (b38) thiophene-methyl amide fungicides; (b39) complex I NADH oxidoreductase inhibitor fungicides; (b40) carboxylic acid amide (CAA) fungicides; (b41) tetracycline antibiotic fungicides (b42) Thiocarbamate fungicides; (b43) Benzylamide fungicides; (b44) Microbial fungicides; (b45) Q _x I fungicides; quinone outside inhibitor (QoSI) fungicides; (b46) plant extract fungicides; (b47) cyanoacrylate fungicides; (b48) polyene fungicides; (b49) oxysterols Oxysterol binding protein inhibitor (OSBPI) fungicides; (b50) aryl-phenyl-ketone fungicides (b51) host plant defense-inducing fungicides; (b52) multi-site active fungicides (b53) Organisms having multiple modes of action; (b54) Bactericides other than fungicides of component (a) and components (b1) to (b53); and salts of compounds (b1) to (b54) kind. The composition of claim 8, wherein component (b) comprises at least one fungicidal compound selected from each of two different groups (b1) to (b54). The composition according to any one of claims 1 to 7, wherein component (b) comprises at least one compound selected from the group consisting of: acibenzolar-S-methyl aldimorph), ametoctradin, indoxazole (amisulbrom), anilazine, azaconazole, azoxystrobin, benalaxyl, benalaxyl-M, benodanil, benomyl, benthiavalicarb, benthiavalicarb -isopropyl), benzovindiflupyr, bethoxazin, binapacryl, biphenyl, bitertanol, bixafen, Blasticidin-S, boscalid, bromuconazole, bupirimate, carboxin, carpropamid, diphenhydramine Captafol, captan, carbendazim, chloroneb, chlorothalonil, chlozolinate, clotrimazole, copper hydroxide , copper salts, cyazofamid, cyflufenamid, cymoxanil, cyproconazole, cyprodinil, dichlofluanid, Desai diclocymet, diclomezine, dicloran, diethofencarb, difenoconazole, diflumetorim, dimethirimol, damifen (dimethomorph), dimoxystrobin, diniconazole, diniconazole-M, dinocap, dithianon, dodemorph , dodine, edife nphos), enestroburin, epoxiconazole, ethaboxam, ethirimol, etridiazole (etridiazole), oxazolidone (van famoxadone), fenamidone, fenarimol, fenbuconazole, fenfuram, fenhexamid, blastamide (rice fenoxanil), fenpiclonil, fenpropidin, fenpropimorph, fenpyrazamine, fentin acetate, fenbutin fentinChloride, fentin hydroxide, ferbam, ferimzone (ferimzone), fluazinam, fludioxonil ), fluindapyr, flumetover, flumorph, fluopicolide, fluopyram, fluoroimide ), fluoxastrobin, fluquinconazole, flusilazole, flusulfamide, flutianil, flutolanil, flutifene ( flutriafol, fluxapyroxad, folpet, fosetyl-aluminum, fuberidazole, furalaxyl, furametpyr, hexaconazole ), hymexazole, guazatine, imazalil, imibenconazole, imnoctadine, iodocarb, Ipconazole, ipfentrifluconazole, iprobenfos, iprodione, iprovalicarb, isoprothi olane), isopyrazam, isotianil, kasugamycin, kresoxim-methyl, mancozeb, dipropargyl mandipropamid, maneb, mepronil, meptyldinocap, metalaxyl, metalaxyl-M, metconazole, Methasulfocarb, Metiram, Metominostrobin, Mepanipyrim, Metrafenone, Myclobutanil, Naftifine, Metrafenone Ammonium acid (neo-asozin), fluoropyrimidine (nuarimol), octhilinone (octhilinone), ofurace (ofurace), orysastrobin (orysastrobin), oxadixyl (oxadixyl), oxori acid ( oxolinic acid), oxpoconazole, oxycarboxin, oxytetracycline, penconazole, pencycuron, penflufen, penthiopyrad ( penthiopyrad, pefurazoate, phosphorous acid and its salts, phthalide, picoxystrobin, piperalin, polyoxin, culling fever Probenazole, prochloraz, procymidone, propamocarb, propamocarb-hydrochloride, propiconazole, propineb, propineb Proquinazid, prothiocarb, prothioconazole, pydiflumetofen, pyraclostrobin, pyrametostrobin, pyraoxystrobin, white powder pyrazophos, pyribencarb, pyributicarb, pyr ifenox, pyrimethanil, pyriofenone, pyrisoxazole, pyroquilon, pyrrolnitrin, quinomethionate, quinofen Quinoxyfen, quintozene, sedaxane, silthiofam, simeconazole, spiroxamine, streptomycin ), sulfur, tebuconazole, tebufloquin, tecloftalam, tecnazene, terbinafine, tetraconazole, thiabendazole, thifluzamide, thiophanate, thiophanate-methyl, thiram, tiadinil, tolclofos-methyl ), tolylfluanid, tolnifanide, Triadimefon, triadimenol, triazoxide, tricyclazole, tridemorph , triflumizole, tricyclazole, trifloxystrobin, triforine, trimorphamide, triticonazole, uniconazole, Validamycin, valifenalate, vinclozolin, zineb, ziram, zoxamide, N '-[4-[ 4-Chloro-3-(trifluoromethyl)phenoxy]-2,5-dimethylphenyl] -N -ethyl- N -methylformamide, 5-chloro-6-(2, 4,6-Trifluorophenyl)-7-(4-methylpiperidin-1-yl)[1,2,4]triazolo[ 1,5a ]pyrimidine (DPX-BAS600F), N- [ 2-[4-[[3-(4-Chlorophenyl)-2-propyn-1-yl]oxy]-3-methoxyphenyl]ethyl]-3-methyl-2-[ (methylsulfonyl )amino]butanamide, N- [2-[4-[[3-(4-chlorophenyl)-2-propyn-1-yl]oxy]-3-methoxyphenyl]ethyl base]-3-methyl-2-[(ethylsulfonyl)amino]butanamide, 4 - fluorophenylN-[1-[[[1-(4-cyanophenyl]ethyl] Sulfonyl]methyl]propyl]carbamate, N -[[(cyclopropylmethoxy)amino][6-(difluoromethoxy)-2,3-difluoro-benzene yl]methylene]phenethylamine, α-(methoxyimino) -N -methyl-2-[[[1-[3-(trifluoromethyl)phenyl]ethoxy] Imino]methyl]phenethylamine, N '-[4-[4-chloro-3-(trifluoromethyl)phenoxy]-2,5-dimethylphenyl] -N -ethyl - N -methylformamide, 2-[[[[3-(2,6-dichlorophenyl)-1-methyl-2-propen-1-ylidene]amino]oxy]methyl ]-α-(Methoxyimino) -N -methylphenethylamine and 1-[(2-propenylthio)carbonyl]-2-(1-methylethyl)-4-(2 -methylphenyl)-5-amino- 1H -pyrazol-3-one, 5-ethyl-6-octyl-[1,2,4]triazolo[1,5-a]pyrimidine -7-Ethylamine. The composition of claim 10, wherein component (b) comprises at least one compound selected from the group consisting of azoxystrobin, benzovindiflupyr, bixafen, chlorothalonil, copper hydroxide, cyproconazole, epoxiconazole, fenpropidin, fenpropimorph, fluindapyr, fluorine Flutriafol, Fluxapyroxad, Mancozeb, Metominostrobin, Picoxystrobin, Prothioconazole, Fluconazole pydiflumetofen), pyraclostrobin, tebuconazole, and trifloxystrobin. A composition comprising: (a) at least one compound selected from the group consisting of compounds of formula 1 as claimed in claim 1, N -oxides thereof, and salts thereof; and at least one invertebrate pest control compound or agent. A composition comprising the composition of any one of claims 1 to 12, and at least one other component selected from the group consisting of a surfactant, a solid diluent, and a liquid diluent. A method of protecting a plant or plant seed from disease caused by a fungal pathogen, comprising applying to the plant or plant seed a fungicidally effective amount of a composition as claimed in any one of claims 1 to 13. A method of protecting a plant from rust, comprising applying to the plant a fungicidally effective amount of a composition as claimed in any one of claims 1 to 13, wherein component (b) comprises at least one fungicidal compound, It is selected from (b11) quinone external inhibitor fungicides, (b3) demethylation inhibitor fungicides, (b5) amine/morpholine fungicides, (b7) succinate dehydrogenase inhibitors Fungicides, (b11) quinone outside inhibitor (QoI) fungicides, (b13) methylbenzimidazole carbamate fungicides, and (b52) multi-site active fungicides .